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“In theory, there is no difference between theory and practice. In
practice there is.”




During my PhD studies, I contributed to four original research articles ([1, 2, 3, 4]), one review ([5]) and
one book (not yet published, December 2019). Being first author of three publications ([2, 3, 4]) and second
author of one publication ([1]) satisfies the requirements for a cumulative dissertation stated by Saarland
University (copy of the valid version of the regulations at time of submission is reprinted in the appendix on
page 199 of this dissertation).
In the first chapter of my dissertation “State of the Art”, I provide an introduction to the field of computa-
tional tumor modeling. In the second chapter “Own work“, I elaborate on the relevant original publications
reprinted in the third chapter ”Original publications“ and finish the third chapter with a ”Summary and
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State of the Art
Tumor growth is a complicated and delicate issue touching all fields of life sciences — and beyond. Starting
with pure mathematical and theoretical models over all kinds of biology up to the clinical routine, all
collective efforts feature a common goal: try to understand, predict and eventually handle cancer.
In this first chapter of my dissertation, I provide background knowledge from biology (section 1.1 ”Cancer
Biology“) and computational modeling (section 1.2 ”Computer simulations in cancer research“) enabling the
reader to follow the original research reported in chapter 3 ”Computer simulations in cancer research“. In
section 1.3 ”Sparse matrices“, I highlight the importance of sparse matrices in computational modeling and
numerics before I end this introductory chapter with a personal reflection about state of the art ”Model,
Code and Data sharing“ in section 1.4.
For a comprehensive overview on the broad field of cancer research, the interested reader is referred to
the cited resources.
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1.1. CANCER BIOLOGY CHAPTER 1. STATE OF THE ART
1.1 Cancer Biology
The notion cancer is very general and usually the notion refers to cells or an agglomeration of cells (tissue)
fulfilling the following characteristics [6, 7]:
 Cell growth and division absent the proper signals,
 Continuous growth and division even given contrary signals,
 Avoidance of programmed cell death,
 Limitless number of cell divisions,
 Promoting blood vessel construction,
 Invasion of tissue and formation of metastases.
The progression from normal cells to cells forming a detectable mass (a tumor) to outright cancer involves
multiple steps known as malignant progression [6, 7]. During the progression, the tumors usually affect
different types of cells advising of the tumors names: sarcomas develop from mesenchymal tissue, or connec-
tive tissue, carcinomas develop from epithelial cells and lymphoma develop from lymphocytes. Malignant
progression, however, does not always result in solid tumors. For example, in Leukemias [8, 9, 10] (cancers
of the blood) the malignant progression affects the blood cells. In my dissertation, I restrict the discussion
to solid tumors.
1.1.1 Cells
Cells are the basic units of all living organisms. The prokaryotic cells in simpler organisms (like bacteria)
feature a simpler structure compared to the more complex structure of eukaryotic cells in animals or humans.
The plasma membrane (lipid bilayer) outlines the eukaryote separating the cell from the environment (see
section 1.1.2 and section 1.1.3). A typical eukaryotic cell spans from 10 to 100 µm being about 100 times
larger than a prokaryotic cell. Aside from the difference in size, the Eukaryote is highly structured compared
to the Prokaryote and the Eukaryote contains a nucleus.
The spherical or ovoidal shaped nucleus of an eukaryotic cell spans about 6 µm in diameter centering in the
cell surrounded by the cell body or the cytoplasm. The nuclear membrane separates the nucleus from the
cytoplasm comprising solid and liquid (cytosol) contributions. The cytosol contains soluble proteins, sugars,
salts, etc. and engulfs numerous organelles with well-defined functions (figure 1.1). I discuss four important
organelles with their functions [11]:
 the cytoskeleton is a complex network of polymeres crossing through the cytosol (figure 1.2) main-
taining cell shape and playing an important role in both, intracellular transport and cellular division;
 the mitochondria (plural of mitochondrion) are responsible for converting sugar molecules into adeno-
sine triphosphate (ATP) providing the energy to drive biological processes;
 the endoplasmic reticulum (ER) extends the nuclear membrane and is involved in the synthesis
and sorting of proteins;
 the Golgi apparatus is a set of membranes composed of flattened sacs responsible for protein mat-
uration and protein transport by labeling the proteins depending of their cellular or even extracellular
destination.
Cells reproduce and the nucleus of an eukaryotic cell contains the genetic information required during the
reproduction step. I summarize the essential steps of the reproduction in a simplified cell cycle (depicted in
figure 1.3). Numerous checks (not discussed here) precede the evolution from one stage to another ensuring
that the cell is ready to enter the next stage [15]. The simplified cell cycle starts in the quiescence state (G0)
where the cell is not actively dividing. Note that most cells (expect some liver, stomach, kidney cancer cells)
exit the G0 stage early and keep actively dividing throughout their entire lifespan. Cells spend about 90% of
their entire lifespan taking up nutrients (interphase) in preparation for the replicating division step (mitosis).
The interphase happens in three successive steps: Gap 1 (G1), synthesis (S) and Gap 2 (G2). First, the
stock of proteins and organelles increases during G1. Second, the deoxyribonucleic acid (DNA) carrying
the genetic information duplicates during the synthesis (S) and third, the cell increases in volume during
G2. During the mitotic division, the cell separates the DNA into two nuclei and organizes the duplicated
10
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Figure 1.1: A schematic of the typical cell structure of an eukaryotic cell surrounded by the plasma membrane
with a nucleus at the center and filled with cytoplasm comprising a Golgi apparatus or Golgi body and a
endoplasmic reticulum [12].
This work is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License. To view
a copy of this license, visit http://creativecommons.org/licenses/by-sa/3.0/ or send a letter to Creative
Commons, PO Box 1866, Mountain View, CA 94042, USA.
Figure 1.2: A schematic of the typical organisation of the cytoskeletal filaments inside an eukaryotic cell
comprising the surrounding plasma membrane next to the cortical actin network, the nucleus in the center,
the centrosome or main microtubule organizing center (MTOC) and the intermediate filaments.
Reprinted with permission (section G) from figure 1 of [13]
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Figure 1.3: Schematic of simplified cell cycle. Outer ring: interphase (I) and mitosis (M); inner ring: mitosis
(M), Gap 1 (G1), synthesis (S), Gap 2 (G2); not in ring: Gap 0/ resting (G0) [14]
This work is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License. To view
a copy of this license, visit http://creativecommons.org/licenses/by-sa/3.0/ or send a letter to Creative
Commons, PO Box 1866, Mountain View, CA 94042, USA.
organelles in preparation for the physical division, which finally separates the mother cell into two daughter
cells. Each daughter cell comprises the same structure than the mother and the cell cycle starts from the
beginning [11, 16].
Recently, Sakaue-Sawano et al. reported a method to visualize the cell cycle dynamics [17]. Fluorescent
ubiquitination-based cell cycle indicator imaging (FUCCI) labels cells in G1 phase in red, cells in S phase in
yellow and cells in G2 and M phase in green. By using this method, first results obtained in animal models
confirm that chemotherapeutant targeting cancer cells in S/G2/M phase are ineffective in solid tumors which
dominantly contain quiescent cells in the G0 phase [18].
It should be noted that the current understanding of the cell in terms of molecular biology is far more
complicated than the description presented in this section. In particular, each molecular process is prone to
errors resulting in mutations of the cell and some consider these mutations as the cause of cancer [19].
1.1.2 Tumors and Multicellular Tumor Spheroids (MTS)
Although tumor growth deregulates the interplay between intrinsic cellular programs (section 1.1.1), tu-
mors are multicellular objects. In multicellular objects, the structural support and biochemical interaction
between individual cells contributes to the collective behavior. In tissue, the extracellular matrix (ECM)
mediates both, the structural support and the biochemical interaction. Although the detailed composition of
the ECM varies between different lineages of multicellular objects, the ECM of different multicellular objects
features common functions: supporting cell adhesion, cell-to-cell communication and differentiation [20].
While tumors emerge from molecular and genetic abnormalities, their growth always happens embedded in a
tumor specific environment. Since tumors enhance cell proliferation, cell motility and cell differentiation, the
local microenvironment changes continuously impairing cell death, cell adhesion and the microenvironmental
architecture. For example: a hypoxic microenvironment modifies survival, growth and metastatic efficiency
of some cancer cells; mechanical stresses in the tumor stroma modify the gene expressions and the cell phe-
notype; tumors co-opt inflammatory cells, vascular cells and fibroblasts to reset the balance between ECM
degradation and ECM biosynthesis. In essence, tumor growth takes place in a highly dynamic landscape
developing from a multifactorial environmental response to tumor growth itself.
Cell migration heavily depends on the ECM. In general, the random migration of cells is complemented
by guided migration due to chemicals (chemotaxis) and mechanical cues (mechanotaxis) like fluidic shear
12
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Figure 1.4: Schematic cross-section of a multicellular spheroid. Within the spherical shape, a concentric
arrangement of large proliferating tumor cells is found in the periphery, while smaller non-proliferating cells
concentrate in deeper regions. Diffusional constraints to oxygen and nutrients supply increase with spheroid
size and a central necrotic core emerges as a result of cell death for a characteristic time-dependent spheroid
radius R(t). The value of the spheroid radius, which largely depends on the cell type and on cell culture
conditions, is one of the main variables considered in MTS growth models.
Reprinted figure 8 of [21] (with permission see appendix G).
stress, substrate stiffness gradients (durotaxis) or cellular adhesion site gradients (haptotaxis). Experimental
findings [21] indicate that tumor growth alters the guiding mechanisms and therefore the dynamics of normal
and cancer cells is differentially affected.
The ECM provides not only the necessary structural support for cell migration, but is also part of a de-
formable continuum transmitting chemical signals. The plasma membrane of each cell is a multi-component
mechanosensory switch. Since the plasma membrane interlaces with the ECM, mechanical stresses and
strains convert into biochemical information influencing the cellular response. To understand the cellu-
lar response to mechanical forces in the presents of solid tumor growth requires an understanding of the
mechanosensory machinery and the chemical signaling processes.
Although the understanding of single cell processes increases, studying realistic tumor growth is extremely
difficult because the dynamically changing microenvironment is an integral part of the problem. For in
vivo studies, the resolution of most imaging technique exceeds the cell level and therapy compromises wide-
ranging studies. For animal models, the studies match reality closely, but the imaging techniques at cellular
resolution require the immolation of individual animals. Therefore, time resolved studies in animal models
are subjected to intersubject variability of the microenvironment, however, studying tumor growth demands
an identical microenvironment. Experimentally, it is straight forward to investigate the growth process of
cells on a homogeneous 2D substrate. Although the genetic information of cultured cells is identical to the
genetic information the of cells in real tissue, a homogeneous 2D substrate fails to mimic the complicated
characteristics of a 3D tumor microenvironment. To overcome some limitations of 2D substrates, experi-
mentalists developed a technique to culture cells in 3D [22].
Since the first successful growth of in vitro multicellular tumor spheroids (MTSs) in 1971 [23, 24], MTSs
became a well established method in cancer research and developed to a main tool in studying tumor growth
and drug evaluation in oncology. Today, there are a lot of different techniques to commence the growth of a
MTS. All techniques promote the cell-to-cell interaction and suppress interactions with confining walls. We
divide the growing concepts in active and passive techniques. The passive techniques involve non-adherent
surfaces disabling the adhesive contact and thereby promoting the cell-to-cell interaction inside the conglom-
erate of cells. The active techniques involve physical forces like surface tension, rotation or flow to prevent
the cells from connecting to the walls an thereby also promoting the cell-to-cell interaction. An extensive
list of experimental techniques is discussed in [22].
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Similar to in vivo tumors, MTSs feature a network of structural and adhesive ECM proteins embedded in
a gel. Further, the cell-to-cell and the cell-to-microenvironment interaction, the different cell proliferation
rates, the specific gene expressions, and the drug response generate a suitable 3D model system to study
not only the tumor growth more realistically, but also to evaluate drugs in a more realistic setting. Large
spheroids (≈ 400-500 µm in diameter) display an spherical symmetric layered cell distribution analogous
to the observed structure in solid tumors (figure 1.4). The structure mainly results from mass transport
limitations interfering with the diffusion of oxygen, nutrients and metabolic wastes through the spheroid
creating specific gradients. In the outermost layer, the close contact of the cells to the substrate (agar is
a common choice of substrate) provides easier access to oxygen and nutrients resulting in a layer of large
actively proliferating cells. For in vivo tumors, this layer corresponds to cells close to the capillaries (section
1.1.3). The access to oxygen and nutrients decreases progressively with increasing distance from the spheroid
periphery and, consequently, the cell metabolism decreases resulting in a middle layer of small proliferating
cells followed by quiescent cells. At the spheroid center, oxygen depletion (i.e. hypoxia), acidosis and nutri-
ent shortage cause cell necrosis. Since the tumor cell type characterizes the necrotic core, the characteristics
at the center vary profoundly. Although the MTS model systems mimic the avascular tumor growth phase
nicely, they neglect relevant aspects of the vascular tumor growth phase in real tumorgenesis such as the
vascular remodeling, the immune system components and the fluid dynamics. Since spheroids naturally
vascularize when implanted into animals, the cell-to-microenvironment interactions must be added into an
integral model of tumor growth. However the vascularization of MTSs would be a first step in this direction,
literature lacks reports about successful experiments of this type. [21, 22, 25]
1.1.3 Vasculature
As discussed in section 1.1.2, tumors comprise the interaction between cells and their microenvironment. An
integral understanding of cancer requires the understanding of the involved interactions. For solid tumors
in vivo or in animal models, these interactions include the vasculature.
The vasculature or the circulatory system of every mammalian is a highly optimized biological transport
network distributing nutrients (such as amino acids and electrolytes), oxygen, hormones and collecting the
metabolic waste (such as carbon dioxide) [27]. The high diffusivity of oxygen in tissue [28] limits the trans-
port of oxygen by diffusion to short distances (100 to 200 µm [29]) although oxygen plays a major role in
cell metabolism and energy production. Because of the high importance of oxygen, life requires an efficient
oxygen transport method and a homogeneous distribution of oxygen inside tissue. Nature’s way of trans-
porting oxygen beyond the diffusion limit in a fast way is remarkably. The natural approach builds upon the
vasculature carrying a complex fluid comprising liquid and solid components: the blood. The liquid blood
plasma contributes about 55 % to the blood volume and different cells contribute the remaining 45 %. While
white blood cells (leukocytes) and platelets (thrombocytes) contribute only little to the cellular volume, the
majority of cells in the blood are red blood cells (RBCs, erythrocytes)[30]. The protein hemoglobin covers
the surface of each RBC allowing to bind an oxygen molecule to the RBC. By binding the oxygen to the
RBCs, the RBCs transport the oxygen as ”cargo“ successively along the blood stream enabling transport
beyond the diffusion limit.
To optimize the oxygen transport, evolution optimized the architecture of the vascular system, in turn,
towards an optimal transport of blood (section 3.4 or [4]). Starting with few feeding arteries, the systemic
circuit pumps the blood with high oxygen content from the arteries to the arterioles, to the capillaries.
At the capillaries, the oxygen and nutrient exchange takes place before the blood with low oxygen content
enters the venous branch and returns via venules to the veins, and finally to the heart again. From the heart,
the blood with the low oxygen content enters the pulmonary circuit where the oxygen content of the blood
increases before the blood with a high oxygen content enters the systemic circuit again closing the loop of
blood circulation.
Many blood vessels of different sizes and type build up the hierachical structure of a mature vasculature.
During vasculargenesis, mesoderm and endothelial cells (EC) form single blood vessels which later connect.
Under physiological conditions, vasculargenesis occures transiently in embriogenesis and wound healing. In
maturated blood vessels, a homogeneous layer of ECs is covered by a perivascular layer of cells forming the
blood vessel wall. Depending on the type of the vessel (artery, vein, capillary), the perivascular layer consists
of pericytes, smooth muscle cells or other components (figure 1.5). After the establishment of first microvas-
cular networks (vasculargenesis), blood vessel networks grow by successively extending mature vessels by
splitting (intussusceptive) and sprouting angiogenesis. The balance between pro- and antiangiogenic factors
regulates angiogenesis. The most prominent examples upregulating angiogenesis are the vascular endothelial
growth factor (VEGF) and tumor angiogenic factors (TAFs). On the other side, the most prominent exam-
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Figure 1.5: Healthy vs. Tumor tissue.(Upper left panel) A well-organized vessel network ensures full-covering
of nutrient supply. (Lower left panel) These vessels are matured with an endothelial cell layer surrounded by a
basement membrane and pericytes (like smooth muscle cells). The endothelial layer is characterized by tight
intercellular junctions. Oppositely, due to high pro-angiogenic signaling, the network of tumor-associated
blood vessels (upper right panel) is chaotic, low in pericyte coverage and has loose inter-endothelial cell
junctions (lower right panel). This generates leaky vessels that increases interstitial fluid (IFP) pressure.
Common blunt-ended or collapsed vessels result in tumor regions that are starved from nutrients including
oxygen (hypoxic cells indicated in green). Moreover, the glycolytic nature of the (hypoxic) tumor cell acidifies
the pH in the tumor microenvironment. Reprinted figure 1 of [26].
Figure 1.6: Schematic of tumor induce blood vessel growth, i.e. angiogenesis, by secreting various growth
factors like vascular endothelial growth factor (VEGF), which binds to receptors present on Endothelial cell
(EC) membrane. ECs then release proteases, escape from the original parent vessel walls (sprouting) and
migrate by chemotaxis toward the tumor where they form new vessels. Single tumor cells can break away
from the tumor mass and enter one of the blood vessels, being then carried to a distant site where they can
initiate the growth of a secondary tumor (metastatis). Reprinted of figure 5 from [21] with permission (see
appendix G).
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ple for downregulating angiogenesis is the angiopoietin (Ang) family (figure 1.6). During the progression of
solid tumors, sprouting angiogenesis dominates splitting angiogenesis. Similar to the situation in MTSs (see
section 1.1.2), metabolic stresses (low pO2, low pH or hypoglycaemia) or mechanical stresses (proliferating
cells) unbalance the pro- and antiangiogenic factors, but in contrast to the avascular growth phase, the in-
teraction with the blood vessels in the vascular phase results in a more complex behaviour of tumor growth
in vivo or in animal models. During tumor growth: holes in the endothelial layer form, the interendothelial
junctions widen and the basement membranes become discontinuous or absent resulting in leaky vessels.
In addition, most tumor vessels lack the layer of functional perivascular cells protecting against changes in
oxygen, accommodating metabolic needs and inducing vascular quiescence [29].
Tumor cells segregate VEGF (and other chemicals) establishing a spatial gradient between the tumor and the
surrounding vasculature. In case a blood vessel experiences an increase in VEGF, the basement membranes
of the endothelial cells degrades until some of the endothelial cells eventually become tip cells. Tip cells sense
VEGF gradients using a filopodia and migrate towards an increasing VEGF concentration (chemotaxis). Be-
hind the leading tip cells, more endothelial cells (stalk cells) follow the migration while proliferating and
elongating to form snail trails of capillary sprouts [21, 31] (figure 1.6). At this point, the tumor growth
crosses the point from the avascular growth phase to the vascular growth phase (angiogenic switch [32, 33]).
During the progression of solid tumor growth, sprouting angiogenesis, vessel dilation and regression remodels
the regular hierarchical structure, geometry and organization of the vasculature towards aberrancy affect-
ing the delivery of nutrients, oxygen and other substances mediated by the blood. In healthy tissue, cells
distribute within the diffusion range of oxygen (100 to 200µm [29]) around blood vessels. As discussed
previously (section 1.1.1), maintaining the cell metabolism homogeneously inside the tissue requires a ho-
mogeneous distribution of oxygen inside the tissue. Since blood carries and delivers the oxygen, maintaining
a homogeneous cell metabolism requires a homogeneous distribution of blood vessels, too. On average, the
distance between two blood vessels is on the same order than the diffusion range of oxygen in tissue (50 µm
for brain, 150 µm for breast [34]). This relationship between blood vessels and oxygen supply restricts the
size of avascular tumors to the order of a few millimeters [35].
The tissue fluid or interstitial fluid (IF) surrounds all cells in multicellular organisms. The IF consists of
similar molecules than the blood plasma allowing water-soluble nutrients to extravasate across the capillary
walls from the blood plasma into the IF [36]. Since the spacial arrangement of the blood vessel networks in-
cluding the topology and the wall integrity of blood vessels in tumors differs from their healthy counterpart,
the interstitial fluid pressure (IFP) varies accordingly [37]. Figure 1.5 concisely summarizes the situation
culminating in necrotic tumor core with elevated acidity as observed in in vitro systems and in in vivo tumors
[21].
Understanding the topology of blood vessel networks, or transport networks in general, is still part of current
research [38]. Generically, transport networks face geometric constrains while the transportation happens.
Although the time scales and geometric boundary conditions differ, traffic or river bed formation faces sim-
ilar problems than the blood vessel network formation. For the vasculature, Cecil D. Murray observed and
analyzed the hierarchical structure in 1926 [39] proposing a formula to determine the blood vessel radii
at vessel branches. In his theoretical derivation of the formula, he considered two energies with opposed
dependency on the vessel radius and required the mutual minimization of the two energies. For each vessel
branching point, his model proposes that the sum of the cubes of the daughter vessel’s radii equals the cube
of a parent vessel’s radius. The derivation of Murray’s law incorporates an optimality criterion, but gives no
further advice on how the vasculature achieves this optimality (see section 3.4 or [4]).
1.2 Computer simulations in cancer research
Tumors emerge from the complicated interaction between cells and their microenvironment. As discussed
in section 1.1, tumors communicate biochemically and biomechanically with the surrounding tissue. In con-
trast to other modeling approaches (animal, in vivo, in vitro, etc.), the mathematical modeling approach
provides fully controlled conditions to investigate the individual contributing interactions and the emergent
clinical behavior. The development of realistic mathematical models describing cells, cell clusters or whole
tumors involves equations describing non linear effects in complicated geometries. Since finding solutions for
non linear equations in complicated geometries ensues a very hard problem, computational methods help to
obtain predictions from the equations.
In general, computer simulations of biological systems split into two major approaches: bottom up and top
down. Bottom up approaches use minimal entities (atoms, molecules, cell constituents or cells) and their
mutual interaction to build up the structure of interest. In bottom up or cell-based approaches (subsection
1.2.1), the length scale of interest is similar to the length scale over which the buildup structure or property
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Figure 1.7: A schematic classification of cell-based modeling approaches. Reprinted figure 1 of [47].
This work is licensed under the Creative Commons Attribution 4.0 International License. To
view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative
Commons, PO Box 1866, Mountain View, CA 94042, USA.
varies e.g. the transport of a vesicle across a membrane in a molecular dynamics simulation. The opposite
approach (top down) seeks for equations describing macroscopic observations of tissue compartments or cell
clusters e.g. using Navier-Stokes equations to describe the necrotic core inside a tumor spheroid. Subse-
quently, the top down or continuum approach (subsection 1.2.2) aims at solving the governing modeling
equations. A successful application of a top down approach requires that the smallest length scale of interest
exceeds the length scale over which the considered property of the tissue compartment or cell cluster varies
e.g. for the oxygen transport: the diffusion length of oxygen exceeds the diameter of a single cell (section 3.1
or [1]). Since a well adapted discretization always satisfies this restriction, the real problem dwells in finding
the level of discretization that provides a trade off between computational resources and new information.
Current state of the art research features hybrids between the two approaches (section 3.3 or [3]). In the
following I describe the cell-based and the continuum approach in more detail with special focus on cancer
and discuss the multi scale issue in subsection 1.2.3 [21, 40, 41, 42, 43, 44, 45, 46].
1.2.1 Cell-based models
With increasing computational resources, the relevance of cell-based, discrete, agent-based or individual
based models in cancer research increased. Current models reach out for simulated tumors of clinical relevant
dimensions.
Cell-based models track individual cells either along a rigid grid (lattice-based models) or without spatial
restrictions (lattice-free or off-lattice models).
Lattice-based Methods use regular structured (e.g. Cartesian, Dodecahedral) or unstructured grids.
Implementation, visualization and combination with partial differential equation solvers integrates easily
with structured meshes, but these meshes suffer artifacts when the discretization falls behind the required
resolution. Unstructured meshes avoid discretization biases at the cost of high complexity.
I discuss three examples for the lattice-based methods categorized by the number of cells associated with
each lattice point (left of figure 1.7). In cellular automaton (CA) models, a single cell occupies a single
lattice site. Discrete lattice-based rules (remain, move to a neighboring lattice site, free a lattice site, or
divide to place a daughter cell in a nearby site) update each lattice site in a random order to reduce grid
artifacts. In lattice gas cellular automaton (LGCA) models, more than a single cell occupies one lattice
site. By neglecting the dynamics of individual cells and tracking the dynamics of cell clusters, LGCA models
simulate very large numbers of cells efficiently over long periods of time. Similar to statistical mechanics,
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building grid averages allow LGCA models to link the discrete model to continuum equations describing
cell densities or populations instead of single cells [48]. In Cellular Potts Models (CPMs), a single cell
occupies more than one lattice site reversing the situation compared to LGCA models. Since more than one
lattice site models a single cell, CPMs track the individual cell morphology in more detail compared to CA
or LGCA models and, therefore, CPMs require much more computational effort.
Off-Lattice Methods Off-Lattice methods require no a priori grid structure. The lack of the grid makes
them more realistic, but also more complex and computationally expensive compared to the Lattice-based
methods. I categorize the Center-based models (CBMs) by the number of software agents associated
to each cell and start with typical CBM models associating a single software agent per cell. Some CBMs
represent cells as point-like objects and other (more sophisticated) models explicitly include cell volumes
modeled as spheres or deformable ellipsoids. The exchange of adhesive, repulsive, locomotive and drag-like
forces between the cell centers results in dynamic cell repositioning. Using more than one software agent
per cell approximates the cell biomechanics and the cell morphology in more detail (the method is called
subcellular element model (SEM)), but at increased computational costs. Building clusters of cells
and using one software agent per cluster eases the computational costs compared to traditional CBMs still
incorporating heterogeneous details.
A different off-lattice method, the boundary-based method, focuses more on the morphology of cells or
cell clusters than on the functional aspects. Two examples of boundary-based methods are: the vertex-
based method and the front tracking method. The vertex-based method outlines cells by polygons in
2D or polyhedra in 3D and compute forces acting on the vertices of the polygons. This approach particularly
helps in modeling confluent tissues. For greater spatial resolution compared to the vertex-based method,
front-tracking methods solve partial differential equations (PDEs) describing fluid flow inside and between
cells. The calculated flow advects the boundary points along the cell membranes. A similar technique,
the immersed boundary method (IBM) [49], considers cells as infinitely thin shells filled with liquid. The
shells respond to deformation with elastic restoring forces transmitted into the fluid establishing a coupling
between the PDE describing the liquid and the cells. Level set methods define surfaces implicitly via the
value of an auxiliary function. Depending on the model, the surface outlines a single cell, a cell cluster or a
tumor and adjusts according to the PDEs modifying the auxiliary function. Theoretically, the combination
and hybridization between of different methods is possible e.g. the implementation in VCell [50] recently
connected the level set method with the front tracking method. Table 1.1 lists available software categorized
by the discussed methods.
In cell-based models, the mutual interactions between individual constituents and the mutual interaction
between individual constituents and the environment heavily depends on the modeling assumptions. Since
the modeling assumptions spread widely depending on the scope of the study, I will not attempt a general
review, but refer to the interaction model of the virtual biology lab (VBL) as example (presented in section
2.3.3).
Figure 1.8 summarizes a computational study reproducing the porous necrotic microstructure in a hanging
drop spheroid experiment in vitro. In particular, the figure 1.8 compares two different implementations of cell
necrosis in a cell-based model: deterministic cell necosis in the left and stochastic cell necrosis in the right.
In the widely used deterministic model, cells become instantly (and deterministically) necrotic whenever
the oxygenation drops below a threshold value. In contrast, the stochastic necrosis model allows cells to
survive hypoxic conditions at random. Although both approaches find the porous microstructure known
from biopsy, the deterministic approach (left column) features a sharp perinecrotic boundary between the
viable and nectrotic tissues while the stochastic approach (right column) features a perinecrotic transition
zone with substantial mixing of viable and nectrotic cells (best visible at 8 days of simulated tumor growth
in figure 1.8). Immunological surveillance and immunotherapy entered cancer treatment recently [?]. During
the formation of tumors, the body naturally deals with malignant cells using the immune system and kills
the majority of tumors before progression. Unfortunately cancer cells have ways to avoid destruction by
the immune system. One way is to coat the surface of a malignant cell with proteins down-regulating the
immune response such as PD-1. Therefore new therapies attempt to prevent the down-regulation of the
immune response by malignant cells using immune checkpoint inhibitors. Since the immunohistochemistry
of immune checkpoint inhibitors depends on the spatial distribution of the cells/ molecules (tumor immuno-
architecture) the immuno-architecture is of great interest. In [51], the authors focus on immunotherapy using
immune checkpoint inhibitors in a cell-based model. Their computational model captures the temporal and
spatial dynamics of cytotoxic T cells (CD8+) during the development of a tumor.
Other recent computational studies using cell-based models investigated hypoxia in breast cancer [52, 53],
tumor-induced angiogenesis and drug delivery [54, 55, 56, 57, 58, 59], cancer stem cells [60, 61, 62], the ”Go
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or Grow“ hypothesis for glioblastoma multiforme [63, 64, 65], cancer invasion and epithelial-mesenchymal
transition [66, 67, 68, 69] and multiple variants of tumor immunosurveillance [51, 70, 71]. [47] [72]
Method Open Source Toolkits
Cellular automata (CA) Repast: https://repast.github.io
Chaste: http://www.cs.ox.ac.uk/chaste
NetLogo: https://ccl.northwestern.edu/netlogo
Lattice gas CA Repast: https://repast.github.io
Cellular Potts model CompuCell3D: http://compucell3d.org
EPISIM: http://tigacenter.bioquant.uniheidelberg.de/episim.html
Morpheus: http://imc.zih.tu-dresden.de/wiki/morpheus/doku.php
Tissue Simulation Toolkit: https://biomodel.project.cwi.nl/software/software#TST
Vertex based Chaste: http://www.cs.ox.ac.uk/chaste
Tyssue: https://github.com/DamCB/tyssue











Table 1.1: Computational methods of cell-based models and open source toolkits.
NOTE: Many computational approaches are available in open source toolkits contributing to open science (section 1.4). Because
their source code is available with standard licenses, they have clear reuse rights. Users can tailor the codes to meet their
particular need, publish the modified source (for greater reproducibility), and contribute bug fixes and new capabilities to the
benefit of the scientific community. Adapted from Table 1 of [47] under license. * indicates packages with nonstandard
(not Open Source Initiative-compliant) licences or are posted online for free but with unclear licenses.
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Figure 1.8: Example of cell-based modeling with PhysiCell. The left column shows a deterministic and
the right column a stochastic modeling approach both implemented in PhysiCell. In all simulation time
snapshots, the colors represents the following cell state: green before and magenta after mitosis, pale blue
quiescence, red apoptotic and brown necrotic. The cell nuclei are shown in dark blue.
The bottom row shows a hanging drop spheroid experiment demonstrating a similar necrotic core mi-
crostructure. Image courtesy Mumenthaler lab, Lawrence J. Ellison Center for Transformative Medicine,
University of Southern California. Reprinted figure 2 of [70]. This work is licensed un-
der the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Moun-
tain View, CA 94042, USA.
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Figure 1.9: Example of a cell-based model including immune and cancer cells. (a) Three-dimensional distri-
bution of different cell subsets. Insets show relative locations of T cells and cancer cells in the interior and
at the tumour boundary. (b)(i) Time courses of cancer cell (PDL1+ and PDL1−) statistics tracked during
simulation. (b)(ii) Time course of T-cell statistics tracked during simulation. Shadow indicates ± standard
deviation. (c) Distribution of IL-2 (T cell activator signaling molecule in the immune system) concentration
on days (i) 20 and (ii) 30. (d) 2D slices through the orange box shown in (a) at a simulated tumor time of
(i) 20 days and (ii) 30 days. Reprinted figure 2 of [51].
This work is licensed under the Creative Commons Attribution 4.0 International License. To view a
copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons,
PO Box 1866, Mountain View, CA 94042, USA.
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1.2.2 Continuum models
Continuum models describe the behavior of cell densities or cell populations neglecting cellular details dis-
cussed in the previous subsection. In biological growth processes, changes of cell densities with respect to
space inherently affect changes with respect to time and vice versa. The math of partial differential equations
suits this kind of problem well.
Single-phase models (section 1.2.2.1) consider tumors of a single cell phenotype while multiphase models
(section 1.2.2.2) describe multiple types of healthy and/or cancerous tissues and their mutual interaction at
the same instance.
1.2.2.1 Single-phase modeling
Simplest single-phase models describe a tumor as an expanding sphere which simplifies solid tumor growth
drastically, but also simplifies the math. Describing the tumor by a single scalar value R (the radius of the




to determine the temporal evolution of the spheroid. The question mark in equation 1.1 indicates the
different model assumptions.
Using a constant cell volume density links the spheroid radius to total tumor mass. Since clinicians utilize
and measure the total tumor mass frequently, available in vivo data allows to check model predictions and
to compare model assumptions to realistic tumor growth curves [73, 74, 75, 76, 77, 78].
In general, continuum models depend critically on the choice of the underlying material laws and the 2D or 3D
geometry with the associated boundary conditions. Since tissue (and similar biological material) resembles
a viscous fluid, the description of the tissue dynamics often follows the Navier-Stokes equations. Established
models of tumors adopt material laws describing fluids, poroelastic, viscoelatic and elasto-viscoplastic media.
Naturally, the modeling of biological tissue includes concentrations of cell substrates such as glucose, lactate,
oxygen, growth factors, inhibitors, hydrogen ions, drugs and their mutual interactions.
In contrast to passive physical systems, strict mass conversation does not apply to active biological systems.
Therefore a more general mass conservation equation should include a reaction term f as introduced by
Turing in 1952 [79] (equation 1.2). Let Φ(~x, t) describe the tumor cell density depending on space coordinate
~x and time t and ~J describe the local volume flux of tumor cells, than the mass conservation equation reads:
dΦ
dt
= −∇ · ~J + f (1.2)
Here, the reaction term f acts as additional source or sink for tumor cells. Usually, the local volume
flux is modeled proportional to the local density gradient using the diffusion constant D (Fick’s first law).




∂t +~u∇Φ results in the generalize form of a diffusion equation, the diffusion reaction equation (DRE):
∂Φ
∂t
+∇ · (Φ~u) = ∇ · (D∇Φ) + f (1.3)
where ~u describes the local speed of the tumor cell density at space coordinate ~x and time t. Meanwhile
DREs are studied carefully in divers fields [80, 81, 82].
However active biological systems (like tumors) violate mass conservation, cell division and cell death still
obey momentum conservation. The general momentum equation (equation 1.4):
d (Φ~u)
dt
= ∇σ + ~F (1.4)
for a viscous fluid includes the Cauchy stress tensor σ and the total body force ~F accounting for gravity
and other external forces. Tumor growth models neglect the elastic behavior of tissue on short time scales
(minutes), because relevant processes of tumor growth happen on long time scales (days). On the tissue
time and length scale, the residual stresses relax by rearrangement of extracellular matrix fibers leading to
viscous behavior including solid pressure, friction and adhesion forces. Since biological growth and migration
happens in a regime of very low Reynolds numbers (Re  1), tumor growth model neglect inertial forces.
The direction and the speed of cell migration depend on environmental stimuli (section 1.1), especially on:
• chemotaxis i.e. gradients of soluble chemicals;
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• haptotaxis i.e. gradients of substrate-attached molecules;
• mechanotaxis i.e. modifications of the ECM mechanical properties;
• durotaxis i.e. gradients of the matrix rigidity.
A crucial point in biophysical cancer modeling is to determine whether the coupling between tumor microen-
vironment evolution, cellular forces and active cell migration sustains or prevents tumor growth. Theoretical
models have included different degrees of complexity to account for cell motility. The book of J D Murray
[81] exhaustively presents such models. In unguided cellular diffusion, the diffusive cell flux ~Jd(~r) at location
~r adjusts proportional to the local cell gradient ∇Φ(~r, t):
~Jd(~r) = −D∇Φ(~r, t) (1.5)
Assuming a constant isotropic diffusion results in random cell motility. In more sophisticated models, the
proportionality factor D depends on cell density Φ(~r, t) itself, strain, different substrate gradients or even
on anisotropic reactions. In the most prominent example regarding tumor growth, the cells move up the
gradient of vascular endothelial growth factor (VEGF) [83, 84].
In first approximation, the chemotactic cell flux ~Jg is proportional to the cell density Φ(~r, t) by a factor α
defining the cell’s sensitivity to the VEGF:
~Jg = αΦ(~r, t)∇g (1.6)
Equations similar to equation 1.6 follow for haptotaxis, mechanotaxis and durotaxis, and have been consid-
ered in a large class of continuous differential tumor models coupling DREs with chemotactic and possibly
haptotactic cell migration processes in 1D [85, 86], 2D [87] and 3D [88, 89].
Since tumor growth includes biomechanical processes with multiple facets ranging from inherent balance
between proliferative pressure and resistive force of surrounding host tissue to the far more complex pro-
cesses of mechanical control of cell dynamics and tumor vascularization, growing tumors actively contribute
mechanical signals to the biological system. Continuum models lack the possibility to include direct cell-cell
mechanics. Instead, authors considered coarse grained quantities like adhesion and surface tension [90, 91, 92]
as source of intratumoral pressure gradients ∇p driving the tumor growth. Since the speed of molecular
diffusion of the nutrients surpasses the speed of a growing tumor by several orders of magnitude, the steady
state assumption for the nutrients simplifies the DREs describing the nutrients. I discuss a generalized model
assumption (equation 1.7) in the following.
The balance between cell proliferation and death produces additional contributions to the cellular movement
depending on the nutrient distribution. Let n(~r, t) describe a nutrient distribution (e.g. oxygen field) and
Γ(n) describe the net balance between the nutrient-dependent proliferating rate and the cell death rate
[92, 93]. Considering the tumor as an incompressible fluid, the continuity equation:
∇ · ~u(~r, t) = Γ(n) (1.7)
links the nutrient concentration to the velocity field ~u(~r, t) of the cell population. A constitutive equation
links the velocity field to the internal pressure p. Usually, models consider the tumor as a porous media and
apply Darcy’s law to obtain the velocity from the pressure:
~u = −γ∇ · p (1.8)
In Darcy’s law (equation 1.8), the proportionality factor γ characterized the hydrostatic, viscous-like proper-
ties of the tumor cells [94, 95]. Together with assumptions on the boundary conditions, the above equations
provide a closed set of partial differential equations enabling numerical studies of the tumor growth. [21]
1.2.2.2 Multiphase modeling
Up to now, the discussion assumed a single cell phenotype per cell population (single-phase models). The
mixing or simultaneous consideration of multiple cell phenotypes (mixed-phase or multiphase models) offers
the possibility to study healthy, cancerous and other populations of phenotypes at the same time and thereby
considerably improving the tumor simulations regarding heterogeneity.
The description of a solid tumor in a multiphase model comprises usually at least one solid phase (necrotic
tissue, viable tissue, ECM, ...) and one liquid phase (water, interstitial fluid, ...). The equations used in
multiphase modeling are similar to the equations used in single-phase modeling (section 1.2.2.1), but consist
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Figure 1.10: (A) to (C) depict a 400 µm thick slice through the origin of a 3D simulation box with lateral
extension of about 8 mm. The scale bar indicates 1 mm. (A) is a close-up. (B) and (C) have the same
scale. The snapshots were taken after 100 h, 400 h, 700 h. (C) and (D) show the same time but from a
different point of view where a quadrant was cut out. The boundary to the viable tumor phase is rendered
as solid yellow surface. Necrotic phases appear as void spaces within the tumor. The blood vessel network
is rendered as collection of cylinders, color coded by blood pressure. Red represents high blood pressure
(arteries), and blue represents low blood pressure (veins).
Reprinted figure 2 of [37] available at https://doi.org/10.1371/journal.pone.0070395.g002.
This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of
this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO
Box 1866, Mountain View, CA 94042, USA.
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Figure 1.11: Tumor volume and morphology changes during progression including exponential growth (T1),
linear expansion (T2), stasis (T3), and secondary growth processes (T4). Brown region: Viable cells; Black
region: Necrotic cells.
of mass and momentum balance equations for each phase separately in combination with an interphase mass
and momentum exchange. Similar to the single-phase models, appropriate constitutive laws and boundary
conditions close the model equations. In contrast to the single-phase models, however, the total volume
in multiscale models splits for the different phenotypes or species. Considering N species with each of the
species occupying a volume fraction φi, the assumption of no voids constrains the total volume at each point
in space and time to
∑N
i=0 φi = 1. Equation 1.9 shows the general mass conservation law for each of the







= −∇ · ~Ji + Si (1.9)
ρi describes the density, σi the stress and ~ui the velocity of component i. The source terms Si generalize the
reaction term f of equation 1.3 to account for inter-component mass exchange. Assuming mass conservation
of the mixture, the summation of equation 1.9 requires that
∑N
i=0
~Ji equals a constant and
∑N
i=0 Si equals
zero. Together with these two consistency equations, the multiphase method allows to compute quantities
of the system such as velocities, forces, stresses or interaction energies. [40]
In [37], Welter et al. used a multiphase model to study the influence of the interstitial fluid pressure on
chemotherapy. In their model, the solid phase comprised tumor tissue, normal tissue, necrotic tissue and
ECM in combination with the liquid interstitial phase as illustrated in figure 1.10.
In [96], Tang et al. proposed a mathematical model coupling 3D tumor growth and angiogenesis to simulate
tumor progression for chemotherapy evaluation. Their model combines cell-based features with continuum
equations to model tumor progression through multiple stages including tumor initiation, avascular growth,
and transition from avascular to vascular growth (shown in figure 1.11). Using cell- and vascular-mediated
interstitial pressure, mass transport, angiogenesis, cell proliferation, and vessel maturation, allowed them to
simulate realistic drug distributions during chemotherapy (compare figure 1.12).
Recently, Vavourakis et al. [97] studied intravenous delivery of cytotoxic drugs in a model accounting
for chemo-, hapto- and mechanotactic vessel sprouting, extracellular matrix remodeling, mechano-sensitive
vascular remodeling and collapse, intra- and extravascular drug transport, and tumour regression as an effect
of a cytotoxic cancer drug (see figure 1.13).
[98] [72] [99] [34] [100, chapter 3: Computer Simulations of the Tumor Vasculature: Applications to Inter-
stitial Fluid Flow, Drug Delivery, and Oxygen Supply]
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Figure 1.12: Solid tumor growth simulation with angiogenesis from a virtual 3D vasculature. The cross-
sectional plane shows the nutrient availability within the simulation area.
Reprinted figure 9 of [96] available at https://doi.org/10.1371/journal.pone.0083962.g009.
This work is licensed under the Creative Commons Attribution 4.0 International License. To
view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative
Commons, PO Box 1866, Mountain View, CA 94042, USA.
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Figure 1.13: Snapshots of tumor growth and angiogenesis over time. Simulation results visualisation com-
parison of the control (center row) versus the treated case for low poresize, and two extreme drug affinity
ratios. From left to right, the snapshots at the second column correspond to day 11, the third column to
day 21, the fourth column to day 31, and the last column to day 40. Note for low drug affinity (bottom
three rows) the low drug concentration in the tumor and for high affinity (top three rows) the significant
concentration of the cytotoxic drug. Notably, the drug distribution is very heterogeneous for early-stage in-
jections due to the non-hierarchical structure of the immature tumor vessels supporting the argument of the
the spatio-temporal variability of the vascular tree in mammary tumors. Comparing the top right snapshot
with the bottom counterpart, the tumor regresses for high drug affinity.
Reprinted figure 4 of [97] available at https://doi.org/10.1371/journal.pcbi.1006460.g004.
This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of
this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO
Box 1866, Mountain View, CA 94042, USA.
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1.2.3 The multi scale issue
As presented in the previous two subsections (subsection 1.2.1 ”Cell-based models“ and 1.2.2 ”Continuum
models“) and discussed by others [21, 101, 102, 40], cancer acts on many length and time scales. To integrate
the knowledge across different scales (and disciplines) is a major challenge in cancer research.
The past two decades shed a lot of light on the subcellular processes in a single cell and the mere complexity
of the single cell processes drives a huge branch of modern biological research. Literature even established a
new notion — the “omics” family of research — to summarize the emerging subdisciplines in system biology.
The “omics” family of research covers (not exclusively) genomics, epigenomics, proteomics, metabolomics
and mechanomics acting on length scales as small as nanometers and time scales as fast as nanoseconds.
Since the typical cell cycle of a healthy cell lasts about one day [103], I consider one day as the upper limit of
the time scale for a single cell phenomena. Considering multicellular processes (cell migration, proliferation)
lifts the length scale to micrometers and time scale to several hours or multiple days defining the meso
scale. The meso scale bridges between the subcellular micro scale and the clinical observable macro scale.
The macro scale completely lacks single cell aspects considering collective cell or tissue phenomena only.
Tissue extends up to several centimeters forming whole organs including the vasculature, which is peculiar
to macro level. Blood vessels sustaining a blood stream with enough nutrients and a lymphatic network
disposing metabolic wast allows living tissue to maintain the “status quo” for decades or even a whole century
(compare figure 1.14).
Unfortunately science lacks the reason for cancer, but scientists widely believe [21] that tumors originate
from a malfunctioning within the “omic” family. However a malfunctioning single cell might cause problems,
tumors comprise multiple cells dynamically interacting with each other and the local environment similar
to the interaction in non cancerous tissue. To incorporate and modify the vasculature is a hallmark of
solid tumor growth. During the progression of solid tumor growth, a cohort of processes such as chemotaxis,
haptotaxis, mechanotaxis combine with topological properties of the cell cluster and form the natural habitat
of the “omic” processes. In other words: feedbacks from the tissue to cell and from the cell to the sub cellular
level establish.
We started to understand some of the processes at their characteristic scale (macro, meso and micro), but
we are just getting an idea about the complicated and diverse feedbacks between the different scales. As
described in [21], solid tumor growth involves processes at all scales and the authors of [101] even gave the
name “cancer system biology“ to this emerging field of research.
Combining cell-based models with continuum models into hybrid models enables in silico modeling to deal
with the multiscale issue.
Figure 1.14: Multiscale model techniques overview showing characteristic techniques for each scale of cancer
modeling: ML = Machine Learning, CA = Cellular Automata, ABM = Agent Based Modeling, PDE =
Partial Differential Equation, ODE = Ordinary Differential Equation.
Relevant biological abbreviations: TGF = Transforming growth factor (member of the epidermal growth
factor family), TNFα = Tumor Necrosis Factor α (important during inflammation), EGFR = Epidermal
growth factor receptor.
Reprinted figure 1 of [104] available at https://doi.org/10.1371/journal.pone.0183810.g001.
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1.3 Sparse matrices
Finding a vector x satisfying the linear equation
Ax = b (1.10)
is a well known and studied problem in math [105] — in pure math as well as in numerics. With increasing
computational power, numerical methods became increasingly relevant for finding solutions to equation 1.10.
In practical, real-world problems occurring in science and engineering, the matrices A are very large and
sparsely populated meaning only a few matrix entries differ from zero (
#{ai,j 6=0}
#{ai,j=0}  1). Studying sparse
matrices intersects numerical linear algebra and graph theory.
In general, a graph represents connection between variables in a mathematical model such as physical forces
between two points inside a mechanical structure or the voltage across a circuit being similar to the blood
pressure at each intersection in a blood vessel network (compare section ”2.2 Computation of blood flow and
hematocrit“ in [5]). The emerging field of machine learning heavily uses sparse matrix techniques because
data categorization and counting smoothly integrates with sparse matrices e.g. in natural language processing
a nonzero entry at (i,j) means that document i contains word j (http://faculty.cse.tamu.edu/davis/research.html,
[106]).
More classical applications of (sparse) linear systems occure when computationally solving differential equa-
tions. As presented in section 1.2.2.2, Partial Differential Equations (PDEs) facilitate continuum descriptions
of physical problems based on suitable material laws. Since finding analytical solutions fails for practical
applications, numerical methods find approximative solutions for the PDEs under consideration. Current
state of the art numerics features two different methods to solve PDEs: Finite Elements Methods (FEM)
and Finite Difference Methods (FDM). FEMs assume that the function solving the PDE could be repre-
sented as a superposition from a suitable set of basic functions defined on small patches (”Finte Elements“)
of the total domain. Therefore, finding a solution to the global PDE reduces to finding the appropriate
coefficients for each of the basic functions in superposition on each patch. Finding the coefficients converts
into solving linear equations where the matrix A is sparse. In contrast to the sophisticated FEMs, Finite
Difference Methods (FDMs) simply divide the domain of the PDE turning derivatives into ”Finite Differ-
ences“ [107, 108, 109, 110] . I describe the transformation of a PDE into sparse linear system explicitly for
the 1D diffusion equation [107].







, x ∈ (0, L), t ∈ (0, T ] (1.11)
u(x, 0) = I(x), x ∈ [0, L]
u(0, t) = 0, t > 0,
u(L, t) = 0, t > 0
where α > 0 is a real parameter and the prescribed function I(x) determines the initial condition at t = 0.
To treat the problem numerically, we discretize the domain [0, L]× [0, T ] with equally spaced mesh points at




tn = n∆t, n = 0, . . . , Nt where ∆t =
T
Nt
Using the standard shortcut uni for u(xi, tn) together with backward difference in time and central difference
in space (known as ”Backward Euler Method“ [108]), the discretization of equation 1.11 becomes a coupled




uni+1 − 2uni + uni−1
∆x2
(1.12)
for each point on the mesh. Defining F = α (∆t)(∆x)2 and sorting the unknowns in equation 1.12 to the left hand
side, equation 1.12 rewrites to
−Funi−1 + (1 + 2F )uni − Funi+1 = un−1i−1 , (1.13)
29
1.3. SPARSE MATRICES CHAPTER 1. STATE OF THE ART
Considering the boundary conditions un0 = 0 and u
n
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, with b0 = 0, bi = u
n−1
i , bNx = 0 (1.15)
At this point, finding a function solving the diffusion equation (equation 1.11) turned in to finding the inverse
matrix of A (written as A−1) to obtain the unknowns in equation 1.13. The explicit representation of the
matrix A (see equation 1.14) shows the sparsity for the discussed 1D problem.
For a PDE of a function defined over 2D- or 3D-dimensional space, the presented reasoning requires an
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Figure 1.15: Sparsity pattern for the 2D diffusion equation. The bullets refer to the nonzero entries and the
dots represent entries with zeros.
additional mapping of the two- or three-dimensional grid points to the matrix. Similar to the 1D case,
the resulting matrices are sparse, but with more complicated sparsity patterns. Figure 1.15 illustrates the
sparsity pattern for the matrix obtained from the 2D diffusion equation.
The mentioned ”Backward Euler“ time-stepping scheme is one of the most simplest approaches. Different
possibilities of mixing forward and backward time-stepping or to approximate the derivatives in the dis-
cretized form of the equation exist. The ”best“ choice depends on the problem, but often the Runge- Kutta
method derived from the described ”Backward Euler“ method is a good starting point.
Now the problem of finding a function satisfying a differential equation turned into finding a vector x satisfy-
ing the (sparse) matrix equation Ax = b and we find lots of tools for this task in computational mathematics
or computer science. During the course of my PhD studies I used ”Trilinos“ ([111], https://trilinos.github.io/)
and ”PETSc“ ([112, 113, 114], https://www.mcs.anl.gov/petsc/). Both packages are highly flexible and im-
plement the latest techniques to solve linear and even non-linear sparse matrix equations. The techniques in-
clude parallel computing with distributed memory using MPI (Message Passing Interface, https://www.mpi-
forum.org) and shared memory multiprocessing using openMP (www.openmp.org).
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1.4 Model, Code and Data sharing
Computers dramatically affect our daily life. More digital data than ever is acquired and stored on ever
increasing storing devices. Data storage in combination with fast distribution of information via the internet
accelerated our communication. The possibility to easily store large amounts of data and the new pace of
communication affects also the scientific community. For example: today, one website hosts a lifetime of
writings from a single person (http://www.alberteinstein.info/) or today, a medical doctor in Europe could
almost instantly evaluate a Magnetic Resonance (MR) scans of a person located in the United States or vice
versa.
Prior to computers and the internet, the library was the place to find the latest science communicated in
professional journals, but the previously well accepted ways of communicating scientific results slowly adapt
to the pace of the digital world. The peer review process managed by the professional journals like the
physical review letters (https://journals.aps.org/prl/) maintained quality standards, improved performance,
and provided credibility in academia. However these advantages, a peer review process raises the cost for
a journal concerning staff members, mail and storage. A critical point of the peer review process is to find
an appropriate peer executing the review of the article. Knowing, finding and contacting an expert on the
scope of an article requires a well established network of the journal’s editor. The internet eased the efforts
to find and contact an expert quickly. Therefore a lot of researchers started questioning whether the clas-
sical journals including their form of the peer review process are still worth the gains [115, 116, 117] with
wikipedia being one successful counter example.
In wikipedia, the review process follows a concept know from open source software development
(https://opensource.org/) where not only a few experts judge the contributions, but everybody interested
contributes. This way, numerous people with diverse backgrounds and contrary opinions find a common
consensus resulting in high quality articles similar to the high quality obtained in open source software
development. Preprint servers like arXiv (https://arxiv.org) and bioRxiv (www.biorxiv.org) offer the pos-
sibility to share research in a form that is independent of classical journals and the classical peer review
process [118]. Instead of a classical peer review process, preprint servers feature different metrics to judge
contributions. The simplest form of a metric counts the response to an article (altmetric) similar to the
facebook’s thumb up or thumb down approach. Current investigations focus on the scientific reliability of
this metric [119].
Computers changed not only the communication in the sciences, but also a lot of the sciences itself. Current
life sciences rely on a lot of techniques indispensable connected with computers during data acquirement and
data analysis. Proper science requires reproducibility of the digital methods and to ensure reproducibility,
sciences relying on computers request reliable data storage. To this end, the community established the FAIR
Principles for scientific data management and stewardship: research data should be Findable, Accessible,
Interoperable and Reusable [120].





 Open Peer Review
 Open Educational Resources.
Several publisher accepted the call for open science with a serious of open access journals. For example
the nature publishing group with the journal Scientific Reports or the royal society publishing group with
the journal ROYAL SOCIETY OPEN SCIENCE. On top, “nonprofit” publishers like the public library of
science PLoS (www.plos.org) or eLife Sciences Publications (www.elifesciences.org) became an established
resource in the scientific community. To contribute to an open access journal, the authors (or their hiring
institutions) pay an article processing charge (APC) covering the expenses of the journal. In return, the
hiring institution of an author avoids journal subscription rates for the open access journals. Therefore paying
an APC is not a drawback for the institution and as a consequence, the science reported in the manuscript
becomes accessible to everybody. To ensure the public availability, manuscripts passing the peer review of an
open access journal usually appear under creative commons licenses https://creativecommons.org/licenses/
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allowing other scientists to access and adapt the already reported research focusing on new scientific results
rather than copyrights.
Like wikipedia being the most prestigious achievement of an open review process, the linux kernel is the
most prestigious achievement of the open source community. Except of the desktop computer segment (where
Microsoft’s Windows is still leading), the linux kernel drives supercomputers, (web-) servers and embedded
devices — also the Android operating system relies on the linux kernel. Although the idea that everybody
can contribute to software (the kernel) was present at the early days of the linux kernel, integrating and
merging code from multiple developer became more tedious the more developer a project had. To automat-
ically coordinate a lot of contributions and to smoothly integrate modifications into the source code of the
kernel, the head developer of the linux kernel, Linus Torvalds, developed a distributed version control system
to track changes in the source code: git. In my opinion, git and other version control systems (VCS) such
as CVS or subversion contributed to the current success of open source software [123].
In the context of open science, the scientific community became aware that source code (e.g. www.github.com)
and data (e.g. www.zenodo.org and Scientific DATA https://www.nature.com/sdata/) sharing is an advan-
tage [97, 124] rather than bearing the risk of being scooped. Today scientists upload and share their software
including documentation and example data to platforms like https://simtk.org/ or www.openhub.net. In
the context of this dissertation, I worked with three listings:
“SimVascular” [125](http://simvascular.github.io/) providing a complete pipeline from medical im-
age data segmentation to patient specific blood flow simulation and analysis;
“Chaste” [126, 127] (http://www.cs.ox.ac.uk/chaste/) providing a cell-based simulation framework
extended by a simple 2D vasculature in
“MicrovesselChaste” [128] (http://jmsgrogan.github.io/MicrovesselChaste/) .
A more general example of data sharing and integration is the human brain project
(https://www.humanbrainproject.eu) attempting to merge knowledge, software and data from multiple dis-
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2.1 Computational Model for Tumor Oxygenation Applied to Clin-
ical Data on Breast Tumor Hemoglobin Concentrations Sug-
gests Vascular Dilatation and Compression
The original research article entitled Computational Model for Tumor Oxygenation Applied to Clinical Data
on Breast Tumor Hemoglobin Concentrations Suggests Vascular Dilatation and Compression was published
at 22nd of August 2016 in PLoS ONE. I reprinted the article with permission (see appendix G at page 215
of this dissertation) in section 3.1 starting on page 55 of this dissertation.
2.1.1 Background
Although oxygen plays a major role in cell biology, the oxygenation of tumors is not well understood and
focus of current research.
Since oxygen plays a key role in the creation of ATP, oxygen also plays a key role in driving biological life
on the molecular level, but only few measurement techniques are available [130] to study oxygen in vivo. In
[131], the authors presented an in silico model to obtain the oxygen distribution in arbitrary shaped tissue
domains based on the blood vessels crossing the domain. Inspired by their work, we propagated the oxygen
from artificial blood vessel networks into the sourrounding tissue to study oxygen saturation of the tissue
during vascular remodeling due to breast cancer.
In contrast to conventional mammography, optical or infrared (IR) mammography scans the tissue with
low energy radiation serving as a none invasive scanning technique and providing information about the
average oxygen distribution in vivo. In detail, IR mammography accesses the average concentration of total
hemoglobin cHb, oxyhemoglobin cHbO and deoxyhemoglobin cHbD [132]. The ratio between oxyhemoglobin
cHbO and deoxyhemoglobin cHbD determines the average blood oxygen saturation Y = cHbO/cHbD as a
derived quantity. In [133], the authors scanned a cohort (87) of patients with carcinomas using IR mam-
mography and reported that the total hemoglobin concentration in tumors exceeds the total hemoglobin
concentration in healthy control tissue (second breast).
Cancer leads to dilated blood vessels increasing the available volume for the blood. Assuming a constant
hemoglobin concentration in the blood, the observed increase in hemoglobin concentration follows from the
increased blood volume. However the total hemoglobin concentration (cHb) increased, the measurements
revealed variations in the blood oxygen saturation Y . High hemoglobin concentrations correlate with high
blood oxygen saturations, but tumors with a low hemoglobin concentration exhibit a wide range of blood
oxygen saturations (see figure 5 in [133]).
In the original research paper [1] (reprinted in section 3.1.1), we provide reasoning for the variation.
2.1.2 Summary of the paper
After the introduction, we explain the theoretical and computational models to calculate the blood vessel and
tissue oxygen saturation. The implementation of these models is part of the Tumorcode software published
in 2018 ([2] and section 3.2 of this dissertation). In the Tumorcode software, the models described in
the publication ”Computational Model for Tumor Oxygenation Applied to Clinical Data on Breast Tumor
Hemoglobin Concentrations Suggests Vascular Dilatation and Compression“ are named ”detailedO2“.
The model development started with previously published models from Hsu, Secomb and Goldman
([134],[135]). Our approach [1] assumes a constant intravascular partial pressure of oxygen (P ) at the cross
section area of a blood vessel. Therefore, the propagation of the intravascular oxygen parallel to the blood
vessel axis (longitudinal) becomes an effectively one dimensional problem. The coupling between vessels and
the surrounding tissue is the most elaborate part of our model. Since the intravascular oxygen acts as source
for the oxygen field inside the tissue surrounding the blood vessel (Pt), the intravascular oxygen pressure
P reduces accordingly as the blood propagates along the vessel axis similar to fluid extravasation. Fluid
extravasation requires a driving pressure gradient, and in analogy, we model the transvascular flux density
of oxygen per unit length jtv proportional to the gradient of oxygen partial pressure inside the vessel P and
outside the vessel (i.e. inside the tissue) Pt.
2πrjtv = 2πrγ (P − Pt) (2.1)
In equation 2.1, r denotes the vessel radius and γ describes a phenomenological mass transfer coefficient
determined from current literature values (details listed in the supporting information ”S1 Appendix: Model
details and validation“ reprinted in chapter 3.1.2 starting on page 98 of this dissertation). We modeled the
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Mesent28 10 subset - 2350 µm 0m47s 0m19s 445 2
artificial 0 0550 µm 2m47s 0m10s 83 1
1 1200 µm 0m58s 0m31s 154 1
2 2200 µm 5m52s 1m39s 352 1
Table 2.1: Simulation details for comparing the Green’s function based method with the finite differences
based method. Runtimes measure on standard desktop computer (Intel(R) Core(TM) i7-4770K CPU @
3.50GHz) and Ubuntu 16.04.
tissue oxygen consumption rate M(Pt) according to the standard Michaelis- Menten relation [135].
For our computational study, we used 90 different artificial blood vessel networks: 10 samples for each of
the 9 root node configurations (see figure 3 of [1]). Given the initial vasculature, we simulated our oxygen
model in three different variants: the case BASE with no additional assumptions, the case CMPR including
vascular compression by the tumor and the case METAB varying the oxygen consumption rate inside the
tumor tissue. After validating the simulations by comparing them to available literature values, we conclude
that: 1) the variance of tissue hemoglobin concentration, tissue blood oxygen saturation and perfusion results
from individual initial vascular configurations; 2) vascular compression causes low tumor oxygen saturation
and 3) the high tumor blood flow rates outweigh the increased oxygen demand.
Our published paper links the statistical variations observed in [133] to the topology and spatial distri-
bution of blood vessel networks confirming several other conjectures about solid tumor (see “Results and
Discussion“ of the paper).
2.1.3 Personal contributions
I revised the manuscript and assisted Dr. Michael Welter during software development by testing and
debugging his implementations. In his implementation, Dr. Michael Welter modified the presumably more
accurate numerical methods described in [131] and [135] towards faster execution, but more coarse grained
resolution. Using ”small“ (discussed in the following) synthetic blood vessel networks enables a direct
comparison of the two implementations with each other and was executed by the author of this dissertation
(see supplemental information ”S1 Appendix“ of [1] and section 3.1.2 starting on page 98 of this dissertation).
Supplementing the already published data, I will discuss my comparison in more detail here.
I downloaded the program implementing the numerical method described in [131] from
https://physiology.arizona.edu/people/secomb/greens and applied minor modifications allowing execution
of the software on current linux systems (tested with Ubuntu 16.04, Ubuntu 18.04 and archlinux 4.18.14).
I host the modified version of the software together with data format modifying scripts on my GitHub site
(https://github.com/thierry3000/green function method). The scripts convert data files into each others
counterpart with the correct file structure considering two main points: 1) Secomb et. al. used units com-
mon in medicine (pressures in mmHg and flows in nlmin ) while Tumorcode uses SI units (kPa for pressure and
µm3
s for flows) and 2) the indexing of the boundary conditions differs. However both programs index fixed
flow boundary conditions by ”2“, the Tumorcode software indexes fixed pressure boundary conditions by ”1“
(see “calcflow linsys.h”) and the implementation of Secomb et al. labels fixed pressure boundary conditions
by ”0“. With the converting scripts at hand, I set up a comparison of the two implementations by applying
the Green’s function based method [131] to artificial blood vessel networks created by the Tumorcode soft-
ware and applying the finite differences based approach described in [1] to the data set Mesent28 10 subset
measured by Secomb et al. (see table 2.1, figure 2.1 and figure 2.2).
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Figure 2.1: Plot of pO2 field for artificial blood vessel networks created by the Tumorcode software. From
top to bottom the number of hierarchical iterations during the network creation step increases from 0 to 2.
Note the increasing lateral size (550 µm to 2200 µm). All color codes represent mmHg. Left column: pO2
field calculated by the finite difference method described in [1] and implemented in the Tumorcode software.
For a clear view on the distribution, the visualization with with POV-Ray truncates the vessels above the
data slice. Right column: pO2 field calculated by the Greens function based method [131] and visualized by
their code.
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(a) Finite Differences based method implemented
by the Tumorcode software. Colors scale between

































(b) Green’s function based method implemented by
Secomb et. al. Colors scale continuously according
to the pO2 color bar on the right.
Figure 2.2: Plot of oxygen partial pressure (pO2) distribution for the mesentery data set
(Mesent28 10 subset) measured by Secomb et al. All color codes represent mmHg.
Green’s function based method to artificial vasculature I created three artificial blood vessel net-
works with root node configuration 5 (RC5, see figure 3 in [1]), increasing lateral size and hierachical
iterations ([2]) using the Tumorcode script “submitVesselgeneration.py” with the parameter set “asymmet-
ric” (“parameterSetsVesselGen generic.py”). After construction of the blood vessel networks, I applied the
finite difference based method (“detailedO2” in the Tumorcode software) to calculate the oxygen field of the
constructed vessel networks with the parameter set “Artificial tumorcode” (“parameterSetsO2 generic.py”).
The left column of figure 2.1 displays a visual representation of the pO2 fields calculated by the finite differ-
ence based implementation. Next, I exported the artificial blood vessel networks created by the Tumorcode
software to the vessel network data format used in the implementation of Secomb et al. (“vesselhdfToSec-
ombNetwork.py”). By manually adjusting the file “SoluteParams.dat” and the total inflow of blood into
the network for each vessel network separately, I converted the parameter set of the Tumorcode software
(“Artificial tumorcode”) to the equivalent required by the implementation of Secomb et al. A complete
list of the parameters is stored at my GitHub repository. The right column of figure 2.1 displays a visual
representation of the pO2 fields calculated by the Green’s function based implementation.
With increasing hierarchical level (from top to bottom), the variation in intravessel pO2 increases because
of the increasing length scale. Note that the overall lateral size increases from 550 µm to 2200 µm similar to
the length scale of the data sets released with Secomb’s software (e.g. Mesent28 10 subset). In contrast to
the finite difference method of the Tumorcode software, the runtime for the Green’s function method does
not scale with the system size in the presented examples. As discussed in [131], the implementation of the
coupling between vessel and tissue depends on the spatial vessel arrangement in the network and therefore
variation of the vessel networks significantly affects the runtime. This is where the mean field approach of
the finite difference method outperforms the Green’s function based approach. With increasing system size,
the deviation between the two methods becomes smaller. With a single hierarchical iteration at the network
creation step (central row of figure 2.1), the outline of the two pO2 distributes are similar and with two
hierarchical iterations at the network creation step, (bottom row row of figure 2.1) the details overlap.
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Finite differences method to the data set Mesent28 10 subset The dataset Mesent28 10 subset was
measured from a rat mesentery network [131] (available for download at http://www.physiology.arizona.edu/
people/secomb/greens c3). I exported the dataset Mesent28 10 subset to a format compatible with the
Tumorcode software (“secomb2hdf2.py”). After exporting, I applied the finite difference based method
(implemented in “submitDetailedO2.py”) using the parameter set ”Artificial tumorcode” (see “parameter-
SetsO2 generic.py”) to the Mesent28 10 subset dataset. Figure 2.2 compares the two pO2 fields obtained
with the different methods (Green’s function based method and finite differences based method).
The finite difference based method runs more than twice as fast as the Green’s function based method (19
seconds vs. 47 seconds, compare table 2.1). A visual difference between the two images shown in figure
2.2 appears along the major veins at the periphery because of two main reasons: First, the Green’s func-
tion approach uses a hematocrit stored in the measurement file (in the case of Mesent28 10 subset , 40%
for all segments) while the artificial blood vessel networks lack a measured value of hematocrit. Instead
the Tumorcode software calculates the hematocrit from the physiological assumption that the hematocrit
propagates downstream in the arterial branch. Fixing the hematocrit at all arterial inlets of the network
allows successive calculation of all vessel’s hematocrit. In the calculation, the Tumorcode software includes
the F̊ahræus–Lindqvist effect [136] and the phase separation effect [137]. Second and similar to the hemat-
ocrit problem, the Tumorcode software neglects any measured pO2 value along the vessel network, but solely
relies on the fixed pO2 values at the arterial inlets. The Green’s function based method follows a more
sophisticated approach including the measured pO2 values along the blood vessels (compare equation 20 in
[131]). In summary, the pO2 distributions shown in figure 2.2 are qualitatively similar however figure 2.2b
shows stepper gradients compared to figure 2.2a.
The two considered programs implement different methods to solve similar, albeit not the same, equa-
tions describing the partial oxygen pressure in tissue penetrated by blood vessel networks. A qualitative
data comparison is not compelling, but I showed that the results agree with each other. In addition, further
testing confirmed that calculating the pO2 saturation with the Green’s function based approach exceeds
moderate memory and time limitations for large synthetic blood vessel networks.
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2.2 Tumorcode - A framework to simulate vascularized tumors
The original research article entitled “Tumorcode - A framework to simulate vascularized tumors” was pub-
lished at the 26th of April 2018 in the European Physical Journal E. I reprinted the article with permission
(see appendix G) in section 3.2 starting on page 115 of this dissertation.
2.2.1 Background
When I started my PhD in 2013, the Tumorcode software was already present albeit not in the current
form. Dr. Michael Welter successively developed large parts of the software base on original work from
Bartha et. al. ([34, 138]). During our common time in the research group of Prof. Dr. Dr. h.c. Heiko
Rieger, Dr. Welter introduced me to the relevant algorithms and taught me how to use the code in personal
communication. Bearing the idea of open science in mind (section 1.4), I realized that a written introduction
to the code and some examples would be helpful for other scientists in the field.
The European Physical Journal E “Soft Matter and Biological Physics” features a section called Tips and
Tricks (T&T) sharing previously unpublished state of the art research methods which the Tumorcode software
in fact was.
2.2.2 Summary of the paper
After a short introduction to the topic, I described the “Design and implementation” principles of the
Tumorcode software in section 2 of [2] (reprinted in section 3.2). Most importantly, the Tumorcode software
presents a hybrid between the two programming languages C++ and Python. Executable machine code
build from C++ source code tailored to the underling hardware results in optimal performance. However
the optimal performance, the code development and compilation of the C++ programming language is often
tedious. In contrast to the compiler based approach of C++, the interpreter based approach of the Python
programming language simplifies implementation effort because Python scripts instruct the Python kernel
rather than creating real machine-readable executables. Without thinking too much about the struggles
present in classical programming languages like datatypes and memory layout, Python allows fast prototyping
of problems and the scientific community offers a lot of packages optimized for different situations.
In the Tumorcode software, computational extensive tasks such as solving sparse matrices to obtain the
hydrodynamics of the blood flow network; solving diffusion convection reaction equations modeling the
tumor growth, nutrient and oxygen transport (section 1.3); and various demanding measurement tasks are
forwarded to a computational core written in C++. This way, the Tumorcode software benefits from the
high performance of the C++ programming language and the handy features of the Python programming
language at the same time.
In section 3 “Workflow”, I described the typical workflow of the simulations conducted with the Tumorcode
software: 1) we create an artificial blood vessel network (algorithmic details reported in [5]); 2) we grow a
tumor, either by continuum diffusion reaction equations (section 1.2) or by a fake tumor simulation that
comprises a homogeneously expanding spherical tumor mass including the full vessel remodeling procedure;
3) we apply one of the sophisticated biological models to the vessel network snapshots stored during the
tumor simulation, before we 4) optionally analyze or visualize any simulation step.
In section 4 ”Applications“, I summarize the two cases ([1] and [37]) where step 3) (the application of the
sophisticated biological models) resulted in original research publications. The interstitial fluid pressure
(IFP) is an experimentally hardly accessible quantity, which is highly relevant in chemotherapy because the
extravascular drug transport is driven by the IFP gradient. One of the biological models calculates the
interstitial fluid pressure based on the vessel arrangement, vessel wall conductivity parameters and Darcy’s
law. Assuming convective transport of drugs driven by the IFP gradient, the interstitial fluid flow module
estimates drug distributions in vascularized solid tumors [37].
Oxygen is a key player in cell metabolism. The transport of oxygen in animals or humans is a complicated
problem by itself (see section 1.1.3) happening in two distinct phases: in bound state where the oxygen
molecule couples to red blood cells (RBCs) streaming along in the blood and in a diffusive state when the
oxygen molecule uncouples from the RBCs. Similar to the IFP distribution, the distribution of unbound
oxygen inside tissue heavily depends on the arrangement and condition of blood vessels. We modeled the two
kinds of oxygen transport and traced the oxygen saturation during the progression of cancer. With this model
we explained the variation in blood oxygen saturation dependent on the total haemoglobin concentration as
measured by Grosenick et al. ([133]) in 87 breast carcinomas (see section 2.1).
In addition to the main text, I compiled 8 supplements (3 digital supplements ”suppl-file1.zip“, ”suppl-
file2.mov“, ”suppl-file3.avi“ and 5 supplements in text form ”suppl-file4.pdf“ to ”suppl-file8.pdf“). ”suppl-
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file1.zip“ contains a snapshot of the source code at time of publishing the article, ”suppl-file2.mov“ illustrates
the network creation process in a movie and ”suppl-file3.avi“ shows a growing tumor simulated and rendered
by the Tumorcode software. The remaining five supplements (reprinted in subsection 3.2.2 of this dissertation
starting on page 124) illustrate how the data used in main text (vessel networks, tumor simulations, IFP
distribution, oxygen distribution) was obtained by the Tumorcode software:
suppl-file4.pdf describes how to create vessel networks with Tumorcode;
suppl-file5.pdf describes how to run tumor simulations with Tumorcode;
suppl-file6.pdf describes how to calculate interstitial fluid pressure and drug transport with Tumorcode;
suppl-file7.pdf describes how to calculate detailed oxygen distributions with Tumorcode;
suppl-file8.pdf describes how to use the visualization tools implemented in Tumorcode.
2.2.3 Personal contributions
I conceived and wrote the manuscript of [2], provided the data comprising all figures and illustrations, and
communicated with the editor and referees of the publishing journal (The European Physical Journal EPJ).
During my Ph.D. studies, I made considerable contributions to the Tumorcode software package illustrated
in the following.
2.2.3.1 Software development
I eased the required technical background to use the Tumorcode software. Since a very broad community
studies cancer, the knowledge about (linux) software development required to use the Tumorcode software
should be as moderate as possible. To this end I:
 created a cmake installation routine allowing inexperienced users to build and install the software,
 trimmed the source code to the standard folder structures and to the standard naming conventions
used in other open source (C++) projects,
 added lots of comments to the source code in the doxygen style helping other software developers to
understand the algorithms
 used python’s “argparse” concept (see https://docs.python.org/2.7/library/argparse.html) to
include help messages for command line arguments of the main routines (e.g. “submitVesselgenera-
tion.py”, “submitBulkTissue.py” and “submitPovrayRender.py”)
 tested the source code on different standard operating systems (Ubuntu 16.04, Ubuntu 18.04, Arch-
Linux, Hardened Gentoo 4.1.7) and provided corresponding installation scripts.
As mentioned earlier, an important feature of the Tumorcode software is the simultaneous usage of two
programming languages: the C++ language used in the computational core and the Python programming
language used for fast and straight forward prototyping of problems.
Numpy is the standard package for numerics in the Python programming language. In the past, Dr. Michael
Welter used his code (https://github.com/DaWelter/numpycpp) to implement the interface between the
computational core of the Tumorcode software and the numpy package. Starting with version 1.64, the boost
library offered an interface to numpy called boost::numpy (see https://www.boost.org/doc/libs/1 64 0/libs/
python/doc/html/numpy/index.html). Therefore I replaced the subproject “numpycpp” in the Tumorcode
software with the newly available standard option provided by the boost library.
The Tumorcode software stores data in the HDF5 file format. The Hierarchical Data Format (HDF) stores
and organizes large amounts of heterogeneous data while allowing easy sharing, cross platform usage and
metadata storage within the same file. Dr. Michael Welter implemented an C++ interface to the HDF5 file
format (https://github.com/DaWelter/HDF5-cpp-wrapper) and used his implementation throughout coding
the computational core of the Tumorcode software. Starting with the minor release version 1.10, the HDF5
file format provided an interface to the C++ programming language. Therefore I replaced the subproject
“HDF5-cpp-wrapper” in the Tumorcode software with the newly available default option.
40
CHAPTER 2. OWN WORK
2.2. TUMORCODE - A FRAMEWORK TO SIMULATE VASCULARIZED TUMORS
2.2.3.2 Cartesian coordinates/ Boundary conditions
Before I joined the project, the hydrodynamic solver of the Tumorcode software worked with vessels on
lattices and fixed pressure boundary conditions only. To deal with experimental data sets such as the one
shown in figure 2.2, I extended the C++ simulation core to work with arbitrary Cartesian coordinates as input
and extended the hydrodynamic solver to work with flow and mixed boundary conditions simultaneously.
2.2.3.3 Continuation of simulation runs
Typically, High Performance Computing (HPC) facilities assign a maximum “Wall time” (<∞) to computing
jobs enabling them to maintain and fix hardware on the fly and to fairly distribute resources among the
users.
The typically runtime of Tumorcode simulations exceeds maximal “Wall time”s preventing an execution of
the Tumorcode software on HPC facilities. To overcome the drawback of runtimes exceeding maximal “Wall
time”s, I implemented the possibility of consecutive runs of a single simulation. At runtime, the Tumorcode
software buffers the current simulation state on the hard disk (in HDF5 file format) allowing to continue the
simulation from the latest simulation state before exceeding the maximum wall time (rerun option in the
“submit”- scripts).
I tested this option successfully on marconi at CINECA for the “fakeTum” simulation combined with Virtual
Biology Lab (VBL, see section 2.3.3) tool.
2.2.3.4 Solver
Solving sparse linear systems (see section 1.3) naturally occurs when dealing with finite elements or finite
difference methods ([139]) and solving the Hagen- Poiseuille equation in large flow networks ([2]). “Belos”
([111]) and “Ifpack2” ([140]) both contribute to the Trilinos project (https://trilinos.github.io/index.html),
and in combination, they are well suited for the sparse matrix problems occurring the scope of the Tumorcode
software. By replacing all solvers with these two options from Trilinos, the code became more structured and
easier to maintain. Further, “Ifpack2” implements state of the art algorithms ready for parallel computing
which will become an important aspect in future.
2.2.3.5 Data Cache
Analyzing large data sets could be tedious and very computational expensive. “Data caching” remembers
costly obtained data. Subroutines equipped with a data cache store the input arguments and the output for
every call. At each call of a cached subroutine, “the cache” checks for previous calls with identical arguments.
In case the subroutine was called with identical arguments before, the data cache reads the output from disk
instead of starting the (costly) computation again.
Dr. Michael Welter began to implement this concept in the Tumorcode software starting in 2015. Together
we improved the implementation of the data cache and used data caching throughout the data analysis
resulting in [1] (reprinted in section 3.1 on page 55 of this dissertation).
In successive code development, I applied the concept of data caching at plenty of appropriate locations.
2.2.3.6 Visualization
To communicate results effectively in an interdisciplinary environment, visualizations of the problems are
obligatory. Computer graphic’s methods of creating visualizations distinguish between two main fields ap-
proaching each other in recent years [141]: the realistic image synthesis and real time rendering. Realistic
image synthesis aims at creating most realistic images including relevant physical details like illumination,
light scattering and refraction. The artist describes a virtual scene in an abstract language and the com-
puter translates the description of scene into pixels of an image ignoring computational costs. As the name
suggests, real time rendering provides interactive scene modifications. To mimic “realtime”, considering the
computational costs is essential because real time rendering requires that the calculations run faster than
the reaction time of the human visual stimulus (about 50 ms).
The Tumorcode software features both possibilities (realistic image synthesis and real time rendering). By
means of realistic image synthesis, the Tumorcode software renders large vascular networks with hun-
dreds of thousands of vessels outrunning real time rendering on current hardware devices. For the re-
alistic image synthesis, the Tumorcode software uses the “Persistence of Vision Raytracer” (POV-Ray,
http://www.povray.org/) as an open-source, high-quality software tool for creating stunning three-dimensional
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Figure 2.3: Visualization of the necrotic core inside a vascularized tumor rendered with the realistic image
synthesis of POV-Ray. Depicted is a simulated tumor and tumor blood vessel network at the age of about
one month (700 h). The full simulation cube of 8 mm lateral length is shown where a quadrant is cut out to
improve visibility. The interface of viable tumor mass to the necrotic core is shown in yellow. The vessels are
color coded according to their blood pressure. The bulk of volume surrounding the (yellow) tumor spheroid
is filled with the initial vascular network. It appears solid due to the large amount of vessels (more than 3
million), but the vessels only fill about 10% of the available volume. Reprinted (with permission, see page
238 of this dissertation) from figure 6 of [5].
graphics [142]. Each single blood vessel is rendered as cylinder. To provide visual continuity at the inter-
section of two vessels in a blood vessel network, a sphere with the radius of the cylinder is added at each
intersection. Figure 2.3 shows an example of a large vessel network rendered by POV-Ray.
For real time rendering, the Tumorcode software exports to the “Visualization Toolkit” (VTK) data
format. VTK is open source software for manipulating and displaying scientific data using state-of-the-art
tools in 3D rendering and data analysis. The graphical user interface based on VTK (called ParaView [143,
144], www.paraview.org) allows to explore small to intermediate size (depending on the graphic hardware)
blood vessel networks in realtime. Figure 2.4 shows two images created by the VTK file export of the
Tumorcode software and ParaView.
I maintained and updated the interface of the Tumorcode software to POV-Ray and to the VTK data format
meeting the file structure of current POV-Ray, VTK and ParaView versions. In addition, I extended the
interface by adding new features like:
 ParaView output for scalar fields such as growth factor distribution shown in orange in figure 2.4a to
the Tumorcode software;
 new clipping, coloring, overlay, filter and camera options to the POV-Ray interface (“submitPovrayRen-
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(a)
(b)
Figure 2.4: Two visualizations of vascularized tumors rendered with VTK and Paraview. The features of
ParaView allow to extract and clip subsets, color data according to arbitrary color codes and interactive
scaling and rotating.Top (a): pH level in vascularized tumor spheroid - vessels are color coded by blood
pressure, cells by pH level, the fading orange in the center indicates the amount of vascular endothelial
growth factor (VEGF) released by the cells.Bottom (b): 500µm thick slice through tumor vasculature of
1cm lateral size. For 3D illustration, vessels with radius bigger than 20µm are continued for another 750µm
above and below the extracted slice. Vessels are colorcoded by their radius according to the lower panels:
arteries are displayed in varying reddish color and veins in varying blueish color (unit of colorbar is µm).
Capillaries and young vessels with radius of 2.5 µm are shown in green. Reprint figure 2 of [3] with permission.
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der.py”). Some of them are used in the videos at https://doi.org/10.6084/m9.figshare.7406183.v1 and
https://doi.org/10.6084/m9.figshare.7406180.v1 ( [145, 146] );
 incorporation of information provided by the Virtual Biology Lab simulation ([3] and section 3.3) to
the VTK/ParaView and the POV-Ray interface.
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2.3. FINE-GRAINED SIMULATIONS OF THE MICROENVIRONMENT OF VASCULARIZED
TUMOURS
2.3 Fine-grained simulations of the microenvironment of vascu-
larized tumours
The original research article entitled “Fine-grained simulations of the microenvironment of vascularized
tumours” was published at the 12th of August 2019 in the journal “Scientific Reports”. I reprinted the
article with permission (see appendix G at page 215) in section 3.3 starting on page 141 of this dissertation.
2.3.1 Background
Although genetics certainly contributes to the diversity of cancer, the contribution of the diversity in the
local environment to the diversity of cancer attracted the interest of the community recently. Meanwhile,
it is well known ([101]) that the tumor microenvironment is a very complicated and heterogeneous entity
affecting the progression of solid tumors. Moreover, the tumor microenvironment is often involved in cancer
therapy e.g. in chemotherapy or in radiotherapy and therefore, an integral understanding of the tumor
microenvironment is not only of scientific interest, but also of high clinical relevance.
Solid tumors grow in two phases: first, in an avascular phase not actively involving the vasculature for
the nutrient transport and second, in a vascular phase actively involving the blood vessels for the nutrient
transport. In the avascular phase, the tumor spheroid is typically smaller than the average distance between
capillary vessels and the nutrient transport happens solely by diffusion resulting in a characteristic spherical
symmetry of the tumor spheroid. Once the size of a tumor spheroid exceeds the average blood vessel distance,
the topology of the blood vessel network breaks the spherical symmetry influencing the nutrient supply and
modifying the further tumor growth process. During progression, solid tumors even remodel the structured
blood vessel networks of healthy tissue towards irregular and unstructured networks comprising dilated and
leaky vessels. Healthy tissue features a high oxygenation and, a balanced pH and interstitial fluid pressure
levels. Tumor tissue, however, features hypoxia, acidosis and elevated interstitial fluid pressure level ([34]).
The angiogenic switch [32] defines the moment when an avascular tumor spheroid turns into the vascular
growth phase. In the publication “Fine-grained simulations of the microenvironment of vascularized tu-
mours” ([3]), I simulated the growth of a multicellular tumor spheroid at the angiogenic switch looking at
the oxygenation of the tumor microenvironment in more detail.
2.3.2 Summary of the paper
After the introduction, I give a brief outline of the two combined computer programs: the “Virtual Biol-
ogy lab” (VBL) and the Tumorcode software. The VBL software simulates the growth of avascular tumor
spheroids including the cell cycle of each individual cell. The Tumorcode software simulates solid tumor
growth at large scales including realistic blood vessel networks and vascular remodeling dynamics during tu-
mor growth. Both programs have been verified separately in previous publications. The results obtained by
VBL were tested against data from in vitro experiments ([147]) and the results obtained by the Tumorcode
software were tested against data from in vivo experiments ([1, 148]).
In the next section “The Merging of the Two Programs”, I discuss the developed interface combining the two
simulations before I describe the main simulation setup in the section “Development of the Microenvironment
in Small Solid Tumours”. I computationally studied the development of small solid tumors starting from
three distinct locations inside a small synthetic arteriovenous network: at the center of the vessel network, in
the middle of a venous bifurcation and in the middle of an arterial bifurcation. This way, I studied the early
formation of the tumor microenvironment considering the vascular remodeling at the angiogenic switch.
I observed a large spatial and temporal variability inside the tumor microenvironment promoting the forma-
tion of ecological niches. In the “Conclusions” of the manuscript, I conjecture that the high niche diversity
enables “Darwinian selection” in solid tumors supporting the clonal section hypothesis [149, 150].
2.3.3 Personal contributions
Solid tumors are multicellular entities. The Tumorcode software and the related earlier publications [1, 37,
148] modeled tumors by continuum equations (see section 1.2.2 “Continuum models”) neglecting cellular
details in favor of larger system sizes. Since inhomogeneities and large chemical gradients characterize the
tumor microenvironment, a realistic tumor model necessitates the inclusion of the cellular details to explain
the inhomogeneities and the chemical gradients.
In [147], Prof. Dr. Edoardo Milotti et al. simulated an avascular tumor spheroids by an off-lattice method
(compare section 1.2.1) called Virtual Biology Lab (VBL). I combined the Tumorcode software and the VBL
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Figure 2.5: Sketch of the metabolic network used in VBL. Variables within circles represent molecular
species. The suffixes ext and int indicate extracellular and intracellular variables respectively: G=glucose,
G6P=glucose-6-phosphate, STORE=glucose stored in the form of glycogen, AL=lactic acid, A=glutamine,
ATPp=pool of ATP molecules, DNA=nuclear mass of DNA (normalized to 1 for the whole genome),
mtDNA=mitochondrial DNA. Variables within rectangles represent rates. The red circuit represents the
oxygen sensor, whereas the green circuit represents the ATP sensor [151, 152]. “Cell cycle checkpoints”
denotes the molecular circuit of cell cycle control that has been modeled on the basis of previous studies
on the dynamics of the allosteric effect [153, 154]. The biological foundations of this simplified metabolic
network have been given in [151, 152]. Recent improvements with respect to earlier previous models include:
internalization rates of glucose, glutamine and lactate are sensitive to extracellular pH and this dependence
is now described by smoothed functions [147]; synthesis of cellular proteins, nuclear DNA and mitochondrial
DNA are now described by double-substrate Michaelis-Menten chemical reactions to take into account the
dependence of protein and nucleic acid biosynthesis on glutamine (which stands phenomenologically for the
wider class of aminoacids) and ATP availability.
Reprinted figure S2 of [147] available at https://doi.org/10.1371/journal.pone.0013942.s003.
This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of
this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO
Box 1866, Mountain View, CA 94042, USA.
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Figure 2.6: The geometry and topology of diffusion. a) Most substances are carried into and out of the
cells by facilitated diffusion and there is an active mass exchange between cell and extracellular space. Each
cell in the simulation program has its own extracellular space. b) Extracellular spaces are interconnected
and there is a diffusion flow through the network of connections. c) The network of interconnected spaces
is defined by a Delaunay triangulation. In this 2D representation, for any red dot we can define a Voronoy
cell, i.e., the set of points in the plane that are closer to the given dot than to any other dot in the set. The
dual structure is the Delaunay triangulation (Voronoy cells are black and Delaunay links are green). There
is a Delaunay link between any two dots only if the respective Voronoy cells touch each other, therefore
we can use the Delaunay triangulation to define proximity. This enables us to set up a discretized version
of diffusion between extracellular spaces, like in b). In addition to the topology of contacts between cells
we also keep into account geometry: gab in part b) is a geometric factor that modulates diffusion. d) The
actual simulation is in 3D: here the Delaunay triangulation of a small cluster of cell centers shows up in
transparency.
Reprinted figure S3 of [147] available at https://doi.org/10.1371/journal.pone.0013942.s004.
This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of
this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO
Box 1866, Mountain View, CA 94042, USA.
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Figure 2.7: The geometry of mitosis in VBL. R0 denotes the radius of the initial mother cell, while R1 and
R2 denote the radii of two daughter cells. Because of random asymmetries during mitosis, the daughter cells
usually have different sizes. The program places the two daughter cells inside the region initially occupied
by the mother, and the axis connecting the centers points in a random direction. Placing the to daughters
closer than R0 forces the two cells to push against each other separating and rotating the axis. The new
cells’ centers separate by roughly 0.4 R0.
Reprinted figure S5 of [147] available at https://doi.org/10.1371/journal.pone.0013942.s006.
software to a hybrid simulation including the cellular and the macroscopic level as reported in the main
manuscript.
I performed data analysis and data visualization to provide the displayed figures. To present my analysis of
the simulation runs, I wrote the results section and revised the manuscript together with all coauthors. As
corresponding author, I communicated with the manuscript assistant, the publishing assistant, the editor
and the referees of the publishing journal (“Scientific Reports”).
Since I used the implementation of the VBL model extensively in [3] (section 3.1.1), I present the main
modeling assumptions of VBL and comment on my personal implementation efforts in the following.
2.3.3.1 Modeling assumptions of VBL
VBL models individual cells as perfect spheres. Apart from the 3D position and the cell volume, 15 bio-
chemical variables (circles inside the cell membrane illustrated in figure 2.5) such as nuclear mass of DNA
or mass of glucose characterize the internal state of each cell. Figure 2.5 visualizes the equations linking the
variables. Since VBL links the cellular volume to the present amount of DNA, to the present amount of ATP
and to the number of mitochondria (equation S.22 in supporting text to [147]), the equations visualized in
figure 2.5 model the cell volume correspondingly.
Except oxygen, other substances included in the model cannot diffuse freely across the cell membrane be-
cause of the complex structure of the membrane (section 1.1.1). Therefore VBL uses facilitated diffusion
from the extracellular space into the cell volume. In the model, a slightly larger sphere surrounds each VBL
cell mimicking the extracellular space (panel A in figure 2.6). The mass of glucose, the mass of lactic acid,
the mass of glutamine and the pH (circles outside the cell membrane illustrated in figure 2.5) characterize the
extracellular space in VBL. These four extracellular parameters and the oxygen content link to the internal
biochemical pathways (figure 2.5) modeling the transport to and from a single cell across the cell membrane.
The spheres modeling the extracellular space are linked to implement the multicellular interaction (panel B
in figure 2.6). To link individual cells, VBL approximates the facilitated diffusion process between neigh-
boring cells using a Delaunay triangulation. The Delaunay triangulation constructed from the centers of all
spheres provides geometric information (Voronoy cell surfaces and distances to the neighboring cells) and
the VBL software models the (facilitated) diffusion process proportional to the geometric information (gab
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Figure 2.8: Pictorial representation of the interaction force between two cells in VBL. The solid curve shows
qualitatively the behavior of the interaction force, while the insets depict the corresponding situations:
A)cells are compressed against each other, force is repulsive; B)cells are in contact, the total force vanishes;
C)cell centers are slightly apart, force is attractive because of adhesive molecules on the cell’s membranes;
D)cells are no longer in contact, the total force vanishes again. The inset on the lower right shows the
definitions of the basic geometric variables.
Reprinted figure S4 of [147] available at https://doi.org/10.1371/journal.pone.0013942.s005.
This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of
this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO
Box 1866, Mountain View, CA 94042, USA.
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in panel B of figure 2.6).
The biomechanical interaction between two VBL cells is derived from the Hertz problem [155, 156] known
in contact mechanics. The Hertz problem deals with the interaction forces of two spherical membranes
approximating the cell-cell interaction forces for small deformations quite well. For two cells with radii R1
and R2, Poisson’s ratios ν1,2 and Young’s moduli E1,2 for cell 1,2 respectively (figure 2.8), the resulting force




























) and x := d−(R1+R2)R1+R2 , the dependence of the forces on the deviation from the
equilibrium position (x = 0) becomes more obvious as shown in equation 2.3.
F = k|x| 32 (2.3)
Under strong compression e.g. after mitosis, the formula for the force (equation 2.2) results in unrealistic
values. Therefore, VBL assumes that the force flattens out towards a constant modulus for small separations
(x << 0). The qualitative shape of the force is depicted in figure 2.8.
In addition to the deterministic equations of the biochemical pathway (figure 2.5) and the biomechanical
forces (figure 2.8), the simulation considers two probabilistic cellular events: mitosis and cell death. The
mitotic cell division in VBL happens inside the volume of the initial mother cell limiting the increase in
volume during this step (situation depicted in figure 2.7). While limited by the size of the mother cell, the
volume of both daughter cells and the direction connecting the new daughter cells are taken at random.
Milotti et al. report all computational details in a supporting text to [147] also available at https://doi.org/
10.6084/m9.figshare.9878588.v1.
2.3.3.2 Implementation efforts
Prof. Dr. Edoardo Milotti released an implementation of the model described in [147] to the public domain
via GitHub (https://github.com/edymil/VBL). I designed a cmake build environment to easily build the
VBL software from the source code. Developing similar cmake build scripts for the VBL and the Tumorcode
software eases the installation effort preceding the combined simulations. Further, I translated a lot of
comments from Italian to English increasing the targeted audience. I arranged the VBL source code in a
more object oriented fashion.
As documented in the main manuscript ([3] and section 3.3.1), I implemented an interface between the VBL
and the Tumorcode software. Complementary to the interface, I conceived a way to store the simulation
data in a common data format. After successfully establishing a communication of the two simulations via
the interface and establishing a common data format, I performed simulation runs on a small beowulf cluster
(named “snowden”) at Saarland University and the high performance computing (HPC) facility in CINECA
(Italy) with the login name “tfredric”.
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2.4. DYNAMIC VESSEL ADAPTATION IN SYNTHETIC ARTERIOVENOUS NETWORKS
2.4 Dynamic vessel adaptation in synthetic arteriovenous net-
works
The original research article entitled “Dynamic vessel adaptation in synthetic arteriovenous networks” was
published at the 31st of August in the Journal of Theoretical Biology. I reprinted the article with permission
(see appendix G at page 229) in section 3.4 starting on page 157 of this dissertation.
2.4.1 Background
The vasculature is a highly dynamic object embedded in surrounding tissue and subjected to numerous
biological regulatory mechanisms (section 1.1.3). Not all of the regulatory mechanism are fully understood
today. Since measurements on alive vasculature are complex, computer simulations offer a non invasive way
to test hypothetical regulatory mechanism. The vessel adaptation model described in [157] modulates the
radii of blood vessels within a network based on biologically inspired stimuli (see main manuscript in section
3.4 or [4]).
As reported in [1], we found that an ad hoc dilation of cancerous blood vessels accounts for measured oxygen
and hemoglobin concentrations in real patient’s tumors. Conjecturing that an integration of the adaptation
model into the Tumorcode software provides reasoning for the ad hoc vessel dilation, I studied the vessel
adaptation model in more detail.
Unfortunately I failed with a successful application of the vessel adaptation model to tortuous, unstructured
and cancerous blood vessel networks (see supplemental material to [4], section 3.4.2). Instead I focused on
the adaptation model with respect to artificial blood vessel networks created by the Tumorcode software.
2.4.2 Summary of the paper
The “Introduction” reviews the biological motivation for a vessel adaptation model before the “Methods”
section explains the details of “the adaptation algorithm”, “the artificial blood vessel networks”, the “pa-
rameter optimization” and the used “biophysical quantities”. The “Results” section of the main manuscript
(section 3.4 or [4]) starts by “reproducing the available data” from the measured rat mesentery network
approving my own implementation of the adaptation algorithm.
The original work of the Pries et al. [157] obtained the required parameters of the vessel adaptation model by
minimizing the deviation between predictions of the adaptation model and experimentally observed vascular
networks. Since artificially constructed blood vessel networks by the Tumorcode software lack a comparison
to measured blood vessel networks, the vessel adaptation model requires a different way to determine the
free model parameters when applied to artificial blood vessel networks.
Therefore I applied a numerical parameter optimization to the problem of finding model parameters pre-
dicting realistic blood vessel networks. The main manuscript (see section 3.4.1 or [4]) describes two testing
scenarios involving artificial blood vessel networks created by the Tumorcode software: “single topology with
varying boundary conditions” and “varying topology with fixed boundary conditions”. In the first scenario, I
applied particle swarm optimization to find parameters of the adaptation algorithm minimizing the variation
in capillary blood flow for a single fixed vessel arrangement. In the second scenario, I applied the adapta-
tion algorithm together with the parameters obtained in the first scenario to varying vessel arrangements.
Studying the two scenarios supports my assumption that a realistic blood vessel radii distribution satisfies
an optimality criterion similar to the assumptions included in the derivation of Murray’s law (section 1.1.3).
I applied the vessel adaptation algorithm to artificial blood vessel networks created by the Tumorcode soft-
ware, but failed in augmenting the biophysical principles of vascular remodeling during solid tumor growth
(as implemented in the Tumorcode software) by the adaptation algorithm. Mainly due to two reasons: 1)
the complexity in obtaining the free parameters for which the set of highly non linear equations converges
and 2) the immediate loss of convergence due to the nonlinearities in the equations occuring when changing
the topology of the vessel network by either adding or removing a vessel to or from the network — both are
valid options during vascular remodeling occurring in solid tumors (supplemental material to [4] or section
3.4.2).
2.4.3 Personal contributions
I extended the Tumorcode software by a module implementing the vessel adaptation algorithm described in
[157].
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Dr. Michael Welter designed the numerical core of the Tumorcode software [2] to deal with lattice coor-
dinates only. To include the vessel adaptation algorithm into the numerical core, I lifted this restriction
allowing arbitrary 3D coordinates in the numerical core of the Tumorcode software. After implementing
the adaptation algorithm, I validated the implementation by reproducing the numerical results published
in [157]. To this end, I downloaded the measured blood vessel networks used in [157], converted the raw
data to the data structure of the Tumorcode software and applied my implementation of the algorithm with
parameters reported in [157].
At the time of conducting the experiments, the measured blood vessel network data was available for down-
loaded at:
http://ajpheart.physiology.org/highwire/filestream/95027/field highwire adjunct files/1/network 546 segments.txt.
(Today on the 7th of October 2019, this link is broken, but I found the same data distributed as supplemental
for [158] and hosted at:
https://www.physiology.org/doi/suppl/10.1152/ajpheart.00757.2002/suppl file/Table%201.txt.)
To convert the raw data into the data structure required by the Tumorcode software, I used the python script
“apj2hdf.py” distributed with the Tumorcode software (in the folder “py/krebs/adaption/ ”). The exact pa-
rameters are stored in the file “parameterSetsAdaption generic.py” (in the folder “py/krebsjobs/parameters/ ”).
After successful validation of my implementation, I investigated the adaptation algorithm on artificial blood
vessel networks created by the Tumorcode software. I identified relevant parameters influencing the stability
of the adaptation algorithm and conducted an extensive parameter study to find applicable parameters for
a single fixed vessel arrangement. Using a robust optimization method (particle swarm optimization), I
considered several objective functions and different hydrodynamic boundary condition during the course of
optimization. In the end, minimizing the variance in capillary blood flow turned out to produce realistic
radii distribution of blood vessel networks (section “Single topology, varying boundary conditions” in [4]).
Conducting the optimization was computationally expensive and demanding (more technical details listed
in the supplemental text to [4]).
Next, I tested the influence of rearranging the vessels in space to the adaptation algorithm by creating an
ensemble of networks featuring the same hydrodynamic boundary conditions, but different vessel radii and
spatial arrangements. For the ensemble, I studied two biophysical observables: the relative blood volume
(rBV) and the surface to volume ratio (s2v). I compared rBV and the s2v of blood vessel networks with
radii obtained by vessel adaptation to the same blood vessel network with vessel radii fulfilling Murray’s law
(section “Varying topology, fixed boundary conditions” in [4]).
The Tumorcode software focuses on the vascular remodeling during the progression of solid tumor. I applied
the adaptation algorithm to blood vessel networks subjected to vascular remodeling during the progression
of solid tumor. As reported in the supplement to [4] (reprinted in section 3.4.2), I found that the highly
nonlinear adaptation algorithm is not suited to describe dynamic vessel adaptation in topologically changing
networks.
I provided all data comprising figures, tables and illustrations of [4]. Further I checked the relevant source
code into my GitHub repository and uploaded the commented raw data to www.zenodo.org (section 3.4 or
[4]).
As corresponding author, I communicated with the editor and referees of the publishing journal (Journal of
Theoretical Biology).
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2.5 Summary and Discussion
In this section, I summarize the contribution of my dissertation to the scientific community.
In the recent years, in silico modeling became a scientific tool helping to unveil the secrets behind the
progression of solid tumors. Similar to conventional science without computers, results should be independent
on the method used to obtain the results. By validating the implementation of the main numerical method
used in [1] against a similar method (section 2.1), I confirmed the numerical method and contributed to [1]
indicating that vascular network remodeling during the progression of breast cancer affects both, the tissue
and blood vessel oxygen saturation.
The implementation of the numerical methods of used in [1] and similar preceding publications [37, 148, 159]
were not well documented hindering other scientists in the broad field of cancer research to benefit from
the developed numerical methods. Therefore I decided to report the main features of the software together
with handy examples illustrating the logic of the simulations and released the source code under the name
”Tumorcode“ software to the public domain in 2018 [2] (section 2.2). My efforts created a sustainable
software from previously unpublished source code contributing to open science (section 1.4).
Oxygen plays an essential role in cell metabolism. Since the vasculature delivers the oxygen (and other
nutrients) to the place where the actual metabolism takes place, the vasculature plays an essential role in
the progression of solid tumors, too. Prio to my work published in [3] (section 2.3), the Tumorcode software
neglected cellular details. With increasing computational power, the consideration of cellular details in
the macroscopic description of the Tumorcode software became feasible. I augmented the abilities of the
Tumorcode software towards an integral model of realistic tumor growth by combining cellular details and
vascular remodeling dynamics to study the tumor microenvironment at the angiogenic switch.
The volume flow of blood highly depends on the blood vessel radius and since blood comprises the nutrients,
the volume flow of nutrients also highly depends on the blood vessel radius. The intriguing question on how
the vasculature maintains its blood vessel radii is still under debate, but some responses to mechanical and
metabolic stimuli have been identified lately. Since the progression of solid tumors is intrinsically tied to the
vasculature, the question on the blood vessel radii affects also tumor growth. To observe vascular networks
in vivo is a complicated issue for which reason a realistic in silico model of vascular networks would support
drug and therapy development in cancer research. In [4](section 2.4), I provided a new tool to study blood
vessel radii regulation in silico by means of the vessel adaptation algorithm.
Further I contributed to [5] reviewing relevant topics for my PhD studies. I replotted data of previous
studies ([37]) in figure 10 of [5] and supplemented [5] by an extensive literature review on available biophysical
parameters at that time.
The research conducted during my PhD studies in the past 6 years comprised multiple aspects of physical
and computational modeling of solid tumors with respect to the vascular growth phase.
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In this chapter, I reprint the relevant original publication (with permissions shown in appendix G).
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Abstract
We present a computational model for trans-vascular oxygen transport in synthetic tumor
and host tissue blood vessel networks, aiming at qualitatively explaining published data of
optical mammography, which were obtained from 87 breast cancer patients. The data gen-
erally show average hemoglobin concentration to be higher in tumors versus host tissue
whereas average oxy-to total hemoglobin concentration (vascular segment RBC-volume-
weighted blood oxygenation) can be above or below normal. Starting from a synthetic
arterio-venous initial network the tumor vasculature was generated by processes involving
cooption, angiogenesis, and vessel regression. Calculations of spatially resolved blood
flow, hematocrit, oxy- and total hemoglobin concentrations, blood and tissue oxygenation
were carried out for ninety tumor and associated normal vessel networks starting from vari-
ous assumed geometries of feeding arteries and draining veins. Spatial heterogeneity in the
extra-vascular partial oxygen pressure distribution can be related to various tumor compart-
ments characterized by varying capillary densities and blood flow characteristics. The
reported higher average hemoglobin concentration of tumors is explained by growth and
dilatation of tumor blood vessels. Even assuming sixfold metabolic rate of oxygen consump-
tion in tumorous versus host tissue, the predicted oxygen hemoglobin concentrations are
above normal. Such tumors are likely associated with high tumor blood flow caused by
high-caliber blood vessels crossing the tumor volume and hence oxygen supply exceeding
oxygen demand. Tumor oxy- to total hemoglobin concentration below normal could only be
achieved by reducing tumor vessel radii during growth by a randomly selected factor, simu-
lating compression caused by intra-tumoral solid stress due to proliferation of cells and
extracellular matrix. Since compression of blood vessels will impede chemotherapy we con-
clude that tumors with oxy- to total hemoglobin concentration below normal are less likely to
respond to chemotherapy. Such behavior was recently reported for neo-adjuvant chemo-
therapy of locally advanced breast tumors.
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Introduction
Adequate supply of tissue with oxygen and nutrients critically depends on the structure and
function of its vasculature. For tumors to grow beyond 2mm in size, new vasculature must
develop, i.e. angiogenesis must occur [1]. The vasculature of solid tumors, however, is known
to differ distinctly from that of surrounding normal tissue. Whereas vasculature in normal tis-
sue is arranged in a hierarchy of arteries, arterioles, capillaries, venules and veins and grows
under tight control of inter-capillary distances, tumor vasculature develops in a chaotic manner
without such control, leading to spatial vascular heterogeneity. In solid tumors necrotic regions
and regions of low microvessel density (MVD) may occur, whereas tumor blood vessels are
more abundant at the tumor-host interface [2]. Tumor vessels are known to be immature, frag-
ile, tortuous, dilated, to form (large diameter) arterio-venous shunts and often it is even diffi-
cult to distinguish arterioles and venules, i.e. the classification of tumor vessels as arterioles,
capillaries and venules is no longer adequate [2–8]. In addition, tumor vessels exhibit high per-
meability to macromolecules [3]. The structurally abnormal tumor vasculature results in spa-
tially and temporally heterogeneous blood flow, affecting tissue oxygenation (acute or
perfusion-limited hypoxia). From intravital dorsal window microscopy on tumor models it is
known that blood flow through tumor capillaries is frequently sluggish and at times may even
be stationary and reverse direction. It follows that blood flow through tumors may not follow a
constant unidirectional path. In addition, red blood cell (RBC) flux varies greatly among tumor
vessels, many tumor vessels do not carry RBCs but contain plasma only [2–4, 6, 7]. Further-
more, tissue solid pressure, generated by proliferating cancer cells and modifications of the
extracellular matrix of tumors, may compress tumor blood vessels thus reducing or impairing
blood flow [9–11]. Tumor cells separated from nearby capillaries beyond the diffusion limit of
oxygen suffer from chronic (diffusion-limited) hypoxia. Hypoxic tumor cells are known to be
resistant to ionizing radiation, since oxygen is needed to stabilize radiation-induced DNA
defects and, in addition, are considered to be resistant to some anticancer drugs. Therefore,
tumor hypoxia is associated with poor prognosis, because it causes resistance to standard thera-
pies and promotes more aggressive phenotypes [12, 13].
Because of their limited spatial resolution present-day non-invasive imaging techniques
used in clinical practice do not allow to visualize tumor vasculature, blood flow and distribu-
tions of oxygen and nutrients at the capillary and cellular level, despite the diagnostic relevance,
e.g. ofMVD and the presence of hypoxic tumor cells. Therefore, computational modeling is an
appropriate tool to analyze the interrelation of clinically amenable characteristics of tumor vas-
culature and oxygenation.
Tissue oxygenation has been measured in human tumors by various methods such as nee-
dle electrodes [14]. In this way oxygen partial pressures were found to be highly heteroge-
neous in tumors with median oxygen pressures below that of the host tissue. More
importantly, tumors often exhibit hypoxic regions with oxygen partial pressures below 10
mmHg. Today, non-invasive positron emission tomography (PET) is employed clinically to
image oxygenation status of tumor tissue [15]. Complementary to tissue oxygenation mea-
surements magnetic resonance imaging (MRI) [16, 17] and tissue optical imaging, such as
optical mammography assess (RBC-volume weighted) blood oxygenation of vascular
segments.
Optical mammography [18–20] has been developed over the past one to two decades and a
large body of data on deoxy-,oxy-, and total hemoglobin concentrations cHbD, cHbO and cHb in
normal breast tissue and breast tumors has been collected from many patients [21–24]. Because
of light scattering photon trajectories through the breast are much (about 5 times) longer com-
pared to the geometrical distance between the point of entry and point of exit of the photons,
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resulting in high sensitivity towards absorption. However, spatial resolution is generally poor
and only average hemoglobin concentrations can be deduced. Tissue hemoglobin concentra-
tion cHb equals the sum of hemoglobin mass of each vessel segment taken over the vessel net-
work within a selected tissue volume per unit volume of tissue and approximately reflects
fractional blood volume. The ratio of oxy- to total hemoglobin concentration, called tissue
blood oxygen saturation Y, is the average of RBC-volume-weighted true blood oxygenation
taken over all vessel segments of the tissue volume selected. Tissue blood oxygen saturation
reflects the balance between vascular flux of oxygen that enters the tissue, i.e. oxygen supply,
and oxygen flux from the vascular network into tissue, reflecting oxygen demand. Besides tis-
sue hemoglobin concentration, tissue blood oxygen saturation is thus another parameter char-
acterizing tumor and host vascular networks.
On average tissue hemoglobin concentration cHb of breast tumors was found to be larger
than in host tissue by a factor of 3.5 [22]. This observation can qualitatively be explained by a
larger blood volume in tumors compared to their host tissue. However, tissue blood oxygen sat-
uration in breast tumors was observed by most authors to be both above or below normal [21–
23] whereas some papers reported tissue blood oxygenation in tumors to generally be below
that of their host tissue [25, 26]. Up to now, there were no microscopic theoretical models
available to account for tissue blood oxygenation in tumors allowing to analyze clinical data.
Computational models as the one we present in this paper contain detailed information about
the vasculature as well as the emerging oxygen distributions of tumors and host tissue. By
coarse graining the obtained detailed information and comparing it with low resolution clinical
data, one can infer potential vascular structure in the tumor of patients—with some uncertainty
of course.
Mathematical modeling and numerical simulation of growth of solid tumors has been
actively pursued since many years, for a recent review see e.g. [27]. In this paper 3D host vas-
culature is obtained by applying stochastic vessel network generation algorithms (see S1 of
[28]). During tumor growth, remodeling of the host vasculature occurs involving vessel
cooption, angiogenesis, vessel circumferential growth, vessel regression and collapse, simu-
lated by corresponding stochastic vessel network remodeling processes (see S1 of [28]). In
the present paper we adopted a simplified tumor growth model where a spherical tumor is
expanding at constant rate. Host tissue and tumor are represented as hybrid models consist-
ing of their vascular network surrounded by a homogeneous medium, representing host cells
or tumor cells, respectively. Intravascular and extravascular oxygen transport has been stud-
ied by several authors. Oxygen dissolved in plasma, being in chemical equilibrium with oxy-
gen bound to hemoglobin, extravasates and diffuses in tissue, where it is metabolized.
Oxygenation by isolated vascular tubes has been studied theoretically in detail since the origi-
nally proposed “Krogh”model [29], see e.g. [30]. Also in several works, simplified two-
dimensional tumor tissues, supplied by point-sources of oxygen, were considered, and the
resulting oxygen concentration distributions were analyzed [31–37]. However, these models
require appropriate intravascular O2 concentrations as input parameters. Previously, Gold-
man [38] coupled oxygen in a vascular network and tissue via boundary conditions which
relate the radial transvascular oxygen flux at each point on the vessel surface to the PO2 gra-
dient at the respective tissue location. For further reading focusing on skeletal muscle oxy-
genation, see [39] and the Refs. therein. Secomb and coworkers [40–43] used a Green’s
function method for solving the diffusion equation in tissue, treating vessels as distributions
of oxygen sources and tissue represented as a distribution of oxygen sinks. We followed the
computational method of Beard [44], discretizing the diffusion equation for oxygen by a
finite difference approach with source terms added locally corresponding to the surface area
of nearby vessels. Our computational method is sufficiently fast to simulate tissue volumes of
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0.5 cm3. Only stationary solutions are sought, ignoring transient variations of blood flow
through tissue discussed above. For each vascular network generated our model allows us to
calculate various biophysical and metabolic quantities, in particular partial oxygen pressure
distributions in tissue, blood flow (perfusion), true vessel length weighted blood oxygen satu-
ration distribution in the vascular network, tissue hemoglobin concentrations and tissue
blood oxygen saturation, the latter two quantities being dominated by high caliber vessel.
Blood vessels that set themselves apart by their diameter (approx. 100 μm) from the bulk of
other vessels were found in corrosion casts of blood vessels of leiomyomata [45]. Moreover,
in mammary carcinoma vessels of up to 200 μm diameter were observed [46].
Recently it was reported [47] that breast cancer patients who underwent neoadjuvant che-
motherapy before surgery and were not classified as complete responders by immuno-histo-
chemistry at the end of chemotherapy, tended to initially exhibit tumor blood oxygenation
below that of host tissue. On the other hand, patients who were ranked as pathological com-
plete responders exhibited the same tissue blood oxygen saturation on average in tumor and
host tissue. Thus, tissue blood oxygen saturation may have diagnostic value for therapy control
and it is important to understand what causes tissue blood oxygen saturation in tumors to fall
above or below normal.
It is the aim of the present paper to gain information on host and tumor vascular networks
from clinical data on tissue hemoglobin concentration and tissue blood oxygen saturation of
breast tumors and their surrounding host tissue. To this end various synthetic host and tumor
vascular networks were generated and tissue total hemoglobin concentration as well as tissue
blood oxygenation calculated. As expected, tumor total hemoglobin concentration was always
found to be larger than that of host tissue, consistent with clinical data. Within reasonable lim-
its of metabolic rates of oxygen consumption by normal and tumorous breast tissue, simulated
tumor blood oxygen saturation always fell above normal, in contrast to clinical data, indicating
that increased perfusion and hence increased oxygen supply outweighs higher oxygen con-
sumption in tumorous tissue. Tumor blood oxygen saturation was simulated below normal
depending on the degree of vascular compression of (high-caliber) tumor vessels assumed to
be caused by tumor solid stress. Although qualitative agreement with clinical data on tissue
blood oxygenation was achieved, other processes than compression of high-caliber tumor ves-
sels may lead to perfusion impairment in at least parts of a tumor and hence tumor blood oxy-
gen saturation to drop below normal.
The main part of this paper is organized as follows: first, we briefly explain our tumor
growth model including the generation of host and tumor vasculature. Then we discuss the
mathematical models used to account for blood flow, intravascular and extravascular oxygen
transport, which are well known [30, 40] but reviewed here for clearness and readability. Fur-
ther below we describe our method to solve the obtained coupled equations describing intra-
and extravascular PO2 distributions efficiently. Section ‘Theoretical models’ concludes with a
description of three model variants, the results of which are presented in the following section
‘Results and Discussion’. There we initially provide examples of simulated PO2 and hematocrit
distributions of host and tumor tissue, illustrating compartmentalization in tumors. Next we
validate our model by comparing simulation results on host und tumorous tissue with biophys-
ical and biochemical data available in the literature. Then we focus on clinical data on tissue
hemoglobin concentration and tissue blood oxygenation of breast tumors, determining which
simulation model variant provides qualitative agreement. Additionally, we correlate various
simulated quantities of host and tumor that are not easily amenable to clinical measurements.
Finally we discuss the limitations of our model and summarize our results in the conclusion
section.
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Overview of tumor growth model for hemodynamic and oxygen transport
simulations
Ideally, one would start from digitized 3D blood vessel networks of each breast cancer patient
to simulate hemodynamic properties, as well as intravascular and extravascular oxygen trans-
port in tumor and surrounding host tissue. Although 3D vascular networks of tumors grown
in animal tumor models can be generated from μ-CT data [48, 49], such techniques are not
applicable to humans. Therefore, 3D vascular trees of tumors and surrounding host tissue are
algorithmically constructed, following methods developed by us previously and applied to
model vasculature in melanomas and gliomas [28, 50–54]. The model described in detail in
Ref. [28] represents an extension of the model used in [55] which is based on wall shear stress
guided random growth of interdigitating vascular trees on a lattice. In contrast to previous
work, the model of the tumor spheroid employed in this paper is very simplified.
Fig 1 illustrates the theoretical model of tumor growth used in the present paper. Starting
from synthetic host vasculature, a small spherical nucleus (Rtum(t = 0) = 250 μm) is inserted at
the beginning (t = 0) of the growth process into host tissue. The tumor spherically expands and
its radius is assumed to grow linearly in time with speed vtum = 2 μm/h up to a preselected time
tend, taken to be 600 h. In real tumors, competition for space and nutrients causes confinement
of cell proliferation to a few cell layers behind the invasive edge and therefore eventually leads
to a linear expansion rate. The tumor tissue is assumed homogeneous. We surround the tumor
with a concentric shell of thickness Rg, within which angiogenesis, i.e. sprouting of new vessels
is activated. The distance Rg represents the diffusion length of vascular endothelial growth fac-
tors (VEGFs), i.e. the distance that growth factors diffuse, before their concentration drops to
Fig 1. Model Overview. Left hand side: the tumor spheroid is represented by a homogeneous sphere, the radius of which
Rtum grows at constant speed vtum and is surrounded by a concentric shell of thickness Rg, the diffusion length of vascular
endothelial growth factors. Vascular remodeling is thought to take place within the tumor and surrounding concentric shell.
Right hand side: block diagram outlining basic simulation procedure. The modification of the present vasculature is
implemented by stochastically applying the processed depicted in Fig 2. At the end of each time step, blood flow is
recomputed, time t and tumor radius Rtum incremented. The iteration steps are repeated until the final simulated time tend is
reached.
doi:10.1371/journal.pone.0161267.g001
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insignificant levels due to degradation and binding. Vascular remodeling takes place during
each time step delta t = 1 h, corresponding to the following biological processes: sprout initia-
tion, sprout migration, vessel wall degeneration, vessel collapse and regression and vessel dila-
tation due to circumferential vessel growth. These biological processes are implemented as
probabilistic addition (angiogenesis), deletion (collapse) of vessel segments, as well as probabi-
listic and deterministic changes of segment associated variables (e.g. wall thickness or vessel
radius, see below). During each time step, we iterate over lattice sites or vessel segments as
required and perform the local alterations. Since the probability for vessel collapse and regres-
sion depends on wall shear stress, blood flow through host and tumor vasculature is calculated
as Poiseuille flow and updated after each time step. Furthermore, for angiogenesis (sprout initi-
ation, sprout migration) to occur, VEGFs have to be present in tumor tissue. To this end more
advanced growth models, such as the one described in [28], calculate a VEGF concentration
field during each time step. For this purpose the (extravascular) oxygen concentration field is
calculated in tumor tissue and hypoxic tumor cells are taken as sources for VEGF, assuming
the same preset blood oxygen saturation throughout the entire vasculature, however. In the
present work we focus on a realistic oxygen transport model taking the decrease of intravascu-
lar oxygen concentration due to oxygen extravasation into account. In order to reduce model
complexity we assume vascular remodeling to take place within the tumor and surrounding
concentric shell, i.e. assume sufficient VEGF to be within the tumor and its outer shell for
angiogenesis to occur. The considerable simplification of our present tumor growth model is
justified because vascular morphologies obtained in this way are consistent with data from real
tumors [56, 57] and predictions of more detailed tissue models. The simulation growth process
was deliberately stopped at t = 600 h when the tumor diameter had grown to ca. 3mm to mini-
mize boundary effects which would occur if the tumor was allowed to grow to the size of the
simulation box.
By simulating tumor growth and vascular remodeling, a tumor-specific vascular network
emerges at the end (t = tend) of each growth process. Because of the stochastic nature of the
growth processes involved, each simulation yields a different network. Based on the networks
obtained, relative blood volume, tissue perfusion, hematocrit, and tissue hemoglobin concen-
tration cHb are calculated. In addition, using a sophisticated model of oxygenation (see below),
tissue blood oxygen saturation Y = cHbO/cHb and maps of oxygen partial pressure (PO2) were
simulated. Note that the assumed spheroidal tumor region generally differs in its physiology,
e.g. metabolic rate of oxygen consumption, from that of the surrounding host tissue. If not
stated otherwise, results for host tissue refer to the entire (unaltered) network at t = 0.
Artificial blood vessel networks in normal breast tissue. We briefly review the genera-
tion of 3D host vascular networks and refer the reader to the supplemental material S1 of
Ref. [28] for details. Simulations are performed on a cubical domain with lateral length of L = 8
mm. Starting point are arterial and venous root nodes, (endpoints of feeding arterioles and
draining venules) located at boundary sites of the face centered cubic lattice. Structural ele-
ments of different shape (linear, tripod) are added to randomly selected terminal branches of
the vascular trees one at a time. This process is continued until further addition of vessel seg-
ments causes segments to overlap, which is forbidden by definition. In the subsequent stage of
the construction scheme, trees generated in this way are pruned and extended to obtain the
final network. It comprises the following steps. Firstly, nearby open ends at terminal branches
are temporarily connected by vessel segments representing capillaries. Radii of capillaries, of
arterial and venous terminal segments are set to 2.5 μm, 2.5 μm and 3.8 μm, respectively,





being the radius of the parent vessel, ra, rb the radii of the two downstream vessels and α = 3
has been selected. Secondly, blood flow through the temporary network is calculated, including
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shear wall stress of segments. With the capillaries removed additional vessel segments are sto-
chastically attached to or removed from terminal branches with probability based on wall
shear stress, corresponding to wall shear stress guided random growth of interdigitating vascu-
lar trees on a lattice [55]. This process is repeated until the number of capillaries reaches a pla-
teau, i.e. the lattice is filled with a interdigitating trees exhibiting a homogeneous distribution
of capillaries. The resultingMVD is determined by the lattice constant hgen, where hgen = 130
μm has been selected in the present paper.
Variations of host vessel networks among patients of a cohort were introduced by arbitrarily
adopting nine root node geometries, illustrated in Fig 3, differing in location and number of
arterial (venous) inlet (outlet) vessels. Starting from each root node geometry ten host vascular
networks were grown which differed among each other because of the statistical nature of the
growth process. Thus a total of 90 different vascular networks were generated, representing
normal tissue vasculature. Using these networks we demonstrated that the specific arrange-
ment of host vessels prior to tumor growth can play a significant role for the outcome of tumor
vascular remodeling. We believe that all generated vascular morphologies are physiologically
plausible. However, we did not make an effort to determine the frequency with which configu-
rations RC1 − RC9 might occur in real breast tissue (s. ‘Limitations‘).
Details of vascular remodeling during growth of synthetic tumor blood vessel net-
works. Starting from one of the 90 vascular networks representing host tissue the associated
tumorous vessel network is formed by following processes, also ilustrated in Fig 2:
1. Angiogenic sprouting: In normal tissue, lattice sites occupied by vessels, have a chance
(probability Dt=t
ðsproutÞ
EC ) to spawn a sprout segment on an adjacent lattice bond provided the
site is close enough to the tumor, i.e. within the growth factor diffusion distance Rg rather
than requiring the growth factor concentration to be sufficiently high, as previously postu-
lated [51]. Furthermore, no other branching points must be nearby, i.e. within the distance
of d(br, min). Vessels within the tumor sphere, switch to circumferential growth (s. below).
The direction of sprouting is chosen randomly, which is non-critical, since the net effect is
either way an increase of vascular density near the invasive edge, extending Rg units into
normal tissue.
2. Sprout growth: sprouting vessels have a chance (probability Dt=t
ðsproutÞ
EC ) to be extended by
another lattice bond. Sprouts have a total life time of t
ðmigrÞ
EC . When sprouts hit an existing
vessel during their lifetime, they are connected to it. Sprouts that are consequently circulated
become normal vessels. Otherwise sprouts are prone to collapse after their lifetime.
3. Circumferential growth: vessels switch from sprouting to circumferential growth after their
residence time t
ðswitchÞ
EC within the tumor. After switching to circumferential growth we
assume each endothelial cell (10 × 10 μm2 surface area) at the inner wall to duplicate every
t
ðprolÞ
EC hours leading to an increase of vascular radius r. We impose an upper limit on the
radius (r(max)) after which circumferential growth stops.
4. Degradation of vessel wall stability: vessels possess a wall stability value w as an abstract
measure of the state of degeneracy of their vessel wall. The stability measure w is initialized
relating it to the wall thickness of healthy vessels [28, Suppl.1, Eq (2)]. The wall stability of
tumor vessels decreases over time at the rate Δw until zero. Once zero, vessels are allowed to
collapse and regress (see below).
5. Vessel collapse and regression: If the wall shear stress f of a segment falls below a threshold
(f(coll)) and w = 0, then the segment is removed from the network at probability p(coll),
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representing collapse, occlusion and complete regression. In this study we set p(coll) to 1,
making collapses deterministic.
The vasculature obtained at the end of the tumor growth process (t = 600 h) comprises the
part of the network altered by the tumor and the remaining normal vasculature. Parameters
used for simulations of oxygen transport (s. Table 1) are to a large extent taken from [58], com-
piled from various sources, not specifically for breast tissue.
Fig 2. Vascular Remodeling Processes. The dynamical processes of vascular network remodeling (A-E) are illustrated by exemplary state
transitions with the current state shown in the left hand side box and the resulting state on the right. Preconditions are indicated above the center
arrows, and transition probabilities are denoted below, respectively. (A) depicts the start of a new sprout (gray) which can happen on any site on the
network provided that given preconditions are true. Here, one of several preexisting segments (blue) is split to create a new branching point. Space
occupied by the tumor spheroid (orange), and space where angiogenic sprouting may take place (green), i.e. where Rtum < |x| < Rtum + Rg, is indicated
by colored background. “In tissue” refers to the exterior of the spheroid, i.e. where |x| > Rtum. “In tumor”means the opposite, obviously. The path length
on the network to the next branching point dbr must be larger than the lower limit d
(br, min). The new segment is initialized with an associated life-time of
τ = 1. (B) depicts the further extension of the sprout from (A). Additional segments inherit τ from the parent segment. Moreover τ is incremented,
globally, for all sprouts once per time step Δt. (C) depicts the degradation of vessel walls. The variablew represents the stability of the vessel wall, here
depicted as varying wall thickness. It decreases continuously at the rate Δw, resulting in a value ofw0 at the next time step. In (D) an unstable vessel
(red) is removed, representing occlusion of blood flow and complete disintegration. Such event is assumed to happen only to vessels with maximally
degenerate wallsw = 0 and low wall shear-stresses f, where f < f(coll). The emerging dead ends (gray) trivially have f < f(coll), and therefore collapse
rapidly, resulting in a long ranged effect. Since collapses can happen anywhere, we left the background blank. (E) depicts the dilation of tumor vessels.
Their radii increase at rate Δr up to the upper limit r(max).
doi:10.1371/journal.pone.0161267.g002
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Mathematical modeling of oxygen transport in networks and tissues
Hemodynamic and blood oxygen transport model. The concentration of oxygen dis-
solved in blood plasma or in tissue is proportional to the oxygen partial pressure, i.e. cp = αp P
and ct = αt Pt, where P, Pt are the oxygen partial pressures in plasma and tissue, respectively,
and αp, αt are the oxygen solubilities. Conventionally, the partial pressures are measured in
mmHg and solubilities inmlO2/ml/mmHg, yielding the oxygen concentrations expressed as
oxygen gas volume at standard conditions (STP 0°C, 1 bar) per unit volume of plasma or tissue.
In blood, oxygen, besides being dissolved in plasma, is bound to hemoglobin. Up to 4 mole-
cules of oxygen can be bound per hemoglobin molecule. The chemical equilibrium between
dissolved oxygen and oxygen-carrying hemoglobin depends on the number of oxygen mole-
cules bound to hemoglobin, and the reaction is sufficiently fast, that the equilibrium state
needs to be considered only. The cooperativity of oxygen-hemoglobin binding leads to the





Fig 3. Illustration of vascular tree configurations. Schematic views from above on simulation cubes
indicate vascular tree root locations for configurations denoted RC1 to RC9. In RC1 to RC3 boundary sites
are occupied in alternating order either with arterial or venous nodes. In RC1 only one face of the simulation
cube is used, in RC2 two opposing sides are used and in RC3 four faces are used. In RC4, RC5 and RC6 we
place nodes at 33% and 66% of the length of the cube faces diagonals on the diagonals. As before, one, two
and four faces are used, where in total only two (RC4, RC5) and four nodes (RC6) are placed. In RC7 and
RC8 we first create fixed parent vessels protruding along the x-axis to 60% of the cube length into the interior.
On each site occupied by these parent vessels a regular root node is created for further growth. Flow
boundary conditions are specified at the actual inlets and outlets at the cube boundaries. In RC9 each
boundary site of the lattice is occupied with a root node with probability proot. Before a network is created,
proot is drawn equally distributed between 0 and 1, however a configuration is only accepted if there is at least
one arterial and one venous node.
doi:10.1371/journal.pone.0161267.g003
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where S(P) is the blood oxygen saturation, PS50 denotes the partial pressure at 50% saturation
and n is the Hill exponent (see Table 1). Consequently, the total blood oxygen concentration,
denoted by c, is the sum of the concentrations of dissolved and bound oxygen.
c ¼ cp þ cb ¼ apP þ Hc0SðPÞ; ð2Þ
whereH is the hematocrit, i.e. the volume fraction of red blood cells (RBCs), and c0 denotes the
concentration of oxygen per unit volume of RBCs at maximal saturation (s. Table 1).
Table 1. Oxygen transport parameters.
Symbol Unit Value Ref/Note
n 2.7 [58]
PS50 mmHg 27 [58]
αp mlO2 ml
−1 mmHg−1 3.1  10−5 [58] (a)
αt mlO2 ml
−1 mmHg−1 2.8  10−5 [58] (a)





PM50(normal) mmHg 4 (c)
PM50(tumor) mmHg 2 (c)
M0(normal) μlO2 ml
−1 min−1 3.7 (d)
M0(tumor) μlO2 ml
−1 min−1 14.8 (d)
γ μm3 O2 μm
−2 s−1 mmHg−1 0.0033 − 0.021 (e)












Shows parameters for throughout all simulations except case METAB whereM0(tumor) is picked at random,
for each simulation. n is the Hill-Exponent, PS50 is the PO2 where the the Hill-curve S(P) is 1/2, αp, αt denote
the oxygen solubilities in plasma and tissue, respectively, c0 is oxygen concentration in saturated red blood
cells, Dp, Dt denote the diffusion coefficients in plasma and tissue, PM50 denotes the M-M pressure whereM
(P) =M0/2,M0 denotes the maximal oxygen consumption rate, γ is the transvascular mass transfer
coefficient. For blood flow, ηplasma is the blood plasma viscosity, H




are the coefficients of the radius dependency of the inlet PO2 PðBCÞðrÞ ¼ minfPðBCÞ
0
þ rDPðBCÞ;PðBCÞc g.
The lattice constants h and hv refer to the numerical grid on which the tissue PO2 distribution is defined, and
the step width with which Eq (5) is integrated.
(a) Assuming 22.4 l/mol under normal conditions.
(b) Computed as the product of the hemoglobin binding capacity (Hüfner factor) 1.36ml O2/g and theMCHC
(mean corpuscular hemoglobin concentration) 0.34 g/ml.
(c) Literature [32, 37, 39, 41] values for PM50 range from 1 to 4mmHg. PM50 represents a threshold below
which cells become hypoxic. We lowered PM50 in tumor tissue by a factor of 1/2 because cancer cells are
generally associated with a resistance to hypoxia.
(d) The maximal consumption rateM0 was estimated assuming zeroth order kineticsMRO2 =M0, using that
MRO2 MTT = cHb, blood  OEF withMTT = rBV/rBF, rBV = 0.008, rBF = 0.06min
−1 [8], cHb, blood = 14 gHb/dl,
andOEF = 0.32.
(e) The lower bound is obtained for r = 60 μm and the upper bound for r = 3 μm.
doi:10.1371/journal.pone.0161267.t001
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Oxygen transport within a single vascular cylindrical tube. The intravascular PO2 varia-
tion along the longitudinal axis of a cylindrical vascular tube is described by P(x), where x is
the spatial coordinate. Following [40], we make the zeroth order approximation that the varia-
tion of PO2, hematocrit, and flow velocity in the radial direction within vascular tubes are neg-
ligible. This approximation reduces the problem to advection in one dimension. Radial
transport, i.e. transvascular oxygen exchange is accounted for by the addition of suitable mass
transfer terms (see below). Hence, the product of the oxygen concentration with the blood flow
rate q yields the oxygen flux ι representing the total amount of oxygen at any given point that
flows per unit time through the tube’s cross-sectional area
iðPÞ ¼ qcðPÞ: ð3Þ
While blood flows along the vessel, some oxygen is continuously lost through the vessel
wall. The respective transvascular flux density jtv is given in units of amount of oxygen per















where the second expression is just the evaluation of dι/dx, and r is the vessel radius. Reorder-










h i : ð5Þ
For simplicity only losses due to diffusion are considered. This is certainly a good approxi-
mation for normal vessels because oxygen is a light molecule and has a proportionately high
diffusion speed. Its diffusion constant in water is ca. 2  103 μm2/s. Walls of tumor vessels, on
the other hand, are leaky e.g. for plasma which is why a significant convective transport is plau-
sible. Interstitial fluid velocities of up to v = 1 μm/s have been reported near tumor vessels [63–
66]. In order to judge whether diffusive or convective transport in tissue is dominant, we calcu-
lated the Peclet number Pe = vL/D which relates advective transport rate to diffusive transport
rate over a certain distance L. A reasonable L is 100 μm, corresponding to typical intercapillary
separations, yielding Pe = 1/20. It follows that the transport is diffusion dominated. Intravascu-
lar radial oxygen transport is in itself a complex problem. To make transvascular oxygen flux
workable, the mass transfer coefficient (MTC) γ is introduced that relates the transvascular
oxygen flux density with the PO2 difference between the plasma and tissue partial oxygen pres-
sure P and Pt.
jtvðxÞ ¼ g  ðPðxÞ  PtðxÞÞ: ð6Þ
Since vessels are represented as lines, we also assume that Pt is constant over the entire cir-
cumference. Note that γ2πr = K−1, where K is the radial transport resistance used in [40, 41,
67]. The MTC depends on several factors like tube radius, blood oxygen saturation, hematocrit,
RBC shape [30] and vessel morphology [68]. We consider a radius dependency according to a
simple fit model, based on empirical data for radial oxygen transfer in vascular tubes [58, 69,
70]: This is typically characterized by the dimensionless flux density, denoted Nusselt number
Nu ¼ 2rD1p a
1
p  g, where Dp and αp are oxygen diffusion coefficient and solubility in blood
plasma. We found that the data presented in the Refs. cited above, ranging up to r = 50 μm, is
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where p1 = 8 μm and p2 = 4.7 are fit parameters. For simplicity we omitted the dependence of
Nu on the saturation S, assuming an approximate S = 0.9.
Blood flow and hematocrit in vascular networks. The vascular network is represented by
a graph where edges represent vessel segments each connected to two nodes, whereas nodes
may be attached to one to three vessel segments. Following the work of Pries et al. [71] we cal-
culated blood pressure p at each node as well as blood flow rate q and hematocritH associated
with each vessel segment. The primary unknowns are the nodal pressures and segment hemat-
ocrits. The hematocrit may differ between various vessel segments due to phase separation.
The flow rates are given by Hagen-Poiseuille’s law for flow through pipes q = πr4Δp/(8ηl),
where r denotes the radius of the segment, l its length, η the (apparent) blood viscosity, and Δp
the difference of the blood pressure at both nodes the vessel segment is attached to. Mass con-
servation demands at each non-boundary node that
X
v
qv ¼ 0 ð8Þ
X
v
Hvqv ¼ 0; ð9Þ
where the index variable v runs over vessels adjacent to the currently considered node. Note
that depending on context, the flow rate qmust be taken as a signed quantity, e.g. in Eq (8) to
correctly account for flow into and out of the considered node. In contrast to Ref. [71] we use
pressure boundary conditions (BCs) where p at root nodes is set to a fixed value p(root) =
p(BC)(r) depending on the radius and the type of vessel (artery or vein) (s. Eq (3) in S1 Appen-
dix). Eq (8) and BCs lead to a system of linear equations, the solution of which yields the nodal
pressures. The system is very large, of the order of 106 unknowns. We found that the Conjugate
Gradient algorithm with the Multilevel (ML) preconditioner from the Trilinos software library
[72] solves it efficiently. The calculated nodal blood pressures impose flow directions upon ves-
sel segments, i.e. blood flows from the end-point with higher pressure to the end with lower
pressure.
The apparent blood viscosity in microvessels varies with r andH (Fahraeus-Lindqvist effect)
and is expressed by decomposing it into η = ηplasma ηrel(r, H), where ηplasma is the viscosity of
pure blood plasma and ηrel(r,H) is known as relative viscosity. We implemented the ηrel for-
mula from more recent work of Pries et al. [73] where ηrel is based on in vivo data. For brevity
we refer to the original publication for the expression for ηrel.
Furthermore RBCs at arterial bifurcations tend to flow into the faster perfused branch
(phase separation effect) resulting in an uneven hematocrit distribution across the network.
Pries et al. [71] devised a phenomenological formula which describes the hematocritH in the
downstream branches of a bifurcation as a function of q and r of all adjacent vessels. For details
we refer to [71]. With the help of this formula we compute the RBC flow qH in down stream
vessels of arterial bifurcations, i.e. where one vessels splits into two downstream vessels. On the
other hand, venous bifurcations have only one downstream branch whereH is determined by
Eq (9). Host vascular networks contain by default only bifurcations and the trivial case of two
adjacent vessels. In the present model of tumor vascular remodeling, we reject sprout connec-
tions to other vessels that resulted in junctions with more than three vessels attached, following
[50]. The hematocrit over the entire network can thus be computed with a simple depth-first
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search graph traversal algorithm [74] starting from the venous ends and determining the
downstream H while backtracking.
The ansatz to solve this coupled system of equations is iterative. In each iteration, the nodal
pressures are computed using the results for the vessel segment hematocrit of the previous iter-
ations, followed by the computation of the hematocrit with new flow rates. Details can be
found in [71] (see also sec. ‘Numerical solution‘).
Oxygen in vascular networks. The ansatz to determine the PO2 across the vascular net-
work is similar to the method followed for calculating the distribution of hematocrit. First we
consider the distribution at an arbitrarily selected node. To this end we define the sets I andO
that contain adjacent up-and downstream vessels. Let further Pi for i 2 I be the PO2 at down-
stream ends of adjacent inlet vessels. Then Pj for j 2 O at the upstream ends of outlet vessels
are to be determined. The main assumption made is that RBCs flowing into the junction
instantly assume a common equilibrium partial pressure ~P , that by definition equals the PO2
at all outlets Pj ¼ ~P for j 2 O. ~P is determined with the help of the oxygen mass balance
X
i2I
qiðc0SðPiÞHi þ apPiÞ ¼ ~i ¼
X
j2O
qjðc0Sð~PÞHj þ ap~PÞ; ð10Þ
where the left hand side is known and provides the total oxygen flux ~i at the node under discus-















where quantities in brackets are known RBC, and blood, flow rates. Eq (11) was solved numeri-
cally for ~P using a bisection search. At inlet (root) nodes, boundary conditions (BCs) must be
specified. We use Dirichlet BCs where P = P(BC) is given according to a curve P(BC)(r) depend-
ing on the arteriolar radius.
PðBCÞðrÞ ¼ min ðPðBCÞ
0
þ DPðBCÞr; PðBCÞc Þ: ð12Þ
For the parameter values of PðBCÞ
0
, ΔP(BC), PðBCÞc see Table 1. The determination of PO2 across
the entire network can be defined procedurally with the help of the depth-first search graph tra-
versal [74] defined analogously to the propagation of hematocrit. Starting from venous root
nodes, the network is traversed towards the upstream ends. Let us consider a given node while
backtracking. P is known at the upstream ends of adjacent inlet vessels, and according to Eq (5)
the down-stream P is determined. Hence, Eq (11) provides P for further backtracking down-
stream. This procedure holds under the caveat that jtv is known, which is addressed below.
Oxygen in tissue. The oxygen concentration in tissue, denoted ct(y), as a function of posi-
tion y, is determined by the solution the following steady state diffusion equation, considering
a cubic domain O = (0, L)3 with lateral size L and Neumann boundary conditions.
Dtr
2ct M þ Q ¼ 0 ð13Þ
rct  n ¼ 0 on @O; ð14Þ
whereM is the oxygen consumption rate per unit volume of tissue and the last term Q repre-
sents the oxygen exchange with vessels. With the help of the solubility αt this equation is
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rewritten in terms of the partial pressure Pt.
atDtr
2Pt M þ Q ¼ 0 ð15Þ
rPt  n ¼ 0 on @O; ð16Þ
where the symbols Q = Q(Pt,y) andM =M(Pt) are redefined as functions of Pt. They emerge
from their former versions by simple scaling of their arguments by αt.
We model oxygen consumption according to the well-known Michaelis-Menten (M-M)
model [30]. The M-Mmodel takes into account that viable cells consume oxygen up to a maxi-
mal rateM0 even at high (excess) oxygen availability, and that consumption must drop to zero






where the subscript for P has been dropped. The partial pressure at whichM equals 50% of its
maximal rateM0 is denoted by PM50.M(P) increases monotonously and approachesM0
asymptotically. The advantage of the M-Mmodel over zero-or first order kinetics is a realistic
description of hyper-and hypoxic situations. Apart from their vasculature, we assume the
tumor tissue and host tissue to be homogeneous and that it behaves according to the M-M rela-
tion. The selected parametersM0 and PM50 are thus representative of the mixture of all tissue
components. This assumption is justified by the small volume of the tumor grown. Otherwise
the expression forM(P) has to be weighted by the fraction of viable cells in tumor and host
tissue.
To find the vascular contribution Q, representing sources and drains, we follow [40] where
line-like sources are embedded into the volume (tissue) with a magnitude equal to jtv. Symboli-






2prjtvðx; rÞdðx  yÞdx; ð18Þ
where the summation is taken over all vessels and the integration along their center lines. δ is
the Dirac delta distribution and jtv is given in Eqs (6) and (7).
Numerical solution. The equation for the vascular oxygen distribution Eqs (5) and (11)
together with the diffusion equation for tissue Eq (15) form a complicated non-linear system of
equations with the partial pressures values as unknowns. The only practical way to treat this is
through a numerical solution.
Previously a similar approach to ours was followed by Beard [44] who distributes the
exchange flux with vessels to nearby sites of a discretization grid of the tissue domain. We jus-
tify this approach with a formulation based on a Finite Element Method (FEM) and in contrast
to [44] also include hemoglobin binding dynamics. As a result we obtain a sparse system of
equations which is efficiently solved by an iterative scheme.
The principal idea of the FEM is to seek an approximate solution within a finite dimensional
vector space V that is spanned by basis functions φi. Various choices are possible, e.g. Fourier
bases, but the common approach is to introduce a grid and organize the φi such that their con-
tribution is centered around a corresponding grid site xi, requiring that φi(xi) = 1 and φi(xj) = 0
for i 6¼ j. Here the choice falls for simplicity on piecewise linear (P1) tensor product bases
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which are defined on a regular cubic grid. Then φi reads








φiðyÞ ¼ wðy  xiÞ;
where h is the lattice constant and y = (y0, y1, y2) and likewise x in three dimensions. Inciden-
tally evaluation of a function f(y) = ∑fi φi(y) with some coefficients fi is equivalent to a (tri-) lin-
ear interpolation of the coefficients between grid sites that are nearest to y. Hence, let the tissue





At this point it is advisable to proceed with the treatment of the vascular system. It is by def-
inition already represented as discrete collection of segments but these are implicitly further
subdivided by the integration points that are introduced for the solution of the axial transport
Eq (5) (see below). We impose an equidistant subdivision with step length of approximately
hv = 4 μm. In general, the last point needs to coincide with the end of the vessel. Therefore the
true step length is adapted to the vessel length, corresponding to dlv/hve + 1 integration points.
Smaller values of hv, given all other parameters fixed, did not yield noticeably different
predictions.
In the following indices k, l are used for points on the vessel network whereas i, j denote
indices to sites on the tissue grid. Now it is convenient to introduce vector and matrix nota-
tions. Hence let coefficient vectors be denoted in bold face, such that Pt = {Pt,i} and P = {Pk}.
And let further linear operators (matrices) be denoted in bold face underlined .
The solution procedure relies on an outer iteration where the tissue degrees of freedom {Pt,i}
and the vessel degrees of freedom {Pk} are updated in alternating order. This can be written
with the aid of two functions F(Pt) and Ft(P,Pt) determining P and Pt from the last known
quantities. An iteration variable n is introduced denoting the current step number. This is not
to be confused with n in the Hill-equation Eq (1).
for n ¼ 1; 2; 3;   




while jjPðnþ1Þt  P
ðnÞ
t jj1 >  and jjP
ðnþ1Þ  PðnÞjj1 > ;
ð21Þ
where || _ ||1 denotes the maximum norm. We set the initial guess for tissue P
ð1Þ
t to Proot,max/2
on all grid points, i.e. to half the maximal inlet PO2. P needs no initial value since it is entirely
determined by Pt. The iteration is stopped when the change between the updates becomes less
than , where we consider  = 0.1mmHg to be small enough. Usually 200 to 400 iterations are
needed for convergence, when applied to our tumor networks.
Evaluation of F: The vascular tree is traversed down stream as explained. At each vessel, first
the upstream PO2 is determined according to Eq (11) or according to the boundary condition
Eq (12) if it is an inlet node.
Then Eq (5) is integrated with the implicit Euler method [75]. Explicit methods are not well
suited to the problem since their stability requirements [75] lead to a step size hv< const  q.
Since many tumor vessels are slowly perfused this would lead to sub-micrometer steps, incur-
ring a prohibitive performance penalty. Note that the representation of Pt as superposition of
Computation of Tumor Oxygenation with Application to Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0161267 August 22, 2016 15 / 42
3.1. COMPUTATIONAL MODEL FOR TUMOR OXYGENATION APPLIED TO CLINICAL DATA
ON BREAST TUMOR HEMOGLOBIN CONCENTRATIONS SUGGESTS VASCULAR DILATION
AND COMPRESSION CHAPTER 3. ORIGINAL PUBLICATIONS
70
basis functions readily provides a means to obtain its function value for the r.h.s of Eq (5).
Since the bases φi have a small support this can be efficiently implemented. Moreover storage
of all Pk values is not required. Instead we perform required operations “on the fly” when the
vascular PO2 is computed in F. This means we either record oxygen exchange contributions
for Pt into the system matrix Eq (35) or compute observables for final output. It is sufficient to
just store Pk at the upstream end of each vessel which is just ~P from Eq (11).
Evaluation of Ft: Our approach for the solution of the diffusion Eq (15) can be derived from
the Galerkin method, where in brief, the general idea is as follows. First, the standard scalar
product over the space of integrable functions over O is introduced (f, g) =
R
fgd x. Furthermore
instead of the true solution, an approximation within the vector space V is searched for. This
solution is defined as f 2 V for which the residual R after evaluation of the differential equation
w.r.t. f is minimal, i.e. we look for f 2 V such that (R, R) =min. Here Pt takes the role of f and
we have
R ¼ atDtr
2Pt MðPtÞ þ QðPtÞ: ð22Þ
It can be shown that minimization of ||R|| is equivalent to finding the Pt where R is orthogo-
nal to V
ðR;φiÞ ¼ 0 8i: ð23Þ
Eventually this results in an equation per grid site i in the unknowns {Pt,i}. The l.h.s. of Eq





for which algebraic expressions are needed.
The benefit of considering a finite element formulation lies in the straight forward treatment
of the transvascular exchange Q with its Dirac delta. Also FEMmakes it straight forward to use
higher order elements for better accuracy. Here however we use P1 elements. Moreover, if the
integration of Eqs (24)–(26) is performed by the trapezoidal rule, then the resulting discretized




i.e. g is sampled at grid points, where we have control values gi = g(xi). Likewise, one obtains for
a sufficiently smooth function f
ðr2f ;φiÞ  h
3½Dh f i þ boundary terms; ð28Þ
where





Dh is the discrete Laplacian [75] known from finite differences. Neighbors of i denotes the 6
nearest grid neighbors. At the boundaries we modify Dh to account for the missing neighbors
[75]. The consumption termM(Pt) is expanded to first order around the oxygen level from the
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where 0 denotes the first derivative. More conveniently in matrix notation and with dropped
super scripts, we write for the right hand side of Eq (30)
MAþMB I Pt; ð31Þ









The last contribution is derived by expanding Eq (26). For better readability, the super
scripts are dropped again. Also the dependence of r and γ on the current vessel v is implied but






































The expression given in Eq (34) approximates the total volume rate of oxygen that extrava-
sates from the entire vascular system into the tissue volume associated with the basis function
φi. Now the integral over the vessel network is approximated with a Riemann sum based on the
integration points {Pk} from step Eq (20). Each integration point k represents a finite length
segment Δxk = hv except at the end points of each segment where Δxk = hv/2. In order to achieve
good accuracy, we require hv<< h. Else, the integration kernel 2πγφi or 2πγφi φj will be
under-sampled. This limitation could be removed to some degree by interpolation of the
numerical solution of P(x), decoupling it from the integration quadrature formula. From Eq


























3 is intuitively understood as vessel surface area per cell volume associ-
ated with vessel centerline integration step k. Finally, the completely assembled system of equa-
tions reads
½atDtDh MB I QBPt ¼ MA QA: ð36Þ
It is easy to see that this is a sparse symmetric system. The Laplacian gives rise to 6 off-diag-
onal entries. The operatorQB gives rise to 26 off-diagonal entries corresponding to the nearest
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and second nearest grid neighbors. For points which are spaced further apart, φi and φj have
no overlap so their product in Eq (35) becomes zero.
In order to improve the efficiency we approximate Pt(xk) with the value from the current
site Pt,i. This approximation is justified physically since the oxygen diffusion length consider-
ably exceeds the lattice spacing h. Consequently,QB is diagonalized such that the new version,







This is a sparse linear system where the only off-diagonal terms stem only from the Lapla-
cian, removing the off-diagonal entries corresponding to the second nearest neighbors. We
solved these systems with an algebraic multigrid method (Trilinos ML [72]). We found the dif-
ference between the ~QB andQB solutions negligible.
The computational cost of our method scales well in the number of discretization points
since the obtained sparse systems can be solved in O(n log n) time. In contrast the Green’s
functions method [41] gives rise to dense systems and is therefore much more computationally
demanding.
We take grid constants h of 40 μm, which is rather coarse for resolving the approximately
exponential decay of the O2 concentration around isolated tumor blood vessels. The therewith





. This estimate is obtained from dPt(x)/dx = −M0/Dαt, under the bound-
ary conditions that Pt(0) = P0, dPt/dx(ldiff) = 0, and Pt(ldiff) = 0. We obtain, ldiff = 295 μm in nor-
mal tissue, and 148 μm in tumor, using the parameters in Table 1 and assuming that P0 = 40
mmHg. In two dimensions, the Krogh model for a capillary of 3 μm radius, yields approxi-
mately ldiff = 150 and 80 μm in normal and tumor tissue, respectively. However, we do not use
Fick’s law as in jtv = −DαtrPt to determine the amount of extravasated oxygen. Instead, jtv is
computed from the difference between P and Pt at the vessel center line. Therefore the result
does not depend critically on the precise resolution of tissue PO2 gradients.
We repeated our calculations with a grid constant h of only 20 μm. As a result, the peaks of
the calculated Pt distributions are better resolved. Concomitant changes in the predicted aver-
ages are rather small. For instance we obtain lower average OEF (0.1 versus 0.11), lower Pt (25
vs. 28mmHg—the most significant change), and higher Y (0.75 vs. 0.73), in tumors of case
CMPR. However, these variations are well within experimental uncertainties. Therefore, our
overall results and conclusions are left unaltered.
In Fig D in S1 Appendix we investigated the convergence of the on-axis oxygen partial pres-
sure P(x) with decreasing lattice constant h and conclude that at h = 40 μm the accuracy is
between 3 to 13% depending on the location along the vessel. Differences of the absolute values
of the intravascular and extravascular partial oxygen pressures P(x) and Pt(y) with respect to
the Green’s function technique of Secomb et al. [41] are illustrated in Fig C in S1 Appendix.
Overall, we estimate uncertainties of absolute intravascular and extravascular partial oxygen
pressures to be in the order of 10 – 20%.
Simulation setup
Expressions for tissue hemoglobin concentration and tissue blood oxygen saturation.
For a comparision of simulated tissue hemoglobin concentration cHb and tissue blood oxy-
genation Y with clinical data we provide expressions for these quantities based on host and
tumor vascular networks. Corresponding expressions for other quantities of interest are
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PLOS ONE | DOI:10.1371/journal.pone.0161267 August 22, 2016 18 / 42
CHAPTER 3. ORIGINAL PUBLICATIONS
3.1. COMPUTATIONAL MODEL FOR TUMOR OXYGENATION APPLIED TO CLINICAL DATA
ON BREAST TUMOR HEMOGLOBIN CONCENTRATIONS SUGGESTS VASCULAR DILATION
AND COMPRESSION
73
given in S2 Appendix.
























where V is the set of vessel segments of host or tumor tissue,MCHC is the mean corpuscular
hemoglobin concentration, |O| the relevant tissue volume, rv, lv, Hv, Sv(x) designate radius,
length, hematocrit and blood oxygen saturation of vessel segment v. In Eq (39) integration of
blood oxygenation is taken over the length of the vessel segment.
Tissue total hemoglobin concentration cHb is the sum over the hemoglobin mass of all vessel
segments per unit volume of tissue. Tissue blood oxygenation Y is the average of RBC-volume-
weighted blood oxygen saturation taken over all vessel segments. It follows that high-caliber
vessels contribute dominantly to cHb and Y, being less sensitive to the capillary plexus.
Simulation model variants. In the following we discuss three different scenarios denoted
BASE, CMPR and METAB. Cases BASE and METAB use the same tumor vascular networks
(t = 600 h), but differ in their assumptions made to calculate tissue metabolic rate of oxygen
consumption variables. CMPR, on the other hand, augments the processes that cause remodel-
ing of the tumor vasculature by accounting for vascular compression by solid pressure, leading
to tumor vascular networks at t = 600 h that differ from the networks of the scenarios BASE
and METAB.
Case BASE This is our base case with parameters for growth of breast tumor vasculature
listed in Table 2. Blood flow, hematocrit distribution, blood and tissue oxygen concentrations
were calculated using each of the 90 realizations of tumor vasculature (t = 600 h) together with
Table 2. List of parameters for tumor growth.
Parameter Value Unit Description
Rtum(t = 0) 250 μm Initial tumor radius
vtum 2 μm/h Tumor radius expansion rate












50 h Sprout activity duration




144 h Endothelial cell proliferation time
r(sprout) 2.6 μm Initial sprout vessel radius
r(max) 10 *, 14 ** μm Maximum dilatation radius
p(coll) 1 Vessel collapse probability
Δw 0.05 μm/h Vessel stability (w) decrease rate
f(coll) 0.25 Pa Critical wall shear stress
h(gen)
† 130 μm Lattice constant of initial network generation
* case BASE.
** case CMPR. Increased maximal dilatation radius compensated for by overall compression of tumor vessels (see text).
† The lattice constant h(gen) corresponds to the vessel segment length in the initial (t = 0) networks. Simulation of tumor growth and vascular remodeling is
performed at only 10 μm lattice spacing. This is possible since segments of the initial t = 0 lattice coincide with bonds and sites of the finer 10 μm lattice.
doi:10.1371/journal.pone.0161267.t002
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parameters related to oxygen transport given in Table 1. The maximal oxygen consumption
rate of tumor tissue was assumed amounting toM0(tumor) = 4 M0(normal) and PM50(tumor)
was assumed equal to 1/2  PM50(normal), reflecting the enhanced need for oxygen of prolifer-
ating tumor cells. Reports on measured oxygen consumption of solid tumors are scarce in the
literature. We include a recent report on metabolic rate of oxygen consumption of viable multi-
cellular spheroids of human colorectal carcinoma cells [77] indicating thatM0(tumor) might
even be underestimated. Compared to previous simulations concerning melanomas [28],
changes in the tumor growth parameters (s. Table 2) include d(br,min), governing theMVD near
the tumor rim, f(coll), and r(max) determining the centralMVD and rBV. Other parameters such
as the sprouting time tðsproutÞEC , and vessel wall degradation rate Δw are unaltered.
Case CMPR: Vascular compressionWe allowed for compression of tumor vessels during
tumor growth by extravascular stress on simulated tissue blood oxygen saturation Ytum based
on the final t = 600 h tumor vasculature. Compression of tumor vessels will change the relation
of Ytum and the tissue blood oxygen saturation of the surrounding normal breast tissue Ynorm
obtained from the corresponding vascular network at t = 0. Elevated interstitial fluid pressure
(IFP) is known to be a hallmark of tumors [10], primarily caused by the increased leakiness of
tumor vessels and the lymph drain being impaired in solid tumors. Yet the precise mechanisms
by which extravascular pressure compresses tumor vessels are still under debate [78, 79]. The
uncontrolled proliferation and growth of tumor cells within a restricted volume generates
extravascular solid stress. Solid stress accumulates within the tumor volume through an
increase in tumor cell density and hyperproduction of interstitial matrix molecules such as col-
lagen and hyaluronan [9–11]. Collagen fibers are resistant to tensile stress whereas hyaluronan
resists compression thus transferring stress on tumor vessels. On the other hand water-loaded
hyaluronan can be considered to be part of the relative immobile fluid phase of the interstitial
fluid, contributing to IFP apart from contributions of the freely mobile fluid phase. Further-
more, solid stress can be exerted on the tumor volume by the surrounding normal tissue. It was
estimated that solid stress becomes significant for tumor volumes larger than 0.065mm3, corre-
sponding to a sphere of Rtum = 250 μm [80]. A detailed simulation of solid stress during pro-
gression of the tumor is beyond the scope of the present paper. Therefore we assume that all
vessels of the tumor vasculature experience compression during the growth process, i.e. a
reduction of their radius by a constant factor. The fundamental difference to the case BASE is
that in this way high-caliber vessels experience a reduction in radius, which cannot be achieved
by the previous model that predicts either growth or complete removal of vessels. Hence we
introduce a new “compressed” vessel radius, denoted ~r which enters the blood flow and oxygen
computation. We consider a function ψ(|x|) of the spatial coordinate x that represents the mag-
nitude of compression relative to the base radius, depending on the distance from the tumor
center |x|. Therefore we define ~r ¼ c  r. We let ψ describe a linear transition between full com-
pression of magnitude 1 − ξcpr, in the tumor center and zero in normal tissue. Thus, vascular
radii ~r within the tumor, with the exception of a small transition zone of width wcpr, are
reduced relative to r by a factor of ξcpr. Since compression affects all vessels, and to obtain a
common mean capillary diameter of cases BASE and CMPR, r(max) was increased in case
CMPR from r(max) = 10 μm to 14 μm. This compensation helps to separate the effect of com-
pression of large vessels from an overall compression of all radii.
cðxÞ ¼
xcpr for x < R wcpr
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where R = Rtum is short for the tumor radius and wcpr is assumed 200 μm. We assume that vary-
ing degrees of compression are present in the tumors of the patient cohort due to phenotypical
differences from tumor to tumor or differences in the micro environment of the host. There-
fore a new ξcpr was drawn for each simulation from a uniform distribution over the interval
between 0.5 and 1. The lower bound of 0.5 was deliberately chosen since it appears to be the
lower bound of what was reported for experiments, i.e. relief of stress resulted in two times
increase of vessel diameters [81].
Case METAB: Variation of tumor oxygen consumption rate In contrast to case CMPR sce-
nario, METAB uses the identical tumor vascular networks as case BASE. However, rather than
selecting the same maximal oxygen consumption rateM0 for all tumors as in scenario BASE we
consider variations of the maximal tumor oxygen consumption rateM0 among various tumors
reflecting phenotypical differences. In this way we probe the impact of tumor tissue oxygen con-
sumption versus tumor vascular restructuring on intra-and extravascular oxygen distributions.
Therefore,M0 / (ml O2/ml/min) is drawn from a lognormal distribution withmu = log(0.0149)
and sigma = 0.3 on a tumor by tumor basis, yielding a medianM0 identical to case BASE and a
standard deviation of 32% of the median. The oxygen consumption rate of normal tissue is kept
at its original value (s. Table 1). Furthermore oxygen partial pressures PM50 were kept
unchanged.
Results and Discussion
Tumor compartmentalization and contributions of tumor core to
hemoglobin concentration, fractional blood volume and tissue blood
oxygenation
Using the model parameters listed in Table 2 together with the root node geometries illustrated
in Fig 3 we simulated vascular networks corresponding to normal breast tissue (t = 0, “initial”)
and tumors (t = 600h, case BASE, case CMPR). As can be seen from Fig 4, tumor vascular net-
works are highly compartmentalized, comprising a central core with lowMVD and a highly
Fig 4. Radial distributions of the microvascular density,MVD, and the relative blood volume, rBV. The
simulation box was divided in 100 μm thick concentric shells over which the regionalMVD and rBV were
determined to obtain radial profiles depending on the distance from the center |x|. Plotted is the ensemble
mean of these profiles, where the error bars display the standard deviation (STD). As can be seen, a
compartmentalization into varying degrees of vascularization (MVD) and vascular dilatation (rBV) exist which
is typical for Melanoma [56] and Glioma [57]. Fig 4 provides evidence that these features are also present in
breast tumors. The STD ofMVD further shows that theMVD of the tumor core is below normal in most
realizations of the ensemble which conforms to our expectations for tumors. Oscillations are an artifact of the
confinement of the vessels to a lattice.
doi:10.1371/journal.pone.0161267.g004
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vascularized peripheral shell of a few hundred micrometer thickness, consistent with previous
results [28, 50–54]. The arterio-venous organization is lost, and the remaining high caliber ves-
sel protruding into and through the tumor are connected with a chaotic network of dilated
capillaries. Although central tumorMVD is lower than normal (s. Fig 4A), relative blood vol-
ume rBV is above normal within the tumor core (s. Fig 4B). It follows that vessels crisscrossing
the tumor core are predominantly of high caliber. As was mentioned above, all vessel segments
contribute to the average blood oxygen saturation hSi proper (s. S2 Appendix), independent of
their volume.
Fig 5 provides examples for vascular networks corresponding to tumor model CMPR, and
root node geometry RC9 (cf. Fig 3). Distributions of partial oxygen pressure (PO2) of blood
vessels, P, and of tissue, Pt, as well as corresponding distributions of blood oxygen saturations S
are shown at the start (t = 0, top row) and at the end (t = 600 h, bottom row) of the growth pro-
cess. The other cases (BASE, METAB) and root node geometries exhibit similar looking distri-
butions of PO2 and blood oxygen saturation S in normal tissue and tumor periphery.
However, the vascularization at the tumor center can be lower or higher than for the example
shown, which is accompanied with varying degrees of oxygenation. We made sure that in good
approximation cases BASE and CMPR exhibited similar radialMVD and rBV profiles. This
requirement is critical since we aim to analyze the effect on tissue blood oxygen saturation Y by
varying the compression factors ξcpr among the ensemble of 90 tumor vascular networks (see
below), while retaining agreement with clinical data onMVD and rBV. We consider details of
the oxygen distribution shown for instance in Fig 5C. Immediately obvious, we see severe hyp-
oxia at the tumor center due the sparse vasculature there. As one would expect, Pt is highest
near vessels and falls off into non-vascularized spaces over a scale of 100 to 200 μm, corre-
sponding to the oxygen diffusion-range.
Redirection of hematocrit modulates blood oxygen saturation
Tumor vessels in the central region of the tumor vary significantly in their oxygen content.
Some vessels carry highly saturated blood, in particular when connected to nearby arterioles.
When isolated vessels thread the tumor over distances of several hundred micrometers,
blood oxygen saturation S visibly decreases to the point where vessels are completely depleted
of oxygen. The tissue PO2 near such vessels follows this trend. Remarkably, the (neo-)vascu-
lar plexus around the tumor rim is dominated by severe oxygen deprivation. However, the
few high caliber vessels which advance towards the tumor center carry normal amounts of
oxygen. We explain this by the phase separation effect taken into account in our simulations.
This means that red blood cells (RBCs) at bifurcations prefer to flow into the more strongly
perfused branch [71]. Accordingly, simulated hematocrit distributions exhibit high hemato-
crit in central tumor vessels, as exemplarily shown in Fig 6. We conclude that RBCs are redi-
rected into central vessels, consequently leading to a lack of RBCs in the peripheral capillary
plexus and a drastically decreased oxygen carrying capacity. The impaired oxygen carrying
capacity, in turn, results in fast oxygen depletion to hypoxic levels which could drive further
invasive behavior in real tumors. On average, the hematocrit taken over the concentric core
region 100μm beyond the invasive edge is elevated to 117% of baseline hematocrit in normal
tissue. In contrast, the average taken over annular shells near the invasive edge of 50 μm
thickness drops to 66%.
For some applications, such as models of tumor growth, it might be sufficient to implement
a simplified model of tissue oxygenation, setting intravascular PO2 constant, thus treating it as
input parameter. Therefore, in S1 Fig we briefly consider such a simplification and highlight
qualitative differences to results obtained by our full model of oxygenation.
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Fig 5. Blood oxygen saturation and oxygen partial pressure corresponding to case CMPR, root node configuration RC9. The
left column (A, C) shows the PO2 of vessels, P and of tissue, Pt in a slice through the center of the simulation domain. The camera is
looking vertically onto the horizontal cutting plane so that the whole lateral extent of 8mm is shown. The vessel network is visualized as
a collection of cylinders that have been truncated 100 μm above and below the central plane. The resulting cross sectional areas are
light grey. Otherwise the color code indicates the PO2, P, of vessels and Pt of tissue, respectively. In the right column (B, D), only the
network is shown color coded by saturation S. The top row (A, B) shows the initial state at t = 0. The bottom row (C, D) shows the final
state at t = 600 h.
doi:10.1371/journal.pone.0161267.g005
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Model validation: vascular morphology, blood flow and oxygenation
In order to validate our simulation model we calculated various biophysical quantities and
compared the results with data available in the literature. Values listed in Tables 3 and 4 repre-
sent averages (means) over the results of all 90 vascular networks, including standard devia-
tions, at a given time. The initial networks (t = 0) are taken to represent vasculature in normal
breast tissue, neglecting the influence of the small tumor of radius 250 μm at the center of the
simulation domain. Data given in column “Initial” are therefore associated with normal breast
tissue. Data for the cases BASE, CMPR and METAB were calculated at the end (t = 600 h) of
the tumor growth process.
Explicit formulas for the parameters listed are given in S2 Appendix. It should be kept in
mind that for most biophysical variables, results corresponding to a particular vascular network
represent (weighted) averages taken over all vessel segments of the network (s. S2 Appendix). For
comparison, Tables 3 and 4 also include clinical data, data obtained from animal models and the-
oretical results taken from the literature. In the following we comment on some of the simulated
and literature data. Additional details are provided in S4 Appendix.
In general, good to fair agreement was achieved between simulation results and correspond-
ing literature data. In particular total hemoglobin concentration and tissue blood oxygenation
Y, known from optical mammography were reproduced both for normal breast tissue and
breast tumors. Likewise, simulated vascular volume densities fall within the range of rBV values
reported in the literature. In Table 3 we take simulated length density LD, i.e. the total length of
Fig 6. Hematocrit distribution corresponding to Fig 5D, showing the same slice of the vessel network,
but color coded forH.Our blood flow model includes the phase separation effect which leads to a severe
reduction of the hematocrit in the peripheral tumor network and an elevated hematocrit in the vessels at the
tumor center.
doi:10.1371/journal.pone.0161267.g006
Computation of Tumor Oxygenation with Application to Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0161267 August 22, 2016 24 / 42
CHAPTER 3. ORIGINAL PUBLICATIONS
3.1. COMPUTATIONAL MODEL FOR TUMOR OXYGENATION APPLIED TO CLINICAL DATA
ON BREAST TUMOR HEMOGLOBIN CONCENTRATIONS SUGGESTS VASCULAR DILATION
AND COMPRESSION
79
the vascular network divided by the tissue volume (s. S2 Appendix), as measure for microvessel
densityMVD, conventionally obtained by microscopically counting the number of microves-
sels per area of a tissue section. Simulated length density LD and clinicalMVD of normal breast
tissue agree quantitatively and length densities LD of the tumor model variants fall within the
range ofMVD reported for breast cancers in the literature. Average vessel radii corresponding
to the tumor model variants BASE, CMPR and METAB are about 60% of those reported by
Stamatelos, probably because the maximal dilatation radius was limited to 10 μm (BASE/
METAB) and 14 μm (s. Table 2). Tumor vessel surface density SD and tumor vessel surface
density over tumor vascular volume density SD/rBV are consistent with the data reported by
Stamatelos et al. [7].
Regional blood flow, rBF, i.e. perfusion, is given by the ratio of total blood flow entering a
selected tissue region O to its volume |O| (s. S2 Appendix). To calculate host perfusion rBFnorm
of the entire simulation cuboid we sum the flow rates q over all arterial root nodes and divide
by the volume of the simulation box |O| = L3. Good agreement between simulated perfusion
rBFnorm and clinical data was achieved. However, for a partial volume, such as a small spherical
tumor inside the tissue cuboid, some caution must be taken. Assuming a constant surface flux
density of blood, the perfusion of the small spherical volume scales as 1/Rtum. Indeed, perfusion
rates rBFtum predicted for the relatively small tumors, simulated here, are much larger than
clinical rBF data from breast tumors which are typically of several cm3 in volume. To estimate
the perfusion rBFscaled that corresponds to larger simulated tumors, we scale rBFtum in the
Table 3. Morphological data: Simulation results and literature values.
Symbol Unit Initial Clin./Lit. BASE/METAB CMPR Clin./Lit.
MVD, LD mm
−2 111 ± 0.4 115 ± 8 [84] 112 ± 19 133 ± 18 88 (15 − 348) [85]
20 (0 − 157) [86]
21 (9 − 101) [7] (a)
rBV % 0.98 ± 0.10 0.8 ± 0.3 [22] (b) 1.9 ± 0.6 1.8 ± 0.9 2.4 ± 1.5 [22] (b)
3.4 ± 0.6 [87] (c) 4.3 ± 1.3 [87] (c)
0.67(0.2 − 3.4) [7] (a)
r μm 4.1 ± 0.1 - 5.9 ± 0.4 5.2 ± 1 9.23 ± 0.27 [7] (a)
SD mm
−1 2.8 ± 0.04 - 4.2 ± 1 4.4 ± 1.1 0.5 − 5.4 [7] (a)
SD/rBV μm
−1 0.29 ± 0.03 - 0.22 ± 0.03 0.27 ± 0.06 0.165 [7] (a)
rBF mlg−1 min−1 0.053 ± 0.014 0.06 [8] 1.6 ± 1.3 1.2 ± 1.3 0.32 [8]
0.056 ± 0.014 [88] 0.19 ± 0.1 [87]
0.04 ± 0.01 [87] 0.29 ± 0.17 [88]
0.028 ± 0.017 [89] 0.07 − 0.16 [90] (d)
0.001 − 2 [7] (a)
rBFscaled mlg
−1 min−1 - - 0.12 ± 0.04 0.091 ± 0.050 -
Shows averages and standard deviations taken over 90 initial networks (t = 0 h) and tumors (t = 600 h) for cases BASE, CMPR and METAB. Morphological
data for BASE is the same as METAB. We compiled clinical data, data from animal models and theoretical data taken from literature in the columns “Clin./
Lit.” for normal (left) and tumor tissue (last col.), respectively. Microvascular density obtained by our model and from [7] is given as the line density LD
whereas data from [85, 86] are the medians of histologicalMVD. rBFscaled is the initial tissue rBF scaled by the ratio of perfusions, rBF, of the iso-volumetric
tumor sphere at t = 0 and at t = 600 h (see text).
(a) Obtained from digitized animal model tumor network obtained by μ-CT.
(b) rBV estimated from cHb assuming 2.18 μmol/l hemoglobin in blood.
(c) Data from [87] was obtained by PET of human breasts. Note that PET data from [87] for tumor tissues are considered unreliable (see text).
(d) obtained from human breast cancer xenografts in animal model.
doi:10.1371/journal.pone.0161267.t003
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following way: rBFscaled = rBFnorm  rBFtum/rBFsph,norm. Here, rBFsph,norm denotes the perfusion
of the isovolumetric spherical volume Vsph of normal tissue (t = 0) that corresponds to the
tumor spheroid at t = 600 h. The perfusion rates rBFtum and rBFsph,norm are obtained from sum-
mation of blood flow q over those vessels that penetrate the surface of the sphere Vsph and have
a blood flow direction into the spherical tissue volume. Scaled perfusion rBFscaled is lower by a
factor 2—3 compared to clinical data on breast cancers. However, scaled perfusion falls within
the range of perfusion values reported by Stamatelos [7] and Kallinowski et al [82] for human
breast cancer animal models. In addition, Table 3 lists the regional blood flow of the small
spherical tumor rBFtum proper.
The metabolic rate of oxygen consumptionMRO2 of normal tissue is mainly determined by
the assumed Michaelis-Menten maximal rateM0 (s. Table 1), since (average) partial oxygen pres-
sure Pt in tissue is considerably larger than the Michaelis-Menten oxygen half pressures. As a
result, the simulatedMRO2 for normal breast tissue favorably compares with clinical data. To
Table 4. Oxygenation data: Simulation results and literature values.
Symbol Unit Initial Clin/Lit. BASE CMPR METAB Clin/Lit.
hSiniq - 0.98 [91] (e) - - - -
rJin μlO2 ml
−1 min−1 12 ± 3 - 331 ± 266 249 ± 282 331 ± 265 11 − 27 [90] (d)
rJin,scaled μlO2 ml
−1 min−1 - - 25 ± 10 18 ± 12 25 ± 10 -
jtv μlO2 min
−1 cm−2 0.12 ± 0.001 0.6 [92] (f) 0.24 ± 0.02 0.20 ± 0.02 0.24 ± 0.06 -
MRO2 μlO2 ml
−1 min−1 3.3 ± 0.1 4.5 ± 1 [87] 12 ± 1 12 ± 2 13 ± 3 6.6 ± 2.8 [87] (c)
33 ± 5 [93] (i) 40.6 ± 7.8 [77] (g)
21 − 52 [83] (g)
33.4 ± 8.3 [83] (h)
4.5 − 11.8 [90] (d)
OEF 0.34 ± 0.10 0.65 ± 0.1 [87] 0.068 ± 0.050 0.11 ± 0.09 0.068 ± 0.051 0.23 ± 0.08 [87]
0.44 ± 0.06 [93] (i) 0.3 − 0.52 [90] (d)
OEFscaled - - 0.55 ± 0.19 0.88 ± 0.46 0.55 ± 0.22 -
cHb μmol/l 24 ± 3 17.3 ± 6.2 [22] 47 ± 14 43 ± 19 47 ± 14 53 ± 32 [22]
16 ± 4 [23] 70 ± 35 [23]
Y 0.70 ± 0.10 0.74 ± 0.14 [22] 0.81 ± 0.10 0.73 ± 0.14 0.81 ± 0.10 0.72 ± 0.14 [22]
0.74 ± 0.09 [23] 0.71 ± 0.10 [23]
P mmHg 39 ± 6 - 45 ± 11 34 ± 13 45 ± 12 -
Pt mmHg 36 ± 6 30 [94] (k) 35 ± 14 29 ± 14 35 ± 14 30 (0 − 100) [14] (j)
65 (12 − 100) [14] (j)
40 − 50 [95] (k)
This is a continuation of Table 3 with data of tumor and normal tissue oxygenation. hSiniq denotes the flow-weighted blood oxygen saturation at input. rJin
denotes the oxygen supply at input rJin = c0 HhSiniq  rBF. For tumors, rJin,scaled denotes the scaled quantity where rBFscaled is used. In addition to the
following notes, see Table 3 for further notes.
(e) Oxygen saturation of human arterial blood at sea level.
(f) Obtained by oxygen micro-electrode measurement in rat brains [92].
(g) Obtained from various human cancer cell spheroids, excluding breast cancer.
(h) Obtained from MDA-MB-468 human breast cell spheroids.
(i) Obtained from human brain by PET.
(j) Median and range; obtained from human breast cancer and normal tissue using polarographic needles.
(k) Obtained from peritumoral skin tissue [94] and muscle tissue in breast tumor-bearing rats [95].
doi:10.1371/journal.pone.0161267.t004
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our knowledge there are no reliable clinical data available on metabolic rates of oxygen consump-
tion of breast cancers. Therefore, we considered a maximal consumption rateM0(tumor) for
cases BASE and CMPR, consistent with the metabolic rates of oxygen consumption reported for
xeno-transplanted human breast cancers in animal models [82] (see above for case METAB).
More recently, metabolic rates of oxygen consumption, ranging from 21 − 52μlO2/g/min, were
determined frommulticellular tumor spheroids of various human cancer cell lines, including
breast cancer (33 ± 8μlO2/g/min), serving as avascular in-vitro tumor models [77, 83], also con-
sistent with our choice ofM0.
The cohort average of the predicted tumor O2 consumptionM(Pt) proper is close to the
assumed maximal rateM0, indicating that predominantly Pt> PM50, in spite of severely
decreased PO2 levels. We explain this result by the assumed value of PM50 = 2mmHg which is
quite small. Furthermore, average partial oxygen pressures in normal breast tissue and breast
tumors are consistent with clinical data.
We conclude that our model is in general capable to correctly account for the biophysical
and physiological quantities simulated taking into account their considerable standard devia-
tions and the considerable variations of clinical, animal and theoretical data available in
literature.
Variance of tissue hemoglobin concentration, tissue blood oxygen
saturation and perfusion due to individual initial vascular configurations
It is the focus of the present paper to simulate tissue total hemoglobin concentrations cHb and
tissue blood oxygen saturation Y of tumors and host tissue and compare the results with the
clinical data on breast tumors and surrounding normal breast tissue obtained from a cohort of
87 breast cancer patients using optical mammography, reported by Grosenick et al. ([22], cf.
Figs 3A, B, Fig 5]). Since the present paper frequently refers to the clinical results, we reproduce
the relevant figures, see Figs 7 and 8.
In Figs 9, 10 and 11 corresponding to the model variants BASE, CMPR and METAB,
respectively, we likewise correlate simulated tissue hemoglobin concentration and tissue blood
oxygenation in normal and tumorous tissue separately for each of the 90 network realizations
at the beginning (t = 0) and at the end (t = 600h) of the tumor growth process, thus mimicking
a patient cohort. Figs 9–13 illustrate that variations of normal vascular configurations in the
Fig 7. Physiological parameters of tumors versus those of corresponding healthy breast tissue for 87
patients. (A, left) total hemoglobin concentration cHb; (B, right) blood oxygen saturation Y. Reproduced from
data shown in Ref. ([22], Fig 3A, B).
doi:10.1371/journal.pone.0161267.g007
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cohort result in considerable data scatter of simulated parameters, explaining the observed
scatter in clinical data on the patient cohort. Additionally the root node configuration (cf. Fig
3), associated with a particular data point, is indicated by a colored symbol.
Depending on root node configuration, drastic variations in microvascular densityMVD at
the tumor center, vascular volume density rBV and tissue hemoglobin concentration cHb as
well as perfusion and tissue blood oxygenation Y in tumors are observed. The same parameters
are subject to fluctuations over the initial networks, yet in many cases to a much lesser relative
magnitude. Our main finding, that vascular compression in solid tumors is responsible for low
tissue oxygen saturation is supported by the sections below.
Perfusion and tissue hemoglobin concentration are positively correlated
Fig 12A and 12B show that perfusion rates rBF correlate positively with tissue hemoglobin con-
centration cHb in both normal tissue and tumors. According to Fig 12A, perfusion of the initial
vasculature (normal tissue) is almost linearly dependent on cHb. Since we take cHb to be propor-
tional to rBV, perfusion rBF and vascular volume density rBV are likewise well correlated, illus-
trated for scaled perfusion rBFscaled in Fig 12C, exhibiting a linear dependence approximately.
Since high caliber vessels crisscrossing the tumor core provide dominant contributions to cHb
and rBV, and, at the same time, carry high blood flow due to low hydrodynamic resistance,
such correlation is to be expected. Details of this correlation are determined not only by vascu-
lar morphology, e.g. the initial vessel network growth model, but also by boundary conditions
at inlets and outlets, i.e. the assumed blood pressure-radius relation (s. Eq (3) in S1 Appendix).
To understand the relation between number of root nodes, vascular volume density rBV
and radii of root nodes in initial networks (t = 0, normal tissue), we consider a simplified sys-
tem in S3 Appendix. There, we calculate rBV assuming perfect binary vascular trees depending
on the number of (identical) trees (i.e. number of root nodes), yet keeping the total number of
vessel segments constant. Vessel radii, in our model of the initial vasculature, are governed by
Murray’s law. Thus, the radius of mother vessels grows by a factor of 21/3 compared to their
Fig 8. Blood oxygen saturation versus total hemoglobin concentration. Error bars ([22], cf. Fig 3a,b) on
tumor data correspond to uncertainties of tumor radius aT and location zT along compression direction,
besides statistical contributions, error bars on healthy breast tissue data reflect statistical uncertainties only.
Reproduced from data shown in Ref. ([22], Fig 5).
doi:10.1371/journal.pone.0161267.g008
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daughter vessels. Geometries with fewer root nodes (e.g. RC4 through RC8, s. Fig 3) corre-
spond to more extended arterio-venous trees compared to configurations (e.g. RC1, RC2, and
RC3) with many arterial and venous roots. It follows that rBV and root node radii are larger for
geometries with fewer root nodes. Furthermore, according to the assumed blood pressure-
radius relation, larger root node radii correspond to larger arterial-venous pressure differen-
tials, increasing perfusion. Conversely, configurations with larger numbers of root nodes are
associated with lower rBV, lower root vessel radii, and hence lower arterio-venous blood pres-
sure differentials.
Thus, vascular network structure and pressure-radius relation of the feeding and draining
vessels determine vascular volume and perfusion. In a cohort of real tissue sections we expect a
similar multitude of vascular configurations with the therewith associated data scatter.
Vascular dilatation leads to elevated tumor oxygen saturation
The cHb(tumor)-cHb(normal) correlations for cases BASE and METAB (Fig 9A) and for case
CMPR (Fig 10A) qualitatively agree with the clinically observed correlation between tissue
Fig 9. Tissue hemoglobin concentrations, volume-weighted tissue blood oxygen saturations Y and
length-weighted blood oxygenation S (Case BASE). Each data point corresponds to a different simulation
run, where the color code indicates the corresponding root node configuration (cf. Fig 3, see text). Panel A
displays hemoglobin concentration cHb of tumor tissue versus cHb in normal tissue. Panel A also corresponds
to case METAB, differing from case BASE in tissue oxygen metabolism only. Panel B correlates RBC-
volume-weighted tissue blood oxygen saturation Y, Panel C length-weighted blood oxygenation S in
tumorous and normal breast tissue. Panel D shows a plot of Y against tissue hemoglobin concentration cHb
where tumor (colored symbols) and normal tissue (black symbols) are both shown as different point sets.
Black lines in Panel A, B and C represent diagonals separating tumor data above from below normal.
doi:10.1371/journal.pone.0161267.g009
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Fig 10. Tissue hemoglobin concentrations, volume-weighted tissue blood oxygen saturations Y and length-
weighted blood oxygenation S (Case CMPR). This figure is the analog of Fig 9, but for case CMPR. Each of the 90
simulation runs was carried out with a different randomly selected factor ξcpr for reducing all tumor vessel radii (s. Eq
(40)) simulating solid stress. Fig 10 Panel A-C correlate tissue hemoglobin concentration cHb, RBC-volume-weighted
blood oxygen saturation Y and length-weighted blood oxygen saturation S of tumor (t = 600 h) and normal (t = 0 h)
tissue, respectively. In Fig 10D tissue blood oxygenation Y is plotted versus tissue hemoglobin concentration cHb
separately for tumors (colored) and normal tissue (black). Fig 10E and 10F correlate tissue blood oxygen saturation Y
of tumors with factor ξcpr and average vessel radius r. Generally, Ytum decreases with decreasing average r and
decreasing ξcpr, corresponding to higher compression. Black lines in (A), (B) and (C) represent diagonals separating
tumor data above from below normal. The color code to identify root node geometry is the same as in Fig 9.
doi:10.1371/journal.pone.0161267.g010
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hemoglobin concentrations in breast tumors and surrounding normal breast tissue (Fig 7a,
([22], Fig 3a)). Since total hemoglobin concentration is approximately proportional to vascular
volume density rBV, the higher hemoglobin concentration reflects the larger rBV of tumors,
explained by neo-angiogenesis and vessel dilatation, outweighing vascular regression. For case
CMPR we raised the maximum dilatation radius r(max) from 10 μm (BASE, METAB) to 14 μm
(s. Table 2) in order to compensate for the decrease of vascular volume density rBV associated
with an overall compression of tumor vessels. Consequently, the ensemble averages of rBV
(BASE, METAB) and rBV(CMPR) are approximately the same (s. Table 3). Likewise, the corre-
lation plots cHb(tumor)-cHb(normal) shown in Figs 9A and 10A agree qualitatively, although
quantitative differences exist comparing individual representations.
For clarity we want to point out the difference between tissue blood oxygen saturation Y =
cHbO/cHb and average vascular oxygen saturation hSi. The latter quantity is the length-weighted
average of blood oxygen saturation taken over all vessel segments of the vascular network (s. S2
Appendix). High caliber tumor vessels contribute to hSi according to their—likely higher—
blood oxygen saturation, but contribute to Y additionally by their large relative RBC volume. A
plot of hSi(tumor) versus hSi(normal) shows hSi(tumor) to fall above and below normal for
case BASE (Fig 9C), whereas hSi(tumor) is generally lower than normal when M-M oxygen
consumption rate is raised toM0(tumor) = 24.6 μlO2/ml/min (s. Panel D of Fig A in S2 Fig)
and in the compression case CMPR (Fig 10C).
Figs 9D, 10D and 11B, being qualitatively similar, illustrate the correlation between tissue
blood oxygen saturation Y and tissue total hemoglobin concentration cHb for cases BASE,
CMPR, METAB, respectively. Analogous to Fig 8, separate correlations are shown for normal
and tumorous tissue. At an arbitrarily selected hemoglobin concentration cHb there exists a
lower bound on Y, clearly discernible in Figs 9D, 10D and 11B despite considerable data scat-
ter. For tumors, tissue blood oxygen saturation Y tends towards an upper limit at high tissue
total hemoglobin concentration.
Fig 11. Volume-weighted tissue blood oxygen saturations Y and hemoglobin concentrations (Case
METAB). This figure is the analog of Fig 9 for case METAB, using the same 90 vascular network realizations
at t = 0 and t = 600 h as in case BASE. For each network realization at the end of the growth process, oxygen
related parameters were simulated by randomly selectingM0 from a lognormal distribution (see text). Fig 11A
correlates tissue blood oxygen saturation in tumorous and normal tissue. In Fig 11B, tissue blood
oxygenation is plotted versus tissue hemoglobin concentration for tumors (colored symbols) and normal
tissue (black symbols) separately. The black lines in (A) represents the diagonal separating tumor data above
from below normal. The color code to identify root node geometry is the same as in Fig 9.
doi:10.1371/journal.pone.0161267.g011
Computation of Tumor Oxygenation with Application to Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0161267 August 22, 2016 31 / 42
3.1. COMPUTATIONAL MODEL FOR TUMOR OXYGENATION APPLIED TO CLINICAL DATA
ON BREAST TUMOR HEMOGLOBIN CONCENTRATIONS SUGGESTS VASCULAR DILATION
AND COMPRESSION CHAPTER 3. ORIGINAL PUBLICATIONS
86
We explain this asymptotic behavior of Y by first recognizing that vascular volume—essen-
tially cHb—and perfusion rBF are positively correlated as shown in Fig 12A and 12B. An
increase in vascular volume allows for stronger perfusion at given blood pressure boundary
conditions. By definition, tissue blood oxygen saturation Y is negatively correlated with oxygen
extraction fraction OEF. Moreover, the amount of oxygen extracted from the blood stream is
bound from above by the rate of radial diffusion and the local metabolic oxygen demand of tis-
sue. An increase of vascular oxygen influx q  c beyond what can be extracted, leads to luxurious
perfusion. In this imbalanced state, most of the oxygen exits the system again through draining
vessels. In this case the oxygen extraction fraction OEF is relatively low. This means, with
increasing perfusion Y approaches asymptotically the blood oxygen saturation level at the
input.
Luxurious perfusion is evidently predicted in tumors exhibiting high tissue hemoglobin
concentrations cHb. We conclude that in such tumors particularly few and thick vessels criss-
cross the central tumor volume. Such vessels are associated with relative large blood flow rates
Fig 12. Correlation of other dynamic vascular andmetabolic quantities (Case CMPR). Fig 12A and 12B relate perfusion to tissue hemoglobin
concentration for normal tissue (t = 0) and tumors (t = 600 h), respectively, whereas Fig 12C correlates tumor scaled perfusion rBFscaled (see text) with
vascular volume density rBV. Fig 12D and 12F correlate oxygen extraction fractionOEFwith perfusion rBF for normal (t = 0) and tumorous (t = 600 h) tissue,
respectively. Fig 12E displays tissue blood oxygen saturation Y versus perfusion (t = 600 h). A comparison of Fig 12E and 12F shows implicitly the negative
correlation ofOEF and Y for normal tissue. Each data point corresponds to one of the 90 simulation runs, where the color code to identify the root node
geometry is the same as in Fig 9.
doi:10.1371/journal.pone.0161267.g012
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q, relatively high blood oxygen saturation S, besides enhanced hematocrit (s. Figs 5D and 6).
Since tissue blood oxygen saturation Y is the RBC-volume-weighted average of blood oxygen
saturation S taken over all vessel segments (s. Eq (39)), high caliber vessels predominantly con-
tribute to Y.
Paradoxically, hypoxia is prevalent in many tumors, including our simulations. However, a
physiologically normal oxygen supply requires a homogeneous distribution of a capillary bed
exhibiting a physiological surface area per vascular volume. Instead, tumor blood vessels are
very heterogeneously distributed.
The resulting simulated tissue blood oxygen saturation Y of tumors falls above normal (case
BASE, METAB), although tumor oxygen demand was raised, i.e. the Michaelis-Menten meta-
bolic rate of oxygen consumptionM0 in tumorous tissue was assumed to be four times higher
compared to normal tissue (s. Table 1).
Figs 9D, 10D and 11B are in qualitative agreement with clinical data (s. Fig 8), apart from
missing simulated data above the lower bounds of Y. This discrepancy might be explained by
partial volume effects. Implicitly our simulations assume the spherical tumor to consist of a
homogeneous distribution of viable tumor cells, apart from its vasculature, thus assuming
homogeneity with respect to oxygen consumption. However, breast tumors of patients may
Fig 13. Correlation of geometric vascular quantities (Case CMPR). Fig 13A and 13B relate vessel surface with vessel volume densities for normal (t = 0)
and tumorous (t = 600 h) tissue, respectively, whereas Fig 13C compares vessel surface densities of tumors and normal tissue. Correlations of surface to
volume ratios SD/rBV with vessel volume density rBV are shown in Fig 13D and 13E for normal tissue (t = 0) and tumors (t = 600 h), respectively. Fig 13F
relates vessel surface to vessel volume densities for tumorous(t = 600 h) and normal (t = 0) tissue. Each data point corresponds to one of the 90 simulation
runs, where the color code to identify the root node geometry is the same as in Fig 9. Black lines in (C), (F) represent diagonals separating tumor data above
from below normal.
doi:10.1371/journal.pone.0161267.g013
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contain necrotic regions or partial volumes consisting of viable tumor cells and normal breast
cells. In either case the effective oxygen demand is reduced leading to higher tissue blood oxy-
gen saturations Y at constant tissue hemoglobin concentration cHb.
Tumor blood flow rates outweigh increased oxygen demand
Clinical data on metabolic rate of oxygen consumption of tumors are scarce. Our choice of
M0(tumor) = 14.8 μlO2/ml/min corresponds to simulated metabolic ratesMRO2 in tumors to
be about 12 μlO2/ml/min (s. Table 4), consistent with the high end of oxygen metabolic rates
reported for human xeno-transplanted breast cancers in animal tumor models [82]. Consider-
ably higher oxygen consumption rates (M0 = 33.4 ± 8.3 μlO2/ml/min) of human breast carci-
noma cells (MDA-MB-468) were recently reported based on in-vitro measurements of oxygen
flux above a monolayer of the tumor cells [83]. Assuming a M-M consumption rate ofM0 =
24.6 μlO2/ml/min raised the simulated tissue metabolic rate of oxygen consumption to 18.6 μl
O2/ml/min (BASE), yet did not change the situation, i.e. tissue blood oxygen saturation Y of
tumors was simulated to be above normal (s. Panels A and B in Fig A in S2 Fig). Likewise, sim-
ulated tissue blood oxygen saturation Y of tumors (case METAB) changed only little compared
to case BASE (s. Figs 9B and 11A), when the metabolic rateM0 was randomly selected from a
lognormal distribution for each of the 90 growth processes to simulate phenotypical differences
between breast cancer patients. We therefore conclude that tissue blood oxygen saturation Y of
breast tumors below normal (Fig 7B) is unlikely caused by high metabolic rate of oxygen con-
sumption in tumorous tissue, rather than by insufficient oxygen supply.
Vascular compression is responsible for low tumor oxygen saturation
It follows that the growth processes of tumor vasculature of case BASE (METAB) need to be
augmented (case CMPR). Our method to simulate tumor vasculature had been developed pre-
viously based on morphologic data (MVD) of melanomas. It is therefore not surprising that
addition of data on tissue blood oxygen saturation Y depending on metabolic characteristics of
tumor tissue besides vascular structure and hemodynamics, requires modifications of previ-
ously employed models. Tissue blood oxygen saturation Y is (negatively) correlated with blood
oxygen extraction fraction OEF =MRO2/rJin, where rJin is the oxygen influx per unit volume of
tissue. In simulations, tumor oxygen extraction fraction can be increased and hence tissue
blood oxygen saturation Y lowered by compressing vessels, thus restricting oxygen influx,
while keeping tissue metabolic rate of oxygen consumptionMRO2 (approximately) constant.
Therefore, we tentatively assume that blood vessels are compressed during tumor growth by
solid pressure, known to be elevated in solid tumors [9, 11], caused by proliferating tumor cells
and modifications of the tumor extracellular matrix, e.g. by increased deposition of hyaluronan
[96]. Previously, compression of intratumoral vessels was observed in an animal model, attrib-
uted to proliferating tumor cells [10]. Presently, the precise mechanisms are still under debate
by which extravascular pressure compresses tumor vessels [78, 79].
For simplicity, CMPR assumes the same radius reduction factor ξcpr for all vessel segments,
where ξcpr is randomly selected for each of the 90 tumor growth processes. Case CMPR shows
tumor blood oxygen saturation Y to fall above and below normal (Fig 10B), consistent with the
clinical data. Qualitatively speaking, for a sufficiently small radius reduction factor ξcpr selected,
vessel segments whose radii fell above the maximal dilatation radius r(max) = 14 μm (CMPR) at
the start of the tumor growth process will most likely end up to be narrower compared to case
BASE, whereas radii of smaller vessel segments (r< r(max)) will be comparable for both scenar-
ios at the end of the growth process, since the higher maximal dilatation radius of case CMPR
compensates for vessel segment compression. It follows that oxygen supply by high caliber
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vessels threading the tumor center (s. Figs 5D and 6) is reduced, causing Y to fall below case
BASE. On the other hand for a radius reduction factor ξcpr close to 1, tissue blood saturation Y
of high caliber vessel segments will be comparable for cases BASE and CMPR, explaining the
difference between Figs 9B and 10B. Likewise, compared to case BASE/METAB, compression
of vessels with radii larger than r(max) contribute to the reduction of the ensemble averages of
perfusion rBF and scaled perfusion rBFscaled by 30% and 35%, respectively (case CMPR, s.
Table 3).
Fig 10E and 10F illustrate that Ytum generally decreases with decreasing factor ξcpr, simulat-
ing increasing vascular compression by solid stress and with decreasing average vascular radius
r. Although we cannot rule out other biological processes that may cause radial extent of tumor
blood vessels to shrink we take clinical data with Ytum/Ynorm < 1 to be indicative of vascular
compression. Based on data from optical mammography [22] one might expect that tumors
with Ytum < Ynorm have vascular networks with morphological characteristics that are very dif-
ferent from tumors with Ytum> Ynorm. However, our results suggest that similar vascular net-
work morphologies and similar compartmentalization cover a wide range of values for Ytum
above and below Ynorm, in good agreement with clinical data. Since compression of blood ves-
sels will impede chemotherapy we conclude that tumors with oxy-to total hemoglobin concen-
tration below normal are less likely to respond to chemotherapy. Such behavior was recently
reported for neo-adjuvant chemotherapy of locally advanced breast tumors [47].
Oxygen extraction and vascular surface density
Fig 12D and 12F correlate oxygen extraction fraction OEF with perfusion rBF for normal and
tumorous tissue, respectively. A comparison of Fig 12E and 12F illustrates implicitly the nega-
tive correlation of tissue blood oxygenation Y and oxygen extraction fraction OEF for tumor-
ous tissue (CMPR). Such a correlation is also seen for normal tissue. As a matter of fact, for
normal tissue, the sum OEF + Y is only slightly larger than 1, being rather independent of per-
fusion. Since metabolic rate of oxygen consumptionMRO2 is essentially an input in either case
and oxygen concentration cin of feeding vessels is nearly constant, Fig 12D and 12F show a
hyperbolic dependence of OEF =MRO2/cin/rBF on perfusion rBF.
Fig 13 relates vascular geometric properties of normal and tumorous (case CMPR) tissue
that are not easily amenable to clinical measurements. As expected, vascular surface density SD
increases with increasing volume density rBV, both for normal (Fig 13A) and tumorous (Fig
13B) tissue. Since vascular volume density is higher in tumorous tissue compared to normal tis-
sue (s. Fig 10A), the same applies to vascular surface density (s. Fig 13C). In contrast, vascular
surface to volume ratios SD/rBV decrease with increasing rBV in either case, probably due to
the presence of larger vessels at higher fractional blood volumes (Fig 13D and 13E), yet vascular
surface to volume ratios of tumors may fall above or below normal (Fig 13F), depending on
whether or not the increase in tumor surface density over that of normal tissue outweighs the
corresponding increase in tumor volume density over normal.
Limitations
Although we explained salient features of the clinically observed correlations of hemoglobin
concentration and tissue blood oxygen saturation between tumorous and corresponding nor-
mal breast tissue (inter-network correlations) as well as the dependence of tissue blood oxygen-
ation on hemoglobin concentration for normal breast tissue and tumors (intra-network
correlations) our model has important limitations.
Our computational method presently based on a uniform grid has limited accuracy due to
poor convergence with lattice spacing h. Optimal convergence of the solution of elliptic partial
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differential equations with Dirac source terms can be achieved by adaptive meshes, concentrat-
ing discretization points near the source contributions [97]. In future, adaptive meshes should
be used to improve the accuracy of our method.
The small size of the spherical tumors embedded in the simulation domain make a compari-
son of simulated data with clinical results uncertain, notably for perfusion. Also, the vascular
structure of cm sized tumors might be different from the mm-sized tumors that were simu-
lated. Apart from its vasculature, we implicitly assumed the growing spherical tumor to be
homogeneous. However, in real tumors, viable, oxygen consuming, tumor cells are concen-
trated near blood vessels, whereas necrotic regions which hardly, if at all, consume O2 occur in
regions void of vessels. This heterogeneity affects tissue PO2 distributions and therefore likely
also tissue blood oxygen saturation Y.
The reduction of tumor vessels radii during the growth process by the same, randomly
selected factor is the simplest way to account for compression by solid stress. In effect, this
method decreases the radii of vessels where r is larger than the maximal radius r(max) reached
by circumferential dilatation. Furthermore, reducing r(max) leads to skewed balance between
microvessel densityMVD and regional blood volume rBV which we currently consider as ade-
quate. However, rather than a reduction of vessel radii, local pinch-offs of vessels are more
likely to occur [12], restricting or obstructing RBC flow and thus delivery of oxygen, yet not
changing significantly vascular volume density. Furthermore, only stationary solutions of per-
fusion were sought, although it is well known that blood flow in capillaries may be chaotic.
If possible anatomical information should be used to generate realistic geometries of feeding
arteries (arterioles) and draining veins (venules), rather than arbitrarily creating geometric pat-
terns of root nodes as in this paper. Following [98] a possible remedy to this problem might be
to exclude root node geometries that result in unrealistic values of biophysical variables, e.g.
unreasonably low or high perfusion rates. Furthermore, probability distributions associated
with the clinical data may allow to select the most probable root node geometries.
Conclusions
We have taken a first step to elucidate the relationship between vascular morphology, vascular
oxygen concentration and oxygen delivery to tumor and host tissue, thus trying to solve an ill-
posed inverse problem, namely to deduce morphological information on vascular networks
from clinical coarse grained data. To this end, we related data on tissue hemoglobin concentra-
tions and tissue blood oxygen saturations of breast cancers and surrounding host tissue to syn-
thetic, algorithmically generated tumor blood vessel networks and networks of surrounding
normal tissue, by simulating intravascular and extravascular distributions of partial oxygen
pressure. Our simulations suggest that elevated fractional volume of blood vessels in breast
tumors is likely the result of vascular dilatation, in spite of a drastic reduction of the number of
vessels by regression and collapse. Considerable data scatter in simulated quantities, e.g. tumor
tissue hemoglobin concentration and tissue blood oxygenation are related to vascular variance
of initial blood vessel networks and qualitatively explain the scatter of clinical data of the
patient cohort. Furthermore, breast tumors with tissue blood oxygenation above normal are
likely associated with high tumor blood flow caused by high-caliber blood vessels penetrating
into the tumor. Tissue blood oxygen saturation Y in tumors that is below normal could only be
achieved by a reduction of the radii of high-caliber blood vessels, emulating compression of
blood vessels caused by intra-tumoral solid stress. Factors contributing to low saturations Y are
the reduction in blood flow, increasing the fractional oxygen extraction, and secondly, the asso-
ciated reduction in vascular volume by which the blood oxygen saturation is weighted. Our
simulations provide a possible explanation for tissue blood oxygenation in tumors below
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normal at baseline reported to be indicative of poorer prognosis for neoadjuvant chemother-
apy. We expect our model to find applications to data analysis of PET, MRI, biomedical optics
and hybrid techniques such as photoacoustics, probing tissue vascularization and oxygenation.
Supporting Information
S1 Appendix. Model details and validation. Details on the derivation of the transvascular
oxygen mass transfer coefficient γ are given, simulation results are compared with literature
references, estimating the accuracy of our method, and finally the blood pressure at inlets and
outlets p(BC)(r) is defined.
(PDF)
S2 Appendix. Explicit Formulas for Relevant Biophysical Quantities. The simulation of
tumor growth and oxygen PO2 distributions in blood and tissue yields vascular flow rates qv,
hematocrit Hv, oxygen partial pressure P at discrete points on vessel axes, and tissue partial
oxygen pressure Pt. In this section explicit formulas of other derived biophysical quantities are
provided.
(PDF)
S3 Appendix. Regional Blood Volume of Confined Perfect Binary Trees. In this section we
derive an approximative relation between the number of root nodes and the regional blood vol-
ume, provided that the total number of vessels is held constant. Here we assume that all vascu-
lar trees are perfect binary trees.
(PDF)
S4 Appendix. Further details on comparison between simulated and literature biophysical
data. In support of our model we further discuss simulated data listed in Tables 3 and 4 in
some detail, comparing our results with clinical data, data obtained from animal models and
theoretical data available in the literature.
(PDF)
S1 Fig. Tissue PO2 distributions at constant vascular blood oxygenation.We compare the
results of our oxygen model (cf. Fig 5C, case CMPR, root node geometry RC9) with predictions
of a simplified model using a constant intravascular oxygen concentration.
(PDF)
S2 Fig. Data for doubled parameter value of maximal O2 consumption rateM0. Correla-
tions of volume (Y) and length (S) weighted blood oxygen saturations at increased metabolic
rate of tissue oxygen consumption are compared with case BASE.
(PDF)
Author Contributions
Conceived and designed the experiments:MW.
Performed the experiments:MWTF.
Analyzed the data:MWTF.
Wrote the paper:MWH. Rinneberg TF H. Rieger.
Suggested the scientific problem, contributed to writing and critical review: H. Rinneberg H.
Rieger.
Computation of Tumor Oxygenation with Application to Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0161267 August 22, 2016 37 / 42
3.1. COMPUTATIONAL MODEL FOR TUMOR OXYGENATION APPLIED TO CLINICAL DATA
ON BREAST TUMOR HEMOGLOBIN CONCENTRATIONS SUGGESTS VASCULAR DILATION
AND COMPRESSION CHAPTER 3. ORIGINAL PUBLICATIONS
92
References
1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971 Nov; 285(21):1182–
1186. doi: 10.1056/NEJM197111182852108 PMID: 4938153
2. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it
important to know? Br J Cancer. 2009 Mar; 100(6):865–869. doi: 10.1038/sj.bjc.6604929 PMID:
19240721
3. Carmeliet P, Jain R. Angiogenesis in cancer and other diseases. Nature. 2000 Sep; 407:249–257. doi:
10.1038/35025220 PMID: 11001068
4. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radio-
therapy response. Nat Rev Cancer. 2008 Jun; 8(6):425–437. doi: 10.1038/nrc2397 PMID: 18500244
5. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science.
2005 Jan; 307(5706):58–62. doi: 10.1126/science.1104819 PMID: 15637262
6. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer. 2005 Jun; 5(6):436–446. doi: 10.1038/
nrc1627 PMID: 15928674
7. Stamatelos SK, Kim E, Pathak AP, Popel AS. A bioimage informatics based reconstruction of breast
tumor microvasculature with computational blood flow predictions. Microvasc Res. 2014 Jan; 91:8–21.
doi: 10.1016/j.mvr.2013.12.003 PMID: 24342178
8. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, et al. Blood flow and metabo-
lism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002 Apr; 43
(4):500–509. Available from: http://jnm.snmjournals.org/content/43/4/500.abstract PMID: 11937594
9. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to
tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng. 2011; 2(1):281–298. doi: 10.
1146/annurev-chembioeng-061010-114300 PMID: 22432620
10. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells com-
press intratumour vessels. Nature. 2004 Feb; 427(6976):695. doi: 10.1038/427695a PMID: 14973470
11. Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, et al. Causes, con-
sequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad
Sci USA. 2012 Sep; 109(38):15101–15108. doi: 10.1073/pnas.1213353109 PMID: 22932871
12. Brown JM, WilsonWR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004 Jun; 4
(6):437–447. doi: 10.1038/nrc1367 PMID: 15170446
13. Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer. 2002 Jan; 2(1):38–47.
doi: 10.1038/nrc704 PMID: 11902584
14. Vaupel P, Schienger K, Knoop C, Hockel M. Oxygenation of human tumors: Evaluation of tissue oxy-
gen distribution in breast cancers by computerized O2 tension measurements. Cancer Research. 1991
Jun; 51(12):3316–3322. PMID: 2040005
15. Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, et al. Imaging tumour hypoxia with
positron emission tomography. Br J Cancer. 2015 Jan; 112(2):238–250. doi: 10.1038/bjc.2014.610
PMID: 25514380
16. Christen T, Bolar DS, Zaharchuk G. Imaging brain oxygenation with MRI using blood oxygenation
approaches: methods, validation, and clinical applications. AJNR Am J Neuroradiol. 2013 Jun-Jul; 34
(6):1113–1123. doi: 10.3174/ajnr.A3070 PMID: 22859287
17. An H, Liu Q, Eldeniz C, Lin W. Absolute oxygenation metabolism measurements using magnetic reso-
nance imaging. Open Neuroimag J. 2011; 5:120–135. Suppl. 1–M8: . doi: 10.2174/
1874440001105010120 PMID: 22276084
18. Taroni P. Diffuse optical imaging and spectroscopy of the breast: a brief outline of history and perspec-
tives. Photochem Photobiol Sci. 2012 Feb; 11(2):241–250. doi: 10.1039/C1PP05230F PMID:
22094324
19. Grosenick D, Moesta KT, Möller M, Mucke J, Wabnitz H, Gebauer B, et al. Time-domain scanning opti-
cal mammography: I. Recording and assessment of mammograms of 154 patients. Phys Med Biol.
2005 Jun; 50(11):2429–2449. doi: 10.1088/0031-9155/50/11/001 PMID: 15901947
20. Taroni P, Torricelli A, Spinelli L, Pifferi A, Arpaia F, Danesini G, et al. Time-resolved optical mammogra-
phy between 637 and 985 nm: clinical study on the detection and identification of breast lesions. Phys
Med Biol. 2005 Jun; 50(11):2469–2488. doi: 10.1088/0031-9155/50/11/003 PMID: 15901949
21. Choe R, Konecky SD, Corlu A, Lee K, Durduran T, Busch DR, et al. Differentiation of benign and malig-
nant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. J Biomed
Opt. 2009 Mar-Apr; 14(2):024020. doi: 10.1117/1.3103325 PMID: 19405750
Computation of Tumor Oxygenation with Application to Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0161267 August 22, 2016 38 / 42
CHAPTER 3. ORIGINAL PUBLICATIONS
3.1. COMPUTATIONAL MODEL FOR TUMOR OXYGENATION APPLIED TO CLINICAL DATA
ON BREAST TUMOR HEMOGLOBIN CONCENTRATIONS SUGGESTS VASCULAR DILATION
AND COMPRESSION
93
22. Grosenick D, Wabnitz H, Moesta KT, Mucke J, Schlag PM, Rinneberg H. Time-domain scanning optical
mammography: II. Optical properties and tissue parameters of 87 carcinomas. Phys Med Biol. 2005
Jun; 50(11):2451–2468. doi: 10.1088/0031-9155/50/11/002 PMID: 15901948
23. Spinelli L, Torricelli A, Pifferi A, Taroni P, Danesini G, Cubeddu R. Characterization of female breast
lesions frommulti-wavelength time-resolved optical mammography. Phys Med Biol. 2005 Jun; 50
(11):2489–2502. doi: 10.1088/0031-9155/50/11/004 PMID: 15901950
24. Quarto G, Spinelli L, Pifferi A, Torricelli A, Cubeddu R, Abbate F, et al. Estimate of tissue composition in
malignant and benign breast lesions by time-domain optical mammography. Biomed Opt Express.
2014 Sept; 5(10):3684–3698. doi: 10.1364/BOE.5.003684 PMID: 25360382
25. Anderson PG, Kainerstorfer JM, Sassaroli A, Krishnamurthy N, Homer MJ, Graham RA, et al. Broad-
band Optical Mammography: Chromophore Concentration and Hemoglobin Saturation Contrast in
Breast Cancer. PLOS ONE. 2015 Mar; 10(3):e0117322. Available from: http://journals.plos.org/
plosone/article?id=10.1371/journal.pone.0117322 doi: 10.1371/journal.pone.0117322 PMID:
25781469
26. Ntziachristos V, Yodh AG, Schnall MD, Chance B. MRI-Guided Diffuse Optical Spectroscopy of Malig-
nant and Benign Breast Lesions. Neoplasia (New York, NY). 2002 Jul; 4(4):347–354. Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661680/ doi: 10.1038/sj.neo.7900244
27. Rieger H, Welter M. Integrative models of vascular remodeling during tumor growth: Integrative models
of vascular remodeling. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. 2015 May; 7
(3):113–129. Available from: http://doi.wiley.com/10.1002/wsbm.1295 doi: 10.1002/wsbm.1295 PMID:
25808551
28. Welter M, Rieger H. Interstitial fluid flow and drug delivery in vascularized tumors: a computational
model. PLoS ONE. 2013; 8(8):e70395. doi: 10.1371/journal.pone.0070395 PMID: 23940570
29. Krogh A. The number and distribution of capillaries in muscles with calculations of the oxygen pressure
head necessary for supplying the tissue. J Physiol (Lond). 1919 May; 52(6):409–415. doi: 10.1113/
jphysiol.1919.sp001839
30. Goldman D. Theoretical models of microvascular oxygen transport to tissue. Microcirculation. 2008
Nov; 15(8):795–811. doi: 10.1080/10739680801938289 PMID: 18608981
31. Da su A, Toma-Da su I, Karlsson M. Theoretical simulation of tumour oxygenation and results from
acute and chronic hypoxia. Phys Med Biol. 2003 Sep; 48(17):2829–2842. doi: 10.1088/0031-9155/48/
17/307
32. Espinoza I, Peschke P, Karger CP. A model to simulate the oxygen distribution in hypoxic tumors for
different vascular architectures. Med Phys. 2013 Aug; 40(8):081703. doi: 10.1118/1.4812431 PMID:
23927300
33. Kelly CJ, Brady M. A model to simulate tumour oxygenation and dynamic [18F]-Fmiso PET data. Phys
Med Biol. 2006 Nov; 51(22):5859–5873. doi: 10.1088/0031-9155/51/22/009 PMID: 17068369
34. Mönnich D, Troost EG, Kaanders JH, OyenWJ, Alber M, Thorwarth D. Modelling and simulation of
[18F]fluoromisonidazole dynamics based on histology-derived microvessel maps. Phys Med Biol. 2011
Apr; 56(7):2045–2057. doi: 10.1088/0031-9155/56/7/009 PMID: 21386142
35. Skeldon AC, Chaffey G, Lloyd DJ, Mohan V, Bradley DA, Nisbet A. Modelling and detecting tumour
oxygenation levels. PLoS ONE. 2012; 7(6):e38597. doi: 10.1371/journal.pone.0038597 PMID:
22761687
36. Lagerlöf JH, Kindblom J, Bernhardt P. The impact of including spatially longitudinal heterogeneities of
vessel oxygen content and vascular fraction in 3D tumor oxygenation models on predicted radiation
sensitivity. Med Phys. 2014 Apr; 41(4):044101. doi: 10.1118/1.4866887
37. Kirkpatrick JP, Brizel DM, Dewhirst MW. A mathematical model of tumor oxygen and glucose mass
transport and metabolism with complex reaction kinetics. Radiat Res. 2003 Mar; 159(3):336–344. doi:
10.1667/0033-7587(2003)159%5B0336:AMMOTO%5D2.0.CO;2 PMID: 12600236
38. Goldman D, Popel AS. Computational modeling of oxygen transport from complex capillary networks.
Relation to the microcirculation physiome. Adv Exp Med Biol. 1999; 471:555–563. doi: 10.1007/978-1-
4615-4717-4_65 PMID: 10659189
39. Fraser GM, Goldman D, Ellis CG. Comparison of generated parallel capillary arrays to three-dimen-
sional reconstructed capillary networks in modeling oxygen transport in discrete microvascular vol-
umes. Microcirculation. 2013 Nov; 20(8):748–763. doi: 10.1111/micc.12075 PMID: 23841679
40. Hsu R, Secomb TW. A Green’s function method for analysis of oxygen delivery to tissue by microvascu-
lar networks. Mathematical Biosciences. 1989; 96(1):61–78. doi: 10.1016/0025-5564(89)90083-7
PMID: 2520192
Computation of Tumor Oxygenation with Application to Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0161267 August 22, 2016 39 / 42
3.1. COMPUTATIONAL MODEL FOR TUMOR OXYGENATION APPLIED TO CLINICAL DATA
ON BREAST TUMOR HEMOGLOBIN CONCENTRATIONS SUGGESTS VASCULAR DILATION
AND COMPRESSION CHAPTER 3. ORIGINAL PUBLICATIONS
94
41. Secomb TW, Hsu R, Park EYH, Dewhirst MW. Green’s Function Methods for Analysis of Oxygen Deliv-
ery to Tissue by Microvascular Networks. Annals of Biomedical Engineering. 2004 Nov; 32(11):1519–
1529. doi: 10.1114/B:ABME.0000049036.08817.44 PMID: 15636112
42. Safaeian N, Sellier M, David T. A computational model of hemodynamic parameters in cortical capillary
networks. J Theor Biol. 2011 Feb; 271(1):145–156. doi: 10.1016/j.jtbi.2010.11.038 PMID: 21130099
43. Safaeian N, David T. A computational model of oxygen transport in the cerebrocapillary levels for nor-
mal and pathologic brain function. J Cereb Blood Flow Metab. 2013 Oct; 33(10):1633–1641. doi: 10.
1038/jcbfm.2013.119 PMID: 23921901
44. Beard DA. Computational framework for generating transport models from databases of microvascular
anatomy. Ann Biomed Eng. 2001 Oct; 29(10):837–843. doi: 10.1114/1.1408920 PMID: 11764314
45. Walocha JA, Litwin JA, Miodoński AJ. Vascular system of intramural leiomyomata revealed by corro-
sion casting and scanning electron microscopy. Hum Reprod. 2003 May; 18(5):1088–1093. doi: 10.
1093/humrep/deg213 PMID: 12721189
46. Less J, Skalak T, Sevick E, Jain R. Microvascular network architecture in a mammary carcinoma. In:
Steiner R, Weisz P, Langer R, editors. Angiogenesis. vol. 61 of Experientia Supplementum. Birkhäuser
Basel; 1992. p. 74–80.
47. Ueda S, Roblyer D, Cerussi A, Durkin A, Leproux A, Santoro Y, et al. Baseline tumor oxygen saturation
correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant che-
motherapy. Cancer Res. 2012 Sep; 72(17):4318–4328. doi: 10.1158/0008-5472.CAN-12-0056 PMID:
22777823
48. Kim E, Stamatelos S, Cebulla J, Bhujwalla ZM, Popel AS, Pathak AP. Multiscale imaging and computa-
tional modeling of blood flow in the tumor vasculature. Ann Biomed Eng. 2012 Nov; 40(11):2425–2441.
doi: 10.1007/s10439-012-0585-5 PMID: 22565817
49. Kim E, Cebulla J, Ward BD, Rhie K, Zhang J, Pathak AP. Assessing breast cancer angiogenesis in
vivo: which susceptibility contrast MRI biomarkers are relevant? Magn Reson Med. 2013 Oct; 70
(4):1106–1116. doi: 10.1002/mrm.24530 PMID: 23225578
50. Welter M, Bartha K, Rieger H. Emergent vascular network inhomogeneities and resulting blood flow
patterns in a growing tumor. J Theor Biol. 2008 Jan; 250(2):257–280. doi: 10.1016/j.jtbi.2007.09.031
PMID: 17996256
51. Bartha K, Rieger H. Vascular network remodeling via vessel cooption, regression and growth in tumors.
J Theor Biol. 2006 Aug; 241(4):903–918. doi: 10.1016/j.jtbi.2006.01.022 PMID: 16545398
52. Lee DS, Rieger H, Bartha K. Flow correlated percolation during vascular remodeling in growing tumors.
Physical Review Letters. 2006; 96(5):058104–1–058104–4. doi: 10.1103/PhysRevLett.96.058104
53. Welter M, Bartha K, Rieger H. Vascular remodelling of an arterio-venous blood vessel network during
solid tumour growth. J Theor Biol. 2009 Aug; 259(3):405–422. doi: 10.1016/j.jtbi.2009.04.005 PMID:
19371750
54. Welter M, Rieger H. Physical determinants of vascular network remodeling during tumor growth. Eur
Phys J E Soft Matter. 2010 Oct; 33(2):149–163. doi: 10.1140/epje/i2010-10611-6 PMID: 20607341
55. Gödde R, Kurz H. Structural and Biophysical Simulation of Angiogenesis and Vascular Remodeling.
Developmental Dynamics. 2001 Apr; 220(4):387–401. doi: 10.1002/dvdy.1118 PMID: 11307171
56. Döme B, Paku S, Somlai B, Tímár J. Vascularization of cutaneous melanoma involves vessel co-option
and has clinical significance. The Journal of Pathology. 2002 Jul; 197(3):355–362. doi: 10.1002/path.
1124 PMID: 12115882
57. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel Cooption,
Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF. Science. 1999 Jun; 284
(5422):1994–1998. doi: 10.1126/science.284.5422.1994 PMID: 10373119
58. Moschandreou TE, Ellis CG, Goldman D. Influence of tissue metabolism and capillary oxygen supply
on arteriolar oxygen transport: a computational model. Math Biosci. 2011 Jul; 232(1):1–10. doi: 10.
1016/j.mbs.2011.03.010 PMID: 21439980
59. Zubieta-Calleja G, Paulev PE. 15. In: New Human Physiology. Paulev-Zubieta; 2015.
60. Pittman RN. Regulation of tissue oxygenation. In: Colloquium Series on Integrated Systems Physiol-
ogy: FromMolecule to Function. vol. 3. Morgan & Claypool Life Sciences; 2011. p. 1–100.
61. Kesmarky G, Kenyeres P, Rabai M, Toth K. Plasma viscosity: a forgotten variable. Clin Hemorheol
Microcirc. 2008; 39(1-4):243–246. PMID: 18503132
62. Yaseen MA, Srinivasan VJ, Sakadzic S, Radhakrishnan H, Gorczynska I, WuW, et al. Microvascular
oxygen tension and flow measurements in rodent cerebral cortex during baseline conditions and func-
tional activation. J Cereb Blood FlowMetab. 2011 Apr; 31(4):1051–1063. doi: 10.1038/jcbfm.2010.227
PMID: 21179069
Computation of Tumor Oxygenation with Application to Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0161267 August 22, 2016 40 / 42
CHAPTER 3. ORIGINAL PUBLICATIONS
3.1. COMPUTATIONAL MODEL FOR TUMOR OXYGENATION APPLIED TO CLINICAL DATA
ON BREAST TUMOR HEMOGLOBIN CONCENTRATIONS SUGGESTS VASCULAR DILATION
AND COMPRESSION
95
63. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng. 1999; 1
(1):241–263. doi: 10.1146/annurev.bioeng.1.1.241 PMID: 11701489
64. Leu AJ, Berk DA, Yuan F, Jain RK. Flow velocity in the superficial lymphatic network of the mouse tail.
Am J Physiol. 1994 Oct; 267(4 Pt 2):H1507–1513. PMID: 7943396
65. Chary SR, Jain RK. Direct measurement of interstitial convection and diffusion of albumin in normal
and neoplastic tissues by fluorescence photobleaching. Proc Natl Acad Sci USA. 1989 Jul; 86:5385–
5389. doi: 10.1073/pnas.86.14.5385 PMID: 2748592
66. Dafni H, Israely T, Bhujwalla ZM, Benjamin LE, Neeman M. Overexpression of vascular endothelial
growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic reso-
nance imaging, confocal microscopy, and histological tracking of triple-labeled albumin. Cancer Res.
2002 Nov; 62(22):6731–6739. Available from: http://cancerres.aacrjournals.org/content/62/22/6731.
abstract PMID: 12438274
67. Safaeian, N. Computational Modelling of Capillaries in Neuro-vascular Coupling. University of Canter-
bury; 2012.
68. Coppola G and Caro C. Oxygen mass transfer in a model three-dimensional artery. Journal of The
Royal Society Interface. 2008 Sept; 5(26):1067–1075. doi: 10.1098/rsif.2007.1338
69. Hellums JD, Nair PK, Huang NS, Ohshima N. Simulation of intraluminal gas transport processes in the
microcirculation. Ann Biomed Eng. 1996 Jan-Feb; 24(1):1–24. PMID: 8669708
70. Nair PK, Huang NS, Hellums JD, Olson JS. A simple model for prediction of oxygen transport rates by
flowing blood in large capillaries. Microvasc Res. 1990 Mar; 39(2):203–211. doi: 10.1016/0026-2862
(90)90070-8 PMID: 2352490
71. Pries A, Secomb T, Gaehtgens P, Gross J. Blood flow in microvascular networks. Experiments and
simulation. Circulation Research. 1990 Oct; 67(4):826–834. doi: 10.1161/01.RES.67.4.826 PMID:
2208609
72. Heroux MA, Bartlett RA, Howle VE, Hoekstra RJ, Hu JJ, Kolda TG, et al. An overview of the Trilinos
project. ACM Transactions on Mathematical Software. 2005 Sep; 31(3):397–423. doi: 10.1145/
1089014.1089021
73. Pries AR, Secomb TW, Gessner T, Sperandio MB, Gross JF, Gaehtgens P. Resistance to blood flow in
microvessels in vivo. Circ Res. 1994 Nov; 75(5):904–915. doi: 10.1161/01.RES.75.5.904 PMID:
7923637
74. Thomas H Cormen RLR Charles E Leiserson, Stein C. 22.3. In: Introduction to Algorithms, third edition.
The MIT Press; 2009.
75. LeVeque RJ. Finite difference methods for ordinary and partial differential equations—steady-state and
time-dependent problems. SIAM; 2007.
76. Knabner P, L A. Numerik partieller Differentialgleichungen. Springer Verlag; 2000.
77. Grimes DR, Kelly C, Bloch K, Partridge M. A method for estimating the oxygen consumption rate in mul-
ticellular tumour spheroids. J R Soc Interface. 2014 Jan; 11(92):20131124. doi: 10.1098/rsif.2013.1124
PMID: 24430128
78. Chauhan VP, Boucher Y, Ferrone CR, Roberge S, Martin JD, Stylianopoulos T, et al. Compression of
pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pres-
sure. Cancer Cell. 2014 Jul; 26(1):14–15. doi: 10.1016/j.ccr.2014.06.003 PMID: 25026209
79. DelGiorno KE, Carlson MA, Osgood R, Provenzano PP, Brockenbough JS, Thompson CB, et al.
Response to Chauhan et al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and
solids, measurement and meaning. Cancer Cell. 2014 Jul; 26(1):16–17. doi: 10.1016/j.ccr.2014.06.004
PMID: 25026210
80. Stylianopoulos T, Martin JD, Snuderl M, Mpekris F, Jain SR, Jain RK. Coevolution of solid stress and
interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res.
2013 Jul; 73(13):3833–3841. doi: 10.1158/0008-5472.CAN-12-4521 PMID: 23633490
81. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses
blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res.
1999 Aug; 59(15):3776–3782. Available from: http://cancerres.aacrjournals.org/content/59/15/3776.
abstract PMID: 10446995
82. Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, et al. Blood flow, metabolism,
cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res. 1989 Jul; 49
(14):3759–3764. Available from: http://cancerres.aacrjournals.org/content/49/14/3759.abstract PMID:
2736517
Computation of Tumor Oxygenation with Application to Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0161267 August 22, 2016 41 / 42
3.1. COMPUTATIONAL MODEL FOR TUMOR OXYGENATION APPLIED TO CLINICAL DATA
ON BREAST TUMOR HEMOGLOBIN CONCENTRATIONS SUGGESTS VASCULAR DILATION
AND COMPRESSION CHAPTER 3. ORIGINAL PUBLICATIONS
96
83. Grimes DR, Kannan P, McIntyre A, Kavanagh A, Siddiky A, Wigfield S, et al. The Role of Oxygen in
Avascular Tumor Growth. PLOS ONE. 2016 Apr; 11(4):e0153692. Available from: http://journals.plos.
org/plosone/article?id=10.1371/journal.pone.0153692 doi: 10.1371/journal.pone.0153692 PMID:
27088720
84. Viacava P, Naccarato AG, Bocci G, Fanelli G, Aretini P, Lonobile A, et al. Angiogenesis and VEGF
expression in pre-invasive lesions of the human breast. J Pathol. 2004 Oct; 204(2):140–146. doi: 10.
1002/path.1626 PMID: 15376259
85. Dhakal HP, Bassarova A, Naume B, Synnestvedt M, Borgen E, Kaaresen R, et al. Breast carcinoma
vascularity: a comparison of manual microvessel count and Chalkley count. Histol Histopathol. 2009
Aug; 24(8):1049–1059. PMID: 19554512
86. Fernandez-Guinea O, Alvarez-Cofino A, Eiro N, Gonzalez LO, del Casar JM, Fernandez-Garcia B,
et al. Lowmicrovascular density at the tumor center is related to the expression of metalloproteases
and their inhibitors and with the occurrence of distant metastasis in breast carcinomas. Int J Clin Oncol.
2013 Aug; 18(4):629–640. doi: 10.1007/s10147-012-0428-2 PMID: 22688161
87. Beaney RP. Positron emission tomography in the study of human tumors. Semin Nucl Med. 1984 Oct;
14(4):324–341. doi: 10.1016/S0001-2998(84)80006-9 PMID: 6387916
88. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and
exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive
dynamic method. Cancer Res. 1992 Mar; 52(6):1592–1597. Available from: http://cancerres.
aacrjournals.org/content/52/6/1592.abstract PMID: 1540969
89. Carp SA, Selb J, Fang Q, Moore R, Kopans DB, Rafferty E, et al. Dynamic functional and mechanical
response of breast tissue to compression. Opt Express. 2008 Sep; 16(20):16064–16078. doi: 10.1364/
OE.16.016064 PMID: 18825246
90. Kallinowski F, Schlenger KH, Kloes M, Stohrer M, Vaupel P. Tumor blood flow: the principal modulator
of oxidative and glycolytic metabolism, and of the metabolic micromilieu of human tumor xenografts in
vivo. Int J Cancer. 1989 Aug; 44(2):266–272. doi: 10.1002/ijc.2910440214 PMID: 2759732
91. Marieb EN, Hoehn K. Human Anatomy & Physiology. Pearson; 2013.
92. Sharan M, Vovenko EP, Vadapalli A, Popel AS, Pittman RN. Experimental and theoretical studies of
oxygen gradients in rat pial microvessels. J Cereb Blood Flow Metab. 2008 Sep; 28(9):1597–1604. doi:
10.1038/jcbfm.2008.51 PMID: 18506196
93. Ito H, Kanno I, Kato C, Sasaki T, Ishii K, Ouchi Y, et al. Database of normal human cerebral blood flow,
cerebral blood volume, cerebral oxygen extraction fraction and cerebral metabolic rate of oxygen mea-
sured by positron emission tomography with 15O-labelled carbon dioxide or water, carbon monoxide
and oxygen: a multicentre study in Japan. Eur J Nucl Med Mol Imaging. 2004 May; 31(5):635–643.
PMID: 14730405
94. Hartmann P, Mirtolouei R, Untersberger S, Ziegler W, Hermann Z, Richtig E, et al. Non-invasive imag-
ing of tissue PO2 in malignant melanoma of the skin. Melanoma Res. 2006 Dec; 16(6):479–486. doi:
10.1097/01.cmr.0000222605.03675.1d PMID: 17119448
95. Ito M, Yang DJ, Mawlawi O, Mendez R, Oh CS, Azhdarinia A, et al. {PET} and Planar Imaging of Tumor
Hypoxia With Labeled Metronidazole. Academic Radiology. 2006 May; 13(5):598–609. doi: 10.1016/j.
acra.2006.01.007 PMID: 16627201
96. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of
the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell.
2012 Mar; 21(3):418–429. doi: 10.1016/j.ccr.2012.01.007 PMID: 22439937
97. D’Angelo C. Finite Element Approximation of Elliptic Problems with Dirac Measure Terms in Weighted
Spaces: Applications to One- and Three-dimensional Coupled Problems. SIAM Journal on Numerical
Analysis. 2012; 50(1):194–215. doi: 10.1137/100813853
98. Sourbron SP, Buckley DL. Tracer kinetic modelling in MRI: estimating perfusion and capillary perme-
ability. Phys Med Biol. 2012 Jan; 57(2):1–33. doi: 10.1088/0031-9155/57/2/R1
Computation of Tumor Oxygenation with Application to Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0161267 August 22, 2016 42 / 42
CHAPTER 3. ORIGINAL PUBLICATIONS
3.1. COMPUTATIONAL MODEL FOR TUMOR OXYGENATION APPLIED TO CLINICAL DATA
ON BREAST TUMOR HEMOGLOBIN CONCENTRATIONS SUGGESTS VASCULAR DILATION
AND COMPRESSION
97
3.1. COMPUTATIONAL MODEL FOR TUMOR OXYGENATION APPLIED TO CLINICAL DATA
ON BREAST TUMOR HEMOGLOBIN CONCENTRATIONS SUGGESTS VASCULAR DILATION




Model details and validation
Transvascular oxygen mass transfer coefficient
We base the transvascular mass transfer coefficient γ on experimental and theoretical data [1, 2]





where r is the vessel radius, and Dp and αp are the diffusion coefficient and solubility of oxygen
in blood plasma, respectively. As seen in Figure A, we use a phenomenological fit function which
approximately describes the literature data [1, 2] for Nusselt numbers (assuming a blood oxygen
saturation of 90%). The form of this function is
Nu(r) = p2(1 − exp(−r/p1)), (2)
with parameters p2 and p1. A best fit gives p1 = 8 µm and p2 = 4.7. This is a good approximation
for small radii r < 100µm. For very large radii of several mm, which are not relevant here, we
expect this approximation to fail because then a vessels may be considered as a large reservoir
of oxygen, where the total transvascular flux is dominantly determined by the vessel surface area.
Hence we expect Nu to become proportional to r for r  p1 so that r cancels out of the flux density
of extravasated oxygen jtv = DpαpNu/2r(P − Pt).
Figure A. Nusselt numbers: The dimensionless Nusselt number Nu describes the oxygen flux
through the vessel wall in proportion to the difference between the average intravascular PO2 and
the PO2 at the wall. Nu(hellums) and Nu(moschandreou) denote experimental [1] and
theoretical data [2, Fig. 6], assuming a blood oxygen saturation of S ≈ 0.9. The red curve is a
best fit to the data.
Validation and comparison with literature data
To validate our model we considered the variation of intravascular PO2 distributions in systems
comprising a single vascular tube which is embedded in a block of a medium through which oxygen
can diffuse. We considered several cases with a tube length of 4 mm and various radii, and
compared these cases with literature data [2, 3] obtained from precise calculations with detailed
models. In general we obtain fair agreement. For comparison Figure B shows blood oxygen
saturations S at the end of the tube depending on tube radius r.
Details of the considered configurations are given in the following. The theoretical model of
Ref. [2] incorporates a multi-layered vascular tube as source of oxygen and a surrounding infinite
1
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tissue with a homogeneous background representing oxygen release from the capillary plexus.
We augmented the tissue diffusion equation (15, s. main text) accordingly by adding the source
term κ − Pt,iκ/P ∗, where κ = 0.625mmHg and κ/P ∗ = 30. Other parameter which are already
present in our model were readily adopted. The flow rate q poses an exception since it was not
provided directly by Ref. [2]. We determined it according to [2, (A6)] using the velocity profile
coefficients in the appendix. The simulation box was made large enough for the radial Pt profile to
assume the asymptotic value (42 mmHg) determined by κ and M0. [3] considered a configuration
where a vascular tube is surrounded by a block of rubber which is in contact with air at a specific
oxygen partial pressure. Two model variants exist. One situation where oxygen rich blood releases
oxygen to the rubber block [3, Fig. 2] and another where oxygen depleted blood takes up oxygen
[3, Fig. 3] from it. In the former case the PO2 of the air is kept at 160 mmHg and the blood PO2
at the inlet is 0. Vice versa for the former case. In either case, gas exchange happens through the
surrounding rubber block. We accounted for this situation by Dirichlet boundary conditions and by
setting the consumption rate M0 = 0. The faces perpendicular to the longitudinal axis are imposed
with no-flux conditions. The system size is set according to the reported half-thickness of the block
as 4mm× 80µm× 80µm. Computation were performed with a grid resolution of h = 20 µm. The
maximal relative error of the saturation obtained at the end of some tube S(x = 4mm) amounts to
approximately 16%.
Additionally, we compared our model with other numerical simulation methods using small
vascular networks. [4] recently published the software that produced the results for the theoretical
studies [5, 6] using a Green’s function method. Using software provided by Ref. [4] we were
limited to small networks confined within volumes of ca. 0.1 mm3 due to the computational cost
of the Green’s function method. Exemplary simulation results can be seen in Figure C. Obtained
PO2 distributions are in good agreement with results obtained by our method. We estimate a local
worst case difference in the intravascular PO2, P , of 30%, and an average difference relative to
the mean of P of ca. 16%.
Poor convergence of the solution with the grid constant h is a significant source of error in our
method. Convergence tests with respect to the grid constant h show sublinear convergence as
shown in Fig D where we plotted vascular and tissue oxygen partial pressures in a single vascular
tube for different grid constants. After an initial settling length, the oxygen partial pressure behind
the inlet is underestimated by an approximately constant offset, depending on h. The difference
between the on-axis value of blood and tissue PO2 remains approximately spatially constant.
Relative errors from the extrapolated true solution therefore start rather small behind the inlet
(approx. 3%) and increase to 13% at the end. The reason for poor convergence is the singular
nature of the oxygen source term (18) in the tissue oxygen diffusion equation , i.e. the use of
the Dirac-δ function. D’Angelo [7] obtained better convergence by using locally refined meshes.
Although it is a very challenging task, steps along those lines could be untertaken to improve
numerical accuracy.
It is possible to arrive at inconsistent solutions when the iteration of (20) and (21) has not
sufficiently converged. Then the amount of oxygen extracted from the network is not the same as
the amount consumed by tissue. Hence, in order to check for conservation of mass we determined




the error etv = (Jtv − Jcons)/Jtv. We also checked for mass conservation errors in the vasculature
due to the numerical integration of P and determined ev = (Jin − Jout − Jtv)/Jin, where Jin and
Jout are the influx and efflux through root nodes. We found both errors to be less than 1% at the
point where further iteration does not change the solution any more.
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Figure B. Comparison of blood oxygen saturations at ends of vascular tubes: We
considered a single 4 mm long vascular tube embedded in a passive medium through which
oxygen can diffuse. We computed the blood oxygen saturation S at the end of the vascular tube
x = 4 mm (red) under various conditions (see text), such as varying vascular radii r, which is
plotted here. Literature data of more sophisticated capillary models for equivalent cases [2, Fig.
4] (◦), [3, Fig. 2] (×), and [3, Fig. 3] (+) are shown as black symbols.
Figure C. Comparison with Green’s function method: (A) shows the oxygen partial pressure
PO2 distribution produced by our program. (B) shows the distribution produced by the software
by [4]. The solution of vascular PO2 distribution P is layered on top of a slice through the tissue
oxygen PO2 distribution Pt. The input to both programs was a small artificial network, identical
parameters, and a spacing of tissue points of h = 40 µm. However, boundary conditions for the
tissue PO2 diffusion equations could not be matched. Therefore we extended the simulation box
beyond the displayed region by 1 mm on every side. The colorscale for P and Pt is given in
mmHg.
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Figure D. Convergence test w.r.t. grid constant h. We consider a small simulation volume with
a single vessel of length 1 mm inside. Vascular (P , crosses) and tissue (Pt, pluses) oxygen
partial pressure PO2 distributions are shown. The development of P and Pt (dotted line) along
the vessel center axis is displayed in (A). In (B) we plotted the transversal profile of Pt, i.e.
perpendicular to the vessel axis along the spatial coordinate y1 at a point half way between the
ends of the vessel. The horizontal lines indicate the vascular PO2 at this point. For smaller h the
curves lie somewhat further apart, indicating sub-linear convergence, i.e. if the error to the true
solution was linear in h we would observe a constant spacing between curves.
Blood Pressure Radius Relation
Blood flow boundary conditions of our model are such that the blood pressure is set to fixed
numbers p(BC) for the solution for nodal pressures. Since blood pressure correlates well with
vascular radius r, we let p(BC) be given as function of r and the type of vessel (arterial or venous).
We first fit a curve to blood pressure data of rat mesentery [8]. Then we scaled the curve (adjusting
A1 and A2) so that physiological blood pressures [9, Fig. 19.6] are obtain in venules and arterioles,
thus obtaining for the blood pressure boundary condition
p(BC)(r) = [A2 + (A1 −A2)/(1 + exp((r′ − r0)/∆r))], (3)
where r′ = r for a vein, else −r, and A1 = 89 mmHg, A2 = 18 mmHg, r0 = −21µm, ∆r = 16µm.
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Explicit Formulas for Relevant Biophysical Quantities
After vascular networks of normal tissue and tumor were constructed, distributions of hemat-
ocrit in vascular networks and oxygen concentrations in vascular networks and tissue are calcu-
lated, yielding for each vessel segment v ∈ V e.g. radius rv , length lv, hematocrit Hv, blood flow
qv, blood oxygen saturation Sv(0) and oxygen concentration cv(0) at vessel entrance as well as
average blood oxygen saturation Sv. Using this information, the following averages are calculated,








taken as measure for microvessel density MVD .


























where I∩V (O∩V) denote set of all vessel segments penetrating surface ∂Ω with blood flow
pointing inwards (outwards).
Tissue hemoglobin concentration :






with mean corpuscular hemoglobin concentration MCHC, regional RBC volume rRBCV .








































where Y is the RBC-volume-weighted average of blood oxygen saturation taken over all
vessel segments.
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where the average concentration of dissolved oxygen in blood is given by c̄p = αp〈P 〉.








where the average oxygen concentration in tissue is given by c̄t = αt〈Pt〉.








where M is the Michaelis-Menten relation (17).







{P (x)− Pt(x)} dx, (12)
and corresponding regional transvascular oxygen flux rJtv = Jtv/|Ω| = MRO2 .









{P (x)− Pt(x)} dx, (13)
i.e. the average transvascular oxygen flux density is the length weighted average over the
mean oxygen flux density of all vessel segments; note that SD〈jtv〉 6= Jtv|Ω| = MRO2 .




qv {c0HvSin,v + αpPin,v} , (14)
with Pin,v = P
(BC)
v and Sin,v given by the Hill equation. The corresponding regional influx is
rJin = Jin/|Ω|.




qv {c0HvSout,v + αpPout,v} (15)
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Regional Blood Volume of Confined Perfect Binary Trees
In this section we derive an approximative relation between the number of root nodes R and
the regional blood volume rBV , provided that the total number of vessels M is held constant,
i.e. all vascular trees are confined to the simulation box Ω and adhere to a fixed vascular density.
Naturally R is also the number of trees. We assume that all vascular trees are perfect binary trees,
i.e. tree levels from k = 0 at the top to k = n− 1 at capillary (leaf) level have the maximum number
of vessels 2k. Furthermore we assume that trees are equal in the number of vessels (connections)
N . Hence M = N ·R is split to equal parts between trees. There is no distinction between arterial









q − 1 , (1)
for some q. N can therefore be written as N = 2n − 1, from which we obtain the depth
n = log2(N + 1), (2)
Let further the radii at a bifurcation be given by Murray’s law, i.e. rαc = rαa + rαb . Since a and b are
the same, we have rc = 21/αra=b, or in relation to the tree level k, we have the radius at level k
rk = 2
(n−1−k)/αrn−1, (3)
where rn−1 is the capillary radius. Now let’s estimate the volume of the tree TV , provided equal





since each level has 2k vessels of radius rk. Replacing rk by Eq.(3) we obtain




This is again a geometric series which is rewritten with the help of Eq.(1) and q = 21−
2
α to remove






(N + 1)− (N + 1)2/α
2− 22/α , (7)
where in the second line we further used that 2n = N + 1. Now to satisfy the constraint that the
total number of vessels taken over all trees is constant M , we substitute N = M/R, using the
number of trees R. For brevity we set the volume of the simulation box |Ω| = 1 without loss of





1 + RM − RM (MR + 1)2/α
2− 22/α . (9)
The denominator 2 − 22/α is a positive increasing function of α that vanishes for α = 2 and which
asymptotically approaches 1 for α → ∞. It can be shown that the nominator is a decreasing
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function in R, which is well approximated for small R/M  1 by 1 − (R/M)(1−2/α). In the edge
case where α = 2 we still obtain a decreasing function by calculating the limit of α → 2 for Eq.(6).
In that case it is logarithmic with rBV = 12 (R+M) log2(M/R+ 1).
Murrays α determines how much parent vessel radii grow at bifurcations. In the limit of α→∞,
Murrays law selects the radius of the thicker child vessel as the radius of the parent vessel. This
means all radii become equal, and indeed rBV (α→∞) = M is obtained from Eq.(9). As we would
intuitively expect, the dependence on R is eliminated. For realistic 2 ≤ α ≤ 3, the dependence on
R cannot be removed. Moreover we can consider the case where all vessels are root vessels, i.e.
R = M . Then again rBV = M is obtained, which is clear since then again all vessels have equal
radii. In actual simulations the assumption of perfect and equally sized trees does not hold, i.e.
frequently, small branches are generated. Moreover, even if all lattice boundary sites are occupied
with root nodes, only a small fraction of them grow to vascular trees of significant size. Most of
them regress to a single starting node without any connections. Despite that, we observe a clear
trend of decreasing rBV with increasing R.
2
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Further details on comparison between simulated and literature
biophysical data (see Tables 3 and 4)
In support of our model we further discuss simulated data listed in Tables 3 and 4 in some
detail, comparing our results with clinical data, data obtained from animal models and theoretical
data available in the literature.
Microvessel density MVD
The microvessel density MVD is measured microscopically by counting the number of microves-
sels per area of a tissue microscopic slide. The MVD is a quantity not easy to simulate. Therefore
we take the simulated length density LD , i.e. the total length of the vascular network divided by the
tissue volume as measure for MVD (s. S2 Appendix). This definition yields the correct dimension
and is identical to the number of vessels per cross-sectional area in case of a Krogh-like arrange-
ment of parallel vessels. However, when comparing experimental MVD data and simulated length
densities LD it should be kept in mind that both parameters are not identical. In a large portion of
the experimental literature on breast tumors, the MVD is obtained from well vascularized areas,
so called hot-spots. Dhakal et al. [1] reported densities between 15-348 mm−2 with a mean of
88 mm−2. Hot-spots are predominantly found near the tumor rim, but apparently not exclusively.
Fernandez-Guinea et al. [2] reported somewhat lower MVD values of 0-157 mm−2 from breast
tumor centers with a median of 20 mm−2. Stamatelos et al [3] reconstructed the vasculature of
a tumor of volume 280mm3 of a human breast cancer animal model and these authors report an
average length density LD of 21mm−2. However, spatial heterogeneity of the vasculature length
density varied considerably within the experimental tumor investigated, ranging from about 9mm−2
up to 101mm−2. We obtain a whole tumor average of 133 ± 18mm−2 (case CMPR, s. Table 3)
which includes a significant contribution of the rim. The prediction of the MVD of the central part
of the tumor agrees with the data of [2]. Microvessel density MVD of normal breast tissue is
reproduced accurately.
Regional vessel volume rBV
The regional vessel volume rBV denotes the volume fraction of tissue occupied by vessels, i.e.
vascular volume density (s. S2 Appendix). Using clinical data on hemoglobin concentrations of
normal breast tissue (cHb = 17.3 ± 6.2 µmol/l [4]), and of tumors (cHb = 53 ± 32 µmol/l [4]),
we estimated the vascular volume fraction. Tissue hemoglobin concentration cHb is the product
of mean corpuscular hemoglobin concentration (MCHC ) and regional RBC volume rRBCV (s.
S2 Appendix). Assuming hematocrit H = 0.45 to be homogeneously distributed within the vas-
cular network, tissue hemoglobin concentration is given by cHb = MCHC · H · rBV = cHb,blood ·
rBV , where cHb,blood is the hemoglobin concentration in whole blood. Using 64.5kg/mol for the
hemoglobin molar mass and assuming for the hemoglobin concentration in blood cHb,blood =
14g/dl (women, normal range: 12 − 16 g/dl), we estimate rBV = 0.008 ± 0.003 (normal breast
tissue) and rBV = 0.024± 0.015 (breast tumors). Results on hemoglobin concentration of normal
breast tissue and breast tumors obtained by a number of groups using optical mammography scat-
ter by about a factor of two [4], resulting in an upper limit of rBV = 0.016 for normal breast tissue
and a range of rBV = 0.01–0.06 for breast tumors. Stamatelos et al [3] report an average of tumor
vessel volume density of 0.007 and rBV to vary within the tumor of the human breast cancer model
from 0.002 up to 0.032. Beaney [5] obtained distinctly larger rBV estimates for human breast tissue
(rBV = 0.034) and human breast tumors (rBV = 0.043), derived from PET measurements using
the steady state 15O2 inhalation technique. Note, however, that the rBV values reported by Beaney
[5] for breast tumors, have to be considered as unreliable since the compartment model used to
analyze the PET data is inaccurate for heterogeneous tissue [6]. For comparison, in normal human
brain regional blood volume was determined from PET measurements to be rBV = 0.038± 0.007
[7]. Using MRI and a brain tumor animal model yielded rBV = 0.026± 0.003 (normal brain tissue)
and rBV = 0.053 ± 0.006 (brain tumor) [8]. Our simulation results on regional vessel volume of
normal breast tissue and breast tumors (case CMPR) agree with clinical data derived from optical
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mammography. Furthermore, rBV of breast tumors (case CMPR) falls within the range of vol-
ume densities reported in [3] for the animal breast cancer model. In addition, for normal breast
tissue, we deduce a venous fraction of the total blood volume fraction vrBV /rBV = 68% in fair
agreement with MRI data of normal human brain (77%) [9]. Because the classification of vessel
segments of the tumor vasculature into arterioles, capillaries and venules no longer applies, the
venous fractional blood volume is meaningless in case of tumors.
Vessel surface to vessel volume
Besides vascular surface density SD, Table 3 lists the vessel surface density to vessel volume
density ratio SD/rBV . For a single vessel segment vessel surface to vessel volume scales as 1/r.
Although this result will no longer be exactly applicable for the ratio of vessel surface density to
vessel volume density, we expect this ratio to decrease with increasing average vessel radius. For
tumor vasculature (case CMPR) we find SD/rBV = 0.27 µm−1 close to the simulated value for
normal breast tissue (SD/rBV = 0.29 µm−1). This modest decrease is ultimately explained by the
low maximal dilation radius r(max) = 14 µm, leading to an average vascular radius of r = 5.2 µm
(case CMPR), only 2 µm above the average radius of initial networks. A contributing factor is the
peripheral plexus of thin and densely packed vessel (high SD/rBV ), part of which is included in the
tumor volume. Stamatelos et al [3] reported a surface to volume ratio of SD/rBV = 0.17 µm−1 for a
human breast tumor animal model together with an average (median) vessel radius of r = 9.2 µm.
Perfusion
Dynamical PET measurements (15O2) on 37 breast cancer patients yielded rBF = 0.06ml/g/min
(mean, normal tissue, range 0.03−0.17ml/g/min) and rBF = 0.32ml/g/min (mean, tumor, range
0.08 − 0.9ml/g/min) [10]. Nearly the same results were reported in [11]. Volumes of human
breast cancers imaged range from one to several cm3, typically. On the other hand, the range
of simulated regional blood flow rBF = qsph,tum/|Ωsph| of the small (0.014 cm3) spherical tumor
amounts to 0.13 − 7.5ml/g/min, with a mean 1.25ml/g/min (case CMPR) being higher by about
a factor of 4 compared to the clinical results (s. Table 3). We attributed the discrepancy between
simulated perfusion and clinical data to the considerable difference in tumor volumes. Indeed, a
general decrease of perfusion with increasing tumor mass was seen previously for human breast
cancer xenografts. Perfusion ranged from 0.5 ml/g/min at mtum = 0.4 g down to 0.025 ml/g/min
at mtum = 8 g [12] . For eliminating the dependence of simulated perfusion on tumor volume,
Table 3 lists the scaled perfusion rBF scaled = rBFnorm · qsph,tum(t = 600h)/qsph,norm(t = 0).
Mean simulated scaled perfusion rBF scaled (case CMPR) is lower by about a factor of 2 compared
to the clinical results, possibly overestimating size dependence of tumor perfusion. Our results for
normal breast tissue (range: 0.032− 0.064ml/ml/min) agree well with clinical data.
Wall shear stress
Simulated wall shear stress of normal vasculature falls within the range of shear stresses mea-
sured for human conjunctival arterioles, capillaries and venoles [13, 14]. Simulated shear stresses
of the tumor model variants are consistent with shear stresses reported by Stamatelos et al [3] for
a human breast cancer animal model.
Tissue oxygen partial pressures
The global ensemble average of simulated PO2 of normal tissue and tumor tissue amounts to
36± 6 mmHg and 29± 13 mmHg, respectively (s. Table 4). Polarographic PO2 measurements at
a large number of sites in normal breast tissue and breast tumors of 15 patients yielded median
PO2 values of 65 mmHg and 30 mmHg, respectively [12]. The simulated PO2 value of tumor tis-
sue (case CMPR) reproduces the clinical result exactly, the coincidence possibly being fortuitous,
considering the skewed histogram of measured partial oxygen pressures [12]. Since the distribu-
tion of measured partial oxygen pressures in normal breast tissue is rather broad, simulated and
measured tissue partial oxygen pressures in normal tissue can be considered to agree.
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Metabolic rate of oxygen consumption
Our model assumes tissue metabolic rate of oxygen consumption to follow a Michaelis-Menten re-
lation and takes the maximal rate M0 and half-pressure PM50 as input. In particular, maximal rate
M0 in tumor tissue was assumed to be four times larger than in normal breast tissue, whereas half-
pressure PM50 of normal breast tissue was adopted to be twice that of breast cancers (s. Table
1). Since (average) partial oxygen pressures in normal and tumorous breast tissue were simu-
lated to be considerably higher than the assumed half-pressures PM50, the simulated metabolic
rates MRO2 = 3.25 µlO2/ml/min (normal tissue) and MRO2 = 12.1 µlO2/ml/min (breast tu-
mor, case CMPR) are essentially determined by the adopted parameter M0 of the Michaelis-
Menten relation. From PET measurements based on the steady-state 15O2 inhalation technique,
Beaney [5] reported MRO2 = 4.5 µlO2/ml/min and MRO2 = 6.6 µlO2/ml/min for normal breast
tissue and breast tumors, respectively. The latter value had been challenged because of tu-
mor inhomogeneity [6]. Recently, a considerably higher metabolic rate of oxygen consumption
M0 = 40.6 ± 7.8µl O2/ml/min was reported of viable multicellular human colorectal carcinoma
spheroids, taken as in-vitro tumor model [15]. In addition, measurements of oxygen flux above a
monolayer of cancer cells in culture medium yielded metabolic rates M0 from 21µl O2/ml/min up
to 52µl O2/ml/min for various human cancer cells, with M0 = 33.4±8.3µl O2/ml/min for human
breast cancer cells MDAMB- 468 [16]. For comparison we note that for normal human brain PET
measurements yielded CMRO2 = 33± 5µl O2/ml/min [7].
Oxygen extraction fraction
Average blood oxygen saturation is (negatively) correlated with oxygen extraction fraction OEF =
Jtv/Jin = (Jin − Jout)/Jin = MRO2/rJin, where Jtv is the total transvascular oxygen flux into
tissue, in Jin(Jout) the total oxygen influx (efflux) into the vasculature (leaving the vasculature) of
the tissue volume and rJin is the oxygen influx per unit volume of tissue considered. For the whole
simulation box, Jin and Jout are determined by summing oxygen flux qc over all root arteries or
veins, respectively. For the tumor, we sum qc over vessels penetrating the tumor surface with a
flow direction into or out of the tumor. For normal breast tissue and breast tumors (case CMPR)
we obtain the result OEF = 0.34 ± 0.1 and OEF = 0.11 ± 0.09, respectively. Oxygen extraction
data on normal breast tissue and breast tumors are scarce in the literature. Beaney [5] reported
the oxygen extraction fraction of normal breast tissue to be OEF = 0.65 ± 0.1. This result seems
to be rather high considering the oxygen extraction of normal human brain measured by PET to
be OEF = 0.44± 0.06 [7].
Using the steady state 15O2 inhalation technique almost the same oxygen extraction fractions
were measured for breast tumors (OEF = 0.23 ± 0.08, [5]) and brain tumors (OEF = 0.22 ± 0.04,
[17]) , however the same reservations remain concerning inadequate data analysis because of
tissue heterogeneity. Our simulations predict for breast tumors (case CMPR) oxygen extraction
fractions of OEF = 0.11 ± 0.09, an estimate likely to be too low. Since MRO2 = ε · cHb,bloodSin ·
rBF · OEF , where ε is the Hüfner factor and Sin the arterial blood oxygenation of the vessels
penetrating the surface of the spherical tumor, overestimation of the tumor regional blood flow
will cause an underestimation of the oxygen extraction fraction OEF , since the metabolic rate
of oxygen consumption is essentially fixed by the input parameters of the model. Conversely,
estimates of scaled perfusion are probably too low, overestimating the dependence of perfusion on
tumor volume. Therefore, corresponding oxygen extraction fractions of breast tumors are probably
on the high side (OEF = 0.66, CMPR). In addition, Table 4 lists the oxygen influx Jin and average
transvascular oxygen flux density jtv, where we write jtv informally for the average over the network
length (s. S2 Appendix).
Tissue blood oxygen saturation
Vessel segments contribute to tissue hemoglobin concentration cHb (tissue oxyhemoglobin con-
centration cHbO) according to their blood hemoglobin concentration, (blood oxyhemoglobin con-
centration) weighted by their fractional volume. In order to simulate cHbO for each vessel seg-
ment its average blood oxygenation has to be known. Simulated tissue blood oxygen saturation
Y = cHbO/cHb agree well with clinical data.
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S1 Figure
Tissue PO2 distributions at constant vascular blood oxygena-
tion
For some applications, such as models of tumor growth, it might be sufficient to implement a
simplified model of oxygenation where the intravascular PO2 is a constant input parameter to the
model. Results obtained from such a model are presented in the following. To this end we modified
our present model, omitting the propagation of oxygen losses through the vascular network, and
instead setting the oxygen partial pressure P to a constant. A map of the resulting oxygen distri-
bution is shown here in Fig. A, where we set P = 39 mmHg, equal to the mean intravascular PO2
taken over initial (t = 0) networks of the simulated cohort as it is obtained from the full model. An
obvious qualitative difference is the absence of long ranged Pt variations in normal tissue. Instead,
fine grained fluctuations in-between neighboring vessels are much more apparent. As expected,
the Pt level along the surviving tumor vessels is nearly constant so that the Pt distribution can
approximately be described by a function of the distance to the closest vessel alone. The neglect
of varying intravascular PO2, leads to overestimation of Pt in the peripheral region (cf. Fig. 5 C).
Naturally, this simplified model implies constant tissue oxygen saturation Y , and thus does not
allow to analyze experimental data on blood oxygen saturation in normal and tumorous tissue.
Figure A. Tissue oxygen distribution at constant vascular PO2: This figure shows a
visualization of the network depicted in Fig 5 C,D but with blood PO2 held constant.
1
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Figure A. Correlations of tissue blood oxygenation Y and length weighted blood oxygen
saturation S for two assumed Michaelis-Menten metabolic rates of oxygen consumption
M0 (case BASE): Tissue blood oxygen saturation of tumors versus host tissue (A) and
length-weighted blood oxygen saturation S of tumors versus host tissue (C) at
M0 = 14.8µl O2/ml/min (case BASE); right column: tissue blood oxygen saturation of tumors
versus host tissue (B) and length-weighted blood oxygen saturation S of tumors versus host
tissue (D) at elevated M0 = 24.6µl O2/ml/min; the color code to identify root node geometry is
the same as in Fig 9.
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Abstract. During the past years our group published several articles using computer simulations to address
the complex interaction of tumors and the vasculature as underlying transport network. Advances in imag-
ing and lab techniques pushed in vitro research of tumor spheroids forward and animal models as well as
clinical studies provided more insights to single processes taking part in tumor growth, however, an overall
picture is still missing. Computer simulations are a non-invasive option to cumulate current knowledge
and form a quasi in vivo system. In our software, several known models were assembled into a multi-scale
approach which allows to study length scales relevant for clinical applications. We release our code to
the public domain, together with a detailed description of the implementation and several examples, with
the hope of usage and futher development by the community. A justification for the included algorithms
and the biological models was obtained in previous publications, here we summarize the technical aspects
following the workflow of a typical simulation procedure.
1 Introduction
Vascular networks play an important role in therapy and
progression of cancer. In particular their formation and
modifications are a special feature of most malignant tu-
mors [1]. In the case of solid tumors, the growth of cancer
cells is facilitated by the diffusion of nutrients within the
vicinity of the cells. Growing beyond the average diffu-
sion length of nutrients, tumors adopt new strategies to
acquire nutrients. By transforming the present blood ves-
sels, the tumor exploits them for his own purposes. The
full complexity of this process is not yet understood.
Since the vasculature transports drugs to cancer cells,
this transformation is certainly of interest for chemother-
apy, and also radio therapy is known to be dependent on
the oxygen level inside the tissue which is again depen-
dent on the vessel morphology and vessel wall properties.
The complex dependence of solute transport or solute dis-
tribution and spatial arrangement of the blood vessels is
therefore of great importance in every cancer therapy.
Obtaining experimental or clinical data of sufficiently
high resolution to reconstruct vascular networks is by it-
self a hard task [2]. To overcome the lack of data, in silico
modeling of vasculature is done by various authors. In [3]
⋆ Supplementary material in the form of one .zip, one .mov,
one .avi and five .pdf files available from the Journalweb page at
https://doi.org/10.1140/epje/i2018-11659-x
a e-mail: thierry.fredrich@googlemail.com
b Present address: Campus E2 6, Saarland University, 66123
Saarbrücken, Germany.
an off-lattice, agent-based model is used to successfully
construct vascular structures of around 1mm in size. Oth-
ers also focus on the extra cellular matrix [4], but most
studies focusing on structural aspects neglect blood trans-
port inside the vessels which is essential for clinical appli-
cations. Well-established models consider the blood flow
but are restricted to two dimensions [5] and only a few are
done in 3D [6]. Apart from blood vessel network construc-
tion, the growth of tumors is of key interest.
The implementation strategies for tumor growth fall
into two categories. First: discrete, particle-based ap-
proaches where each cancerous cell is modeled individ-
ually [7]. Naturally this takes considerable computational
efforts providing greater details on the cell level. Sec-
ond: models where the tumor is described by continuous
equations, reaching dimensions relevant for diagnostics [8].
Nevertheless, it is mostly neglected that tumors in patients
or animal models grow within well-vascularized environ-
ments which means the original or initial network is not
adequately represented.
Another problem in the field is that the code is main-
tained and used by corresponding groups only, rather than
sharing implementations which would simply save time.
Repositories for open source code are well known in com-
puter science and started to become useful in life science
as well [9, 10].
To create blood vessel networks, we use a lattice-based
attempt which discretizes the angular freedom and enables
us to explore large scales. To the best of our knowledge
there is no other software constructing synthetic arterio-
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venous blood vessel networks on macroscopic tissue vol-
umes in 3 dimension matching topological, morphological
and hydrodynamic properties observed in real samples.
Our multi-scale approach describes tumor growth by par-
tial differential equations and thus it is possible to simu-
late system sizes of the order of centimeters.
Subsequently, the interpretation of clinical studies, an-
imal models and testing of hypotheses on biological pro-
cesses is feasible. Our approach allows us to study topo-
logical and functional aspects at the same time which is
relevant for therapeutics.
Since the understanding of malignant tumors is of
great interest in the life science community and in sil-
ico experiments are an extension of traditional biological
techniques, we make our code, together with a detailed
user manual, available to the public.
2 Design and implementation
Like modern implementations we reassemble two most dis-
tinct aspects. On the one hand, we use python together
with the scipy packages for an easy and straightforward
scripting of scientific problems. On the other hand, com-
putationally expensive tasks are delegated to a core writ-
ten in C++ for performance reasons. Following up, a
pythonic interface to this core has been created with the
help of Boost.Python. We decided to use the “hdf5”-file
format [11] to store data since it is highly scaleable and
supported by both programming languages used.
2.1 Computational core
Standard C++ coding is used where the comments fol-
low the doxygen notation enabling the user to retrieve in-
formation about dependences and inheritance within the
object-oriented kernel. Instructions on how to create the
documentation can be found in the subfolder “doc”.
Examples for demanding main applications are: 1) cal-
culating the hydro- and hemodynamics and 2) solving par-
tial differential equations. Both problems reduce to solv-
ing systems of sparse linear equations which we do by the
Trilinos package [12].
2.1.1 Hydro- and hemodynamics
Before determining hydro- and hemodynamics of the net-
work, the topology itself is created by the vesselgen-
erator (see folder “src/common/vesselgen”). The idea
follows a 3-dimensional generalization of the algorithm
presented in [13]. An example output can be found in
fig. 1 and a complete description of the algorithm is pro-
vided in [2], sect. 2.1. We summarize the basic steps
as follows: First, arterial and venous root nodes are
placed on a lattice and blood pressure or blood flow
rate is assigned. The phenomenological formula, eq. (3)
in https://doi.org/10.1371/journal.pone.0161267.
s001, is well suited for this task. Next, segments are ap-
pended at random until arterial and venous trees meet.
Fixing the radii of the capillaries, Murray’s law allows us
Fig. 1. Rendering of blood vessel network. The rendering of
the blood vessel network created in suppl-file4 is shown. In-
structions on how to obtain such images from the software are
explained in suppl-file8. Blood pressure is color-coded in kPa
and a scale bar of 250µm is present. A slice throughout the
whole 3D cube is displayed in the figure.
to determine the radii of all mother vessels up to the root
node level. Once the radii are known, we assume mass
conservation at each vertex to get a matrix equation anal-
ogous to a Kirchhoff circuit in electrodynamics. Solving
this sparse matrix equation provides blood pressure val-
ues and blood flow rates for every vessel. Subsequently,
the formula for laminar flow allows to calculate the shear
force acting on the wall. In a last step, the total shear force
is optimized in a Monte Carlo manner which requires to
solve the sparse matrix equation frequently. Capillaries
are deleted and inserted as long as the total shear force
is minimized and the spatial distribution of capillaries is
maximized. At the end of the construction step we take
the F̊ahræus-Lindqvist and phase separation effect into
account.
2.1.2 Tumor growth
The bulk tissue tumor model is based on a framework de-
veloped in [8], where the tissue is described as a mixture
of various components. Our implementation includes nor-
mal, tumor and necrotic phases. The levelset-method is
used to distinguish the different phases and defines the
interface between them. Assuming incompressibility, one
can describe the composition in terms of volume fractions
which leads to a system of partial differential equations
of diffusion-convection-reaction type for each phase. In-
troducing a regular cubic lattice for bulk tissue allows
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Fig. 2. Workflow of tumorcode. Dotted lines indicate that connected modules can be interchanged. The straight arrows must
be followed in the direction indicated by the arrow head.
to solve these equations by Finite Difference techniques.
Consequently, the numerical resolution of the tumorcode
is governed by the lattice constant chosen. The number of
grid points and vessels is limited by the provided hardware
memory. Note that the bulk tissue and vascular network
coexist in the same space, however, on different lattices. To
fully utilize the modern computing equipment we paral-
lelized our code with the shared memory API of OpenMP.
More details about this methodology could be found in the
well-written article [14].
For explorative studies, a fake tumor calculation which
neglects the full dynamics of the cells and represents a tu-
mor as spherically expanding mass of cells at a constant
speed is implemented. Still the remodeling of the vascu-
lature via vessel cooption, regression, and growth takes
place.
2.1.3 Finite elements method
In [15] we showed that the equation for the vascular oxy-
gen distribution together with the diffusion equation for
the tissue form a complicated nonlinear system of equa-
tions with the partial pressure values of oxygen as un-
knowns. For the longitudinal transport a bisection search
is used to gather the partial oxygen pressure values within
each vessel. Constructing consistent expressions for the
transvascular exchange of oxygen across the vessel lumen
was a challenging task, but enabled us to use the exchange
as source or sink for the diffusion equation of the tis-
sue oxygen field. Standard Galerkin methods were used
to translate the task of solving the diffusion equation into
solving sparse linear equations. To this end, the algebraic
multigrid methods implemented in Trilinos were appropri-
ate. Alternating the solver for vascular oxygen transport
and the solver for the partial oxygen pressure of the tis-
sue results in a stable self-consistent equilibrium oxygen
distribution.
2.2 Python API
After successful installation, the main tools can be
found in the “bin” folder. Note that the Input Inter-
face is written in python and that necessary parame-
ters are also stored as python dictionaries (see folder
“py/krebsjobs/parameters”).
tumorcode is ready to use on computing clusters
equipped with a queuing system. To remember the fact
that the computation will be submitted to a queuing sys-
tem, the name of the simulation programs start with sub-
mit. Currently we support “PBS (Portable Batch Sys-
tem)” and “Slurm Workload Manager”. Job details such
as expected runtime and allocated memory could be pro-
vided as optional command line arguments. If no sup-
ported queuing system is present or the flag (–q-local)
is invoked, the computation runs on the local machine.
Possible command line arguments and their structure are
illustrated to the user by running the main programs with
the help flag (-h). Each submit scripts expect the user to
supply at least the name of a parameter set as command
line argument.
How the single calculations are invoked and executed is
presented in the supplementary material (suppl-file4–
suppl-file8).
3 Workflow
The following subsections track a typical workflow corre-
sponding to the yellow frames in fig. 2, where we visualize
the procedure.
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Fig. 3. Illustration of vessel data structure. This minimal example contains 3 arteries, 3 veins and 2 capillaries. Inset A:
the topological structure given by labels of the node points in yellow and the label of the edges in green. Inset B: morphology
calculated by tumorcode, note the size radii of the vessels and the color-code due to the pressure given in kPa. Inset C: structure
of the “hdf5”-file containing the vessel structure.
3.1 Vessels
In general, one starts by creating synthetic blood vessels
which serve as host and transport network (see 2.1.1).
Another possibility is to provide measured input data.
A transformation from the published data in [16] to the
structure used by our software is described in the file
“py/krebs/adaption/apj2hdf.py”. To elaborate the char-
acteristic structure of a vessel file, a minimal work-
ing example is created where 3 arteries, 3 veins and 2
capillaries form a loop. In principal, each vessel is de-
fined as an edge linking two nodes. Details can be ob-
tained from fig. 3 as well as from the source stored
in “py/tests/simpleVesselConfig.py”. The hemodynamic
and morphological data calculated throughout the cre-
ation process as described in sect. 2.1.1 is stored for
each vessel within the “edges” directory, e.g., flow, ra-
dius and hematocrit. Further, the parameters used to
calculate the hemodynamics, as specified by the “-p”
flag, are written into the sub-folder “parameters”. The
arrangement of root nodes accross the lattice is spec-
ified by the type (“-t”) flag. The choice between 0
and 8 corresponds to one of the distribution shown
in https://doi.org/10.1371/journal.pone.0161267.
g003. The flag (“–twoD”) is of particular interest here.
If selected, the creation process is restricted to a plane.
All other programs are in full 3D.
3.2 Tumor
Once vessels are constructed or read from experimental
data, the workflow continues to the tumor stage where
Fig. 4. Rendering of a bulk tissue tumor simulation.
suppl-file5 explains how to obtain this image. The camera
position “pie” is chosen in order to see the tumor inside the
cube. The vessel network is the same as shown in fig. 1.
the simulation of either a fake tumor or a bulk tissue tu-
mor can be started. “submitBulkTissue” runs simulations
using the algorithm from the core discussed in sect. 2.1.2
and “submitFakeTum” includes the discussed simplifica-
tions. Both types of tumor simulation need a parameter
set and a “hdf5”-file containing proper vessels as com-
mand line input. When running, these simulations output
their current configuration at time intervals as specified by
the parameters. The groups in the output file are named
out0000, out0001, etc. Figure 4 shows a snapshot of the
simulation carried out in the suppl-file5.
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3.3 Biological models
After the tumor stage, a “hdf5”-file containing time snap-
shots of either tumor simulation should be present. To
invoke one of the biological models, the time point needs
to be passed as additional argument. Therefore one needs
to provide the name of a parameter set, the tumor file
and the name of the time point. Note that time points are
labeled consecutively by out0000, out0001 etc.
“submitIff ” allows you to calculate distributions of
the interstitial fluid flow and corresponding advection
maps of drugs. Valid parameter sets can be found
in “/krebsjobs/parameters/parameterSetsIff.py”. The sub-
dictionary “iff” adjusts the interstitial fluid while the
“ift” sub-dictionary adjusts the treatment of the tumor
by the chemotherapy. Currently, we provide 2 administra-
tion protocol:
– DF INJECT MODE EXP decreases the drug within
the bloodstream in an exponential fashion. We corre-
late this with the injection of a single bolus decaying
in the bloodstream.
– DF INJECT MODE JUMP lets the level of drug
within the blood stream jump from a constant value
to zero. This mimics permanent infusion of a drug.
Varying the diffusion constant of the drug and its vessel
wall permeability allows to screen for different modalities
(see suppl-file6 and refererences therein).
Secondly, an elaborated model of blood and tissue
oxygenation was developed [15]. Similarly to “submitIff ”,
“submitDetailedO2” needs a parameter set, a tumor sim-
ulation and a specified time point as input.
3.4 Analyzing and visualization
Finally, we offer a large number of scripts that we use to
analyze raw simulation data.
Like the simulations, our analysis programs are hybrids
between C++ and python. Since the datasets can become
quite large in filesize and take a long time to be processed,
most evaluation programs are equipped with datacache,
i.e., the results of certain costly computations are saved
to disk and loaded from there next time the execution
is called with the same arguments. This facilitates the
iterative development, at least to some degree, without
recomputation.
In order to use state-of-the-art visualization tech-
niques, we export datasets created with tumorcode in 2
different data formats as demonstrated in suppl-file8.
ParaView allows an elaborated inspection of the vessel
network structure. It offers interactive viewing and basic
statistics on medium size systems, depending on your ma-
chines RAM. To render even the largest systems, we follow
the ray trace approach of POV-Ray. Similar to ParaView,
we offer a wrapper which converts vessel, tumor, oxygen
and drug datasets to POV-Ray scene files, and run POV-
Ray automatically in succession. Images of this kind are
depicted in our latest publications [15,17].
4 Applications
As an illustration of the capabilities of tumorcode, we
designed the supplemental examples (suppl-file4,
suppl-file5, suppl-file6, suppl-file7 and
suppl-file8) within the realm of the two studies
already published. However doing the same, we scaled
the simulation in the examples to be smaller and quickly
reproducible. On a standard desktop PC (Intel i7,
2 × 8GB RAM) they are executed within minutes.
For details on the exact setup we refer to [15,17].
4.1 Blood vessels and tumor morphology
In silico modeling features the opportunity to measure
structural and dynamical quantities at the same time.
Simple averages of, e.g., flow, radii and vessel volume are
implemented straightforward in our software. Addition-
ally, we can average data over spherical surfaces to mimic
various experimental measurements. A profound inspec-
tion of a bulk tissue tumor simulation on a large scale
could be found in [17], fig. 3. There the graphs display mi-
crovessel density (MVD), vessel radius, cell velocity, oxy-
gen, wall thickness and wall shear stress where the time
course of tumor growth is visualized by different colors.
The level set method allows to localize the distance of
the tumor-tissue interface which is used as ordinate for
the cited plots. Within that framework it is easy to define
the “inside” and “outside” of a tumor and focus on the
differences.
Distinct experimental techniques such as MRI, micro-
CT or xenografts are available to access morphological
data of tumor tissue as well. But comparable data ob-
tained from animal models usually requires the immola-
tion of an animal per time point. Therefore such stud-
ies are heavily biases by inter-subject variation. Recently,
we used this framework to create networks matching the
morphology of a swine animal model. In suppl-file4, we
create a dataset of this kind and present the analysis.
4.2 IFF and drug distribution
To measure IFF and the related interstitial fluid pres-
sure (IFP) in vivo is an especially hard task even with
modern measurement methods. Regarding the medical as-
pects, special interest is drawn to the vasculature as source
for therapeutics and nutrients. A solid understanding of
IFF and IFP is also crucial for fighting cancer since an el-
evated IFP is believed to pose a barrier to drug delivery
and oxygenation. The resulting hypoxia leads to inefficacy
of drugs and radiation. For this type of simulation we con-
sider the IFP as driving force of the flow, i.e. via Darcy’s
law. Differences between IFP, blood pressure and the fluid
pressure within lymphatics drive transvascular fluxes ac-
cording to Starling’s equation. We solve the stationary
case leading to a Poisson equation for the pressure.
Ensuing the determination of IFF, solute transport
into tissue can be simulated. If specified by parameters
(see suppl-file6), the mass balance equation for solutes
is integrated numerically based on the calculated flow,
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Fig. 5. Snapshots of interstitial fluid flow quantities. (A) Vessel volume fraction, (B) IFP, (C) fluid source term, (D) x-component
of the IF velocity, (E) magnitude of the IF velocity, (F) projection of IF velocity in outward direction. The plots were generated
from 2d slices through the center of the simulation result obtained in suppl-file6. The contour line indicates the boundary of
the viable tumor mass. The internal regions consist of necrotic tissue, while the outer area is normal host tissue.
Fig. 6. Overview of detailed oxygen simulation. (A) Partial oxygen pressure within vessels and surrounding tissue. Note the
hypoxic core in the center where the tumor grows. (B) Amount of oxygenated hemoglobin within the vessels. For illustration
purposes the tissue is not depicted. (C) Blood oxygen saturation within the vessels. Note that all three figures show the same
blood vessel network. See suppl-file7 for construction details.
diffusion coefficients, rate constants, etc. For an exem-
plary overview of such quantities, see fig. 5. Quantitatively
these agree well with the results obtained by simulating
larger systems where the administration of doxorubicin
was included (see [17], figs. 4, 7). Notably, our results ob-
tained by these simulations suggest that despite of an IFP
plateau within the tumor, IFF does not cease and still
allows for substantial convective transport which was in
contradiction to the view at that time. Furthermore we
varied numerous parameters and the administration pro-
tocol emulating clinical studies which would be extensive
and lengthy in practice.
4.3 Detailed oxygen distribution
We augmented the model of oxygen transport such that
intravascular variation of the oxygen content along ves-
sel center lines is taken into account. Moreover a varying
hematocrit based on the (Red Blood Cell) phase sepa-
ration effect (see [18] and sections “Hydro- and hemo-
dynamics”, “Finite elements method”) has been imple-
mented. Since most oxygen is transported through the
body while bound to the RBCs, the hematocrit distri-
bution is the physical key to the oxygen transport. To-
gether with the unbound oxygen within the blood, we im-
plemented a coarse-grained model of oxygen concentration
along the direction of blood flow which causes tissue oxy-
genation. An example of this type of simulations is pre-
sented in suppl-file7. Here we show the visualization of
the simulation results as fig. 6.
The focus of the published study was to simulate tis-
sue total hemoglobin concentrations cHb and tissue blood
oxygen saturation Y of tumors and host tissue and com-
pare the results with clinical data on breast tumors and
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surrounding normal breast tissue obtained from a cohort
of 87 breast cancer patients using optical mammograph.
Following the workflow of tumorcode we began by con-
structing 90 distinct host vasculatures followed by the
growth of fake tumors. Using the detailed oxygen simu-
lation, we showed that the redirection of the hematocrit
during the tumor growth is accompanied by changes in
flow rates and identified this as key element of the modula-
tion in blood oxygen saturation. In contrast, the fact that
vascular dilatation leads to an elevated tumor oxygen sat-
uration is not intuitive but confirmed by our simulations.
Strikingly, we found evidence that different types of ini-
tial vascular configurations are correlated to the variance
of tissue hemoglobin concentration, tissue blood oxygen
saturation and perfusion which raises biological insight.
5 Conclusion
This manuscript describes the software used to draw con-
clusions about elevated interstitial fluid pressure, drug and
oxygen distribution in previous publications. All simula-
tions are based on constructing synthetic arterio-venous
blood vessel networks on macroscopic tissue volumes
matching topological, morphological and hydrodynamic
properties observed in real samples. To the best of our
knowledge there is no comparable software for this task.
Development, implementation and debugging of soft-
ware is tedious, and distracts from biological or medi-
cal aspects. By varying the parameters in our simulation
framework, we allow everybody to tackle its own ques-
tions within the realm of this software. Further, we al-
low everybody to reproduce the experiments we carried
out so far, as it is required by good scientific practice.
We share the source-code under open source license at
https://github.com/thierry3000/tumorcode.
Despite the code is platform independent, successful
compilation and usage as described in this article is re-
stricted to Unix-based systems at the moment. If required,
support for different operating systems is feasible. Like-
wise, implementing a graphical user interface as extension
of our module-based code is straightforward and could
serve other researchers in life science with less background
in computer science. Following the direction towards a
common code base in the field, we hope this article and
mainly the examples in the supplementary material help
to overcome technical struggles. In the future, merging
tumorcode with other codes may be an option.
Currently, the drug as well as the detailed oxygen dis-
tribution is calculated at time snapshots of the tumor
growth process only. To engage pharmacodynamics and
improve predictions, correlating the time points could be
considered in the future. Also additional features rele-
vant for clinics like, pH, ATP consumption or formation of
metastasis could be included. The questions in the broad
field of cancer research are immense.
This work was financially supported by the German Research
Foundation (DFG) within the Collaborative Research Center
SFB 1027.
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Supplementary material
suppl-file1.zip: Data created in the examples. We
add an archive of all data produced in suppl-file4–
suppl-file8.
suppl-file2.mov: Blood vessel network creation process.
To illustrate the process of network creation, we show an
example in fast motion. The resulting dataset is quite
big and therefore all intermediate stages are omitted.
The complete source used to construct the data for the
movie can be found in the file povrayRenderVesselgenera-
torDbg.py for references.
suppl-file3.avi: 3D model of tumor-induced angiogen-
esis. To illustrate the tumor model we show a video of the
dynamical growth process.
suppl-file4.pdf: Blood vessel network creation. In this
supplementary example we create an artificial blood ves-
sel network using submitVesselgeneration and show some
measurement tools. The algorithmically description is doc-
umented in [2].
suppl-file5.pdf: Tumor growth. In this supplementary
example we grow tumors on the previous created artifi-
cial blood vessel networks and show how to invoke some
quantifications.
suppl-file6.pdf: Interstitial fluid flow and drug trans-
port. Providing a tumor simulation, we describe here how
interstitial fluid pressure and drug distributions could be
calculated and visualized. These simulation where used for
the publication [17].
suppl-file7.pdf: Detailed oxygen distribution. Provid-
ing a tumor simulation, we calculate the detailed oxygen
distribution as described in [15] and run the scripts in
order to analyze those oxygen distribution.
suppl-file8.pdf: Visualization tools. Using the data cre-
ated in previous examples, we show how the simulation
results can be visualized using your tools facilitated by
Povray and ParaView.
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3.2.2 Supplemental Material
3.2.2.1 Supplemental 1-3
The supplemental material 1-3 is in electronic from only.
Supplemental 1 is a snapshot of your repository at time of publication
(available for download at: https://static-content.springer.com/esm/
art%3A10.1140%2Fepje%2Fi2018-11659-x/MediaObjects/10189 2018 11659 MOESM1 ESM.zip)
Supplemental 2 is a video illustrating the vessel network construction algorithm.
(available for download at: https://static-content.springer.com/esm/
art%3A10.1140%2Fepje%2Fi2018-11659-x/MediaObjects/10189 2018 11659 MOESM2 ESM.mov)
Supplemental 3 is a video illustrating a bulk tissue tumor simulation including a necrotic core.
(available for download at: https://static-content.springer.com/esm/
art%3A10.1140%2Fepje%2Fi2018-11659-x/MediaObjects/10189 2018 11659 MOESM3 ESM.avi) Supplemen-
tal 4-8 are in written form and reprinted in the following:
3.2.2.2 Supplemental 4: Vessel Network Generation
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In this supplementary example we create an artificial blood vessel net-
work using submitVesselgeneration and show some measurement tools. The
algorithmically description is documented in [1].
Usage
Entering
submitVes se lgenerat i on −h
in your console should print possible options as seen in Listing 1.
Listing 1: Console options for submitVesselgeneration
usage : submitVesse lgenerat ion [−h ] [− t TYPE [TYPE . . . ] ] [−p VESSELPARAMSET]
[−w WIDTH CUBE] [−−twoD ] [− i ITER H ]
[−e ENSEMBLE SIZE ]
Compute an a r t i f i c i a l blood v e s s e l network .
opt i ona l arguments :
−h , −−help show th i s help message and exit
−t TYPE [TYPE . . . ] , −−type TYPE [TYPE . . . ]
Type o f root node con f i gu ra t i on s , range from 0 to 8
−p VESSELPARAMSET, −−VesselParamSet VESSELPARAMSET
sp e c i f y Parameterset for creat ion , p o s s i b l e c on f i g s
are found in / krebs jobs / parameters /vesselGenParams . py
−w WIDTH CUBE, −−width cube WIDTH CUBE
Size o f ve s s e l cube you want to c r ea t e
−−twoD Creates only 2D network , d e f au l t i s 3D
−i ITER H , −−i t e r h ITER H
Number o f h i e r a c i a l i t e r a t i o n s
−e ENSEMBLE SIZE, −−ens emb l e s i z e ENSEMBLE SIZE
Number o f r e a l i z a t i o n s
We will create systems of type 8 which means that the inlets (arterious
roots) and the outlets (venous drains) are randomly distributed around a
cube with length 2000µm. Different types are shown here. One hierarchal
iteration step is applied and in total 5 different realizations are created.
The default parameters used in this example are illustrated in Fig 1. The
command is:
submitVes se lgenerat i on −t 8 −p d e f a u l t −w 2000 − i 1 −e 5
In about 10 minutes this will create the files vessels-default-typeI-15x19L130-
sample00.h5 to vessels-default-typeI-15x19L130-sample04.h5 which we could
analyze now.
Analyzing
One of the main tools to extract information about a vessel network is
python2 /your/ i n s t a l l /path/py/ krebs / p l o t V e s s e l s . py −h
This call lists the following options
usage : p l o tVe s s e l s . py [−h ] [−O] [−T] [−a ] [− s ]
[ vesse lF i l eNames [ vesse lF i l eNames . . . ] ] g rp pat te rn
Plot / Analyze i n f o s about v e s s e l network .
p o s i t i o n a l arguments :
vesse lF i l eNames Vesse l f i l e to c a l c u l a t e
grp pat te rn Where to f i nd the v e s s e l group in the f i l e
opt i ona l arguments :
−h , −−help show th i s help message and exit
−O, −−with−o2 look at d e t a i l e d o2 data
−T, −−on ly two root f l a g to change the cons idered types
−a , −−w i t h a l l t y p e s take a l l types
−s , −−s i n g e l t y p e
1
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default (parameterset name)
tip radius arterial = 2.5
tip radius capi = 2.5
tip radius vein = 3.8
murray alpha vein = 3
murray alpha artery = 3
scale = 130
max sprout radius artery = 8






Figure 1: Structure of a vessel creation parameters as stored in vessel-
GenParams.py.
By default the group where a vessel network is stored is labeled ‘vessels‘.
In order to analyze the bunch of created vessel networks we hand the files
together with group to the plot program.
python2 /your/ i n s t a l l /path/py/ krebs / p l o t V e s s e l s . py \
v e s s e l s−de fau l t−typeI−15x19L130−sample00 . h5 v e s s e l s
This will create a file called vessels-default-typeI-15x19L130-sample00.pdf
where the results are stored. The instructions to visualize such a data set
are could be found in an other example.
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In this supplementary example we grow tumors on the previous created
artificial blood vessel networks and show how to invoke some quantifica-
tions. In principal there are two programs starting tumor simulations,
submitBulkTissue [1] and submitFakeTum [2] where the API works the
same for both. The difference is that submitBulkTissue exploits our full
tumor model also mimicking cells in contrast to submitFakeTum where the







in your console should print possible options as seen in Listing 1.
Listing 1: Console options for submitBulkTissue
usage : submitBulkTissue [−h ] [−n ]
tumParamSet [ vesse lF i l eNames [ vesse lF i l eNames . . . ] ]
Compute BulkTissue tumor . Either with or without v e s s e l s
p o s i t i o n a l arguments :
tumParamSet Valid con f i gu r a t i on are found in
/py/ krebs jobs / parameters /fakeTumorParams . py
vesse lF i l eNames Vesse l f i l e to c a l c u l a t e
opt i ona l arguments :
−h , −−help show th i s help message and exit
−n , −−no v e s s e l compute the continuum model o f tumor c e l l s , no v e s s e l s
needed for that
We chose the parameter setting defaultconfig bulktissue and provide a
vessel network file created in previous examples by typing:
submitBulkTissue d e f a u l t c o n f i g b u l k t i s s u e \
v e s s e l s−de fau l t−typeI−15x19L130−sample00 . h5
It takes a desktop PC about 20 minutes to execute the simulation where the
file tumBulkdefaulttypeIsample00defaultconfig bulktissue.h5 with the struc-




To extract so informations about the oxygen content your can use
python2 \
/your/ i n s t a l l /path/py/ krebs / analyzeTissueOxygen . py −h
we run
python2 \
/your/ i n s t a l l /path/py/ krebs / analyzeTissueOxygen . py \
tumBulk−de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e . h5
1
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out0000 ....................................timeframe of simulation
out0001
fieldGf ........................growth factor conc. at timepoint











Figure 1: Structure of bulk tissue tumor file as stored in tumBulk-default-
typeI-sample00-defaultconfig bulktissue.h5. Exemplary a single time frame
is zoomed in.
Fractal dimension
The fractal dimension are calculated by
python2 \
/your/ i n s t a l l /path/py/ krebs / f r a c t a l d i m . py −h
This program comes with 2 modes. First, without any arguments we cal-
culate the fractal dimensions by box counting. This could also be done on
cluster computers. We run
python2 \
/your/ i n s t a l l /path/py/ krebs / f r a c t a ld im . py \
tumBulk−de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e . h5 \
out0005
After calculating you created a file called
fractaldim tumBulk-default-typeI-sample00-defaultconfig bulktissue.h5. Us-
ing the plot flag, you can now plot your data by
python2 \
/your/ i n s t a l l /path/py/ krebs / f r ac ta ld im . py −−p lo t \
fractaldim tumBulk−de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e . h5 \
out0005
Morphological data
Some morphological data is sampled by
python2 \
/your/ i n s t a l l /path/py/ krebs / analyzeVesselsBulkTumor . py −h
2
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iff default (parameterset name)
field ld
iff ...........results of the IFF simulation
measurements
out0000





iff ......................related to IFF
ift .....................related to drug
Figure 1: Structure of IFF simulation file as result of submitIff.
Providing a tumor simulation, we describe here how interstitial fluid
pressure and drug distributions could be calculated and visualized. These
simulation where used for the publication [1].
Usage
Entering
s u b m i t i f f −h
in your console should print possible options as seen in Listing 1.
Listing 1: Console options for submitIff
usage : submi t I f f [−h ]
I f fparams [ tumorFileNames [ tumorFileNames . . . ] ] g rp pat te rn
Compute IFF d i s t r i b u t i o n s and drugs analyze them .
p o s i t i o n a l arguments :
I f fparams choose the parameter for the s imulat ion , p o s s i b l e c on f i g s
are found in / krebs jobs / parameters / pa ramet e rSe t s I f f . py
tumorFileNames tumor f i l e s to c a l c u l a t e
grp pat te rn Where to f i nd the tumor . Usual ly t h i s i s somthing with out∗
opt i ona l arguments :
−h , −−help show th i s help message and exit
We will simulate IFF for bulk tumors created in previous examples (tumBulk-
default-typeI-sample00-defaultconfig bulktissue.h5 ). From the parameters
we choose the ’iff default’ where the evolution of the drugs is only calcu-
lated for 0.5 hours which is doable in about 2 minutes. See the parameter
’out times’ for this.
submi t I f f i f f d e f a u l t \
tumBulk−de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e . h5 \
out0005
Upon a successful run the file
iff default ulk-default-typeI-sample00-defaultconfig bulktissue.h5 with struc-
ture as depicted in Fig 1 will be created.
1
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One of the main tools to extract information about an IFF simulation file
is
python2 /your/ i n s t a l l /path/py/ krebs / p l o t I f f . py −h
We run
python2 /your/ i n s t a l l /path/py/ krebs / p l o t I f f . py \
i f f d e f a u l t u l k −de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e . h5
This gives a detailed analysis on the iterstitial fluid pressure and flow which
was calculated. Integral plots as well as radial averages are calculated and
shown in diagrams. Further a 2D histograms on the dataset is shown as
image.
Drug
Quantitative informations on the evolution of drugs within the blood and
the interstial volume could be drawn with the help of
python2 /your/ i n s t a l l /path/py/ krebs / plotDrug . py −h
We run
python2 /your/ i n s t a l l /path/py/ krebs /plotDrug . py \
i f f d e f a u l t u l k −de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e . h5
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p2field .............................O2 tissue field
po2vessels ...........................O2 in vessels
recomputed flow ............. flow computed before O2
Figure 1: Structure of DetailedO2 simulation file as result of submitDe-
tailedO2.
Providing a tumor simulation, we calculate the detailed oxygen distri-





in your console should print possible options as seen in Listing 1.
Listing 1: Console options for submitDetailed
usage : submitDetailedO2 [−h ] [−a ] [− r ] [−−sys tems i ze SYSTEMSIZE]
o2params [ vesse lF i l eNames [ vesse lF i l eNames . . . ] ]
g rp pat te rn
Compute po2 d i s t r i b u t i o n s and analyze them . In normal mode i t takes arguments :
parameter set name , f i l enames , h5 group pattern . In ana l y s i s mode −a , i t takes
arguments : f i l enames , h5 group pattern .
p o s i t i o n a l arguments :
o2params choose the parameter for the s imulat ion . found at
/py/ krebs jobs / parameters /parameterSetsO2 . py
vesse lF i l eNames Vesse l f i l e to c a l c u l a t e
grp pat te rn Where to f i nd the v e s s e l group in the f i l e
opt i ona l arguments :
−h , −−help show th i s help message and exit
−a , −−analyze loop through a l l f i l e s analyze data and make p lo t
−r , −−render launch render ing o f overview images
−−sys tems i ze SYSTEMSIZE
num threads = 1 ∗ systemsize , memory = 2 Gb ∗
sys tems i ze ( for o2 computation ; ana l y s i s uses
d i f f e r e n t s c a l i n g ( see source )
We will simulate the detailed oxygen distribution for bulk tumors created in
previous examples (here tumBulk-default-typeI-sample00-defaultconfig bulktissue.h5 ).
From the parameters we choose the ’default o2’.
submitDetailedO2 de f au l t o 2 \
tumBulk−de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e . h5 \
out0005
Upon a successful run the file
o2 tumBulk-default-typeI-sample00-defaultconfig bulktissue default o2.h5 with
structure as depicted in Fig 1 will be created.
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Analyzing
In principal most of our evaluation scripts focus on averaging multiple runs
of a single parameter set to get some statistics. However, in the scope of
this example we restrict the application to a single file only due to the
computational efforts.
The script which draws conclusions about perufsion, tissue oxygen sat-
uration etc. is plotVessels.py together with the flag -O indication the
calculation of the detailed oxygen quantities.
python2 /your/ i n s t a l l /path/py/ krebs / p l o t V e s s e l s . py −h
Running
python2 /your/ i n s t a l l /path/py/ krebs / p l o tVe s s e l s . py −O \
o2 tumBulk−de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e d e f a u l t o 2 . h5 \
po2/out0005
This creates a pdf containing necessary informations.
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Using the data created in previous examples, we show how the simu-





in your console should print possible options as seen in Listing 1. There are
quite some options here for adjusting the graphical representation. Note
that you can also store and load these settings from the file povrayRender-
Settings.py as it is done in your other scripts. In order to not track every
graphic setting ever made, we decided not to include the file povrayRen-
derSettings.py in the repository. However we provide a template called
povrayRenderSettingsTemplate.py.
Listing 1: Console options for submitPovrayRender
usage : submitPovrayRender [−h ] [−p POVPARAMSSET] [−d DATALIST] [− f ]
[−− f i l t e r r a d i u s h i g h p a s s FILTERRADIUSHIGHPASS]
[−− f i l t e r r a d i u s l owp a s s FILTERRADIUSLOWPASS]
[−−over lay ] [−−dpi DPI ] [−−format FORMAT] [−c CAM]
[−u ] [−a ] [−− f o n t c o l o r FONTCOLOR]
[−− t emp f i l e d i r TEMP FILE DIR ] [−− k e e p f i l e s ]
[−−assumed gamma ASSUMEDGAMMA]
[−−background BACKGROUND]
[−−ambient co lor AMBIENT COLOR] [−− r e s RES]
[−−num threads NUM THREADS] [−−out a lpha ]
[−−cam d i s t anc e mu l t i p l i e r CAM DISTANCE MULTIPLIER]
[−− c o l o r e d s l i c e COLORED SLICE]
[−−not render volume ] [−−no t r e nd e r v e s s e l s ]
vesse lF i l eNames [ vesse lF i l eNames . . . ] g rp pat te rn
Povray wrapper
p o s i t i o n a l arguments :
vesse lF i l eNames
grp pat te rn
opt i ona l arguments :
−h , −−help show th i s help message and exit
−p POVPARAMSSET, −−povParamsSet POVPARAMSSET
use parameters found in povrayRenderSett ings . py
( de f au l t : None )
−d DATALIST, −−data DATALIST
which data ( pressure , flow , shear f o r ce , hematocr i t ) as
comma separated l i s t ( d e f au l t : [ ’ pressure ’ ] )
−f , −− f i l t e r −unc i r cu l a t ed
f i l t e r unc i r cu l a t ed v e s s e l s ( d e f au l t : Fa lse )
−−f i l t e r r a d i u s h i g h p a s s FILTERRADIUSHIGHPASS
f i l t e r v e s s e l s from t r e e above t h i s value ( d e f au l t :
−1.0)
−−f i l t e r r a d i u s l owp a s s FILTERRADIUSLOWPASS
f i l t e r v e s s e l s from t r e e below th i s value ( d e f au l t :
−1.0)
−−over lay dec ide i f mpl over lay i s c reated ( de f au l t : True )
−−dpi DPI dpi for the render ing ( d e f au l t : 300 .0 )
−−format FORMAT output format o f image ( d e f au l t : png )
−c CAM, −−cam CAM camera mode : topdown , pie , topdown s l i c e ( d e f au l t :
topdown s l i c e )
−u , −−p lo t auc for area under curve , we have only a s i n g l e t imepoint
( d e f au l t : Fa lse )
−a , −−au t o c o l o r s c a l e
( d e f au l t : Fa lse )
−−f o n t c o l o r FONTCOLOR
fon t c o l o r in over lay , use mpl s t y l e c o l o r s ( d e f au l t :
b lack )
−−t emp f i l e d i r TEMP FILE DIR
d i r for temp povray scene ( d e f au l t : None )
−−k e e p f i l e s keep tmp f i l e ? ( d e f au l t : Fa lse )
−−assumed gamma ASSUMEDGAMMA
( de f au l t : 1 . 0 )
−−background BACKGROUND
( de f au l t : 1 . 0 )
−−ambient co lor AMBIENT COLOR
( de f au l t : ( 0 . 1 , 0 , 0 ) )
−−r e s RES ( de f au l t : (1024 , 1024))
−−num threads NUM THREADS
( de f au l t : 7)
−−out a lpha ( de f au l t : Fa lse )
−−cam d i s t anc e mu l t i p l i e r CAM DISTANCE MULTIPLIER
( de f au l t : 1 . 0 )
−−c o l o r e d s l i c e COLORED SLICE
( de f au l t : True )
−−not render volume For combined images ( d e f au l t : Fa lse )
−−no t r e nd e r v e s s e l s For combined images ( d e f au l t : Fa lse )
1
3.2. TUMORCODE - A FRAMEWORK TO SIMULATE VASCULARIZED TUMORS
CHAPTER 3. ORIGINAL PUBLICATIONS
138
This program automatically recognizes the type of file your entered. De-
pending your input, different subroutines to render vessels, tumors, IFF or
detailed oxygen datasets are called. We provide examples for all.
Vessels
We begin by visualizing a vessel network.
submitPovrayRender \
v e s s e l s−de fau l t−typeI−15x19L130−sample00 . h5 v e s s e l s
creates the file vessels-default-typeI-15x19L130-sample00 vessels pressure.png
which is also show in main document. The -d, –data flag allows you to
switch the data which is colorcoded on the vessels e.g.
submitPovrayRender \
v e s s e l s−de fau l t−typeI−15x19L130−sample00 . h5 v e s s e l s \
−d flow , s h e a r f o r c e
will create renderings of the flow or the shearforce. The figure shown in
the main document was created by
submitPovrayRender \
v e s s e l s−de fau l t−typeI−15x19L130−sample00 . h5 v e s s e l s \
−p ’ f i g u r e p l o s v e s s e l s ’
Tumors
We create a rendering of the tumor simulation at time point out0005 from
the file tumBulk-default-typeI-sample00-defaultconfig bulktissue.h5.
submitPovrayRender \
tumBulk−de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e . h5 \
out0005
Upon a successful run the image
tumBulk-default-typeI-sample00-defaultconfig bulktissue-out0005.png slice.png
should be present. To illustrate the camera option (-c, –cam), we run an
other example with
submitPovrayRender \
tumBulk−de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e . h5 \
out0005 \
−c p i e
The figure shown in the main document was created by
submitPovrayRender \
tumBulk−de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e . h5 \
out0005 \
−p ’ f i gu r e p l o s tumor ’
Detailed Oxygen
Of course these datasets can also be visualized. We run
submitPovrayRender \
o2 tumBulk−de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e d e f a u l t o 2 . h5 \
po2/out0005
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Note here the –render volume and –render vessels option which allows you
to visualize datasets with and without the vessels in the same plane.
submitPovrayRender \
o2 tumBulk−de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e d e f a u l t o 2 . h5 \
po2/out0005 \
−−no t r e nd e r v e s s e l s
IFF
Analogously we run here
submitPovrayRender \
i f f d e f a u l t u l k −de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e . h5 \
out0004
ParaView
To export our file format to paraView, we exploit the script
python2 /your/ i n s t a l l /path/py/ krebs / hdf2vtk . py −h
Vessels
For example, here with the lately produced vessels
python2 /your/ i n s t a l l /path/py/ krebs / hdf2vtk . py \
v e s s e l s−de fau l t−typeI−15x19L130−sample00 . h5 v e s s e l s
creating the file
vessels-default-typeI-15x19L130-sample00-vessels.vtk which is readable by
paraView.
Tumor
Here, with tumor file.
python2 /your/ i n s t a l l /path/py/ krebs / hdf2vtk . py \
tumBulk−de fau l t−typeI−sample00−d e f a u l t c o n f i g b u l k t i s s u e . h5 \
out0005 \
This creates input files for paraView. One for the vessels and one for the
field. When you load these sets into your paraView, make sure to change
representation style to something meaningful e.g. “Points”.
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Fine-grained simulations of the 
microenvironment of vascularized 
tumours
Thierry Fredrich  1, Heiko Rieger1, Roberto Chignola  2 & Edoardo Milotti  3
One of many important features of the tumour microenvironment is that it is a place of active Darwinian 
selection where different tumour clones become adapted to the variety of ecological niches that make 
up the microenvironment. These evolutionary processes turn the microenvironment into a powerful 
source of tumour heterogeneity and contribute to the development of drug resistance in cancer. Here, 
we describe a computational tool to study the ecology of the microenvironment and report results 
about the ecology of the tumour microenvironment and its evolutionary dynamics.
The tumour microenvironment is characterized by large chemical gradients and contains a mixture of normal 
and tumour cells. The presence of high gradients favours the formation of different ecological niches which can 
become an important source of tumour heterogeneity1–6.
The actual size of the niches is quite small, as it is mostly determined by the structure of the scaffold of capil-
lary vessels that envelope and feed the tumour mass. This structure is highly irregular, with a chaotic blood vessel 
network, a missing lymphatic network, elevated acidity, poor oxygenation, and high interstitial fluid pressure. 
The distance between blood vessels may be as large as a few hundred µm, and the regions in between them can 
become highly hypoxic4.
The fine-graininess and the large spatial variability are essential features in the formation of the ecological 
niches and they must belong to any mathematical model that aims to explain tumour heterogeneity as the result 
of Darwinian selection driven by the local environment. The importance of the microenvironment is widely 
recognized, and several researchers have tackled the problem of its description and understanding from the com-
putational point of view, e.g.7–13, and the reviews14,15.
The studies, however, mainly focus on the biochemical, cellular and biophysical properties of the tumour 
microenvironment and not on its active role in providing varied evolutionary paths to genetic variants of the 
tumour cells. As it has already been pointed out16,17, the adaptive evolution of tumour clones (central concept of 
Darwinian dynamics) is driven by the formation of new environmental niches. Many practical difficulties limit 
the experimental study of the adaptation process, while computer simulations can shed light — albeit in a limited 
way — on the dynamics of many steps like the convergent evolution of different genotypes to the same phenotype, 
and the selective loss of specific cell functions.
Simulations of avascular solid tumours show that the microenvironment of these small cell aggregates is 
formed by rather homogeneous niches with smooth gradients of oxygen, of other nutrients, waste molecules and 
cell viability18. After the angiogenic transition, however, the microenvironment differentiates in unpredictable 
ways. To identify underlying processes and provide reasoning, we have developed a computational model that 
is a tool to understand the fine-grained features of a simplified tumour microenvironment, i.e. of a microenvi-
ronment that contains only tumour cells and blood vessels. This is a rather strong simplifying assumption, since 
experimental observations show that in addition to tumour cells the microenvironment contains several other 
important cell types such as stromal and immune cells. We wish to stress that this assumption is a necessary 
compromise, because no computer model can presently describe the huge biological complexity of the tumour 
microenvironment and capture its growth at appropriate spatial and temporal resolutions.
Our computational model combines two different simulation programs, namely, a lattice-free simulation of 
small avascular solid tumours and a lattice-based simulation of the blood vessels dynamics in solid tumours. As 
we discuss below, both models have been individually validated with experimental data, and here we provide 
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a first validation of the combined model by correctly reproducing the relevant observed gradients of tumour 
oxygenation and other biochemical and biological features. Next, we use the combined model to explore how the 
tumour microenvironment takes shape in small solid tumours at the transition from the avascular to the vascular 
growth phases, the so-called angiogenic switch19. We follow the complex dynamics of this process in detail and 
in real time and show that, already at these early stages of tumour development, the diversity of environmental 
niches is high enough to promote adaptive evolution of tumour variants.
Figure 1. Distribution of cell phases in a tumour spheroid (avascular in vitro tumour) simulated with VBL. 
The figure shows a clipped spheroid, to display the cell phases in the inside of the spheroid. The colors represent 
different cell phases, and in this example it is only important to note that the necrotic regions are red. Note that 
there is no clear cut boundary between the proliferating part of the necrotic core. The triangulation used by VBL 
is also shown. This simulated tumour spheroid comprises almost 24000 cells.
Figure 2. 500 µm thick slice trough tumour vasculature of 1 cm lateral size. For 3D illustration we extent vessels 
with radius bigger than 20 µm for another 750 µm above and below the slice. According to the lower panels: 
arteries are displayed in varying reddish color and veins in varying blueish color (unit is also µm). Capillaries 
and young vessel are shown in green.
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Brief Outline of “Virtual Biology Lab” (VBL) and Tumorcode
In this section we give a short description of the two programs that have been merged. The present account is very 
brief as both programs have been described in detail in past papers (for VBL, see18,20–23, for Tumorcode, see24–26).
VBL. VBL is a lattice-free, cell-based program that can simulate both: the growth and proliferation of disperse 
cells and of more complex, avascular cell clusters (tumour spheroids). It contains a detailed simulation of the 
metabolic activity of each cell including discrete events at the individual cell level (for instance: mitochondrial 
Figure 3. Flowchart of combined VBL and Tumorcode simulation.
Figure 4. Artificial blood vessel network containing a tumour after 23 simulated days past the initial seeding. 
For visualization we removed a quarter of the system. The color code in the bottom left corresponds to the blood 
pressure at a given vessel segment. Cells are colored by their cell phase. Red: phases G1m and G1p; yellow: 
phases S, G2 and M; light green: dead cells.
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partitioning at mitosis), and has the potential to activate phenotypic differentiation. More specifically, the model 
has the following features:
•	 The model of human tumor cells includes both- the internal biochemical processes and a phenomenological 
description of the biomechanics of cells.
•	 Spatially, each cell is a two-compartment structure, the inside of the cell and the adjacent extracellular envi-
ronment or intercellular space; this is important to handle simple diffusion and facilitated diffusion across the 
cell membrane at the same time.
•	 Discrete events are simulated and interleaved between successive deterministic steps; the random nature of 
some of them contributes to the stochasticity of the simulation as a whole.
•	 Each cell is characterized by its own phenotype which means that a specific set of parameters is linked to an 
individual cell.
•	 Enzyme activity is modulated both by pO2 concentration and by pH.
•	 Weighting of molecular paths and cellular mechanisms is possible.
•	 The program simulates dispersed tumor cells and cell clusters (tumor spheroids) including the intercellular 
space.
•	 The surrounding environment is an integral part of the simulation.
The numerical methods used in VBL have been described elsewhere27, here we only mention that although the 
simulation is lattice-free, continuum processes are actually discretized on the continually-variable irregular lat-
tice defined by the Delaunay triangulation28 based on the cells’ centres which also defines the proximity relations 
among cells that are necessary to compute the cell-cell forces. We find that the computational geometry library 
CGAL (https://www.cgal.org)29 is an easy tool that offers necessary triangulation features amended by the pos-
sibility to calculate alpha shapes. This is necessary to define the surface or contact zone of the spheroid with the 
environment. It is important to note that the simulation spans many orders of magnitude in time which makes the 
large system of differential equations describing the deterministic part of the program extremely stiff. Therefore 
we solve the equations by means of implicit integration methods, that allow for comparatively large time steps (of 
the order of 1–10 s in terms of simulated time)30.
Figure 1 shows an example of a tumour spheroid simulated by VBL. As we have shown in the past, the main 
metabolic, morphologic and kinetic parameters are correctly reproduced both for isolated cells and for cells 
grown as three- dimensional clusters21,27.
Tumorcode. While cell-cell interactions like in VBL naturally produce nearly spherical structures, modelling 
the growth of blood vessels moves the complexity of the simulation one step higher to the level of tissue mor-
phogenesis. The list of models is long. For an appropriate discussion of the existing models for tumor vasculature 
see31.
Solid tumours grow in originally healthy tissue featuring a normal vasculature build up by a hierarchically 
organized arterio-venous blood vessel network that is then dynamically modified by the growing tumor. An 
integrative modeling approach thus has to address two issues: first, it has to find an appropriate representation 
of the original vasculature of the host tissue; and second, the dynamics of the given blood vessel network has to 
be defined, which includes the insertion of new vessels via angiogenesis as well as the removal of existing vessels 
(old and new) via vessel regression, and the modification of existing vessels via dilation, constriction or occlusion. 
Moreover, the network carries a blood flow and transports and emits oxygen, nutrients and drugs, which has to be 
represented, too. Various modeling approaches have been presented in the past (for a review see e.g.24,31,32), here 
Figure 5. Empirical distribution of the distance to the closest vessel for all cells in the developing tumour. 
The snapshots are taken at simulated times 280 hours, 380 hours, 480 hours and 580 hours past the initial seed. 
Colors represent the different simulation times.
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we use the simulation framework Tumorcode described in25, which does not only create artificial arterio-venous 
blood vessel networks representing the healthy initial vasculature, but includes vascular remodeling during solid 
tumour growth by angiogenesis, vessel dilation, regression and collapse. The created networks were tested against 
Figure 6. Sampled cell quantities vs. the distance to the nearest vessel. Top panel: cell radius, center panel: 
partial oxygen pressure, bottom panel: extracellular pH. Each box plot has been obtained using the values in 
cells at a given distance from the nearest vessel as indicated by the abscissa. As usual, the vertical error bars 
(“whiskers”) represent the lower and upper quartile. The data is sampled 280, 380, 480 and 580 hours past the 
initial seeding. For better clarity, we omit the complete boxes for the time points 280, 380 and 480 and plot only 
the mean value in different colors.
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experimental data and successfully reproduced: 1) morphology and flow characteristics33,34, 2) interstitial fluid 
flow and pressure35, and 3) tissue oxygenation26 for both, healthy and tumour tissue.
Again, here is a short list of its main features of Tumorcode:
Figure 7. Distribution of the cell phases at different distances from the closest blood vessel. From top row to 
bottom row the data is take after 280, 380, 480, 580 hours past this inital seed. The left panels show the number 
of cells in the corresponding phase relative to the total number of current cells. G1m and G1p in red, S in yellow, 
G2 and M in green and dead cells in black. In the right panels we consider only alive cells. The abscissa is the 
distance to the nearest vessel.
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•	 Hemodynamics includes the phase separation effect (Fåhræus-Lindqvist effect) and different rheologies.
•	 Concentrations in the surrounding environment are computed according to a continuum model, i.e., accord-
ing to a set of partial differential equations discretized by finite elements method solved with the Trilinos 
C++ library (https://trilinos.org)36.
•	 Angiogenesis, i.e., the addition of new segments, is driven by the VGEF gradient and is partly stochastic24.
•	 As the tumour grows, the vasculature and the blood flows change, and the modified shear stress leads to blood 
vessel dilation or to blood vessel collapse24.
•	 A low local VGEF growth factor concentration produces blood vessel regression24.
•	 The program computes the interaction with surrounding tissues to compute the extraction of oxygen and 
nutrients from blood vessels.
•	 The program returns blood flow, oxygen concentration, metabolite concentration, etc, in blood vessels and 
surrounding tissues.
Figure 8. Distribution of distance from tumour centroid to cells in contact with the environment (normal 
tissue). The colors indicate the different sampling times past the inital seeding. The bin size is 30 µm.
Figure 9. Sampling the partial oxygen pressure pO2 along lines between blood vessels. We sampled along the 
line joining two blood vessels (bright green). Inset (A) shows the simulation state 350 hours past initial seeding; 
the main image shows the state after 527 hours. Note the additional vessel due to angiogenessis. The scale 
marked “pressure_at_node” refers to the pO2 value at vessel nodes in mmHg. The scale marked “o2” referes to 
the value of pO2 inside cells. See also Supplemental Material for more information.
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•	 The blood vessel hematocrit acts as source for oxygen dissolved in tissue and the tissue simultaneously con-
sumes the oxygen. In26 we explain how the coupled set of non linear differential equations is solved to obtain 
the oxygen partial pressure for each blood vessel segment.
Figure 2 shows an example of a tumour vasculature simulated by Tumorcode. You can clearly distinguish 
the vasculature inside the tumour from the surrounding healthy tissue. Note the difference in length scale when 
comparing Figs 1 and 2, and the fact that the tumour is a continuous structure (governed by reaction-diffusion 
equations25) in Tumorcode. In contrast to VBL, it cannot describe the evolutionary features of the microenviron-
ment at the single cell level.
The Merging of the Two Programs
To merge the two programs into one, we had to match the spatial structures of the two programs. The cells are not 
confined to a lattice however the diffusion processes in VBL are calculated by means of a disordered Delaunay 
triangulation which is not permanent and has a variable size, as cells position change at each time step while 
the cells grow and proliferate. The situation is almost the reverse in Tumorcode where blood vessel segments 
belong to an FCC lattice and the continous space is discretized by a cubic lattice to solve the partial differential 
Figure 10. Data for the three measured lines. Each row corresponds to one specific line. The left column 
represents data taken at 350 hours of simulated time, and the right column at 495 hours past the initial tumour 
seeding. Each panel shows the sampled partial oxygen pressure (pO2) in black (left hand y-axis) and the pH 
in blue (right hand y-axis). To improve visibility, the data points of pO2 and pH are shifted against each other 
by 2 µm. Each line was sampled by 30 points within a sphere of radius 10 µm. The vertical lines represent the 
standard deviation.
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equations. We interpolated cell properties from the cells position to the surrounding nodes of the cubic lattice 
(compare Fig. 3). In particular, the Tumorcode requires an oxygen consumption field and each cell is considered 
as point- like source of growth factor. Once the growth factor field exceeds the threshold, the vessel remodelling 
of Tumorcode starts.
We estimate that the accurate calculation of any substance concentration for a given cell requires N N( )C BV  
number of operations, where NC is the number of cells and NBV is the number of blood vessels segments. Since 
both NC and NBV easily exceed 10
6 in the smallest-sized biologically relevant simulation runs,  ∼N N( ) 10C BV
12 
per time step, making the simulations utterly unmanageable. To reduce the computational complexity, we take 
into account that only the nearest blood vessels actually contribute to the inputs and outputs of the different mol-
ecules in the vicinity of a given cell trimming the large number of cell-blood vessel pairs to N( )C . Moreover, the 
timesteps to follow cell biochemistry are of order 1–10 s while biological relevant timesteps for vascular remodel-
ling are in the order of hours. Therefore we introduce two different time steps to avoid a huge number of useless 
sweeps over the blood vessel network (compare Fig. 3).
Development of the Microenvironment in Small Solid Tumours
With the program described before, we studied selected aspects of the tumour microenvironment. To this 
end, we carried out simulation runs with three different tumour seeds: 1. at the center of a blood vessel net-
work, 2. close to an arterial bifurcation, 3. close to a venous bifurcation. The details of each simulation are 
reported in the Supplemental Material. Here we display the results in a way that allows an easy comparison with 
measurements37,38.
As expected, the seeding is important in the very first steps of tumour growth: a seed close to blood vessels 
leads to fast growth and to a quick remodelling of the blood vessel network; for seeds far from blood vessels, the 
initial growth is slower and the subsequent initial development of the tumor microenvironment differs slightly.
Seed at the center of a blood vessel network. The computational approach provides an easy access to 
information that is hard to obtain with experiments and allows multiple ways of visualization (compare Fig. 4). 
Here we take advantage of the information about the distance to the nearest blood vessel for every cell. We start 
with the distribution which is a defining feature of the microenvironment, as larger distances mean less oxygen 
and nutrients, and therefore starvation and death for many tumour cells. In Fig. 5 we see how the distribution 
changes while the tumour grows. The distribution at the early stage (280 hours past seeding) ranges from 0 to 
80 µm ensuring a optimal oxygenation to all cells and gets distorted until it covers a range of up to 160 µm at a 
later stage (580 hours past seeding) where cells not receive a sufficient input of oxygen and nutrients.
Intuitively the increase in the mean of cell-blood vessel distances leads to a decrease of available oxygen and 
nutrients, and to an increase of lactate ions and to a lower pH. Since the cell-blood vessel distance is known, we 
can display space-time data on the distributions of cell radii, pO2 and pH (Fig. 6) - the data confirms the intuition. 
We uploaded two videos where we visualize pO2 (fredrich:po2:2018) and pH (fredrich:pH:2018) 
during the complete of the growth processes.
Finally, the changes in the microenvironment stretch the cell proliferation period and therefore modifies the 
cell cycle distribution as seen in Fig. 7 where we can follow the formation of a necrotic core. At the beginning 
(280 hours past initial seed) the relative amount of cells in the different phases varies with the distance from 
the nearest vessel. Surprisingly this relative amount stays almost constant after the establishment of different 
niches. Compare with Fig. 4 were we show the cell phase distribution in a more pictorial way. Even in such a 
Figure 11. Change of pO2 due to the blood vessel dynamics. This data extends those in the first row of Fig. 10. 
In contrast to Fig. 10, we show all intermediate time points in this plot.
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small tumour we observe the initial development of necrotic regions which characterizes the development of the 
tumour microenvironment.
Actual tumours have irregular shapes, while the cells in VBL are not polarized, and when grown in uniform 
environments produce nearly spherical shapes. In the presented case the blood vessel network drives the growth 
in specific directions and we expect a marked deviation from sphericity already with small simulated tumours. 
Ideally, in a spherical tumour all cells on the surface have the same distance to the centroid. We find that the 
distribution of distances from the spheroid’s surface to the centroid a) broadens and b) deviates from symmetric 
form as the tumour grows (Fig. 8) which is a clear indication of the deformation of the cell cluster and of its devi-
ation from sphericity.
Seed close to an arterial or venous bifurcation. Helminger et al.38 measured the partial oxygen pres-
sure and pH within different tumours. To compare our simulations with their experimental results, we seeded the 
initial tumour cell close to bifurcations, both arterial and venous, and sampled the cells along different lines (for 
details see Supplemental Material). Figure 9 is meant to illustrates the sampling procedure while we show data for 
a early and a late simulation state in Fig. 10.
It is interesting to note that the left panel in first row in Fig. 10 shows a dip in both pO2 and pH approximately 
midway between the two blood vessels. The right panel in the same row, taken at a later time, shows a maximum 
at roughly the same position because a new blood vessel sprouted into the intervening space. A detailed view of 
this dynamic change is shown in Fig. 11, where the mean of the pO2 data is plotted for all intermediate time points 
as the new blood vessel grows.
Conclusions
As explained in the introduction, the study of the ecology of the tumour microenvironment at the angiogenic 
switch is the primary motivation for the work described in this paper and for the development of the presented 
complex software tool. Indeed, the Figs 10 and 11 display a surprisingly large spatial and temporal variability 
already in a very small vascularized tumour. In particular, Fig. 11 shows a continually changing and rugged 
landscape: this means that the niche diversity is large, and consequently that there is a high evolutionary pressure, 
and a high probability that the microenvironment selects different tumour clones even in small tumours. This is 
important in view of the long time required for tumour growth, as it has been estimated that a tumour requires 
about 10 years to reach a size of 1 cm39. According to the clonal selection hypothesis new and aggressive tumour 
clones develop through Darwinian selection during this extended growth time39,40. The results discussed in this 
paper lend further credibility to the clonal selection hypothesis, and in our future studies we plan to demonstrate 
the spatial and temporal variations of different clone populations in this very complex tumour microenviron-
ment. In order to highlight common and diverse evolutionary pathways in different cancers, we also plan to 
explore the adaptive evolution of cell clones in different microenvironments mimicking different organs or tissue 
types to reproduce the distinguishing features of selected tumour types.
Finally, we note that the molecular mechanisms that promote genotypic changes in tumour clones are well 
known and understood, but genotypic variability is only one feature of cancer’s evolutionary landscape. The other 
important feature is the variability of the environment that supervenes the genome and drives evolution itself, and 
with our computational tool we can start to explore its Darwinian dynamics16.
Data Availability
We uploaded the full simulation raw data to zenodo with following digital object identifiers: https://doi.
org/10.5281/zenodo.2541688, https://doi.org/10.5281/zenodo.2541655, https://doi.org/10.5281/zenodo.2541678, 
https://doi.org/10.5281/zenodo.2541667.
Code Availability
All source code containing the used parameters is distributed with this article as Supplementary Material and 
hosted at GitHub https://github.com/thierry3000/tumorcode.
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ABSTRACT
In this little supplementary file to the main manuscript we elaborate on the implementation, hardware and simulation details.
1 Introduction
All source code and parameters to reproduce our simulations are publicly available at GitHub
VBL : https://github.com/thierry3000/VBL
Tumorcode : https://github.com/thierry3000/tumorcode
and distributed with this supplemental material. For the VBL parameters, see the subfolder parameters and for Tumorcode
parameters, see the subfolder py/krebsjobs/parameters within their sources.
The initial vasculature was created with the Tumorcode program1
submitVesselgeneration and the following arguments:
-p default -t 8 -w 1500 -i 1 , see command line help (-h option) for their explanation. The resulted initial vasculature
comprises a lattice with a constant of 130 µm and a total size of (1690 µm x 2080 µm x 1820 µm ). For the cancerous
modifications, this is subdivided by a factor of 10 such that the tumor vasculature’s lattice constant is 13 µm . Note that the
subdivision of a face centered cubic lattice is again a face centered lattice which is an essential feature of our lattice based
simulation. As reported in2, 3, the vessel network is superimposed by regular cubic grid taking care of the continuum equations.
We chose a constant of 30 µm .
We chose VBL to operate with a time step of 50 seconds while the minimal time step in Tumorcode is one hour, so the
time scales from VBL and Tumorcode are sufficiently different to interleave the two programs. To this end, the VBL software
was redesigned with the submodule or library approach in mind that allows single calls execution a complete procedure.
1.1 Finding the nearest vessel
Finding the nearest vessel for every cell is nearly impossible from measured datasets. For our in silico system this is
straightforward.
For every vessel, we compute its center of mass and hand it to the ANN library (https://www.cs.umd.edu/
~mount/ANN/)4. The library uses a special storage structure allowing a quick read out of the nearest neighbors for a given
query point which is the cell’s position in our case.
1.2 Variation of initial seed
In the main document, we report simulations with 3 different tumor seeding positions: one in the center of the simulation
domain, one next to an arterial bifurcation and one next to a venous bifurcation. All other parameters stay the same.
For the seeds next to the bifurcation, we report measurements along 3 different lines. For simplification, we label them here
as follows:
case Ap a parallel line along an arterial bifurcation
case Vp a parallel line along a venous bifurcation
case Vo an orthogonal line in between an venous bifurcation
1
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case sampling line start sampling line end seeding point taken time step
Ap (195,356.5, -424.5) (195,506.6,-318.4) (240, 400, -310) 350,495
Vp (349,157,-350) (344,185,-281) (360, 180, -310) 350,495
Vo (350, 248,-327) (327, 78,-281) (360, 180, -310) 350,495
Table 1. Detailed position of sampled lines.
2 Computing the oxygen content
VBL outputs the amount of oxygen carried per cell in piko gramm (pg). Knowing the cells volume from the radius and the
solubility of oxygen, the partial pressure is calculated and used in all our analysis. For the oxygen solubility within the cell we





To highlight the temporal evolution, we visualized the simulation were the spheroid was seeded in the center by means of 2
videos. Each frame is rendered by Tumorcode which provides a direct call to POV-Ray (http://www.povray.org/). The successive
images were combined into to movie of 20 frames per second by the ffmpeg tool (http://www.ffmpeg.org/). The movies show
the initial vasculature colored by their blood pressure (left color bar) and cut open in a pie like fashion which allows a better
view on the developing spheroid in the center. In the file (https://figshare.com/articles/VBL_tumor_PO2/7406180) the cells are
color code due to their value of oxygen partial pressure (right colorbar). Note that we can observe the hypoxic rim by pure eye.
In the second file (https://figshare.com/articles/VBL_tumor_pH/7406183) , the cells are color coded by their value of pH . The
formation of the regions with different values of pH is observed in the presented microenvironment.
4 Hardware
We used nodes of a linux cluster with 28 cores and 128GB memory. The runtime varied from 4 to 6 weeks. This is expected,
because of the large number of random events.
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3.4. DYNAMIC VESSEL ADAPTATION IN SYNTHETIC ARTERIOVENOUS NETWORKS
3.3.2.2 Supplemental 2-3
Supplement 2 and 3 contain source code that is only available in digital form. Supplement 2 contains the
files of the Virtual Biology Lab (VBL) code
(https://static-content.springer.com/esm/art%3A10.1038%2Fs41598-019-48252-8/MediaObjects/41598 2019 48252 MOESM2 ESM.zip)
and supplement 3 contains the files of Tumorcode
(https://static-content.springer.com/esm/art%3A10.1038%2Fs41598-019-48252-8/MediaObjects/41598 2019 48252 MOESM3 ESM.zip)
with which the reported simulations where conducted.
3.4 Dynamic vessel adaptation in synthetic arteriovenous net-
works
Reprinted with permission from Elevier: Journal of Theoretical Biology, Dynamic vessel adaptation in syn-
thetic arteriovenous networks by Thierry Fredrich, Michael Welter and Heiko Rieger copyright 2019.
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna-
tional License (see appendix G).
3.4.1 Main Manuscript
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a b s t r a c t 
Blood vessel networks of living organisms continuously adapt their structure under the influence of 
hemodynamic and metabolic stimuli. For a fixed vessel arrangement, blood flow characteristics still de- 
pend crucially on the morphology of each vessel. Vessel diameters adapt dynamically according to inter- 
nal and external stimuli: Endothelial wall shear stress, intravascular pressure, flow-dependent metabolic 
stimuli, and electrical stimuli conducted from distal to proximal segments along vascular walls. Pries 
et al. formulated a theoretical model involving these four local stimuli to simulate long-term changes of 
vessel diameters during structural adaption of microvascular networks. Here we apply this vessel adapta- 
tion algorithm to synthetic arteriovenous blood vessel networks generated by our simulation framework 
“Tumorcode”. We fixed the free model parameters by an optimization method combined with the re- 
quirement of homogeneous flow in the capillary bed. We find that the local blood volume, surface to 
volume ratio and branching ratio differs from networks with radii fulfilling Murray’s law exactly to net- 
works with radii obtained by the adaptation algorithm although their relation is close to Murray’s law. 
© 2019 Elsevier Ltd. All rights reserved. 
1. Introduction 
Life depends crucially on the efficiency of transport networks 
and therefore it is essential to understand how they are function- 
ing and why they are efficient ( Banavar et al., 1999 ). In particular, 
the vasculature of all mammalians demonstrates how nature 
efficiently transports and distributes nutrients at minimal costs. 
Cecil Murray observed blood vessel networks in 1926 and 
proposed a formula describing observations on the thickness of 
the branches ( Murray, 1926 ). In his theoretical derivation of the 
formula, he considered two energies with opposed dependency 
on the vessel radius r: the energy required to drive the flow 
and the energy required to maintain the metabolic demands of 
the surrounding tissue. To drive the flow, the system needs to 
overcome the viscous drag that is proportional to 1/ r 4 in case of 
Hagen–Poiseuille flow and to maintain the metabolic demands, 
a constant volume of “fresh” blood is required in a first approx- 
imation. By minimizing the sum of these two energies, he found 
that the sum of the cubes of the daughter vessel’s radii equals the 
cube of a parent vessel’s radius. In case of a simple junction with 
one mother vessel of radius r c and two daughter vessels of radius 
∗ Corresponding author. 
E-mail address: thierry@lusi.uni-sb.de (T. Fredrich). 
URL: https://www.github.com/thierry30 0 0 (T. Fredrich), http://www.uni- 
saarland.de/fak7/rieger/index.html (H. Rieger) 
r a and r b , this reduces to: 
r 3 c = r 3 a + r 3 b (1) 
Since his assumptions are rather general, they hold true for the 
respiratory system of animals and insects, xylem in plants and di- 
verse other kinds of transport networks as well ( Stephenson et al., 
2015 ). Murray’s law is based on an optimality criterion and 
suggests the intriguing question how the vasculature of living 
organisms achieves this optimality? The blood vessel wall is 
formed by endothelial cells with a surrounding layer of smooth 
muscle cells. Because the muscular layer adjusts the vessel caliber 
continuously during growth, maturation, in response to exercise, 
wound healing and diseases, the vasculature is non-stationary with 
regulatory mechanisms that are still under investigation. While 
the vascular reactions to shear stress have been known for a long 
time ( Thoma, 1893; Wetterdal, 1920 ), recent studies showed that: 
1) The shear stress is linked to the local intravascular pressure 
( Pries Axel R. et al., 1995 ); 2) the vascular diameter is controlled 
by the metabolic needs of the tissue (local oxygen partial pressure, 
metabolic signaling substances) ( Adair et al., 1990; Berne, 1964; 
Berne et al., 1983; Björnberg et al., 1989 ) and the metabolites 
remaining in blood after the exchange ( Ellsworth, 2004 ); 3) 
electrical signals are conducted along the blood vessel wall by 
endothelial and smooth muscle cells via gap junctions ( Segal and 
Duling, 1986; de Wit et al., 2003; Bagher and Segal, 2011 ) and 
4) in case of hypertension, the vasculature switches to inward 
remodeling ( Jacobsen et al., 2003; Pries and Secomb, 2008 ). 
https://doi.org/10.1016/j.jtbi.2019.109989 
0022-5193/© 2019 Elsevier Ltd. All rights reserved. 
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Beginning in 1995, Pries Axel R. et al. (1995) published a series 
of papers ( Pries et al., 1998; 2001; 2003; Pries and Secomb, 2008; 
Pries et al., 2009 ) where they constructed a feedback loop between 
the discussed mechanisms and the blood vessel radii. Provided 
the resulting radius adaption dynamics leads to a stable state, this 
algorithm determines the blood vessel radii of a given network 
topology, in particular the relation between mother and daughter 
vessel radii at each junction without referring to Murray’s law. 
In this manuscript we explore the application of the adaptation 
algorithm to in silico arteriovenous networks and analyze the 
emerging vessel radii and blood flow characteristics. Initially, the 
networks created by our in-house simulation framework Tumor- 
code ( Fredrich et al., 2018 ) are consistent with Murray’s law. The 
vessel adaptation algorithm modifies each single vessel radius and 
we analyze the resulting distribution of radii. After validating our 
implementation by comparison with existing data in Section 3.1 , 
we optimize the free model parameters for a fixed vessel network 
in Section 3.2 with respect to a maximally homogeneous blood 
flow in the capillary bed. In Section 3.3 , we compare the distribu- 
tion of radii from the initial networks with the one emerging after 
the application of the vessel adaptation algorithm to them. 
2. Methods 
2.1. The adaptation algorithm 
Pries et al. (1998) presented a theoretical model to simulate 
vessel radii of arteriovenous networks. They constructed a feedback 
loop between the spatial position of the vessels (topology) and 
their biological functions including hydrodynamics, shear stress 
and metabolism of the surrounding tissue. For an elaborated re- 
view and some applications of the model see Secomb et al. (2012) . 
In the following, we describe the vessel adaptation algorithm of 
Pries et al. (1998) . 
Considering a vessel of radius r during a time step t , its 
adaption or change r = S tot r t is proportional to the sum of 
five signals S tot = 
∑ 5 
i =1 S i which are defined below. 
S 1 - Shear stress. Based on the correlation between wall shear 
stress and vessel radius, the adaptation algorithm reduces the 
vessel radius whenever the wall shear stress ( τw ) falls below 
1 dyn/cm 2 = 10 −4 kPa and extends the radius otherwise, i.e: 
S 1 = log 10 ( τw ) (2) 
S 2 - Blood pressure. Pries Axel R. et al. (1995) studied the inter- 
action of the transmural pressure P and the wall shear stress τ e 
Table 1 
Parameters of the adaptation model. The values in the right col- 
umn are used in Pries et al. (1998) . 
Signal Free Fixed 
S 3 k m Q ref = 40 nl/min 
S 4 k c L = 1500 μm, 
S 0 = 40 
S 5 k s 
proposing a “pressure-shear” hypothesis 
τe (P ) = 100 − 86 exp 
(
−5000 { log 10 [ log 10 ( P ) ] } 5 . 4 
)
(3) 
The functional form of the shear-pressure dependency is sig- 
moidally increasing from 14 dyn/cm 2 for pressures of 10 mmHg–
100 dyn/cm 2 for pressures at 90 mmHg ( Eq. (3) ). With this 
S 2 = − log 10 [ τe (P ) ] (4) 
S 3 - Metabolic demand. Similar to the idea of Murray (see Section 
1 Introduction), the metabolic demand needs to be maintained at 
all times. Since oxygen is transported as cargo by the red blood 
cells (RBC), a constant volume flow of RBCs is required to sustain 
a constant oxygen supply. Given the volume flow of blood Q with 
hematocrit H, the volume flow of RBCs is HQ and maintained at a 
reference value Q ref by the metabolic signal S 3 . 







The definition of S 3 results in a strictly positive signal where 
the amplitude increases stronger for vessels with a lower flow rate 
( HQ < Q ref ) compared to vessels with a higher flow rate ( HQ > Q ref ) 
than the reference flow Q ref . In contrast to the biologically moti- 
vated reference flow, k m is an unknown model parameter (com- 
pare Table 1 ). 
S 4 - Topological position. S 4 is sensitive to the position of the ves- 
sel within the entire network structure. The signal propagates from 
the capillary bed to the most upstream vessel in the arterial branch 
and to the most downstream vessel in the venous branch. While 
the downstream propagation of metabolic waste to the draining 
vein is reasonable, the upstream signaling is less obvious, but re- 
cent studies confirmed that vessels communicate via electrical sig- 
nals within their endothelial layer ( Segal and Duling, 1986; de Wit 
et al., 2003; Bagher and Segal, 2011 ). In principle the algorithm 
works with arbitrary number of vessels per intersection. For sim- 
plicity, we limit the discussion to Y-shaped intersections ( Fig. 1 ) 
where a vessel c has two downstream connections (to vessel a 
of length x a and to vessel b of length x b ) in an arterial branch 









Fig. 1. Recursive propagation of the conducted signal at a vessel junction. Left: Arterial case. Right venous case. Arrows indicate the direction of information propagation. 
See Eq. (6) . 
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length x b ) in a venous branch. The conducted or topological sig- 
nal is calculated in a recursive fashion by the weighted sum of the 
metabolic signals (S 3 ) along the direction of information propaga- 
tion ( Eq. (6) ). The weighting factor is proportional to the exponen- 
tial of the normalized length of the vessel segments ( x a L and 
x b 
L ). 
S 4 ,c = S 3 ,a + S 3 ,b + S 4 ,a exp ( −x a /L ) + S 4 ,b exp ( −x b /L ) (6) 
Since the recursive summation might result in excessive values, 
the signal is damped by a reference value S 0 such that the com- 
plete conducted signal for a single vessel becomes: 
S 4 = k c S 4 ,c 
S 4 ,c + S 0 
(7) 
Note that the constant k c , the reference value S 0 and the 
normalization length L are unknown model parameters (compare 
Table 1 ). 
S 5 - Shrinking tendency. The introduction of a strictly positive 
metabolic (S 3 ) and conducted signal (S 4 ) necessitates a negative 
counterbalance. Its biological motivation is the tension in the 
endothelial layer which leads to a contraction of the vessel radius 
in the absence of all other signals. In the formula of the adaptation 
model this is embedded by subtracting a overall constant k s . 
S 5 = −k s (8) 
2.2. The artificial blood vessel networks. 
We construct artificial 3D arteriovenous networks by means 
of our simulation framework Tumorcode ( Fredrich et al., 2018 ). 
We report the complete methodology in Rieger et al. (2016) and 
summarize only the main steps here. First, at least one arterial and 
one venous root node have to be distributed in space and assigned 
with a hydrodynamic boundary condition (either a blood pressure 
value or a flow rate) before straight or Y- shape elements are 
appended until the arterial and venous branch merge by the capil- 
laries. Second, the position of the capillaries within the volume is 
optimized towards a homogeneous capillary volume density using 
a hierarchical iteration scheme. For the scope of this paper, we 
consider only a root node configuration (RC) where one artery is 
opposite to one vein on the same axis ( Fig. 2 , compare also RC5 
in Fig. 4 of Welter et al., 2016 ) and a single hierarchical iteration. 
Since the construction algorithm in the Tumorcode fixes the radii 
of all capillaries (2.5 μm in presented case) and determines the 
radii of all intermittent vessels between root nodes and capillaries 
by Murray’s law, all radii at the intersections fulfill Murray’s law 
by construction. Therefore we label them M-networks in contrast 
to the A-networks which obtain their vessel radii by applying the 
adaptation algorithm to the M-networks . 
Fig. 2. Schematic root node configuration (RC) for construction the arteriovenous 
networks. Red (left): arterial root, blue (right): venous root. 
2.3. Parameter optimization 
Inspecting Section 2.1 , we count six unknown model pa- 
rameters as summarized in Table 1 . Considering the additional 
hydrodynamic boundary condition at the two root nodes, we end 
up with 8 degrees of freedom for the model. To find the unknown 
parameters, we presume that a properly working vasculature 
requires a homogeneous flow inside the capillary bed to maintain 
the nutrient exchange and apply a computational optimization 
technique where the variance of the volume blood flow inside all 
capillaries ( Q capillaries ) is used as cost function 
f = V ar(Q capil l aries ) (9) 
We used particle swarm optimization (PSO) ( Kennedy and Eber- 
hart, 1995 ) to minimize the cost function f defined in Eq. (9) . Al- 
though there is no guarantee to find the best solution, PSO finds 
at least a “robust” solution i.e. a solution that is robust against 
varying the initial conditions. In our case, the initial conditions are 
the values of the parameters k m , k c and k s . During the PSO, we 
vary these parameters in the range of 0.5–4.0 for each fixed set of 
hydrodynamic boundary conditions. The hydrodynamic boundary 
conditions are the arterial inlet flow and the venous outlet pres- 
sure which we also varied in a systematic way (see supplemental 
text). 
The numerical values of Q ref = 40 nl/min , L = 1500 μm and 
S 0 = 20 were kept fix at the values reported in Pries et al. (1998) . 
All exact numbers, computational details and the implementa- 
tion are reported in a supplemental text to this manuscript. 
2.4. Definition of biophysical quantities 
Given a blood vessel network inside a volume V that consists 
of N tubes with radii r i and lengths l i , two quantities of interest 
are the regional blood volume (rBV) and the surface to volume 
ratio (s2v). 
2.4.1. Regional Blood Volume (rBV) 
The regional blood volume measures the percentage of blood 
within the volume. 
r BV = 
∑ N 






2.4.2. Surface to volume ratio (s2v) 
The surface to volume ratio measures the ratio between the 
surface of an object and the volume included by this surface. 
Since nutrient exchange happens across the vessel surface, the 
exchange is proportional to the surface and therefore the s2v is an 
interesting quantity. 




2 π r i l i 





3.1. Reproducing available data 
We applied our implementation of the adaptation algorithm 
to a experimentally determined rat mesentery network. Since 
the hydrodynamic boundary conditions were measured, we in- 
corporated them accordingly. The same procedure was done in 
Pries et al. (1998) (Network I). Unfortunately, the used time step 
t is not documented. We used t = 0 . 1 and the other adaptation 
parameters in Table 2 . To verify our implementation, we repro- 
duced two figures comparing the shear stress, vessel diameters, 
and the adaptation signals S 1 , S 2 , S 3 and S 4 before and after 
application of the algorithm. 
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Fig. 3. Left column (black and white): reprint of Fig. 4 and 5 from Pries et al. (1998) with permission. Right column (colored): reproduced by our implementation/ software. 
(A): Values obtained with experimentally determined vessel diameters, (B): values obtained by simulated vessel adaptation. Top and second from top row: Distribution of 
shear stress and diameter for a rat mesentery network with 546 segments (162 arterioles, 167 capillaries and 217 venules). Hemodynamic parameters were calculated using 
the network flow model based on measured network morphology and topology. Last before bottom row: hydrodynamic stimuli derived from shear stress ( τ w ) and blood 
pressure (P) are plotted as functions of pressure. Last row: the metabolic (M) and conducted stimuli (C) are plotted as functions of flow rate, to show functional dependence 
of these stimuli. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
Table 2 
Parameters used to adapt vessel radii of rat mesentery net- 
work with Tumorcode. Parameter labeled by ∗ is not shown in 
Pries et al. (1998) . 
k c k m k s Q ref S 0 t L 
2.74 0.83 1.79 40 nl/min 20 0.1 ∗ 1500 μm 
Due to the lack of quantitative data in Pries et al. (1998) we 
cannot compare directly, but our figures are in qualitative agree- 
ment with the original ( Fig. 3 ). For the hydrodynamics (top row 
and second from top row of Fig. 3 ), we observe that the shear 
stress saturates with increasing blood pressure (top row) and the 
diameter varies for veins in a broader range than for the arteries 
with the same pressure (second row). The adaptation tends to 
increase the radius of the capillaries (coral labeled points in right- 
most image of second row). For the distribution of the adaptation 
signals S 1 and S 2 (last before bottom row of Fig. 3 ), we find 
vessels in the adapted network with a higher blood pressure than 
100 mmHg and therefore we extended the pressure axis (x-axis) to 
120 mmHg. For the distribution of the adaptation signals S 3 and S 4 
(bottom row of Fig. 3 ), we find that adaptation shifts the spectrum 
towards increased flow. In agreement with model assumptions, 
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(a) (b)
Fig. 4. Results of the particle swarm optimization (PSO). (a) Contour plot of the logarithm of the cost function f ( Eq. 9 ) used for the PSO. x-axis: flow boundary condition 
at the arterial inlet. y-axis: pressure boundary condition at the venous outlet. The cross shows the boundary conditions used in Section 3.3 ; (b) Distribution of optimized 
choice for k m , k c and k s . Only the convergent hydrodynamic boundary conditions are considered. The median value is write above the corresponding line. 
(a) (b)
Fig. 5. Biophysical variables influenced by the adaptation algorithm. Distribution is obtained from a single configuration of vessels in space ( Section 3.2 ), but different radii 
distributions obtained during particle swarm optimization. We considered the 248 convergent boundary conditions here. (a) Distribution of regional blood volume ( rBV ); 
(b) Distribution of surface to volume ratio ( s2v ) in 1/μm. 
the metabolic signal/ demand (S 3 ) is higher for low flow segments 
and the conducted signal (S 4 ) increases for segments with higher 
flow that are more up or downstream respectively. 
3.2. Single topology, varying boundary conditions 
As already discussed in Pries et al. (1998) , there are two possi- 
ble outcomes when applying the adaptation scheme in a repeated 
manner: either one reaches a steady state where the changes 
of radii become arbitrary small with each iteration or the radii 
changes increase to unrealistic values which also implies unrealis- 
tic values for pressure and flow, and are not further consider. 
In the remaining, we switch from the rat mesentery network 
to synthetic arteriovenous networks constructed by Tumorcode. 
We start with a single fixed topology and apply the optimization 
procedure described in Section 2.3 . Thereby we identified the 
hydrodynamic boundary conditions and parameters that result in 
convergence of the adaptation algorithm with the fixed network 
topology (see Fig. 4 (a)) and achieved an optimal homogeneity in 
the blood flow of the capillaries. Interestingly, the distribution of 
optimization parameters ( Fig. 4 (b)) indicates the same relation 
between the parameters (k m < k s < k c ) as found by Pries et al. in 
their three samples of rat mesentery networks ( Pries et al., 1998 ). 
To estimate the biological relevance of the optimized net- 
works, we analyze two biophysical variables ( Section 2.4 ): The 
regional blood volume ( Fig. 5 (a)) and the surface to volume ratio 
( Fig. 5 (b)). The total regional blood volume varies within a phys- 
iological regime from 2% up to 10% (left column in Fig. 5 (a)). To 
estimate the contributions from arteries, capillaries and veins to 
the total rBV, we segmented them in Fig. 5 (a). 
The results for the surface to volume ratio are shown in similar 
fashion ( Fig. 5 (b)). As expected, the surface to volume ratio is 
highest for small capillaries, smaller for arteries and the smallest 
for the large veins. 
3.3. Varying topology, fixed boundary conditions 
In contrast to the previous section, we now 1) keep the hy- 
drodynamic boundary conditions and adaptation parameters fixed 
and 2) vary the topological arrangement of the vessels i.e. we 
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(a) (b)
Fig. 6. Biophysical variables influenced by the adaptation algorithm. Distribution is taken from 10 different arrangements of vessels in space with radii obtained by 1) 
construction by Tumorcode (blue) and 2) application of the adaptation algorithm with a fixed set of parameters ( Table 2 , orange). (a) Distribution of regional blood volume 
( rBV ); (b) Distribution of surface to volume ratio ( s2v ) in 1/μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version 
of this article.) 
Table 3 
Mean value and standard error of the mean for rBV and s2v averaged over the 10 considered 
networks. 
All types Artery Vein Capillary 
rBV Tumorcode 0.80 ± 0.03 0.227 ± 0.006 0.532 ± 0.03 0.039 ± 0.001 
Adaptation 3.3 ± 0.2 0.80 ± 0.03 2.4 ± 0.2 0.076 ± 0.003 
s2v Tumorcode 0.605 ± 0.002 0.672 ± 0.004 0.439 ± 0.002 0.8 ∗
Adaptation 0.412 ± 0.001 0.443 ± 0.003 0.293 ± 0.002 0.586 ± 0.003 
∗ Note that the radius of a capillary is fixed in synthetic networks constructed by Tumorcode. 
Data also visualized in Fig. 6 . 
grow different networks with same root node configuration. Based 
on the results of the PSO (red cross in Fig. 4 (a)), we decided to 
use a pressure of 2.8 kPa at venous outlet and a volume flow 
rate of 2 · 10 7 μm 3 /s at the arterial inlet to create 10 independent 
realizations of arteriovenous networks ( M-networks ) of lateral 
size 1500 μm (see Section 2.2 ). 
3.3.1. Biophysical quantities 
We apply the adaptation algorithm with the parameter set 
listed in Table 2 to the 10 samples. Hence we constructed 10 
A-networks which we compare regarding their regional blood 
volume rBV ( Fig. 6 (a)) and their surface to volume ratio s2v 
( Fig. 6 (b)) to the M-networks (numerical values listed in Table 3 ). 
For the A-networks , the overall rBV is more than 4 times 
higher than for the M-networks (left column of Fig. 6 (a)). In each 
case, the contribution of the veins to the rBV is the highest (66% 
for Tumorcode and 72% for Adaptation). For the M-networks , the 
overall s2v ratio is about 1.5 times higher than for the A-networks 
(left column of Fig. 6 (b)). The s2v is highest at the capillary bed 
followed by the arteries and the veins. 
The observed behavior follows from the hierarchical structure 
of the vascular network. Considering a fixed volume and vessels 
with fixed segment length (as in our case), the s2v scales propor- 
tional to the inverse of the radius and the rBV scales proportional 
to the vessel radius squared ( Section 2.4 ). Since capillaries are 
smaller than arteries and veins in a hierarchical structure, the 
s2v increases and the rBV decreases when going from the upper 
(artery, vein) to the lower level (capillary), as observed. 
Essentially, the M-networks feature systematically smaller 
vessel radii increasing the s2v ratio at the cost of higher flow 
resistance. 
3.3.2. Adaptation signals 
Similar to Fig. 3 , we plot: a) The hydrodynamic characteristics 
(top and next to top row in Fig. 7 ), b) the hydrodynamic signal 
(last before bottom row in Fig. 7 ), and c) the conducted and 
metabolic signals (bottom row in Fig. 7 ) for one representative of 
the A-networks in Fig. 7 . For the other nine networks, the plots 
look qualitatively similar. 
Before adaptation, there is no correlation between the wall 
shear stress and the pressure, and since the signal S 1 (positive 
values of last before bottom row) depends only on the logarithm 
of the shear stress, there is also no functional dependence of S 1 
on the pressure. After the adaptation however, the dependence of 
the shear stress and the signal S 1 on the pressure becomes more 
pronounced (right column of Fig. 7 ): Veins approach a plateau 
with increasing pressure and the arteries with decreasing pressure. 
For the shear stress, the plateau is between 50–100 dyn/cm 2 and 
for the signal S 1 around 2. The diameter depends on the pressure 
as expected for our networks: starting with the vessels of the 
smallest diameter (the capillaries), the diameter increases as we 
raise the pressure along the arterial branch and decrease the 
pressure along the venous branch (second row of Fig. 7 ). The 
negative values in the last before bottom row of Fig. 7 present the 
signal S 2 ( Eq. 4 ). Here we notice that the values for S 2 are more 
restricted for veins (between −1.2 and −1.7) than for arteries 
(between −1.1 and −2.0). The metabolic and conducted signal 
(bottom row of Fig. 7 ) shift their maximum / minimum from 0.01 
nl/min to increased flows at about 1 nl/min. 
3.3.3. Visual inspection 
Although the distribution of radii changes from the M- 
networks (bottom left of Fig. 8 ) to A-networks (bottom right 
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Fig. 7. The characteristics for a single arteriovenous network. Left column: Without adaptation. Right column: convergent adaptation with parameters listed in Table 2 . A 
graphical representation of this particular network is shown in Fig. 8 . From top to bottom we compare the shear stress, the vessel diameter, the hydrodynamic signals (S 1 
and S 2 of Section 2.1 ) and the metabolic and conducted signal (S 3 and S 4 of Section 2.1 ). (For interpretation of the references to colour in this figure legend, the reader is 
referred to the web version of this article.) 
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Fig. 8. Color coded vessel properties for one representative of the ensemble of synthetic arteriovenous networks. Left column: radii distribution from Tumorcode (Murray’s 
law). Right column: Radii distribution after adaptation. From top to bottom: Pressure in mmHg, volume flow (logarithmic scale) in μm 3 /s, radius in μm. (For interpretation 
of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
column of Fig. 8 ), the distribution of the blood pressure does 
not change because of the fixed boundary conditions (colors of 
top row in Fig. 8 ). The shear force is proportional to the flow 
and therefore the distribution of the shear force looks similar to 
the distribution of flow as show in the center row of Fig. 8 . In 
the bottom row of Fig. 8 , we colored the vessel by their radii to 
highlight changes of the vessel radii by the adaptation algorithm. 
Finally, Fig. 9 shows data that is only available in the adaptation 
case (metabolic signal and conducted signal). In agreement with 
model assumptions, the metabolic signal is highest at the thin 
capillaries and the conducted signal is highest at the most distal 
points. 
3.4. Murray’s law 
The networks created by Tumorcode fulfill Murray’s law by 
construction ( Section 2.2 ). Here we check for a single network 
(shown in Fig. 8 ) whether it still fulfills Murray’s law after the 
application of the adaptation algorithm. 
In Fig. 10 we plot for each bifurcation the cubic root of the sum 
of daughter vessel radii cube against the radius of the mother ves- 
sel. If the mother and daughter vessel radii would fulfill Murray’s 
law, the data points would lie on the straight line, which they do 
remarkably closely. Applying Murray’s law locally at each bifurca- 
tion in large networks results in a complicated dependence of the 
vessel radius on the global vessel arrangement. Nevertheless the 
distribution of the differences between the radii of two daughter 
vessels in M-networks displays characteristic features like discrete 
peaks at specific difference values, as shown in Fig. 11 . This can be 
understood as follows: since the network construction algorithm 
of Tumorcode uses a fixed capillary radius and a discrete vessel 
length (on a lattice), repeated application of Murray’s law leads 
more often to the same proportions at an intersection. To illustrate 
this, we use a hypothetical capillary bed as shown in Fig. 12 . For 
the bifurcations b 1 , b 2 and b 3 ( Fig. 12 ), we calculate the quantity 
used in the histogram shown in Fig. 11 : The differences of the 
daughter vessel radii normalized by the mother vessel radius. 
b 1 b 2 b 3 
2 . 5 μm −2 . 5 μm 
3 . 15 μm = 0 . 0 3 . 15 μm −2 . 5 μm 3 . 61 μm = 0 . 18 3 . 61 μm −2 . 5 μm 3 . 97 μm = 0 . 28 
The three highest peaks of the histogram are located around the 
calculated values (0.0, 0.18 and 0.28). 
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Fig. 9. Adaptation signals ( Section 2.1 ) for one representative of the ensemble of synthetic arteriovenous networks. Left column: Metabolic signal (S 3 ) Right column: con- 
ducted signal (S 4 ). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
Fig. 10. The black diagonal represents Murray’s law for α = 3 . The data points are 
taken from the A-network shown in Fig. 8 in the right column. Blue dots are venous 
intersections (431) and red dots are arterial intersections (475). (For interpretation 
of the references to colour in this figure legend, the reader is referred to the web 
version of this article.) 
On the other hand, the distribution of the differences between 
the radii of daughter vessels in A-networks is much smoother and 
lacks discrete peaks. The adaptation algorithm adjusts each vessel 
radius and removes the initial vessel radii discretization, resulting 
in a radii distribution in A-networks that differs significantly from 
M-networks . The more remarkable is the observation that the 
radii still obey Murray’s law very closely. 
4. Discussion 
We compared arteriovenous networks constructed by the Tu- 
morcode ( M-networks , radii obey Murray’s law by construction) 
with networks having the same topology, but with vessel radii 
obtained by the adaptation algorithm ( A-networks ). 
The most interesting result is that structural adaptation leads 
to a network that differs significantly from one generated by strict 
application of Murray’s law, yet the adapted network satisfies 
Murray’s law quite closely. Small but systematic deviations from 
Murray’s law at each bifurcation level (compare Fig. 10 ) accumu- 
late over subsequent levels and result in generally larger vessel 
radii in A-networks compared to M-networks and consequently 
in global differences in regional blood flow (rBV) and surface to 
volume ratio (s2v). A quantitative analysis of rBV ( Fig. 5 (a), 6 (a) 
and Table 3 ) and s2v ( Fig. 5 (b), 6 (b) and Table 3 ) confirms that 
the A-networks carry more blood while the M-networks show a 
higher surface to volume ratio — especially at the capillary level 
— at the expense of an elevated flow resistance. 
Moreover, the adaptation algorithm smoothens the distribution 
of the differences of the radii of the two daughter vessels at each 
(a) Tumorcode (b) Adaptation
Fig. 11. Normalized distribution of differences between two daughter vessels at a Y- shaped intersection. The used topology is the same for both cases and shown in Fig. 8 . 
Left column: before adaptation (vessel radii fulfilling Murray’s law by construction in Tumorcode). Right column: same topology as left column but vessel radii adapted with 
parameter set listed in Table 2 . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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Fig. 12. Schematic view on capillary bed as constructed by the Tumorcode Soft- 
ware. The vessels indicated in coral are capillaries with radius r cap = 2.5 μm. At bifur- 
cation b 1 , b 2 and b 3 the upstream vessel radii r 1 , r 2 and r 3 are calculate by Murray’s 
law with exponent 3. (For interpretation of the references to colour in this figure 
legend, the reader is referred to the web version of this article.) 
bifurcation. This observation demonstrates that for a given net- 
work topology more than one radii distribution can fulfill Murray’s 
law, at least very closely. The reproduction of Murray’s law by 
structural adaptation is particularly remarkable since the algorithm 
produces radii variation due to signals involving chemical energy 
(metabolic signal), the tension of endothelial layer (shrinking 
tendency) and non-local contributions (conducted signal). It is 
interesting to find a relation close to Murray’s law although drag 
and flow are not directly used in the adaptation model. Instead, 
our choice of the objective function in the optimization procedure 
( Section 2.3 ) is based on a requirement for optimal homogeniza- 
tion of the capillary flow. Among several other objective functions, 
we found that minimizing the overall variance of the capillary 
flow achieves convergence of the adaptation algorithm for our 
synthetic arteriovenous networks. 
It would be interesting to study structural adaptation in the 
case of pathological networks such as blood vessel networks 
modified by a growing tumor ( Carmeliet and Jain, 20 0 0 ), involving 
angiogenesis, vessel regression and collapse. We tried to include 
the adaptation algorithm into our model of tumor vascularization 
( Welter and Rieger, 2010; Rieger et al., 2016; Welter et al., 2016 ), 
implemented in Tumorcode ( Fredrich et al., 2018 ). Using a con- 
vergent set of adaptation parameters for a given arteriovenous 
network (as analyzed in this manuscript), the convergence was 
not achieved when the network topology is subsequently altered 
during tumor growth. The potential reasons for the failure of 
convergence are analyzed in a supplemental text. A successful 
application of the adaptation algorithm in the presence of vascular 
remodeling was reported in Secomb et al. (2013) : Angiogenesis 
combined with vascular pruning based on low oxygen saturation 
resulted in stable radii distributions. The application of structural 
adaptation amended by angiogenesis and pruning to vascular 
remodeling in growing tumors is topic of future research. So far, 
there seems to be no consensus in the field how to include struc- 
tural adaptation into vascular tumor growth. The discussion of the 
stability of networks with low generation shunts in the appendix 
of Pries et al. (1998) proves that the adaptation algorithm cannot 
be stable without the conducted signal. However, some mathe- 
matical models of vascularized tumor growth include vessel radius 
adaptation ( McDougall et al., 2006 ), but no conducted signal, 
although it is an integral component of the structural adaptation 
theory, at least in the non-cancerous setting. 
The signals introduced by the adaptation algorithm are based 
on biological relevant processes which provide an input for 
mathematical modeling. Currently the signals are modeled with 
parameters (compare Table 1 ), but in the future the variations in 
endothelial cell membrane potential along a vessel or its metabolic 
uptake might become experimentally measurable fixing the free 
parameters of the adaptation model used here. 
5. Data availability 
We support open science by sharing our software and the 
created raw data at www.zenodo.org . 
5.1. Software 
A developer version of the Tumorcode software tool 
( Fredrich et al., 2018 ) is hosted at www.github.com/thierry30 0 0/ 
tumorcode . For the presented manuscript, we worked with the 
Pre-release v1.1.0-alpha.1 (Adaptation) version of the code which 
we also archived ( Fredrich and DaWelter, 2019 ). 
5.2. Data 
We store the results of executed simulations, the used settings 
and parameters, the network topologies and the images in a single 
compressed archive ( Fredrich, 2019 ). 
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1. Details of the particle swarm optimization used in 3.1 “Single
topology, varying boundary conditions”
Our aim was to use deap (Distributed Evolutionary Algorithms in Python)
to spread the evaluation of multiple vessel adaptations with different boundary
conditions and algorithm parameters across multiple processors.5
1.1. Required Software
We used the Intel Parallel Studio XE 2018 with its compiler to achieve fast
hardware execution times. The intel python bindings (IntelPython) were used
consistently with Tumorcode. We had to install libzmq and the python bindings
from source. We used SCOOP (Scalable COncurrent Operations in Python)10
which is nice module to distribute computational task from heterogeneous grids
to supercomputers. In our case we used a small beowulf cluster (64 Nodes
with up to 28 cores) hosted by the theoretical physics department of Saarland
University. Apart from the aforementioned software the cluster runs operationg
system Gentoo linux hardened SLURM queuing system.15
1.2. Particle swarm optimization
We conducted Particle swarm optimization with the deap software based on
their example in the documentation. Our source code is available on GitHub
at: https://github.com/thierry3000/tumorcode. (py/krebs/adaption).
All optimizations listed in table 1 were conducted with a population of 32020
individuals and 10 generations of mutation. We used 20 Nodes with 16 cores
each to have 320 independent tasks. For the discussion presented in the main
article, we evaluated the PSO with the parameter set value list 14 however we
performed more optimizations. All successful runs could be downloaded at: [1].
2
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name #boundary conditions flow/107 µm3/s pressure/ kPa
value list 11 160 1-9 3.5-4.5
value list 12 160 1-9 3.5-4.5
value list 13 864 1- 90 1.8-4.5
value list 14 342 0.5-10 0.5-9.5
Table 1: Datasets resulting from successful PSO (downloadable at: ). All optimizations were
conducted with a population of 320 individuals and 10 generations of mutation.
2. Application to cancerous networks25
The adaptation algorithm accounts for the modification of radii in blood
vessel networks without topological modifications. In solid tumors, topologi-
cal modifications are an essential part of the growth procedure and therefore
considered in our simulation framework [2]. In [3], we simulated the oxygen
distribution in breast carcinoma and found that an additional vessel dilation is30
required to obtain oxygen distributions in agreement with the clinical measure-
ments. We conjectured that the adaptation algorithm could possibly provide
a physiological mechanism for this vessel dilation. Indeed we observe the ex-
pected behaviour in a minimal example (figure 1): the high metabolic demand
(HQ < Qref) of the vessels created by angiogenesis increases the radii during35
adaptation (see zoom in the upper right of figure 1). The new tumor vessels cou-
ple two previously uncoupled branches and thereby raise the topological signal
in the connected branches as intended by the adaptation algorithm (see value
of main inlet and outlet in bottom right of figure 1).
Although this works in this simplified example, we found that such modifica-40
tions destabilize the convergence of the adaptation algorithm when occuring in
a repeated manner or at multiple locations at the same time as it happens our
simulations of tumor growth in large arteriovenous systems.
3
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Figure 1: Critial behaviour during angiogenesis. We constructed a minimal example consist-
ing of four closed capillary loops which is representative for the situation larger arteriovenous
networks. Left column: w/o tumor, right column: slightly remodelled situation by angiogen-
esis during tumor growth with zoom into the critical area. Top row: vessels color-coded by
their vessel radius. Bottom row: vessels color-coded by their value of the conducted signal.
The complete example with the topology, the boundary conditions and the adaptation pa-
rameters is documented in the source code distributed with this manuscript or on GitHub at
https://github.com/thierry3000/tumorcode (py/krebs/adaption/testAdaption.py)
4
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[65] K. Böttger, H. Hatzikirou, A. Chauviere, and A. Deutsch, “Investigation of the Migration/Proliferation
Dichotomy and its Impact on Avascular Glioma Invasion,” Mathematical Modelling of Natural
Phenomena, vol. 7, no. 1, pp. 105–135, 2012. [Online]. Available: https://www.mmnp-journal.org/
articles/mmnp/abs/2012/01/mmnp201271p105/mmnp201271p105.html
[66] J. C. L. Alfonso, K. Talkenberger, M. Seifert, B. Klink, A. Hawkins-Daarud, K. R. Swanson,
H. Hatzikirou, and A. Deutsch, “The biology and mathematical modelling of glioma invasion: a re-
view,” Journal of the Royal Society, Interface, vol. 14, no. 136, 2017.
[67] T. Brabletz, R. Kalluri, M. A. Nieto, and R. A. Weinberg, “EMT in cancer,” Nature
Reviews Cancer, vol. 18, no. 2, pp. 128–134, Feb. 2018. [Online]. Available: https:
//www.nature.com/articles/nrc.2017.118
[68] D. Reher, B. Klink, A. Deutsch, and A. Voss-Böhme, “Cell adhesion heterogeneity reinforces tumour
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Promotionsausschusses genehmigt werden müssen. 
 
Sollten Sie trotz größter Bemühungen keine Genehmigung zur Einbindung der 
Veröffentlichung/en in Ihre Dissertationsschrift erhalten, müssen Sie für Ihren individuellen 
Fall schriftlich eine Ausnahmegenehmigung des Vorsitzenden des Promotionsausschusses 
beantragen, dahingehend, dass die copyright-geschützten Originalpublikationen in den 
Pflichtexemplaren entfernt werden und anstelle dessen lediglich der DOI und bibliographische 
Daten, die das Auffinden der Publikation ermöglichen (z.B. Autoren, Titel, Journal, Volume, 
Issue, Seiten) aufgeführt werden. 1 
 
ACHTUNG: 
Mit Verabschiedung einer überarbeiteten Promotionsordnung, spätestens aber ab dem 
01.01.2020 gilt: 
Sollten Sie keine Genehmigung zur Einbindung der Veröffentlichung in Ihre 
Dissertationsschrift erhalten, ist eine kumulative Dissertationsschrift mit dieser Publikation 
ausgeschlossen. Die Dissertationsschrift muss stets den gesamten Text der Arbeiten 
einbinden. 
                                                 
1 Sollten die Verlage Ihnen nicht das Recht einräumen, Ihre Artikel als Teil Ihrer Dissertationsschrift zu veröffentlichen, können Sie auch nicht die 
Manuskriptform der Artikel nutzen, da die Rechte an dieser inhaltsgleichen Version ebenfalls an die Verlage übertragen sind.  
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Modeling vascular tumors
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SFB 1027 photo competition
The author of this dissertation contributed with three images to the photo contest anounced by the SFB
1027 in 2018. The contributing images are reprinted in figure E.1, figure E.2 and figure E.3.
The image shown in figure E.1 was awarded to decorate the poster of the “Cell Physics“ conference in 2019
(http://www.cell-physics.uni-saarland.de/poster/poster 2019/Cell-Physics-2019-A4.pdf).
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Figure E.1: pH level in vascularized tumor spheroid - vessels are color coded by blood pressure, cells by pH
level, the fading orange in the center indicated the amount of vascular endothelial growth factor (VEGF)
released by the cells.
A lot of aspects of the SFB 1027 deal with low number of cells. In A3 - physical processes during T cell
activation, polarization, and killing - we focus not only on single cells, but also on the complete micro
environment required for effective killing which is inherently linked cancer. The presented simulations are a
first attempt to combine our vasculature model with cellular information.
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Figure E.2: A tumor modifying the surrounding healthy vasculature. The 3D network is cut to appreciate
the tumor in the center. We colored amount of released vascular endothelial growth factor (VEGF) by their
value from blue to cyan. The Vessels outside the tumor are depicted by their respective blood pressure from
red to blue.
Project A3 deals with biological killing which is dominated by the micro-environment. In our simulations
we include the vasculature to understand killing beyond the diffusion limited regime which hallmarks solid
tumors in vivo.
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Figure E.3: Vascularized tumor. We display the vasculature as volume fraction occupied by vessels shown
from green to brown and the surface as calculated by our simulations.
Project A3 deals with biological killing which is dominated by the micro-environment. In our simulations
we include the vasculature to understand killing beyond the diffusion limited regime which hallmarks solid
tumors in vivo.
Appendix F
Cover Page of The EPJ E
The author of this dissertation designed the cover page of the The European Physical Journal E Volume 41
/ No 4 (April 2018). Available at
https://epje.epj.org/articles/epje/abs/2018/04/contents/10189 0041 004 2018.tif and reprinted with permis-
sion (see page 244 of this dissertation) in figure F.1. The image shows a tumor created by the bulk tissue
tumor simulation of Tumorcode inside a small vascular network. For more information about the content
contact the associated publication reprinted in chapter 3 section 3.2.
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Figure F.1: Cover of The European Physical Journal E Volume 41 / No 4 (April 2018).
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Creative Commons Legal Code
Attribution 4.0 International
Official translations of this license are available in other languages.
Creative Commons Corporation (“Creative Commons”) is not a law firm and does not provide
legal services or legal advice. Distribution of Creative Commons public licenses does not
create a lawyer-client or other relationship. Creative Commons makes its licenses and related
information available on an “as-is” basis. Creative Commons gives no warranties regarding its
licenses, any material licensed under their terms and conditions, or any related information.
Creative Commons disclaims all liability for damages resulting from their use to the fullest
extent possible.
Using Creative Commons Public Licenses
Creative Commons public licenses provide a standard set of terms and conditions that
creators and other rights holders may use to share original works of authorship and other
material subject to copyright and certain other rights specified in the public license below. The
following considerations are for informational purposes only, are not exhaustive, and do not
form part of our licenses.
Considerations for licensors: Our public licenses are intended for use by those authorized
to give the public permission to use material in ways otherwise restricted by copyright and
certain other rights. Our licenses are irrevocable. Licensors should read and understand the
terms and conditions of the license they choose before applying it. Licensors should also
secure all rights necessary before applying our licenses so that the public can reuse the
material as expected. Licensors should clearly mark any material not subject to the license.
This includes other CC-licensed material, or material used under an exception or limitation to
copyright.
Considerations for the public: By using one of our public licenses, a licensor grants the
public permission to use the licensed material under specified terms and conditions. If the
licensor’s permission is not necessary for any reason–for example, because of any applicable
exception or limitation to copyright–then that use is not regulated by the license. Our licenses
Creative Commons — Attribution 4.0 Internation... https://creativecommons.org/licenses/by/4.0/leg...
1 of 7 8/16/19, 10:43 AM
G.1. PERMISSIONS FOR REPRINTING [1] AND [3] APPENDIX G. PERMISSIONS
216
grant only permissions under copyright and certain other rights that a licensor has authority to
grant. Use of the licensed material may still be restricted for other reasons, including because
others have copyright or other rights in the material. A licensor may make special requests,
such as asking that all changes be marked or described. Although not required by our
licenses, you are encouraged to respect those requests where reasonable.
Creative Commons Attribution 4.0 International Public License
By exercising the Licensed Rights (defined below), You accept and agree to be bound by the
terms and conditions of this Creative Commons Attribution 4.0 International Public License
("Public License"). To the extent this Public License may be interpreted as a contract, You are
granted the Licensed Rights in consideration of Your acceptance of these terms and
conditions, and the Licensor grants You such rights in consideration of benefits the Licensor
receives from making the Licensed Material available under these terms and conditions.
Section 1 – Definitions.
Adapted Material means material subject to Copyright and Similar Rights that is derived
from or based upon the Licensed Material and in which the Licensed Material is translated,
altered, arranged, transformed, or otherwise modified in a manner requiring permission
under the Copyright and Similar Rights held by the Licensor. For purposes of this Public
License, where the Licensed Material is a musical work, performance, or sound recording,
Adapted Material is always produced where the Licensed Material is synched in timed
relation with a moving image.
a. 
Adapter's License means the license You apply to Your Copyright and Similar Rights in
Your contributions to Adapted Material in accordance with the terms and conditions of this
Public License.
b. 
Copyright and Similar Rights means copyright and/or similar rights closely related to
copyright including, without limitation, performance, broadcast, sound recording, and Sui
Generis Database Rights, without regard to how the rights are labeled or categorized. For
purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not
Copyright and Similar Rights.
c. 
Effective Technological Measures means those measures that, in the absence of proper
authority, may not be circumvented under laws fulfilling obligations under Article 11 of the
WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international
agreements.
d. 
Exceptions and Limitations means fair use, fair dealing, and/or any other exception or
limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.
e. 
Licensed Material means the artistic or literary work, database, or other material to whichf. 
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the Licensor applied this Public License.
Licensed Rights means the rights granted to You subject to the terms and conditions of
this Public License, which are limited to all Copyright and Similar Rights that apply to Your
use of the Licensed Material and that the Licensor has authority to license.
g. 
Licensor means the individual(s) or entity(ies) granting rights under this Public License.h. 
Share means to provide material to the public by any means or process that requires
permission under the Licensed Rights, such as reproduction, public display, public
performance, distribution, dissemination, communication, or importation, and to make
material available to the public including in ways that members of the public may access
the material from a place and at a time individually chosen by them.
i. 
Sui Generis Database Rights means rights other than copyright resulting from Directive
96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal
protection of databases, as amended and/or succeeded, as well as other essentially
equivalent rights anywhere in the world.
j. 
You means the individual or entity exercising the Licensed Rights under this Public
License. Your has a corresponding meaning.
k. 
Section 2 – Scope.
License grant.
Subject to the terms and conditions of this Public License, the Licensor hereby grants
You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to
exercise the Licensed Rights in the Licensed Material to:
reproduce and Share the Licensed Material, in whole or in part; andA. 
produce, reproduce, and Share Adapted Material.B. 
1. 
Exceptions and Limitations. For the avoidance of doubt, where Exceptions and
Limitations apply to Your use, this Public License does not apply, and You do not need
to comply with its terms and conditions.
2. 
Term. The term of this Public License is specified in Section 6(a).3. 
Media and formats; technical modifications allowed. The Licensor authorizes You to
exercise the Licensed Rights in all media and formats whether now known or hereafter
created, and to make technical modifications necessary to do so. The Licensor waives
and/or agrees not to assert any right or authority to forbid You from making technical
modifications necessary to exercise the Licensed Rights, including technical
modifications necessary to circumvent Effective Technological Measures. For purposes
of this Public License, simply making modifications authorized by this Section 2(a)(4)
never produces Adapted Material.
4. 
Downstream recipients.
Offer from the Licensor – Licensed Material. Every recipient of the LicensedA. 
5. 
a. 
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Material automatically receives an offer from the Licensor to exercise the Licensed
Rights under the terms and conditions of this Public License.
No downstream restrictions. You may not offer or impose any additional or different
terms or conditions on, or apply any Effective Technological Measures to, the
Licensed Material if doing so restricts exercise of the Licensed Rights by any
recipient of the Licensed Material.
B. 
No endorsement. Nothing in this Public License constitutes or may be construed as
permission to assert or imply that You are, or that Your use of the Licensed Material is,
connected with, or sponsored, endorsed, or granted official status by, the Licensor or
others designated to receive attribution as provided in Section 3(a)(1)(A)(i).
6. 
Other rights.
Moral rights, such as the right of integrity, are not licensed under this Public License,
nor are publicity, privacy, and/or other similar personality rights; however, to the extent
possible, the Licensor waives and/or agrees not to assert any such rights held by the
Licensor to the limited extent necessary to allow You to exercise the Licensed Rights,
but not otherwise.
1. 
Patent and trademark rights are not licensed under this Public License.2. 
To the extent possible, the Licensor waives any right to collect royalties from You for
the exercise of the Licensed Rights, whether directly or through a collecting society
under any voluntary or waivable statutory or compulsory licensing scheme. In all other
cases the Licensor expressly reserves any right to collect such royalties.
3. 
b. 
Section 3 – License Conditions.
Your exercise of the Licensed Rights is expressly made subject to the following conditions.
Attribution.
If You Share the Licensed Material (including in modified form), You must:
retain the following if it is supplied by the Licensor with the Licensed Material:
identification of the creator(s) of the Licensed Material and any others
designated to receive attribution, in any reasonable manner requested by the
Licensor (including by pseudonym if designated);
i. 
a copyright notice;ii. 
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a notice that refers to the disclaimer of warranties;iv. 
a URI or hyperlink to the Licensed Material to the extent reasonably practicable;v. 
indicate if You modified the Licensed Material and retain an indication of any
previous modifications; and
B. 
indicate the Licensed Material is licensed under this Public License, and include the
text of, or the URI or hyperlink to, this Public License.
C. 
You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on
the medium, means, and context in which You Share the Licensed Material. For
example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink
to a resource that includes the required information.
2. 
If requested by the Licensor, You must remove any of the information required by
Section 3(a)(1)(A) to the extent reasonably practicable.
3. 
If You Share Adapted Material You produce, the Adapter's License You apply must not
prevent recipients of the Adapted Material from complying with this Public License.
4. 
Section 4 – Sui Generis Database Rights.
Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the
Licensed Material:
for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse,
reproduce, and Share all or a substantial portion of the contents of the database;
a. 
if You include all or a substantial portion of the database contents in a database in which
You have Sui Generis Database Rights, then the database in which You have Sui Generis
Database Rights (but not its individual contents) is Adapted Material; and
b. 
You must comply with the conditions in Section 3(a) if You Share all or a substantial
portion of the contents of the database.
c. 
For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations
under this Public License where the Licensed Rights include other Copyright and Similar
Rights.
Section 5 – Disclaimer of Warranties and Limitation of Liability.
Unless otherwise separately undertaken by the Licensor, to the extent possible, the
Licensor offers the Licensed Material as-is and as-available, and makes no
representations or warranties of any kind concerning the Licensed Material,
whether express, implied, statutory, or other. This includes, without limitation,
warranties of title, merchantability, fitness for a particular purpose, non-
infringement, absence of latent or other defects, accuracy, or the presence or
a. 
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absence of errors, whether or not known or discoverable. Where disclaimers of
warranties are not allowed in full or in part, this disclaimer may not apply to You.
To the extent possible, in no event will the Licensor be liable to You on any legal
theory (including, without limitation, negligence) or otherwise for any direct,
special, indirect, incidental, consequential, punitive, exemplary, or other losses,
costs, expenses, or damages arising out of this Public License or use of the
Licensed Material, even if the Licensor has been advised of the possibility of such
losses, costs, expenses, or damages. Where a limitation of liability is not allowed in
full or in part, this limitation may not apply to You.
b. 
The disclaimer of warranties and limitation of liability provided above shall be interpreted in
a manner that, to the extent possible, most closely approximates an absolute disclaimer
and waiver of all liability.
c. 
Section 6 – Term and Termination.
This Public License applies for the term of the Copyright and Similar Rights licensed here.
However, if You fail to comply with this Public License, then Your rights under this Public
License terminate automatically.
a. 
Where Your right to use the Licensed Material has terminated under Section 6(a), it
reinstates:
automatically as of the date the violation is cured, provided it is cured within 30 days of
Your discovery of the violation; or
1. 
upon express reinstatement by the Licensor.2. 
For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may
have to seek remedies for Your violations of this Public License.
b. 
For the avoidance of doubt, the Licensor may also offer the Licensed Material under
separate terms or conditions or stop distributing the Licensed Material at any time;
however, doing so will not terminate this Public License.
c. 
Sections 1, 5, 6, 7, and 8 survive termination of this Public License.d. 
Section 7 – Other Terms and Conditions.
The Licensor shall not be bound by any additional or different terms or conditions
communicated by You unless expressly agreed.
a. 
Any arrangements, understandings, or agreements regarding the Licensed Material not
stated herein are separate from and independent of the terms and conditions of this Public
License.
b. 
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Section 8 – Interpretation.
For the avoidance of doubt, this Public License does not, and shall not be interpreted to,
reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could
lawfully be made without permission under this Public License.
a. 
To the extent possible, if any provision of this Public License is deemed unenforceable, it
shall be automatically reformed to the minimum extent necessary to make it enforceable. If
the provision cannot be reformed, it shall be severed from this Public License without
affecting the enforceability of the remaining terms and conditions.
b. 
No term or condition of this Public License will be waived and no failure to comply
consented to unless expressly agreed to by the Licensor.
c. 
Nothing in this Public License constitutes or may be interpreted as a limitation upon, or
waiver of, any privileges and immunities that apply to the Licensor or You, including from
the legal processes of any jurisdiction or authority.
d. 
Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons
may elect to apply one of its public licenses to material it publishes and in those instances will
be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated
to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose
of indicating that material is shared under a Creative Commons public license or as otherwise
permitted by the Creative Commons policies published at creativecommons.org/policies,
Creative Commons does not authorize the use of the trademark “Creative Commons” or any
other trademark or logo of Creative Commons without its prior written consent including,
without limitation, in connection with any unauthorized modifications to any of its public
licenses or any other arrangements, understandings, or agreements concerning use of
licensed material. For the avoidance of doubt, this paragraph does not form part of the public
licenses.
Creative Commons may be contacted at creativecommons.org.
Additional languages available: Bahasa Indonesia, Español, euskara, Deutsch, Español,
français, hrvatski, italiano, latviski, Lietuvių, Nederlands, norsk, polski, português, suomeksi,
svenska, te reo Māori, Türkçe, čeština, Ελληνικά, русский, українська, العربية, 日本語, 한
국어. Please read the FAQ for more information about official translations.
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Springer Nature Customer Service Centre GmbH
Terms and Conditions
This agreement sets out the terms and conditions of the licence (the
Licence) between you and Springer Nature Customer Service
Centre GmbH (the Licensor). By clicking 'accept' and completing the
transaction for the material (Licensed Material), you also confirm your
acceptance of these terms and conditions.
1. Grant of License
1. 1. The Licensor grants you a personal, non-exclusive, non-transferable, world-wide licence to
reproduce the Licensed Material for the purpose specified in your order only. Licences are granted for
the specific use requested in the order and for no other use, subject to the conditions below.
1. 2. The Licensor warrants that it has, to the best of its knowledge, the rights to license reuse of the
Licensed Material. However, you should ensure that the material you are requesting is original to the
Licensor and does not carry the copyright of another entity (as credited in the published version).
1. 3. If the credit line on any part of the material you have requested indicates that it was reprinted or
adapted with permission from another source, then you should also seek permission from that source to
reuse the material.
2. Scope of Licence
2. 1. You may only use the Licensed Content in the manner and to the extent permitted by these Ts&Cs
and any applicable laws.
2. 2. A separate licence may be required for any additional use of the Licensed Material, e.g. where a
licence has been purchased for print only use, separate permission must be obtained for electronic re-
use. Similarly, a licence is only valid in the language selected and does not apply for editions in other
languages unless additional translation rights have been granted separately in the licence. Any content
owned by third parties are expressly excluded from the licence.
2. 3. Similarly, rights for additional components such as custom editions and derivatives require
additional permission and may be subject to an additional fee. Please apply to
Journalpermissions@springernature.com/bookpermissions@springernature.com for these rights.
2. 4. Where permission has been granted free of charge for material in print, permission may also be
granted for any electronic version of that work, provided that the material is incidental to your work as a
whole and that the electronic version is essentially equivalent to, or substitutes for, the print version.
2. 5. An alternative scope of licence may apply to signatories of the STM Permissions Guidelines, as
amended from time to time.
3. Duration of Licence
3. 1. A licence for is valid from the date of purchase ('Licence Date') at the end of the relevant period in the
below table:
Scope of Licence Duration of Licence
Post on a website 12 months
Presentations 12 months
Books and journals Lifetime of the edition in the language purchased
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4. 1. The Licensor's permission must be acknowledged next to the Licenced Material in print. In electronic
form, this acknowledgement must be visible at the same time as the figures/tables/illustrations or abstract,
and must be hyperlinked to the journal/book's homepage. Our required acknowledgement format is in the
Appendix below.
5. Restrictions on use
5. 1. Use of the Licensed Material may be permitted for incidental promotional use and minor editing
privileges e.g. minor adaptations of single figures, changes of format, colour and/or style where the
adaptation is credited as set out in Appendix 1 below. Any other changes including but not limited to,
cropping, adapting, omitting material that affect the meaning, intention or moral rights of the author are
strictly prohibited.
5. 2. You must not use any Licensed Material as part of any design or trademark.
5. 3. Licensed Material may be used in Open Access Publications (OAP) before publication by Springer
Nature, but any Licensed Material must be removed from OAP sites prior to final publication.
6. Ownership of Rights
6. 1. Licensed Material remains the property of either Licensor or the relevant third party and any rights not
explicitly granted herein are expressly reserved.
7. Warranty
IN NO EVENT SHALL LICENSOR BE LIABLE TO YOU OR ANY OTHER
PARTY OR ANY OTHER PERSON OR FOR ANY SPECIAL,
CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES, HOWEVER
CAUSED, ARISING OUT OF OR IN CONNECTION WITH THE
DOWNLOADING, VIEWING OR USE OF THE MATERIALS
REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH
OF CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE,
INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES,
USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES),
AND
WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY
LIMITED REMEDY PROVIDED HEREIN.
8. Limitations
8. 1. BOOKS ONLY:Where 'reuse in a dissertation/thesis' has been selected the following terms apply:
Print rights of the final author's accepted manuscript (for clarity, NOT the published version) for up to 100
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copies, electronic rights for use only on a personal website or institutional repository as defined by the
Sherpa guideline (www.sherpa.ac.uk/romeo/).
9. Termination and Cancellation
9. 1. Licences will expire after the period shown in Clause 3 (above).
9. 2. Licensee reserves the right to terminate the Licence in the event that payment is not received in full or
if there has been a breach of this agreement by you.
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Creative Commons Legal Code
Attribution-NonCommercial-NoDerivatives 4.0 International
Official translations of this license are available in other languages.
Creative Commons Corporation (“Creative Commons”) is not a law firm and does not provide
legal services or legal advice. Distribution of Creative Commons public licenses does not
create a lawyer-client or other relationship. Creative Commons makes its licenses and related
information available on an “as-is” basis. Creative Commons gives no warranties regarding its
licenses, any material licensed under their terms and conditions, or any related information.
Creative Commons disclaims all liability for damages resulting from their use to the fullest
extent possible.
Using Creative Commons Public Licenses
Creative Commons public licenses provide a standard set of terms and conditions that
creators and other rights holders may use to share original works of authorship and other
material subject to copyright and certain other rights specified in the public license below. The
following considerations are for informational purposes only, are not exhaustive, and do not
form part of our licenses.
Considerations for licensors: Our public licenses are intended for use by those authorized
to give the public permission to use material in ways otherwise restricted by copyright and
certain other rights. Our licenses are irrevocable. Licensors should read and understand the
terms and conditions of the license they choose before applying it. Licensors should also
secure all rights necessary before applying our licenses so that the public can reuse the
material as expected. Licensors should clearly mark any material not subject to the license.
This includes other CC-licensed material, or material used under an exception or limitation to
copyright.
Considerations for the public: By using one of our public licenses, a licensor grants the
public permission to use the licensed material under specified terms and conditions. If the
licensor’s permission is not necessary for any reason–for example, because of any applicable
exception or limitation to copyright–then that use is not regulated by the license. Our licenses
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grant only permissions under copyright and certain other rights that a licensor has authority to
grant. Use of the licensed material may still be restricted for other reasons, including because
others have copyright or other rights in the material. A licensor may make special requests,
such as asking that all changes be marked or described. Although not required by our
licenses, you are encouraged to respect those requests where reasonable.
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Public License
By exercising the Licensed Rights (defined below), You accept and agree to be bound by the
terms and conditions of this Creative Commons Attribution-NonCommercial-NoDerivatives 4.0
International Public License ("Public License"). To the extent this Public License may be
interpreted as a contract, You are granted the Licensed Rights in consideration of Your
acceptance of these terms and conditions, and the Licensor grants You such rights in
consideration of benefits the Licensor receives from making the Licensed Material available
under these terms and conditions.
Section 1 – Definitions.
Adapted Material means material subject to Copyright and Similar Rights that is derived
from or based upon the Licensed Material and in which the Licensed Material is translated,
altered, arranged, transformed, or otherwise modified in a manner requiring permission
under the Copyright and Similar Rights held by the Licensor. For purposes of this Public
License, where the Licensed Material is a musical work, performance, or sound recording,
Adapted Material is always produced where the Licensed Material is synched in timed
relation with a moving image.
a. 
Copyright and Similar Rights means copyright and/or similar rights closely related to
copyright including, without limitation, performance, broadcast, sound recording, and Sui
Generis Database Rights, without regard to how the rights are labeled or categorized. For
purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not
Copyright and Similar Rights.
b. 
Effective Technological Measures means those measures that, in the absence of proper
authority, may not be circumvented under laws fulfilling obligations under Article 11 of the
WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international
agreements.
c. 
Exceptions and Limitations means fair use, fair dealing, and/or any other exception or
limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.
d. 
Licensed Material means the artistic or literary work, database, or other material to which
the Licensor applied this Public License.
e. 
Licensed Rights means the rights granted to You subject to the terms and conditions off. 
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this Public License, which are limited to all Copyright and Similar Rights that apply to Your
use of the Licensed Material and that the Licensor has authority to license.
Licensor means the individual(s) or entity(ies) granting rights under this Public License.g. 
NonCommercial means not primarily intended for or directed towards commercial
advantage or monetary compensation. For purposes of this Public License, the exchange
of the Licensed Material for other material subject to Copyright and Similar Rights by
digital file-sharing or similar means is NonCommercial provided there is no payment of
monetary compensation in connection with the exchange.
h. 
Share means to provide material to the public by any means or process that requires
permission under the Licensed Rights, such as reproduction, public display, public
performance, distribution, dissemination, communication, or importation, and to make
material available to the public including in ways that members of the public may access
the material from a place and at a time individually chosen by them.
i. 
Sui Generis Database Rights means rights other than copyright resulting from Directive
96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal
protection of databases, as amended and/or succeeded, as well as other essentially
equivalent rights anywhere in the world.
j. 
You means the individual or entity exercising the Licensed Rights under this Public
License. Your has a corresponding meaning.
k. 
Section 2 – Scope.
License grant.
Subject to the terms and conditions of this Public License, the Licensor hereby grants
You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to
exercise the Licensed Rights in the Licensed Material to:
reproduce and Share the Licensed Material, in whole or in part, for NonCommercial
purposes only; and
A. 




Exceptions and Limitations. For the avoidance of doubt, where Exceptions and
Limitations apply to Your use, this Public License does not apply, and You do not need
to comply with its terms and conditions.
2. 
Term. The term of this Public License is specified in Section 6(a).3. 
Media and formats; technical modifications allowed. The Licensor authorizes You to
exercise the Licensed Rights in all media and formats whether now known or hereafter
created, and to make technical modifications necessary to do so. The Licensor waives
and/or agrees not to assert any right or authority to forbid You from making technical
modifications necessary to exercise the Licensed Rights, including technical
4. 
a. 
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modifications necessary to circumvent Effective Technological Measures. For purposes
of this Public License, simply making modifications authorized by this Section 2(a)(4)
never produces Adapted Material.
Downstream recipients.
Offer from the Licensor – Licensed Material. Every recipient of the Licensed
Material automatically receives an offer from the Licensor to exercise the Licensed
Rights under the terms and conditions of this Public License.
A. 
No downstream restrictions. You may not offer or impose any additional or different
terms or conditions on, or apply any Effective Technological Measures to, the
Licensed Material if doing so restricts exercise of the Licensed Rights by any
recipient of the Licensed Material.
B. 
5. 
No endorsement. Nothing in this Public License constitutes or may be construed as
permission to assert or imply that You are, or that Your use of the Licensed Material is,
connected with, or sponsored, endorsed, or granted official status by, the Licensor or
others designated to receive attribution as provided in Section 3(a)(1)(A)(i).
6. 
Other rights.
Moral rights, such as the right of integrity, are not licensed under this Public License,
nor are publicity, privacy, and/or other similar personality rights; however, to the extent
possible, the Licensor waives and/or agrees not to assert any such rights held by the
Licensor to the limited extent necessary to allow You to exercise the Licensed Rights,
but not otherwise.
1. 
Patent and trademark rights are not licensed under this Public License.2. 
To the extent possible, the Licensor waives any right to collect royalties from You for
the exercise of the Licensed Rights, whether directly or through a collecting society
under any voluntary or waivable statutory or compulsory licensing scheme. In all other
cases the Licensor expressly reserves any right to collect such royalties, including
when the Licensed Material is used other than for NonCommercial purposes.
3. 
b. 
Section 3 – License Conditions.
Your exercise of the Licensed Rights is expressly made subject to the following conditions.
Attribution.
If You Share the Licensed Material, You must:1. 
a. 
Creative Commons — Attribution-NonCommerci... https://creativecommons.org/licenses/by-nc-nd/4...
4 of 8 11/5/19, 3:06 PM
APPENDIX G. PERMISSIONS G.3. PERMISSION FOR REPRINTING [4] IN SECTION 3.4
233
retain the following if it is supplied by the Licensor with the Licensed Material:
identification of the creator(s) of the Licensed Material and any others
designated to receive attribution, in any reasonable manner requested by the
Licensor (including by pseudonym if designated);
i. 
a copyright notice;ii. 
a notice that refers to this Public License;iii. 
a notice that refers to the disclaimer of warranties;iv. 
a URI or hyperlink to the Licensed Material to the extent reasonably practicable;v. 
A. 
indicate if You modified the Licensed Material and retain an indication of any
previous modifications; and
B. 
indicate the Licensed Material is licensed under this Public License, and include the
text of, or the URI or hyperlink to, this Public License.
C. 
For the avoidance of doubt, You do not have permission under this Public License to
Share Adapted Material.
You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on
the medium, means, and context in which You Share the Licensed Material. For
example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink
to a resource that includes the required information.
2. 
If requested by the Licensor, You must remove any of the information required by
Section 3(a)(1)(A) to the extent reasonably practicable.
3. 
Section 4 – Sui Generis Database Rights.
Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the
Licensed Material:
for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse,
reproduce, and Share all or a substantial portion of the contents of the database for
NonCommercial purposes only and provided You do not Share Adapted Material;
a. 
if You include all or a substantial portion of the database contents in a database in which
You have Sui Generis Database Rights, then the database in which You have Sui Generis
Database Rights (but not its individual contents) is Adapted Material; and
b. 
You must comply with the conditions in Section 3(a) if You Share all or a substantial
portion of the contents of the database.
c. 
For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations
under this Public License where the Licensed Rights include other Copyright and Similar
Rights.
Section 5 – Disclaimer of Warranties and Limitation of Liability.
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Unless otherwise separately undertaken by the Licensor, to the extent possible, the
Licensor offers the Licensed Material as-is and as-available, and makes no
representations or warranties of any kind concerning the Licensed Material,
whether express, implied, statutory, or other. This includes, without limitation,
warranties of title, merchantability, fitness for a particular purpose, non-
infringement, absence of latent or other defects, accuracy, or the presence or
absence of errors, whether or not known or discoverable. Where disclaimers of
warranties are not allowed in full or in part, this disclaimer may not apply to You.
a. 
To the extent possible, in no event will the Licensor be liable to You on any legal
theory (including, without limitation, negligence) or otherwise for any direct,
special, indirect, incidental, consequential, punitive, exemplary, or other losses,
costs, expenses, or damages arising out of this Public License or use of the
Licensed Material, even if the Licensor has been advised of the possibility of such
losses, costs, expenses, or damages. Where a limitation of liability is not allowed in
full or in part, this limitation may not apply to You.
b. 
The disclaimer of warranties and limitation of liability provided above shall be interpreted in
a manner that, to the extent possible, most closely approximates an absolute disclaimer
and waiver of all liability.
c. 
Section 6 – Term and Termination.
This Public License applies for the term of the Copyright and Similar Rights licensed here.
However, if You fail to comply with this Public License, then Your rights under this Public
License terminate automatically.
a. 
Where Your right to use the Licensed Material has terminated under Section 6(a), it
reinstates:
automatically as of the date the violation is cured, provided it is cured within 30 days of
Your discovery of the violation; or
1. 
upon express reinstatement by the Licensor.2. 
For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may
have to seek remedies for Your violations of this Public License.
b. 
For the avoidance of doubt, the Licensor may also offer the Licensed Material under
separate terms or conditions or stop distributing the Licensed Material at any time;
however, doing so will not terminate this Public License.
c. 
Sections 1, 5, 6, 7, and 8 survive termination of this Public License.d. 
Section 7 – Other Terms and Conditions.
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The Licensor shall not be bound by any additional or different terms or conditions
communicated by You unless expressly agreed.
a. 
Any arrangements, understandings, or agreements regarding the Licensed Material not
stated herein are separate from and independent of the terms and conditions of this Public
License.
b. 
Section 8 – Interpretation.
For the avoidance of doubt, this Public License does not, and shall not be interpreted to,
reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could
lawfully be made without permission under this Public License.
a. 
To the extent possible, if any provision of this Public License is deemed unenforceable, it
shall be automatically reformed to the minimum extent necessary to make it enforceable. If
the provision cannot be reformed, it shall be severed from this Public License without
affecting the enforceability of the remaining terms and conditions.
b. 
No term or condition of this Public License will be waived and no failure to comply
consented to unless expressly agreed to by the Licensor.
c. 
Nothing in this Public License constitutes or may be interpreted as a limitation upon, or
waiver of, any privileges and immunities that apply to the Licensor or You, including from
the legal processes of any jurisdiction or authority.
d. 
Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons
may elect to apply one of its public licenses to material it publishes and in those instances will
be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated
to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose
of indicating that material is shared under a Creative Commons public license or as otherwise
permitted by the Creative Commons policies published at creativecommons.org/policies,
Creative Commons does not authorize the use of the trademark “Creative Commons” or any
other trademark or logo of Creative Commons without its prior written consent including,
without limitation, in connection with any unauthorized modifications to any of its public
licenses or any other arrangements, understandings, or agreements concerning use of
licensed material. For the avoidance of doubt, this paragraph does not form part of the public
licenses.
Creative Commons may be contacted at creativecommons.org.
Additional languages available: Bahasa Indonesia, Español, euskara, Deutsch, Español,
français, hrvatski, italiano, latviski, Lietuvių, Nederlands, norsk, polski, português, suomeksi,
svenska, te reo Māori, Türkçe, čeština, Ελληνικά, русский, українська, العربية, 日本語, 한
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국어. Please read the FAQ for more information about official translations.
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Terms and Conditions
Springer Nature Customer Service Centre GmbH
Terms and Conditions
This agreement sets out the terms and conditions of the licence (the
Licence) between you and Springer Nature Customer Service
Centre GmbH (the Licensor). By clicking 'accept' and completing the
transaction for the material (Licensed Material), you also confirm your
acceptance of these terms and conditions.
1. Grant of License
1. 1. The Licensor grants you a personal, non-exclusive, non-transferable, world-wide licence to
reproduce the Licensed Material for the purpose specified in your order only. Licences are granted for
the specific use requested in the order and for no other use, subject to the conditions below.
1. 2. The Licensor warrants that it has, to the best of its knowledge, the rights to license reuse of the
Licensed Material. However, you should ensure that the material you are requesting is original to the
Licensor and does not carry the copyright of another entity (as credited in the published version).
1. 3. If the credit line on any part of the material you have requested indicates that it was reprinted or
adapted with permission from another source, then you should also seek permission from that source to
reuse the material.
2. Scope of Licence
2. 1. You may only use the Licensed Content in the manner and to the extent permitted by these Ts&Cs
and any applicable laws.
2. 2. A separate licence may be required for any additional use of the Licensed Material, e.g. where a
licence has been purchased for print only use, separate permission must be obtained for electronic re-
use. Similarly, a licence is only valid in the language selected and does not apply for editions in other
languages unless additional translation rights have been granted separately in the licence. Any content
owned by third parties are expressly excluded from the licence.
2. 3. Similarly, rights for additional components such as custom editions and derivatives require
additional permission and may be subject to an additional fee. Please apply to
Journalpermissions@springernature.com/bookpermissions@springernature.com for these rights.
2. 4. Where permission has been granted free of charge for material in print, permission may also be
granted for any electronic version of that work, provided that the material is incidental to your work as a
whole and that the electronic version is essentially equivalent to, or substitutes for, the print version.
2. 5. An alternative scope of licence may apply to signatories of the STM Permissions Guidelines, as
amended from time to time.
3. Duration of Licence
3. 1. A licence for is valid from the date of purchase ('Licence Date') at the end of the relevant period in the
below table:
Scope of Licence Duration of Licence
Post on a website 12 months
Presentations 12 months
Books and journals Lifetime of the edition in the language purchased
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4. Acknowledgement
4. 1. The Licensor's permission must be acknowledged next to the Licenced Material in print. In electronic
form, this acknowledgement must be visible at the same time as the figures/tables/illustrations or abstract,
and must be hyperlinked to the journal/book's homepage. Our required acknowledgement format is in the
Appendix below.
5. Restrictions on use
5. 1. Use of the Licensed Material may be permitted for incidental promotional use and minor editing
privileges e.g. minor adaptations of single figures, changes of format, colour and/or style where the
adaptation is credited as set out in Appendix 1 below. Any other changes including but not limited to,
cropping, adapting, omitting material that affect the meaning, intention or moral rights of the author are
strictly prohibited.
5. 2. You must not use any Licensed Material as part of any design or trademark.
5. 3. Licensed Material may be used in Open Access Publications (OAP) before publication by Springer
Nature, but any Licensed Material must be removed from OAP sites prior to final publication.
6. Ownership of Rights
6. 1. Licensed Material remains the property of either Licensor or the relevant third party and any rights not
explicitly granted herein are expressly reserved.
7. Warranty
IN NO EVENT SHALL LICENSOR BE LIABLE TO YOU OR ANY OTHER
PARTY OR ANY OTHER PERSON OR FOR ANY SPECIAL,
CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES, HOWEVER
CAUSED, ARISING OUT OF OR IN CONNECTION WITH THE
DOWNLOADING, VIEWING OR USE OF THE MATERIALS
REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH
OF CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE,
INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES,
USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES),
AND
WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY
LIMITED REMEDY PROVIDED HEREIN.
8. Limitations
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8. 1. BOOKS ONLY:Where 'reuse in a dissertation/thesis' has been selected the following terms apply:
Print rights of the final author's accepted manuscript (for clarity, NOT the published version) for up to 100
copies, electronic rights for use only on a personal website or institutional repository as defined by the
Sherpa guideline (www.sherpa.ac.uk/romeo/).
9. Termination and Cancellation
9. 1. Licences will expire after the period shown in Clause 3 (above).
9. 2. Licensee reserves the right to terminate the Licence in the event that payment is not received in full or
if there has been a breach of this agreement by you.
Appendix 1 — Acknowledgements:
For Journal Content:
Reprinted by permission from [the Licensor]: [Journal Publisher
(e.g. Nature/Springer/Palgrave)] [JOURNAL NAME]
[REFERENCE CITATION (Article name, Author(s) Name),
[COPYRIGHT] (year of publication)
For Advance Online Publication papers:
Reprinted by permission from [the Licensor]: [Journal Publisher
(e.g. Nature/Springer/Palgrave)] [JOURNAL NAME]
[REFERENCE CITATION (Article name, Author(s) Name),
[COPYRIGHT] (year of publication), advance online publication,
day month year (doi: 10.1038/sj.[JOURNAL ACRONYM].)
For Adaptations/Translations:
Adapted/Translated by permission from [the Licensor]: [Journal
Publisher (e.g. Nature/Springer/Palgrave)] [JOURNAL NAME]
[REFERENCE CITATION (Article name, Author(s) Name),
[COPYRIGHT] (year of publication)
Note: For any republication from the British Journal of
Cancer, the following credit line style applies:
Reprinted/adapted/translated by permission from [the Licensor]:
on behalf of Cancer Research UK: : [Journal Publisher (e.g.
Nature/Springer/Palgrave)] [JOURNAL NAME] [REFERENCE
CITATION (Article name, Author(s) Name), [COPYRIGHT] (year
of publication)
For Advance Online Publication papers:
Reprinted by permission from The [the Licensor]: on behalf of
Cancer Research UK: [Journal Publisher (e.g. Nature/Springer
/Palgrave)] [JOURNAL NAME] [REFERENCE CITATION (Article
name, Author(s) Name), [COPYRIGHT] (year of publication),
RightsLink Printable License https://s100.copyright.com/CustomerAdmin/PLF...
4 of 5 8/16/19, 9:53 AM
G.4. PERMISSION TO REPRINT CONTENT OF FIGURE 2.3 APPENDIX G. PERMISSIONS
242
advance online publication, day month year (doi: 10.1038/sj.
[JOURNAL ACRONYM])
For Book content:
Reprinted/adapted by permission from [the Licensor]: [Book
Publisher (e.g. Palgrave Macmillan, Springer etc) [Book Title] by
[Book author(s)] [COPYRIGHT] (year of publication)
Other Conditions:
Version  1.2
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-646-2777.
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terms and conditions determined by the rights holder.
Additional Terms & Conditions applicable to each Creative
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CC BY: The CC-BY license allows users to copy, to create extracts,
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and to make commercial use of the Article (including reuse and/or resale
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http://creativecommons.org/licenses/by/4.0.
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create
extracts, abstracts and new works from the Article, to alter and revise
the Article, provided this is not done for commercial purposes, and that
the user gives appropriate credit (with a link to the formal publication
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changes were made and the licensor is not represented as endorsing the
use made of the work. Further, any new works must be made available
on the same conditions. The full details of the license are available at
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Rightsholder shall not reimburse any fees which User pays for such
licences and permissions.
As well as CCC, the Rightsholder shall have the right to bring any legal
action that it deems necessary to enforce its rights should it consider
that the Work infringes those rights in any way.
For STM Signatories ONLY (as agreed as part of the STM Guidelines)
Any licence granted for a particular edition of a Work will apply also to
subsequent editions of it and for editions in other languages, provided
such editions are for the Work as a whole in situ and do not involve the
separate exploitation of the permitted illustrations or excerpts.
Other Terms and Conditions:
STANDARD TERMS AND CONDITIONS
1. Description of Service; Defined Terms. This Republication License
enables the User to obtain licenses for republication of one or more
copyrighted works as described in detail on the relevant Order
Confirmation (the “Work(s)”). Copyright Clearance Center, Inc. (“CCC”)
grants licenses through the Service on behalf of the rightsholder
identified on the Order Confirmation (the “Rightsholder”).
“Republication”, as used herein, generally means the inclusion of a
Work, in whole or in part, in a new work or works, also as described on
the Order Confirmation. “User”, as used herein, means the person or
entity making such republication.
2. The terms set forth in the relevant Order Confirmation, and any terms
set by the Rightsholder with respect to a particular Work, govern the
terms of use of Works in connection with the Service. By using the
Service, the person transacting for a republication license on behalf of
the User represents and warrants that he/she/it (a) has been duly
authorized by the User to accept, and hereby does accept, all such terms
and conditions on behalf of User, and (b) shall inform User of all such
terms and conditions. In the event such person is a “freelancer” or other
third party independent of User and CCC, such party shall be deemed
jointly a “User” for purposes of these terms and conditions. In any event,
User shall be deemed to have accepted and agreed to all such terms and
conditions if User republishes the Work in any fashion.
3. Scope of License; Limitations and Obligations.
3.1 All Works and all rights therein, including copyright rights, remain
the sole and exclusive property of the Rightsholder. The license created
by the exchange of an Order Confirmation (and/or any invoice) and
payment by User of the full amount set forth on that document includes
only those rights expressly set forth in the Order Confirmation and in
these terms and conditions, and conveys no other rights in the Work(s)
to User. All rights not expressly granted are hereby reserved.
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3.2 General Payment Terms: You may pay by credit card or through an
account with us payable at the end of the month. If you and we agree
that you may establish a standing account with CCC, then the following
terms apply: Remit Payment to: Copyright Clearance Center, 29118
Network Place, Chicago, IL 60673-1291. Payments Due: Invoices are
payable upon their delivery to you (or upon our notice to you that they
are available to you for downloading). After 30 days, outstanding
amounts will be subject to a service charge of 1-1/2% per month or, if
less, the maximum rate allowed by applicable law. Unless otherwise
specifically set forth in the Order Confirmation or in a separate written
agreement signed by CCC, invoices are due and payable on “net 30”
terms. While User may exercise the rights licensed immediately upon
issuance of the Order Confirmation, the license is automatically revoked
and is null and void, as if it had never been issued, if complete payment
for the license is not received on a timely basis either from User directly
or through a payment agent, such as a credit card company.
3.3 Unless otherwise provided in the Order Confirmation, any grant of
rights to User (i) is “one-time” (including the editions and product family
specified in the license), (ii) is non-exclusive and non-transferable and
(iii) is subject to any and all limitations and restrictions (such as, but not
limited to, limitations on duration of use or circulation) included in the
Order Confirmation or invoice and/or in these terms and conditions.
Upon completion of the licensed use, User shall either secure a new
permission for further use of the Work(s) or immediately cease any new
use of the Work(s) and shall render inaccessible (such as by deleting or
by removing or severing links or other locators) any further copies of the
Work (except for copies printed on paper in accordance with this license
and still in User's stock at the end of such period).
3.4 In the event that the material for which a republication license is
sought includes third party materials (such as photographs, illustrations,
graphs, inserts and similar materials) which are identified in such
material as having been used by permission, User is responsible for
identifying, and seeking separate licenses (under this Service or
otherwise) for, any of such third party materials; without a separate
license, such third party materials may not be used.
3.5 Use of proper copyright notice for a Work is required as a condition
of any license granted under the Service. Unless otherwise provided in
the Order Confirmation, a proper copyright notice will read substantially
as follows: “Republished with permission of [Rightsholder’s name], from
[Work's title, author, volume, edition number and year of copyright];
permission conveyed through Copyright Clearance Center, Inc. ” Such
notice must be provided in a reasonably legible font size and must be
placed either immediately adjacent to the Work as used (for example, as
part of a by-line or footnote but not as a separate electronic link) or in
the place where substantially all other credits or notices for the new
work containing the republished Work are located. Failure to include the
RightsLink Printable License https://s100.copyright.com/CustomerAdmin/PLF...
5 of 8 8/29/19, 12:23 PM
APPENDIX G. PERMISSIONS G.7. PERMISSION TO REPRINT FIGURE 5 AND 8 OF [7]
263
required notice results in loss to the Rightsholder and CCC, and the
User shall be liable to pay liquidated damages for each such failure
equal to twice the use fee specified in the Order Confirmation, in
addition to the use fee itself and any other fees and charges specified.
3.6 User may only make alterations to the Work if and as expressly set
forth in the Order Confirmation. No Work may be used in any way that is
defamatory, violates the rights of third parties (including such third
parties' rights of copyright, privacy, publicity, or other tangible or
intangible property), or is otherwise illegal, sexually explicit or obscene.
In addition, User may not conjoin a Work with any other material that
may result in damage to the reputation of the Rightsholder. User agrees
to inform CCC if it becomes aware of any infringement of any rights in a
Work and to cooperate with any reasonable request of CCC or the
Rightsholder in connection therewith.
4. Indemnity. User hereby indemnifies and agrees to defend the
Rightsholder and CCC, and their respective employees and directors,
against all claims, liability, damages, costs and expenses, including legal
fees and expenses, arising out of any use of a Work beyond the scope of
the rights granted herein, or any use of a Work which has been altered
in any unauthorized way by User, including claims of defamation or
infringement of rights of copyright, publicity, privacy or other tangible or
intangible property.
5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR
THE RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT,
CONSEQUENTIAL OR INCIDENTAL DAMAGES (INCLUDING WITHOUT
LIMITATION DAMAGES FOR LOSS OF BUSINESS PROFITS OR
INFORMATION, OR FOR BUSINESS INTERRUPTION) ARISING OUT OF
THE USE OR INABILITY TO USE A WORK, EVEN IF ONE OF THEM
HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. In any
event, the total liability of the Rightsholder and CCC (including their
respective employees and directors) shall not exceed the total amount
actually paid by User for this license. User assumes full liability for the
actions and omissions of its principals, employees, agents, affiliates,
successors and assigns.
6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED
“AS IS”. CCC HAS THE RIGHT TO GRANT TO USER THE RIGHTS
GRANTED IN THE ORDER CONFIRMATION DOCUMENT. CCC AND
THE RIGHTSHOLDER DISCLAIM ALL OTHER WARRANTIES RELATING
TO THE WORK(S) AND RIGHT(S), EITHER EXPRESS OR IMPLIED,
INCLUDING WITHOUT LIMITATION IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS,
GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER
PORTIONS OF THE WORK (AS OPPOSED TO THE ENTIRE WORK) IN A
MANNER CONTEMPLATED BY USER; USER UNDERSTANDS AND
AGREES THAT NEITHER CCC NOR THE RIGHTSHOLDER MAY HAVE
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SUCH ADDITIONAL RIGHTS TO GRANT.
7. Effect of Breach. Any failure by User to pay any amount when due, or
any use by User of a Work beyond the scope of the license set forth in
the Order Confirmation and/or these terms and conditions, shall be a
material breach of the license created by the Order Confirmation and
these terms and conditions. Any breach not cured within 30 days of
written notice thereof shall result in immediate termination of such
license without further notice. Any unauthorized (but licensable) use of a
Work that is terminated immediately upon notice thereof may be
liquidated by payment of the Rightsholder's ordinary license price
therefor; any unauthorized (and unlicensable) use that is not terminated
immediately for any reason (including, for example, because materials
containing the Work cannot reasonably be recalled) will be subject to all
remedies available at law or in equity, but in no event to a payment of
less than three times the Rightsholder's ordinary license price for the
most closely analogous licensable use plus Rightsholder's and/or CCC's
costs and expenses incurred in collecting such payment.
8. Miscellaneous.
8.1 User acknowledges that CCC may, from time to time, make changes
or additions to the Service or to these terms and conditions, and CCC
reserves the right to send notice to the User by electronic mail or
otherwise for the purposes of notifying User of such changes or
additions; provided that any such changes or additions shall not apply to
permissions already secured and paid for.
8.2 Use of User-related information collected through the Service is
governed by CCC’s privacy policy, available online here:
http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html.
8.3 The licensing transaction described in the Order Confirmation is
personal to User. Therefore, User may not assign or transfer to any
other person (whether a natural person or an organization of any kind)
the license created by the Order Confirmation and these terms and
conditions or any rights granted hereunder; provided, however, that
User may assign such license in its entirety on written notice to CCC in
the event of a transfer of all or substantially all of User’s rights in the
new material which includes the Work(s) licensed under this Service.
8.4 No amendment or waiver of any terms is binding unless set forth in
writing and signed by the parties. The Rightsholder and CCC hereby
object to any terms contained in any writing prepared by the User or its
principals, employees, agents or affiliates and purporting to govern or
otherwise relate to the licensing transaction described in the Order
Confirmation, which terms are in any way inconsistent with any terms
set forth in the Order Confirmation and/or in these terms and conditions
or CCC's standard operating procedures, whether such writing is
prepared prior to, simultaneously with or subsequent to the Order
Confirmation, and whether such writing appears on a copy of the Order
Confirmation or in a separate instrument.
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Cancer is a hard problem touching numerous branches of life science. One reason for the complexity of
cancer is that tumors act across many different time and length scales ranging from the subcellular to
the macroscopic level. Modern sciences still lack an integral understanding of cancer, however in recent
years, increasing computational power enabled computational models to accompany and support conven-
tional medical and biological methods bridging the scales from micro to macro. Here I report a multiscale
computational model simulating the progression of solid tumors comprising the vasculature mimicked by ar-
tificial arterio-venous blood vessel networks. I present a numerical optimization procedure to determine radii
of blood vessels in an artificial microcirculation based on physiological stimuli independently of Murray’s
law. Comprising the blood vessels, the reported model enables the inspection of blood vessel remodeling
dynamics (angiogenesis, vaso-dilation, vessel regression and collapse) during tumor growth. We successfully
applied the method to simulated tumor blood vessel networks guided by optical mammography data. In
subsequent model development, I included cellular details into the method enabling a computational study of
the tumor microenvironment at cellular resolution. I found that small vascularized tumors at the angiogenic






Krebs ist ein schwieriges Thema und tritt in zahlreichen Gebieten auf. Ein Grund für die Komplexität
des Tumorwachstums sind die unterschiedlichen Zeit- und Längenskalen. In der aktuellen Forschung fehlt
immernoch ein ganzheitliches Verständnis von Krebs, obwohl die computergestützten Methoden in den ver-
gangenen Jahren die konventionellen Methoden der Medizin und der Biologie erweitern und unterstützen.
Damit wird die Kluft zwischen subzellulären und makroskopischen Prozessen bereits verringert. In der
vorliegenden Arbeit dokumentiere ich ein computergestütztes Verfahren, welches das Tumorwachstum auf
mehreren Skalen simuliert. Insbesondere wird das Blutgefäßsystem durch künstliche Gefäße nachgeahmt. Es
wurde ein numerisches Optimierungsverfahren zur Bestimmung der Gefäßradien eines künstlichen Blutkreis-
laufes entwickelt, welches auf physiologischen Reizen basiert und unabhängig von Murray‘s Gesetz ist.
Da das beschriebene Verfahren zur Simulation von Tumoren Blutgefäße beinhaltet, kann die Umbildung
des Gefäßbaumes während des Tumorwachstums untersucht werden. Das Modell wurde erfolgreich mit
krankhaften Gefäßsystemen verglichen. In der darauffolgenden Weiterentwicklung des Modells berücksichtigte
ich zelluläre Feinheiten, die es mir erlaubten das Mikromilieu in zellulärer Auflösung zu untersuchen. Meine
Resultate zeigen, dass bereits kleine Tumore eine hohe ökologische Vielfalt besitzen, was den Selektionsdruck
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